

# CV

**YEHUDA SHOENFELD, M.D., FRCP (Hon.)  
.MaACR**

## **CURRICULUM VITAE**

**2015**

**Chaim Sheba Medical Center  
The Zabłudowicz Center  
for Autoimmune Diseases  
Tel Hashomer 5265601, Israel.**

**Incumbent of the Laura Schwarz-Kipp Chair  
for Research of Autoimmune Diseases,  
Sackler Faculty of Medicine,  
Tel-Aviv University, Israel.**

**Tel: 03-5308070 Fax: 03-5352855  
E-mail: [shoenfel@post.tau.ac.il](mailto:shoenfel@post.tau.ac.il)**

CURRICULUM VITAE**YEHUDA SHOENFELD, M.D.****Date and place of birth:** February 14, 1948, Slovakia.**Marital Status:** Married + 3 (Nettea, Amir, Guy)EDUCATION

- 1965 - 1972 Hadassah Medical School, Hebrew University, Jerusalem
- 1972 - M.D. Thesis: "Osteogenesis Imperfecta" (Advisor: Prof. A. Fried) cum laude
- 1976 - 1978 Diploma cum laude upon completion of post graduate studies in internal medicine, Postgraduate Medical School, Tel Aviv University
- 1976 - Senior resident, Department of Internal Medicine "D" and Out-Patient Clinic of Hematology and Immunology, Beilinson Medical Center, Petach Tikva, Israel
- 1978 (3m) - Clinical Fellowship, Hematology/Oncology, Department of Hematology, City of Hope, Duarte, California (Director: Prof. E. Beutler)
- 1979 (3m) - Clinical Fellowship Hematology/Oncology, Tufts New England Medical Center, Boston, Mass. (Director: Prof. Robert S. Schwartz)
- 1980 (3m) - Clinical Fellowship Hematology/Oncology, Cornell Medical Center, New York Hospital (Director: Prof. R. Nachman)
- 1980 - Master in Internal Medicine, Postgraduate Medical School, Tel-Aviv University
- 1983 - 1984 Senior Physician, department of Internal Medicine "D", Beilinson Medical Center, Petach Tikva, Israel
- 1984 -1985 Head, Department of Medicine "D" and Outpatient Clinic for Clinical Immunology and Allergy, Soroka Medical Center, Beer-Sheva, Israel
- 1985 - Head of the Hybridoma Unit and Research Laboratory for Autoimmune Diseases, Soroka Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
- 1989 - Head of Department of Medicine "B" Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Israel. Head of Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Israel
- 2003- Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel.
- 2011 - Head of Zabłudowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel.

**RESEARCH EXPERIENCE**

- 1974 - 1975      Research in environmental physiology and physiology of the effort. Heller Institute of Medical Research, Tel-Hashomer Hospital and Tel-Aviv University (Director: Prof. E. Zohar).
- 1974 - 1979      Clinical Immunology, Section of Clinical Immunology, Beilinson Medical Center (Director: Prof. A.I. Pick).
- 1976 - 1984      Clinical research in hematology and internal medicine, Department of Medicine "D", Beilinson Medical Center (Director: Prof. J. Pinkhas).
- 1978              Gaucher's disease and monoclonal gammopathy. Department of Hematology, City of Hope, Duarte, California (Director: Prof. E. Beutler).
- 1981 - 1983      Production of monoclonal autoantibodies by human-human hybridomas. Research in autoimmune diseases. Cancer Research Center, Tufts New England Medical Center (Director: Prof. Robert S. Schwartz).
- 1984              Production of human hybridomas secreting monoclonal antibodies reactive with mammary carcinoma cells. The detection of dominant idiotypes of anti-DNA antibodies in SLE, in first degree relatives of SLE patients, in drug induced SLE, in plasma cell dyscrasia and other autoimmune conditions. The detection of anti-histone antibodies in autoimmune diseases.
- 1985              Infection and autoimmunity.
- 1986              Studies on idiotypes and anti-idiotypes in autoimmunity and cancer.
- 1987              Induced models of SLE in mice by common Ids and anti-Ids of anti-DNA antibodies. Anti-RNP, Sm, Ro and La in autoimmune conditions. Anti-neuronal antibodies in CNS involvement in SLE. TB and autoimmunity.
- 1988              Induction of SLE like disease in mice by immunization with anti-DNA antibody (16/6 Id). T-cell lines reactive with dominant anti-DNA idiotypes. Humoral and cellular immunity against MMTV induced by anti-idiotypic immunization. IgA deficiency and autoimmunity (Ts, hormonal manipulations, drugs).
- 1989              Therapeutic manipulation of SLE induced by pathogenic anti-DNA idiotypes (cytokines).
- 1990              Induction of experimental model of anti-phospholipid syndrome. Idiotypes of anti-cardiolipin antibodies. In vitro production of anti-breast human monoclonal antibodies.
- 1991              Therapeutic manipulation of experimental anti-phospholipid syndrome. Anti-mitochondrial antibodies. Nucleotide sequence of human monoclonal autoantibodies.
- 1992              Generation of ANCA antibodies. Induction of experimental model of PBC. Analysis of anti-PDH (mitochondrial) antibody idiotypes. Analysis of anti-PDH (mitochondrial) antibody idiotypes. Analysis of natural autoantibodies.
- 1993              Induction of experimental Wegener's granulomatosis, anti-idiotypes to anti-cardiolipin antibodies, T cell lines, anti-idiotypic (with toxin) therapy, interleukin-3 and APS, ACA inhibitors, bone-marrow transplantation in APS, silicone and autoimmunity, hyperprolactinemia.
- 1994              Induction of thyroiditis and Goodpasture's syndrome by idiotypic manipulation, bromocriptine in autoimmunity, valves, CNS and kidneys involvement in APS, seed oil and dietary manipulation in experimental SLE and APS, adhesion molecules and catalytic antibodies in Wegener's.
- 1995              Induction of heparin induced thrombocytopenia (HIT), diet and autoimmunity, mutant of  $\beta_2$ GPI, monoclonal anti-endothelial autoantibodies, Th<sub>1</sub>/Tb<sub>2</sub> in exp. SLE (TNF<sub>1</sub>, and Il-4).

- 1996 New therapeutic modalities in autoimmunity, cyprofloxacin, IL-3 and APS, diet and APS, INFg, anti- INFg in Exp. SLE, scVF of anti-DNA and anti-cardiolipin antibodies.
- 1997 Fishing of aCL/b<sub>2</sub>GP-I epitope from a phage library, atherosclerosis and autoimmunity (Exp. mouse models, HSP-65, oxLDL), Anti-endothelial Abs epitopes, AECA in scleroderma, induction of vasculitis by AECA (human and mouse mAbs) Mg<sup>++</sup> and atherosclerosis.
- 1998 Atherosclerosis and Autoimmunity: Oral tolerance.
- 1999 Atherosclerosis and Autoimmunity: immunomodulation, IVIG in SLE, vasculitis, cancer.
- 2000 – 2013 Infection and autoimmunity.  
 Specific IVIG for autoimmunity and Cancer..  
 ASIA – Autoimmune syndrome induced by adjuvant.  
 New peptide to treat APS  
 Tolerance and dendritic cells.  
 Anti-P-Ribosomal induced depression in mice.  
 Penetration of anti-P-R into cells.  
 Vaccination and autoimmunity.  
 Smell and autoimmunity.  
 Vitamin D and autoimmunity.  
 Vitamin D and Ant-phospholipid syndrome (APS).  
 ASIA Syndrome. (ASIA - Autoimmune Syndrome Induced by Adjuvants)  
 Infectious and Autoimmunity.

#### **ACADEMIC EXPERIENCE**

- 1974 Guest lecturer in Environmental Physiology, Tel-Aviv University.  
 Guest lecturer in courses of Scientific Methods in Medicine, Tel-Aviv University Medical School.
- 1975 Appointed lecturer in internal medicine, Tel-Aviv University Medical School.
- 1980 Appointed senior lecturer in internal medicine, Tel-Aviv University Medical School.
- 1985 Appointed associate professor in Tel-Aviv University and Ben-Gurion University of the Negev.
- 1990 Appointed Professor of Medicine in Tel-Aviv University, Sackler Faculty of Medicine.

#### **PHD OPPONENTS, INTERNATIONAL**

1. 1995 - Institute Pasteur (France).
2. 1996 – Leuven University (Belgium).
3. 1999 – Helsinki University, Medical School.
4. 2003 – Karolinska Hospital, Stockholm, Sweden.

#### **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

- 1973 Israel Medical Association
- 1974 Israel Society of Internal Medicine
- 1975 Israel Society of Physiology and Pharmacology

- 1976 Israel Society of Immunology
- 1979 ISIM: The International Society of Internal Medicine
- 1980 New York Academy of Sciences, N.Y., U.S.A.
- 1981 Associate: American College of Physicians
- 
- 1982 American Federation of Clinical Research
- 1984 International Association for Breast Cancer Research
- 1985 Israel Society for Rheumatology
- 1985 **American College of Rheumatism**
- 1986 American Society of Clinical Immunology
- 1989 The World Academy of ART and Science
- 1990 European Association for Cancer Research
- 1998 European Atherosclerosis Society
- 1998 British Society of Immunology.
- 1999 European Society for Clinical Investigation.
- 2000 American Association of Immunologists (AAI).
- 2003 Member of IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases, September 23, 2003, Orlando, FL, USA.
- 2003 **Member of the IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies Minutes of the Business Meeting. USA, October 26, 2003, Orlando, FL, USA.**
2006. Member of the Steering Committee of IVRI (Israel Vaccine Research Initiative), Ben-Gurion University of the Negev, Beer-Sheva, Israel, May 2006.
2006. Member of Technical Evaluation Group. Scientific Review Administration Review Branch NIAMS Innovation Therapies for Rheum Dis. Special emphasis panel meeting ZAR EHB-HC3(2) National Institute of Arthritis & Musculoskeletal and Skin Diseases Innovative Therapy for Rheumatic and Skin Diseases RFP NIH- NIAMS – BAA 07-01, 16 October 2006, Rockville, USA.
- 2008- 2013 Member of IUIS/WHO/AF/CDC Committee for the standardization of Autoantibodies in Rheumatic and Related Diseases, Italy.
2009. Associate Member of the Slovenian Academy of Science and Arts, Ljubljana, Slovenia, May 21, 2009.
2010. New York Academy of Sciences. 01 Apr. 2010 – 31 March 2011.
2013. Member of the CHAIRS ' (Cathedras' ) committee of the Sackler Faculty of Medicine. Tel-Aviv University, Israel.

## **PRIZES AND AWARDS**

1. Fulbright Hays Grant, USA 1981. The production of human monoclonal antibodies. Boston, Mass.
2. The Baltzar WA Von Platen Foundation. The production of human-human hybridomas from patients with malignant diseases. 1984/85.
3. Award of the Slovak Society of Immunology for excellence in scientific work and humanity, Piestany , Slovakia, September 1997
4. The Kroc/McDonald award for scientific performance, U.C. Davis,CA., 1997.
5. Roy and Robert Kroc Distinguished Professor in Medicine and Immunology, University of California, Davis School of Medicine, September 4, 1997.
6. Nana Svartz award, Gutenberg, (Sweden), 23.11.1998.
7. EULAR/Abbot Abstract Award for the abstract: Catastrophic antiphospholipid syndrome (CAPS): analysis of the international Consensus statement of preliminary classification criteria for CAPS using the "CAPS Registry". Annual European Congress of Rheumatology, Lisbon 18-21 June, 2003.
8. S. Einhorn Tel-Aviv Mayor Award for Life Contribution to the Hebrew Medical Language and Literature. September 2003, Tel-Aviv, Israel.
9. The Carol Nachman Award for Rheumatology 2004, for outstanding innovative research work in the field of clinical and experimental rheumatology., Wiesbaden, Germany. 2004.
10. Honoris Causa – Pleven University, Bulgaria, 2004.
11. The Thirty-Sixth Annual Helen and Payne Whitney Lectureship: "Antiphospholipid syndrome from an infectious etiology to a systemic autoimmune disease". North Shore / LIJ University Hospital, May 26, 2005.
12. EULAR prize 2005: The infectious etiology of anti-phospholipid syndrome. Vienna, Austria, 2005.
13. Gold Medal from the Slovak Society of Physicians for Israel - Slovakia scientific collaboration. Slovakia, Piestani, 2006.
14. The Arthritis Foundation (Alabama Chapter): Outstanding Speaker Award for 2006.
15. The Nelson Professorship award for distinguished biomedical scholars, at the University of California, School of Medicine, Davis, CA. USA, 2008.
16. Honoris Causa – The Hungarian Society of Rheumatology, Budapest, Hungary, 2008.
17. Israeli Medical Association's prize for life-time contribution to Internal Medicine in Israel, 2009.
18. Master of the ACR. From the ACR - American Congress of Rheumatology, San-Diego, USA, October 2013.
19. Sodalem Honoris Causa: Honorary member, of the Slovak Society of Internal Medicine. June 2014.

## **CHAIR**

- 2003 Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel.

**MEETINGS ORGANIZER**

1. French-Israeli meeting on the production of hybridoma. Immunology Today 7:350-351, 1986.
2. The First Autoimmune Meeting in Israel - Guest speaker: David B. Stollar, 1986, Beer-Sheva. Isr J Med Sci 24:351-378, 1988.
3. The Second Autoimmune Meeting in Israel - Guest speaker: Norman Talal, 1987, Beer-Sheva. Isr J Med Sci 24:725-758, 1988.
4. XII World Congress of the Israel Medical Association, Jerusalem 16-19, 1988. Scientific Committee.
5. Israel Scientific Research Conference, Int. Symposium on multiple facets of immunoglobulin, May 10-12, Jerusalem, 1988 Scientific Committee.
6. The Third Autoimmune Meeting in Israel - Guest speaker: Donato Alarcon-Segovia, 1988, Tel-Aviv. Isr J Med Sci 25:667-705, 1989.
7. The 14th World Congress of Israel Medical Association, May 16-19, Jerusalem, 1988. (Organizing committee).
8. International Breast Cancer Research Conference. March 5-9, 1989, Tel-Aviv, Israel, (Organizing committee).
9. Xth Congress of the International Society of Hematology (European & African Division) Jerusalem, Israel, September 3-8, 1989. (Organizing committee).
10. The Fourth Autoimmune Meeting in Israel: Guest speaker: Noel Rose. 1990, Tel-Aviv. Isr J Med Sci, 26:662-698, 1990.
11. The Fifth Autoimmune Meeting in Israel: Guest speaker: Jean-Francois Bach. 1990, Tel-Aviv. Isr J Med Sci, 26:662-698, 1990.
12. International Conference on Rheumatic Diseases in Pregnancy. 17-22 May 1992. Jerusalem, Israel (Organizing committee).
13. The Six Autoimmune Meeting in Israel. Guest speaker: Georg Wick. 1992. Tel-Aviv 23.3.92 Isr J Med Sci 30: 1993.
14. Third International Congress on SLE. London 18-23 April 1992 (Organizing committee).
15. The 8<sup>th</sup> International Congress of Immunology, Budapest Hungary, August, 23-29, 1992 Autoimmunity Section.
16. The 7<sup>th</sup> Autoimmune Meeting in Israel. Guest speaker: Terry Davies. 1993 Tel-Aviv, 2.3.1993. Isr J Med Sci 30: 1994.
17. The 8<sup>th</sup> Autoimmune Meeting in Israel. Guest speaker: Eric M. Gershwin. 25.1.94. Isr J Med Sci 31: 1995.
18. The 6<sup>th</sup> Int. Congress on Anti-Phospholipid Antibodies. 14-17/9/1994, Leuven, Belgium. (Organizing committee).
19. The 9<sup>th</sup> Autoimmune Meeting in Israel. Guest Speaker: Joachim Kalden. 30/1/95. Isr J Med Sci.
20. The 4<sup>th</sup> International Congress on SLE, 20-25 March 1995, Jerusalem (President).

21. The 4<sup>th</sup> Int. Conference on Human Antibodies and Hybridoma. 26-28 April 1995, Amsterdam, The Netherland.
22. The 10<sup>th</sup> Autoimmune Meeting in Israel. Guests Speakers: Takao Koike (Japan) and James Peter (U.S.A.). 20.3.1996.
23. The 5<sup>th</sup> Int. Conference on Human Antibodies and Hybridoma. 1-5 January 1996, Jerusalem Israel (Organizer).
24. The 11<sup>th</sup> Autoimmune Meeting in Israel. Guests Speakers: Fabbrizius Fabbrizi (Italy), Graham Hughes (U.K.), Michel Kazatchkine (France), Michael Bachman (Germany). 26.3.1997.
25. The 12<sup>th</sup> Autoimmune Meeting in Israel. Guests Speakers: D. Cines (USA), G. Valessini (Italy), L. Gullevin (France). 25.3.1998.
26. The 2<sup>nd</sup> International Congress of Autoimmunity. 7-12 March 1999, Tel-Aviv, Israel.
27. The 3<sup>rd</sup> International Congress of Autoimmunity. 20-24 February, 2002, Geneva, Switzerland.
28. The 1<sup>st</sup> Tutzing Antiphospholipid Conference, 22-25 April, 2002, Tutzing, Germany.
29. 6th Dresden Symposium on Autoantibodies 4-7 September 2002, Dresden, Germany.
30. The 10<sup>th</sup> International Symposium on Antiphospholipid Antibodies, September 29 - October 3, 2002, Taormina, Sicily
31. Honoray President of Heart, Rheumatism and Autoimmunity Congress, February 2003, Milano, Italy.
32. Honoray President of I Latinamerican Congress on Autoimmunity, September 2003, Galapagos.
33. The 4<sup>th</sup> International Congress on Autoimmunity, Budapest, October 2004.
34. Singapore International Scientific Meeting on Arthritis & Rheumatology, November 2004.
35. Vaccination, Infection and Autoimmunity: Myth and Reality – VIAMR 2005, October 2005, Lausanne, Switzerland.
36. 2<sup>nd</sup> Asian Autoimmunity meeting Hong-Kong, March 2006.
37. 2<sup>nd</sup> Latino-American Congress of Autoimmunity, Rio de Janeiro, Brazil, April 2006
38. The 5<sup>th</sup> International Congress on Autoimmunity, Sorrento, Italy, November 8-12, 2006.
39. The 6<sup>th</sup> International Congress on Autoimmunity, Porto, Portugal, September 10-14, 2008.
40. The 7<sup>th</sup> International Congress on Autoimmunity, Ljubljana, Slovenia, 5-9 May 2010.
41. The 3<sup>rd</sup> Latin American Congress on Autoimmunity, July 2-5. 2010, Buenos Aires, Argentina.
42. CORA – Controversies in Rheumatology & Autoimmunity Congress. Florence, Italy, March 10-12, 2011.
43. The 8<sup>th</sup> International Congress on Autoimmunity, Granada, Spain, May 2012.
44. LACA– 4th International Congress on Antiphospholipid Antibodies and 4th Latin American Congress on Autoimmunity. Rio de Janeiro, Brazil. 18-21 September, 2013.
45. The 9<sup>th</sup> International Congress on Autoimmunity, Nice, France, March 2014.



**EDITORIAL BOARDS**

1. 1984 - Editorial member of "American Journal of Reproductive Immunology and Microbiology". (USA).
2. 1986 - Editor, "Quarterly Medical Journal", The Journal of I.M.A. World Fellowship, Mifal Haveruth Hutz - 1986 - 1990.
3. 1988 - 1997 Associate Editor, "Israel Journal Medical Sciences".
4. 1988 - Editorial member of "Viral Immunology" (USA).
5. 1989 - Editorial Board of "Human Antibodies and Hybridomas".
6. 1991 - Editorial Board of "Clinical Experimental Rheumatology".
7. 1991 - 2009 Editorial Board of "Clinical Rheumatology".
8. 1991 - Editorial Board of "The Lupus Journal".
9. 1992 - Associate Editor - Int Arch Allergy and Clin Immunology.
10. 1992 - Editorial Board of Immunologic Research.
11. 1993 - Editorial Board of Critical Reviews in Allergy.
12. 1994 - Editorial Board of Early Pregnancy Biology and Medicine.
13. 1996. Editorial Board of Les Annales de Medicine Interne - Editor - Immunopathology Section.
14. 1997. Editorial Board of J. Autoimmunity.
15. 1997. Editorial Board of Rheumatologia (Slovakia).
16. 1997. Editorial Board of the Int. Oncology.
17. 1997. Editorial Board of the APLAR Journal of Rheumatology.
18. 1999-2011 Editorial Board of European Journal of Internal Medicine.
19. 2000 Editor in chief and founder of Israel Medical Association Journal - IMAJ.
20. 2000. Editorial Board of Annals Rheumatic Diseases 2000.
21. 2000 Editor, "Harefuah", The Journal of Israeli Society of Medicine (Hebrew).
22. 2000. Editorial Board of Japanese Journal of Rheumatology.
23. 2000. Editorial Board of Autoimmunity (U.K).
24. 2000 International Advisory Board of Modern Rheumatology, The Japan Rheumatism Association.
25. 2001 Editor and founder of Autoimmunity Reviews.
26. 2001 Editorial Board of the Clinical and Experimental Medicine.
27. 2002 Editorial Board of the Osteoarthritis Today.

28. 2003-2009 Editorial Board of The Society for Experimental Biology and Medicine, USA.
29. 2003 Editorial board of Clinical Application of Immunogogy, Bulgaria.
30. 2003 Editorial board on subjects of Immunology/ Microbiology/ Virology, of Experimental Biology and Medicine, Michigan State University, USA.
31. 2003-2010 Editorial Board of The Journal of Clinical Immunology, USA.
32. 2003 Editorial Board of Immunology Letters, Prague, Czech Republic, and Amsterdam, The Netherlands.
33. 2004 Editorial Board of Joint Bone Spine, Paris, France.
34. 2004 Editorial Board of Therapy, London, UK.
35. 2004 Editorial Board of European Journal of Gastroenterology & Hepatology, London, UK.
36. 2005 Advisory Board of Nature Clinical Practice Rheumatology , UK.
37. 2005 Editorial Board of the (BJR) Journal of Rheumatology, Official Organ of Brazilian Society of Rheumatology, Sao Paulo, Brazil.
38. 2007 Editorial Board of the Journal of Clinical Immunology, California, USA.
39. 2007 International Advisory Board of the "Fondazione Umberto Di Mario" (The Foundation in memory of Umberto Di Mario, for Diabetes and Autoimmunity), University of Roma, Italy.
40. 2007 Member of the International Review Board of the Turkish Journal of Immunology.
41. 2007 Editorial Board of Clinical and Developmental Immunology, Hindawi Publishing Corporation, Cairo, Egypt.
42. 2007 Editorial Board of Journal of Molecular Medicine, Berlin-Buch, Germany.
43. 2007 Editorial Board of the Acta Reumatologica Portuguesa, Portugal.
44. 2007 Editorial Board of the Mediterranean Journal of Nutrition and Metabolism, Italy.
45. 2008 Editorial Board of Archives of Medical Science (AMS), Poznan, Poland.
46. 2008. Member of the Editorial Board of Indian Journal of Rheumatology. Official Publication of the Indian Rheumatology Association, India.
47. 2008. Member of the International Editorial Board of the Journal: MD- Medical Data, in Serbia.
48. 2009 Member of the International Editorial Board of the Revista Argentina de Rheumatologia, Buenos Aires, Argentina.
49. 2009 Member of the International Editorial Board of the Australasian Medical Journal – AMJ- European representatives.
50. 2009 Member of the Editorial Board of the European Journal of Clinical Investigation (EJCI). The official journal of European Society for Clinical Investigation (ESCI), The Netherlands.
51. 2009 Member of the Editorial Board of the Liver Disease Review Letters (LDRL), Beijing, China. ([www.wjgnet.com/LCRL/ch/index.aspx](http://www.wjgnet.com/LCRL/ch/index.aspx)).
52. 2009 Chief of the International Editorial Board of the new Immunology quarterly published by Medicina, Budapest, Hungary.

53. 2009 Member of the Editorial Board of the Medicinski Pregled – medial review published by the Medical University – Sofia, Bulgaria.
54. 2009 Member of the Editorial Board of World Journal of Hepatology (WJH), Beijing, China.
55. 2009 Member of the Editorial Board of Journal of Medicinal Food, New Rochelle, NY, USA
56. 2009 Member of the Editorial Board of the Journal *Autoimmunity Highlights*, Milano, Italy.
57. 2010 Member of the Editorial Board of **PLoS ONE** - Public Library of Science , UK.
58. 2010 Member of the Editorial Board of Journal of Geriatric Cardiology, Beijing, China.
59. 2011 Member of the Editorial Board of WJEM - World Journal of Experimental Medicine, Beijing, China.
60. 2011-2015 Member of the Editorial Board of World Journal of Clinical Pediatrics, Beijing, China.
61. 2012 Member of the Editorial Board of PeerJ (<http://PeerJ.com>).
62. 2012 Member of the Editorial Board of Datasets Papers in Medicine, a division of Hindawi Publishing Corporation. <http://mts.datasets.com/>
63. 2012 Member of the Editorial Board of BMC Medicine, London, UK.
64. 2013 Member of the Editorial Board of International Journal of Rheumatic Diseases. The official journal of the Asia Pacific League of Associations for Rheumatology. Melbourne, Australia. Email: [cs-journals@wiley.com](mailto:cs-journals@wiley.com).
65. 2013. Member of the Editorial Board of Journal of Hematology Research. PA, USA. E-mail: [publication.manager@savvysciencepublisher.com](mailto:publication.manager@savvysciencepublisher.com)
66. 2013 Member of the Editorial Board of International Journal of Celiac Disease, Romania. <http://www.sciepub.com/journal/IJCD/EditorialBoard#.UiOpA39qRkg>
67. 2013 Continue nomination as a member of the Editorial Board of *Clinical Rheumatology*. From 2013 – 2016.
68. 2013 Member of the International Advisory Board of Modern Rheumatology – Journal of Japan College of Rheumatology, Tokyo, Japan. [MR@ryumachi-jp.com](mailto:MR@ryumachi-jp.com).
69. 2014 Member of the Editorial Board of "Disaster and Military Medicine" The Journal of pre-hospital, trauma and emergency medicine. c/o BioMed Central London, United Kingdom. [\*Disaster and Military Medicine\*](#)
70. 2014 Member of the editorial Board of "Brain and Gut", Mary Ann Liebert, Inc., publishers, New Rochelle ,NY, USA. [wcuba@liebertpub.com](mailto:wcuba@liebertpub.com) , [www.liebertpub.com](http://www.liebertpub.com)
71. 2014 Academic Editor for *Medicine*. [Lippincott Williams & Wilkins](http://journals.lww.com/md-journal/pages/aboutMedicine.aspx) . Philadelphia, PA, U.S.A. <http://journals.lww.com/md-journal/pages/aboutMedicine.aspx>..
72. 2014 Associate Editor of *Recent Patents on Anti-Infective Drug Discovery*. Bentham Science Publishers. <http://www.benthamscience.com/journal/index.php?journalID=rpaidd>
73. 2014 Member of the Editorial Board of "Journal of Immune Research". Austin Publishing Group, New Jersey, USA. [immunes@austinpublishinggroup.us](mailto:immunes@austinpublishinggroup.us)

74. 2014 Member of the Editorial Board of "Human Antibodies", IOS press, Amsteream, The Netherlands.
75. 2015 Member of the Editorial Board of "Acta Rheumatologica", 483 Green Lanes, London, UK. [Acta Rheumatologica](#) .
76. 2015 Member of the Editorial Board of " Journal of Immunology Research: Open Access Journal" . Hindawi Publishing Corporation, 410 Park Avenue,15th Floor, #287 pmb, New York, NY 10022,USA . Hindawi Publishing Corporation Cairo Free Zone ,Road 5, Block E ,Nasr City, Cairo 11816 ,Egypt. <http://scirexonline.com/immune-research.html/>

#### **OTHER SCIENTIFIC ROLES**

1. Member of the Ethical Helsinki Committee, Sheba Medical Center 1990.
2. Member of the Scientific Committee of the Ela Kodesh Institute for Research in Biology of Cancer. Life Sciences Faculty, Tel-Aviv University 1993.
3. Member of Grant Committee, the Chief Scientists of the Israeli Ministry of Health 1990.
4. Member of Grant Committee, Israel Academy of Sciences. 1990.
5. Founder and the Chief Scientific Advisor to the Israeli Lupus Society.
6. Chief Advisory in Immunology - The Chief General of the Israeli Medical Forces. (IDF) 1992-
7. Member of Grant Committee - Israel Cancer Society - 1994.
8. Member of National Committee on Imaging - 1994.
9. Director - Dead Sea Works Ltd and Perio Ltd. - 1995.
10. Member of the Board of Trustee of the Israely Cancer Society-1989
11. The Medical Committee for the Israel Forum on Medicine and Halacha. Jerusalem Center for Research.
12. Chairperson of the Ethics Committee (Helsinki) for experimants of animals - 1996.
13. President of the Israel Society of Clinical Immunology and Alergy, 1998 – 2001.
14. Central Committee of the Ministry of Health for Clinical Studies to approve medical equipment, 1999-2001.
15. National Scientific Advisory Board of American Autoimmune- Related Diseases Association Int.-1999.
16. International Advisory Board member, Okayama University Graduate School of Medicine and Dentistry, Japan, October 2003.
17. Member of the Clinical Committee for Hebrew medical items in the Israeli Academy for the Hebrew Language, 2003.
18. Academic Member - The Board of Trustee of the Tel-Aviv University, 2005.
19. Ratified Academic Member (2005-2007), Board of Governors, Tel-Aviv University, 2005.
20. Scientific President AESKU.KIPP Institute. Research for Human Health. 2006.

21. Member of the International Steering Committee of the Israel Vaccine Research Initiative (IVRI), 2007.
22. Member of the World Health Organization (WHO), in the Rheumatology Working Group, within the Topic Advisory Group (TAG) for Internal Medicine that is contributing to the revision of the International Classification of Diseases (ICD) towards its 11<sup>th</sup> edition. 2009.

### **HONORARY MEMBER**

1. Honorary membership of the La Sociedad Argentina de Rheumatologia (SAR), October 1999.
2. Honorary FRCP of the Royal College of Physicians, London, UK, 2003.
3. Member of the IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies Minutes of the Buisness Meeting. Orlando, Florida, USA.
4. Honorary membership of the Hungarian Association of Rheumatology, Budapest, Hungary, 2008.

### **PATENTS**

1. Patent No. 5.562.902: Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.
2. Patent No. 5.965,130 : Immunotherapeutic method of treating cancerous diseases by administration of gamma globulins.
3. Patent No. US 6,825,319 : Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome.
4. Patent of European Patent Office No. 03725556.9-2402-IL0300424 : Method for obtaining anti-idiotypic antibodies.
5. PCT application No. PCT/IL03/00424 "Method for obtaining anti-idiotypic antibodies". Ref: 1434349.
6. Patent registration in Europe, National Phase of PCT/IL00/00600-WO01/22996: "Administration of Gamma Globulins to treat Lymphoma", in the name of: ARP Biomed Ltd. Application / Patent No. 00964595.3-2402 / 1220687 , Reference: G 1750 EP. Date: 22- 02- 07.
7. Israeli Patent Application No. 140732. Yeda Research and Development Co. Ltd. Ref.: 9814. Inventors: Miri Blank, Shmuel Cbilly, Yehuda Shoenfeld and Ephraim Katchalski-Katzir. Synthetic peptides for diagnosis and treatment of anti-phospholipid syndrome. 12-05-2008.
8. US patent application National Phase of PCT/US07/03918. Immunoglobulins from vitiligo plasma for; melanoma; therapy. Inventors: Shoenfeld Yehuda et al. AssigneeL GammaCan Ltd. US Serial No.: 12/279,495. US filling Date: August 14, 2008. International Publication Number WO 2007/095293 A2. International publication date: 23 August 2007.
9. International publication number WO 2008/137159 A1, Published date: 13 November 2008; US publication number US 2009/0053217 A1, Published date: Feb 26, 2009. Human Anti-VEGF polyclonal antibodies and uses thereof. International Patent Classification: A6IK 39/395 (2006.01).
10. US Patent Application No. 61/776,801, entitled "CITRULLINATED PEPTIDES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS".

11. "Systemic peptides and kits for diagnosis of anti-phospholipid syndrome"; Miri Blank, Shmuel Kabilly, Yehuda Shoenfeld and Ephraim Katchalski-Katzir. Number US-20050107584-A1, 19 May 2005. Yeda Research and Development. Co. Ltd. Israel Company at the Weizmann Institute of Science, Rehovot.
12. "Administration of gamma globulins to treat cancer"; Miri Blank and Yehuda Shoenfeld. Number- US 20070166313, accepted in 2007.
13. 2012; Phosphorylcholine-based agents and use thereof. At provisional state SBA/006 US Prov. App. No 61/590830.  
The invention relates to phosphorylcholine based agents and pharmaceutical compositions comprising same for the prevention and treatment of autoimmune diseases, particularly autoimmune diseases associated with pathological inflammation.
14. Nur Israel, Shoenfeld Y, Blank M. Method for obtaining anti-idiotypic antibodies. USA patent No.8450067 B2. 2013.
15. "Phosphorylcholine-based agents and use thereof". Yehuda Shoenfeld and Miri Blank. US provisional patent application number 61/760,668, identified as Attorney Docket: SBA/006 USP-1. 2013.

#### **EXTERIOR DIRECTOR IN PUBLIC COMPANIES**

1. 1995 – 2000 Dead Sea Works (DSW).
2. 2000 – 2002 Vulcan Batteries Ltd.
3. 2004 - Fertilizers & Chemicals Ltd. subsidiary company of ICL Israel Chemicals LTD.

#### **STUDENTS WHO BECAME HEADS OF DEPARTMENTS / UNITS**

- 1) Shlomo Berliner MD, Head of Internal Medicine Department at the Tel Aviv Sourasky Medical Center (Ichilov).
- 2) Mahmud Abu-Shakra MD, Head of Internal Medicine Department, Soroka Medical Center, Beer-Sheva.
- 3) Avner Reshef MD, Head of the Allergy and Clinical Immunology Unit, The Chaim Sheba Medical Center, Tel-Hashomer.
- 4) Yair Levy MD, Head of Internal Medicine F' Department, Meir Hospital, Sapir Medical Center, Kfar-Saba.
- 5) Hedi Orbach MD, Head of Internal Medicine B' Department, Wolfson Medical Center, Holon, Israel
- 6) Haward Amital MD, Head of Internal Medicine D' Department, Meir Hospital, Sapir Medical Center, Kfar-Saba
- 7) Gisele Zandman-Goddard, Head of Internal Medicine C' Department, Wolfson Medical Center, Holon.
- 8) Jacob (Kobi) George, MD. Head of the Cardiology Unit at "Kaplan Medical Center", Rehovot, Israel.
- 9) Ilan Krause, MD., Head of Department of Internal Medicine 6, Rekanati Center at Rabin Medical Center Bilinson Hospital, Petah-Tikva, Israel.
- 10) Dan Buskila, MD., Head of Department of Internal Medicine, Soroka Medical Center, Beer-Sheva, Israel.

- 11) Yaakov Berkun , MD., Head of Children Department, Hadassa Medical Center, Har-Hatzofim Campus, Jerusalem, Israel.

**STUDENTS WHO BECAME PROFESSORS**

- 1) Shlomo Berliner.
- 2) Mahmud Abu-Shakra.
- 3) George Jacob.
- 4) Ilan Krause.
- 5) Miri Blank.
- 6) Yehuda Adler.
- 7) Yaron Tomer.
- 8) Haward Amital.
- 9) Yair Levy.

**INSTRUCTION IN THESIS (MD, Basic Sciences, M.Sc.)**

1. Instruction (with Dr. Y. Shapiro) in the thesis on: "Aerobic work capacity of high school students" (by Dr. S. Kovatz, Tel-Aviv University, 1976).
2. Instruction (with Dr. Y. Shapiro) in the thesis on: "SLE survey of 40 patients" (by Dr. D. Ron, Tel-Aviv University, 1976).
3. Instruction (with Dr. Y. Shapiro, R. Rosin and Y. Drory) in the thesis: "Orthostatic examinations in amputees and spinal cord injuries" (by Dr. Y. Levy, Haifa University, 1976).
4. Instruction (with Dr. IA Pick) in the thesis on: "SLE survey of 40 patients" (by Dr. Y. Dazinger, Tel-Aviv University, 1976).
5. Instruction (with Dr. IA Pick) in the thesis on: "Multiple myeloma - A survey of 70 patients" (by Dr. A. Panush, Tel-Aviv University, 1976).
6. Instruction with (Prof. E. Sohar and Dr. Y. Shapiro) in the thesis on: "Accidental hypothermia" (by Dr. G. Keren, Tel-Aviv University, 1976).
7. Instruction (with Dr. AI Pick) in the thesis on: "Macroglobulinemia - A survey of 33 patients" (by Dr. M. Hershkovitz, Tel-Aviv University, 1976).
8. Instruction (with Dr. Y. Shapiro) in the thesis on: "Subjects prone to heat stroke" (by Dr. G. Ben-Baruch, Hadassah Medical School, The Hebrew University, Jerusalem, 1977).
9. Instruction (with Dr. AI Pick) in the thesis on: "Cryoglobulinemia: A survey of 40 patients" (by Dr. S. Berliner, Tel-Aviv University, 1977).

10. Instruction in the thesis on: "The frequency of the ear lobe sign among patients with coronary disease" (by Dr. R. Mor, Tel-Aviv University, 1977).
11. Instruction in the thesis on: "The physical fitness of the subjects and staff of the Tel-Aviv University: A survey of 1500 subjects" (by Y. Shenkar, Hadassah Medical School, The Hebrew University, Jerusalem, 1977).
12. Instruction in the thesis on: "The heart rate of Yemenite Jews and its relation to their high physical fitness" (by Dr. Y. Kazav, Tel-Aviv University, Medical school, 1977).
13. Instruction in the thesis on: "Circulatory anticoagulant among patients with true and false positive serological test for syphilis" (by Dr. S. Shaulian, Tel-Aviv University, Medical School, 1978).
14. Instruction in thesis on: "Distribution on ECG changes among 400 athletes in Israel" (by Dr. M. Oren, Tel-Aviv University, Medical school, 1978).
15. Instruction in the thesis on: "The incidence of G-I bleeding in patients with aortic stenosis" (by A. Bedezivski, Tel-Aviv University, Medical School, 1978).
16. Instruction in the thesis on: "The correlation between risk factors for cardiovascular disease among casual hypertensive men aged 50-60 years" (by Z. Eldar, Tel-Aviv University, Medical School, 1978).
17. Instruction in the thesis on: "The comparison of lying and sitting blood pressure in normotensive, borderline and hypertensive males aged 50-60 years" (by Dr. Ch. Snopkovski-Snir, Tel-Aviv University Medical School, 1978).
18. Instruction in the thesis on: "The effect of physical activity on the absolute number of white blood cells in Yemenite Jews" (by Dr. Aloni, Tel-Aviv University Medical School, 1978).
19. Instruction in the thesis on: "The efficiency of walking with backpack loads as a method for improving physical fitness" (by Dr. T. Shimoni, Hadassah Medical School, Jerusalem, 1979).
20. Instruction in the thesis on: "The humoral system in patients with Gaucher's disease" (by Dr. L. Galant, Tel-Aviv Medical School, 1979).
21. Instruction in the thesis on: "Central nervous system involvement in adult non-lymphocytic leukemia" (by Dr. M. Rotenberg, Haifa, Technion Medical School, 1979).
22. Instruction in the thesis on: "The association of hypophosphatemia with sepsis" (by Dr. S. Hager, Tel-Aviv University Medical School, 1980).
23. Instruction on the thesis on: "Hypersensitivity reaction to antibiotics in patients with infectious
24. Instruction in the thesis on: "Leukocytosis induced by corticosteroids" (by Dr. Y. Gurevitch, Tel-Aviv University Medical School, 1981).
25. Instruction in the thesis on: "The incidence of risk factors and myocardial infarction among Yemenite jews during the years 1968-1977" (by R. Shohat, Tek-Aviv University Medical School, 1981).
26. Instruction in the thesis on: "Myeloid leukemias and monoclonal gammopathy" (by B. Ayalon, Tel-Aviv University Medical School, 1982).
27. Instruction in the thesis on: "Labor induced leukocytosis in Yemenite Jews" (by Dr. Shindel, Tel-Aviv University Medical School, 1983).
28. Instruction in the thesis on: "Leukocytosis associated with malignant diseases" (by A. Tal, Tel-Aviv University Medical School, 1983).
29. Instruction in the thesis on: "Sepsis and leukocyte counts in Tel-Aviv University Medical School, 1983).



30. Instruction in the thesis on: "Detection of dominant idiotypes of anti-DNA antibodies in sera of patients with monoclonal gammopathies" (by O. Ben-Yehuda, Tel-Aviv University Medical School, 1984. (cum laude).
31. Instruction in the thesis on: "Detection of dominant idiotypes of anti-DNA antibodies in sera of patients with drug induced lupus" (by Y. Wilner, Hadassah Medical School, Jerusalem, 1984).
32. Instruction in the thesis on: "Detection of dominant idiotypes of anti-DNA antibodies in sera of patients with autoimmune conditions" (by Y. Messinger, Tel-Aviv University Medical School, 1984).
33. Instruction in the thesis on: "Detection of anti-histones antibodies in drug-induced lupus-correlation with clinical and serological parameters" (by A. Borenstein, Tel-Aviv University Medical School, 1984).
34. Instruction in the thesis on: "Monoclonal anti-tuberculosis antibodies with DNA antibodies react with M. tuberculosis" (by D. Shaul, Tel-Aviv University Medical School, 1984). (cum laude).
35. Instruction in the thesis on: "Detection of anti-histones antibodies in SLE patients and their first degree relatives" (by G. Segol, The Technion Medical School, Haifa, 1985).
36. Instruction in the thesis on: "Detection of anti-histone antibodies in autoimmune diseases" (by G. Segol, Technion Medical School, Haifa, 1985).
37. Instruction in the thesis on: "Detection of common anti-DNA idotype (16/6 Id) in the sera of patients with infection with Klebsiella and active tuberculosis" ( by O. Sela, Tel-Aviv University Medical School, 1985). (cum laude).
38. Instruction in the thesis on: "Cross-reaction between pneumococcal antigens on DNA, shown by human monoclonal anti-pneumococcal antibody" (by G.J. Gardin, Tel-Aviv University Medical School, 1986).
39. Instruction in the thesis on: "The cross-reaction of monoclonal immunoglobulins from monoclonal gammopathies with anti-DNA activity with mycobacterial antigens" (by D. Buskila, Basic Sciences, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1986).
40. Instruction in the thesis on: "The detection of anti-nuclear antibodies in normal populations: The analysis of genetic preponderance" (by E. Tauber, Basic Sciences, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1986).
41. Instruction in the thesis on: "Detection of a common anti-DNA idotype in the sera of patients with uveitis" (by I. Hundret, Basic Sciences, Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1986).
42. Instruction in the thesis on: "The detection of lupus band test and anti-nuclear antibodies in normal families" (by I. Avinoach, Basic Sciences, Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1986).
43. Instruction in the thesis on: "The significance of common anti-DNA idotype" (by D. Murowitz, M.D. Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1986).
44. Instruction in the thesis on: "The production of human monoclonal antibodies, anti-idiotypic antibodies and the study of idotype immune regulation" (by R. Bakimer M.Sc. student), Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1987).
45. Instruction in the thesis on: "Anti-histones antibodies and their subfractions in chronic autoimmune liver disease" (by Ch. Swissa, M.D. student, Ben-Gurion University of the Negev, Beer-Sheva, 1988).
46. Instruction in the thesis on: "Autoantibodies in different types of uveitis" (by Dr. I. Klemperer, Basic Sciences, Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1988).
47. Instruction of the thesis on: "Induction of anti-phospholipid syndrome" (by Y. Cohen, Basic Sciences, Sackler School of Medicine, Tel-Aviv University, 1991).

48. Instruction in the thesis on: "Idiotypes of anti-phospholipid antibodies" (by I. Krause, Basic Sciences, Sackler School of Medicine, Tel-Aviv University, 1991).
49. Instruction in the thesis on: "Autoimmunity in melanoma" (by I. Shelkowitz, Basic Sciences, Sackler School of Medicine, Tel-Aviv University, 1991).
50. Instruction in the thesis on: "Prevention of anti-phospholipid syndrome" (by O. Inbar, Basic Sciences, Sackler School of Medicine, Tel-Aviv University, 1992).
51. Instruction in the thesis on: "Silicone induced autoimmune disease", (by Eran Bar-Meir, Hadassah Medical School, Jerusalem) 1993/1994.
52. Instruction in the thesis on: "Titer of diagnostic antibodies in sera of patients with melanoma activity and therapeutic indexes", (Ofer Merimsky), Thesis for Master, Tel-Aviv University, 1995.
53. Instruction in the thesis on: "Pathogenic role of anti-endothelial cell autoantibodies" (Eyal Grunbaum), Thesis for Master, Tel Aviv University, 1997.
54. Instruction in the thesis on: "Evaluation of heart valve in the antiphospholipid syndrome (Libman-Sacks endocarditis)" (Dr. Roni Manor), M.D. Thesis, Tel Aviv University, 1997.
55. Instruction in the thesis on: "The role of antiphospholipid and anti-oxLDL autoantibodies in the prediction of restenosis following percutaneous transluminal coronary angioplasty (PTCA)", M.D. Thesis, Tel Aviv University, 1998.
56. Instruction (with Dr. Dror Harats) in the thesis on: "Magnesium fortification of drinking water suppresses atherogenesis in male LDL-receptor deficient mice" (Yaniv Sherer, MD student), as part of the requirements for acquisition of MD degree by Sackler Faculty of Medicine, Tel-Aviv University, 2000.
57. Instruction (with Dr. Miri Blank) in the thesis on: "Anti-prothrombin antibodies, atherosclerosis and thrombosis. Is there any relationship?" (Haj-Yahia Salim, Dept. of cardiac surgery in Sheba Medical Center), as basic science research, 2001.
58. Instruction (with Dr. Miri Blank) in the thesis on: "The effect of different diets on experimental APS in mice". (Dr. Manor Ron, Gynecology Dept., Asaf-Harofe Medical Center, Zrifin), as basic science research., 2001.
59. Instruction in the thesis on: "Characteristics of 46 epileptic patients with anti phospholipids syndrome" (Shaul Lev M.D., Dept of Medicine E, Rabin Medical Center Kampus Beilinson, Petah-Tikva and Dept of Medicine B and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hasomer), as basic science research, 2001.
60. Instruction (with Dr. Miri Blank) in the thesis on: "The effect of IVIG" on bleomycin induced pulmonary fibrosis in mice". (Vered Molina, M.D. Thesis, Tel Aviv University, 2002), as basic science research.
61. Instruction in the thesis on the subject of: "The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders" Maya Ram, Technion, Israel Institute of Technology, Haifa, Israel, 2008).
62. Instruction in the thesis on: "Neuropsychiatric manifestations induced by lupus autoantibodies", Master's degree Thesis, Faculty of Life-Science, Tal Sapir (Ben-Ziv) Bar-Ilan University, 2008.
63. Instruction (with Prof. Miri Blank) in the thesis on: Vitamin D effect on activation of endothelial cells mediated by antiphospholipid antibodies", as basic science research (Dr. Maya Glazer, Kaplan Medical Center, Children's Department, 2011).
64. Instruction in the thesis on: Is Parkinson's disease an autoimmune disease. (published). Michal Benkler, Medicine Faculty - Ben Gurion University. MD thesis 2008 – 2010.
65. Instruction in the thesis on: Vitamin D levels in patients with autoimmune thyroid diseases (published). Michael Zisapel. Sackler School of Medicine, Tel-Aviv University. 2009 – 2010.
66. Instruction in the thesis on: Geography and autoimmunity among healthy and diseased subjects. (published). Yinon Shapira. Sackler School of Medicine, Tel-Aviv University. 2009 – 2011.

67. Instruction in the thesis on: Toxoplasma Gondii and autoimmune diseases (published). Shaul Katzn. Sackler School of Medicine, Tel-Aviv University. 2010 – 2011.
68. Instruction in the thesis on: The role of vitamin-D in Sjogren's syndrome. (published). Inga Efes, Sackler School of Medicine, Tel-Aviv University. 2010 – 2011.
69. Instruction in the thesis on: Infections agents in PBC. Tal Shilton, Sackler School of Medicine, Tel-Aviv University. 2010 – 2012.
70. Instruction in the thesis on: The role of vitamin-D in inflammatory myopathies. Toi Teman, Sackler School of Medicine, Tel-Aviv University. 2010 – 2013.
71. Instruction in the thesis on: The prevalence of autoantibodies in primary biliary cirrhosis. Sara Sella, Medicine Faculty – Technion, Israel Institute of Technology, Haifa. 2008 – 2013.
72. Instruction in the thesis on: Infections and Sjogren Syndrome. Omer Tehori, Sackler School of Medicine, Tel-Aviv University. 2011 – 2014.
73. Instruction in the thesis on: Infections and Sjogren Syndrome. Omer Tehori, Sackler School of Medicine, Tel-Aviv University. 2011 – 2014.
74. Instruction in the thesis on: The association of anti-RO and anti-LA antibodies with Infectious agents in various autoimmune diseases. Yogev Peri, Sackler School of Medicine, Tel-Aviv University. 2012– present.
75. Instruction in the thesis on: Vitamin D in PBC. Ron Kopilov, Sackler School of Medicine, Tel-Aviv University. 2013.
76. Instruction in the thesis on: Anti phospholipids profiles as a marker of APS subtypes. Ilan Volkov., Sackler School of Medicine, Tel-Aviv University. 2013 – 2014. Arrow head project.

#### **INSTRUCTION OF MASTER AND PhD STUDENTS**

1. Ronit Bakimer(PhD) - Idiotype of human antibodies in autoimmune conditions and malignant states. Faculty of Health and Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 1988-1993.
2. Lea Ziporen(PhD) - Systemic aspects of experimental APS. Tel-Aviv University - 1993 - 1996.
3. Ofer Merimsky - Titer of antibodies in sera of patients with melanoma as a diagnostic and prognostic parameter. Master in Internal Medicine and Basic Sciences, Tel-Aviv University, Sackler Faculty of Medicine - 1994.
4. Orli Kozero(Master) - T cell line anti-phospholipids and human anti- $\beta_2$ GP-I antibodies - 1995.
5. Smadar Garbet(PhD) - The employment of the Cellscan to detect the autoantigens in rheumatoid arthritis. PhD, Tel - Aviv University 1996.
6. Pnina Keren(PhD) - Atherosclerosis as an autoimmune disease. PhD, Tel-Aviv University.
7. Sonja Praprotnik, PhD thesis on the subject of: Anti-endothelial cell antibodies in TTP: microvascular or macrovascular. (Ljubljana, Slovenia) 1999.
8. Sonja Praprotnik, PhD thesis on the subject of: Specificity and pathogenic significance of anti-endothelial cell antibodies against microvascular and macrovascular endothelial cells. (Ljubljana, Slovenia) 2000-2001.
9. Yossi Borenstein, thesis for Master on the subject of "Medical Buffoonery in hospitals and its influence on hospitalized children", Lesely University, 2003.
10. Instruction in the thesis on: "The role of acquired and innate autoantibodies in autoimmune diseases". Solodcev Inna, Ph.D. Tel Aviv University, 2008.

11. Solodaiv Inna PhD thesis 2002 – 2007, Subject: Immunomodulation of experimental fibrosis Sackler School of Medicine, Tel-Aviv University.
12. Moran Cohen Msc thesis. Subject: Phosphorylcholin as an immunomodulator for experimental lupus. Sackler School of Medicine, Tel-Aviv University, 2010.

### **LETTERS TO THE EDITOR**

1. Shoenfeld Y, and Udassin, R. Heart diseases and physical fitness in Yemenite Jews. Harefuah 94:349, 1973.
2. Shoenfeld Y, and Sheinberg A. Hypophyseal insufficiency due to metastases of breast carcinoma in males. Harefuah 84:301-302, 1973.
3. Shoenfeld Y, Pick AI, and Dnaziger Y. Tests for syphilis in patients with SLE. New Eng J Med 296:451, 1977.
4. Shoenfeld Y, Berliner S, Eldar M, Segenreich E, Asherov J, and Pinkhas J. Simultaneous appearance of testicular and nasopharyngeal lymphoma. S Afr Med J 54:469, 1978.
5. Asherov J, Shoenfeld Y, and Pinkhas J. Bone pains in chronic myelomonocytic leukemia treated by cytosine arabinoside. Ann Rheum Dis 37:298-299, 1978.
6. Eldar M, Aderka D, Shoenfeld Y, Livni E, and Pinkhas J. Aspirin induced aplastic anemia. S Afr Med J 55:318, 1979.
7. Shoenfeld Y, Shaklai M, Livni E, and Pinkhas J. Thrombocytopenia from acetaminophen. New Eng J Med 383:47, 1980.
8. Berliner S, Shoenfeld Y, Dean H, Avisar R, and Pinkhas J. Central vein thrombosis in a patient with primary pulmonary hypertension. Amer Heart J 100:134, 1980.
9. Shoenfeld Y, and Pinkhas J. Leukopenia and incidence of myocardial infarctions. New Eng J Med 304:1606, 1981.
10. Berliner S, Shoenfeld Y, Weinberger A, and Pinkhas J. Idiopathic mixed cryoglobulinemia in two sisters. Acta Haematol. 65:219-220, 1981.
11. Dean H, Berliner S, Shoenfeld Y, and Pinkhas J. Warfarim treatment during pregnancy in patients with prosthetic valves. Acta Haematol 66:65-66, 1981.
12. Shoenfeld Y, Berliner S, and Pinkhas J. Aggressive plasma cell myeloma. Acta Haematol 68:160-161, 1982.
13. Shoenfeld Y. Leukopenia: Idiopathic or drug induced - how to differentiate. New Eng J Med 307:251, 1982.
14. Shoenfeld Y, Shaklai M, Ben-Baruch N, Hirschorn M, and Pinkhas J. Neutropenia induced by hypercarotenemia. Lancet 1:1259, 1982.
15. Shoenfeld Y, and Isenberg D. Transient monoclonal gammopathy in hydralazine induced lupus erythematosus. Brit Med J 1:224, 1983.
16. Isenberg DA, Shoenfeld Y. Anti-DNA antibody idiotypes in SLE. Lancet 2:821, 1984.
17. Isenberg DA, Shoenfeld Y. Comments on the article by Crains et al. Arthritis Rheum 29:1438-1439, 1986.
18. Sperber AD, Shoenfeld Y. Arthralgia associated with hypercarotenemia. J Rheumatol 15:151-152, 1988.
19. Huminer D, Tomer Y, Pitlick S, Shoenfeld Y. Autoantibodies in cancer patients. Are they tumor related or age related? Autoimmunity 1991.
20. Leibovitch L, Levy Y, Shoenfeld Y: Pancreatitis induced by clarithromycin. Ann Int Med 125: 701. 1996.
21. Bar-Dayan Y, Amital H, Levy Y, Shoenfeld Y: Low dose aspirin and secondary myocardial infaction. Isr J Med Sci 32: 789 - 790, 1996.
22. Shoenfeld Y: T cell help and antiphospholipid antibody immunogenesis (letter). Arthritis Rheumat 40: 196-197, 1997.
23. Shoenfeld Y: Finding a valid model for antineutrophil cytoplasmic antibody-related vasculitis. Letter (comment). Arthritis Rheum 5: 986-987;1997.
24. Portugese S, Amital H, Tenenaum A, Bar-Dayan Y, Levy Y, Afek A, Shemesh J, Shoenfeld Y: Clinical characteristics of ruptured chordae tendinae in hospitalized patients: primary tear versus infective endocarditis ( Letter). Clin Cardiol ; 21: 813-816, 1998.

25. Levy Y, Sherer Y, George J, Fabbri F, Shoenfeld Y. Use of intravenous immunoglobulin in idiopathic membranous nephropathy. *Int Med* 38; 11: 917, 1999.
26. Adler Y, Finkelstein Y, Guindo J, Rodriguez De La Serna A, Bayes -Genis A, Bayes De Luna A, Shoenfeld Y, Sagie A, Spodick DH. Recurrent pericarditis as a manifestation of familial mediterranean fever. *Circulation* 101: E71-72, 2000.
26. Gerli R, Bartolono B, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjogren's syndrome – role of dyslipidamia. *Rheumatology* 45: 1581-1582, 2006.
27. 1441. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: Tuberculosis and splenectomy as possible triggering factors? Another example of the "Mosaic" of autoimmunity. Letter to the Editor, *The Journal of Rheumatology* 35:6: 1224 - 1227, 2008.
28. 1672. Shoenfeld Y. Letter to the Editor: HPV vaccines and autoimmune diseases. *J Intern Med* 2012; 272: 98.
29. 1793. Konikoff T, Konikoff F.M, Shoenfeld Y. Letter to the Editor: Israel–Gaza conflict. *The Lancet* 2014. [www.thelancet.com](http://dx.doi.org/10.1016/S0140-6736(14)61298-8) Published online August 1, 2014. [http://dx.doi.org/10.1016/S0140-6736\(14\)61298-8](http://dx.doi.org/10.1016/S0140-6736(14)61298-8)
30. Kivity Shaye, Yehuda Shoenfeld. Comment on the article by Lauvsnes et-al. *Arthritis Rheumatology* 2015. DOI 10.1002/art.39077.

### **HONORARY PROFESSORSHIP**

1. Immunological Society of Slovakia, 1998.
2. Visiting Professor (Gostujoci Profesor) Medical School of Lubljana, Slovenia, 1998.
3. Honorary professorship in Old Herborn University (Theology Seminar) Herborn, Germany, 1999.
4. Honorary Professorship, Faculty of Medicine, University of Lublijana, Slovenia (Plechnik Honorary), 1999.
5. Honorary Membership of the Argentinean Society of Rheumatology (S.A.R.), 2002.
6. Honorary Membership of the Mexican Association of Rheumatology, (Miembro Honorario de Colegio Mexicano de Reumatologia, A.C.), 2003.

### **BOOKS**

1. Shoenfeld Y. The Skin and the Body (Hebrew). Akademon, The Hebrew University, Jerusalem, 1976. pp 400.
2. Shoenfeld Y, Shapiro Y, Bar-Chama A. Physical Activity and Health. (Hebrew). Akademon, The Hebrew University, Jerusalem, 1977. pp. 380.
3. Pick AI, Shoenfeld Y. Clinical Immunology: Diseases with Defects in the Humoral System. (Hebrew). Akademon, The Hebrew University, Jerusalem, 1979. pp 400.
4. Shoenfeld Y. Scientific Editor. Living Well. (Hebrew). Yediot Aharonoth Pub. Tel-Aviv, 1979. pp. 167.
5. Shoenfeld Y, Berliner S. Medicines and You. (Hebrew). Yediot Aharonoth Pub. Tel-Aviv, 1979. pp 207.
6. Shoenfeld Y, Berliner S. Textbook of Physical Fitness. (Hebrew). Wingate Institute., Ministry of Education, Natanya, 1979. pp. 177.
7. Shoenfeld Y, Berliner S. Biological, Biochemical and Health Aspects in Physical Education. (Hebrew). Ministry of Education, The Hebrew University, Jerusalem, 1979. pp. 128.
8. Shoenfeld Y. Cancer: Vital Information for all. (Hebrew). Yediot Aharonoth Pub. Tel-Aviv, 1980. pp. 240.

9. Shoenfeld Y, Bar-Chama A, Shuman E. The Israeli Fitness Strategy. Morrow Pub. New-York (English) 1981. pp. 260.
10. Shoenfeld Y. Arthritis (Hebrew). Yediot Aharonoth Pub. Tel-Aviv, 1982. pp. 271.
11. Shoenfeld Y, Berliner S. Internal Medicine. Zerikover Inc. Tel-Aviv, (Hebrew) 1983. pp. 287.
12. Shoenfeld Y. Scientific Editor - Encyclopedia - The Human Body. (Illustrated) 20 volumes (Hbrew Edition). Yediot Aharonoth, 1986.
13. Shoenfeld Y. Scientific Edition - "Publish or Perish" - A guide for research planning and scientific article writings. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 1986, pp. 244.
14. Zehavi I, Shoenfeld Y, Isenberg DA. The Heart in Health and Diseases. (Hebrew). Hakibutz Hameuchad, Tel-Aviv, 1988. pp. 360.
15. Shoenfeld Y, Isenberg DA (authors). The Mosaic of Autoimmunity. (English). Elsevier, Holland 1989, pp. 523.
16. Zimlichman R, Shoenfeld Y. Hypertension. (Hebrew). Yediot Aharonoth Pub. pp. 339.
17. Shoenfeld Y, Isenberg DA. Natural Autoantibodies: Their Physiological Role and Regulatory Significance. CRC Press. 2000 Boca Raton Florida, USA, 33431.
18. Shoenfeld Y, Goldwasser B. Good Trip. A Directory for Travellers. Hebrew, 1992.
19. Peter JB, Shoenfeld Y (Editors): Autoantibodies. Elsevier, Amsterdam, The Netherlands, pp. 1 - 880, 1996.
20. Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Editors). The Antiphospholipid Syndrome. CRC Press, Inc, 2000 Corporate Blvd., N.W., Boca Raton, Florida 33431, U.S.A.
21. Special Editor: Israel Journal of Medical Sciences. Beilinson 60th Anniversary. Rabin Medical Center, 1st Anniversary 1936-1996, Vol. 32 no. 12 1996.
22. Hebrew Translation of **Harrison's** Principles of Internal Medicine, 13<sup>th</sup> edition. Editor and Scientific advisor: Shoenfeld Y. McGraw-Hill, Diunon, 1996.
23. Shoenfeld Y, Bar-Dayan Y. (authors). The Complete Guide for Signs Symptoms and Diseases. (Hebrew) pp. 1-377, 1996. Prolog Pub., Tel-Aviv, Israel.
24. George K, Shoenfeld Y (authors). Diseases of the Joints. (Hebrew) pp. 1-64, 1995. Prolog Pub., Tel-Aviv, Israel.
25. George K, Shoenfeld Y (authors). Hypertension. (Hebrew) pp. 1-64, 1995. Prolog Pub., Tel-Aviv, Israel.
26. Amital H, Shoenfeld Y (authors). The Immune System. (Hebrew) pp. 1-95, 1996. Prolog Pub., Tel-Aviv, Israel.
27. Lorber M, Aharon A, Shoenfeld Y (authors). Systemic Lupus Erythematosus (Hebrew) Prolog Pub., Tel-Aviv, Israel, pp. 1-86, 1997
28. Zimlichman R, Shoenfeld Y (authors). Treatment of Hypertension (Hebrew) Prolog Pub., Tel-Aviv, Israel. pp. 1-70, 1997.
29. Shoenfeld Y, Kennedy R, Ferrano S. (Editors). Idiotypes in Medicine: Autoimmunity, Infectious Diseases and Cancer. Elsevier Publ. Amsterdam, The Netherlands pp. 1-500, 1997.

30. Conrad K, Humbel R.L., Meurer M, Shoenfeld Y, Tan E.M. (Editors). Pathogenic and Diagnostic Relevance of Autoantibodies. Report on the 4<sup>th</sup> Dresden Symposium on Autoantibodies held in Dresden on October 21-24, 1998. 450 pp. PABST science Pub. Berlin, Germany, 1998.
31. Shoenfeld Y. (Editor). The Decade of Autoimmunity. Elsevier Publ Amsterdam, The Netherlands. pp. 1-500, 1999.
32. Hebrew Translation of **Harrison's** Principles of Internal Medicine, 14<sup>th</sup> edition. Editor and Scientific advisor: Shoenfeld Y. McGraw-Hill, Diunon, 2000.
33. Shoenfeld Y, Gershwin Eric M. (Editors). Cancer and Autoimmunity. Elsevier Publ. Amsterdam- Lausanne- New York- Shannon- Singapore-Tokyo; The Netherlands, pp. 1 - 446, 2000.
34. Conrad K, Humbel R.L., Meurer M., Shoenfeld Y, Tan E.M. (Editors). Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity. Report on the 5<sup>th</sup> Dresden Symposium on Autoantibodies held in Dresden on October 18-21. 2000. pp: 1-766, PABST science Pub. Berlin, Germany.
35. Shoenfeld Y, Harats D, Wick G. (Editors). Atherosclerosis and Autoimmunity. Elsevier Publ. Amsterdam- Lausanne- New York- Shannon- Singapore-Tokyo; The Netherlands, pp. 1 - 370, 2001.
36. Shoenfeld Y. Autoimmune Diseases – "Shooting on our forces". Galey Zahal – Transmitted University. Ministry of Defence Publication. 2011. pp. 1- 94.
37. Asherson RA, Cervera R, Piette JC, Shoenfeld Y. (Editors). The Antiphospholipid Syndrome II , Autoimmune Thrombosis. Elsevier Publ. Amsterdam- The Netherlands, pp 1-457, 2002
38. Conrad K, Fritzler M, Meurer M, Shoenfeld Y, (Editors). From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies (Report of the 6<sup>th</sup> Dresden Symposium on Autoantibodies Sept. 4-7, 2002). PABST Science Pub. , Germany, pp. 1-700, 2002.
39. Shoenfeld Y, Zandman-Goddard G. (Authors). Autoimmune Diseases "The Enemy from Within". Published by Bio-Rad Laboratories, pp. 1-83, 2003.
40. Sherer Y, Shoenfeld Y, (Authors). Antiphospholipid Syndrome. (Hebrew). Ramot - Tel-Aviv University Publ. pp. 1-64, 2004.
41. Ferencik M, Rovensky J, Shoenfeld Y, Matha V. (Editors). Imunity system – dobry obranca, ale aj mozny diverzant. (Slovakian). Vydanie prve. Vydal SAP – Slovak Academic Press Publ, Bratislave, Slovakia, pp: 1-273, 2004.
42. K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld (Editors). From animal models to human genetics: research on the induction and pathogenicity of autoantibodies. Report on the 7<sup>th</sup> Dresden symposium on autoantibodies, September 1-4, 2004. Pabst Science Publishers, Germany, pp: 1-610, 2004.
42. Yehuda Shoenfeld, Noel R. Rose (Editors). Infection and Autoimmunity. Elsevier Publ. Amsterdam- The Netherlands, pp 1-747, 2004.
43. M. Eric Gershwin, Yehuda Shoenfeld (Editors). Autoimmunity Concepts and diagnosis at the cutting edge. Annals of the New York Academy of Sciences, V volum 1050, 2005.
44. Yehuda Shoenfeld, M. Eric Gershwin (Editors). Autoimmune Diseases and Treatment, Organ-specific and systemic disorders. Special issue of Annals of the New York Academy of Sciences, Volum 1051, 2005.
45. Yehuda Shoenfeld, M. Eric Gershwin (Editors). Autoimmunity, Part D. Autoimmune Diseases, Annus Mirabilis. Annals of the New York Academy of Sciences, Volum 1108, 2007.
46. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y. Shoenfeld, A.S. Wiik (Editors). From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on

autoantibodies held in Dresden on September 12-15,2007. Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publishers, Germany.

47. Shoenfeld Y (Editor). The Israeli Medical Encyclopedia, 10 volumes, written by 1200 physicians. Yediot Achronot Publisahers, pp. 2370, 2007.
48. Sherer Y, Shoenfeld Y (Editors). Autoantibodies Guide in Systemic Lupus Erythematosus. Published by: Bio-Rad Laboratories. 2007.
49. Shoenfeld Y, Gershwin ME, Meroni PL (Editors). Autoantibodies 2<sup>nd</sup> Edition. Elsevier Publ. Amsterdam-The Netherlands, pp 1-838, 2007.
50. Shoenfeld Y, Cervera R, Gershwin M.E. Diagnostic Criteria in Autoimmune Diseases. Humana Press, Springer Science + Business Media, LLC, USA. pp 1-593, 2008.
51. Conrad K, Chan EKL, Fritzler MJ, Humbel RL, von Landenberg P, Shoenfeld Y (Editors). From pathogenesis to therapy of autoimmune diseases. Report on the 9<sup>th</sup> Dresden Symposium on Autoantibodies held in Dresden on September 2-5, 2009. PABST Science Publishers, 49525 Lengerich, Germany. Pp 1-568, 2009.
52. Shoenfeld Y, M Eric Gershwin (Editors). Contemporary challenges in autoimmunity. Annals of the New York Academy of Sciences, Volume 1173. Blackwell Publishing on behalf of the New York Academy of Sciences Boston, Massachusetts, 2009.
53. K Conrad, E.K.L. Chan, M.J Fritzler, R.L. Humbel, P. von Landenberg, Y. Shoenfeld (Editors). From Pathogenesis to therapy of autoimmune diseases. Report on the 9<sup>th</sup> Dresden Symposium on Autoantibodies, held in Dresden on September 2-5, 2009. Autoantigens, Autoantibodies, Autoimmunity Volume 6 – 2009. PABST Science Publishers, pp: 1-568.
54. Shoenfeld Y, Youinou P, Gershwin EM. (Guest Editors). The environment geoeidemiology and autoimmune diseases. Elsevier Publ. Amsterdam- The Netherlands. Printed in the UK and The Netherlands. 2010.
55. Shoenfeld Y, Agmon-Levin N. (Guest Editors). New Pearls on CTDs. In: Best KPractice & Research Clinical Rheumatology, Volume 26, No.1, February 2012. pp. 1-157. Elsevier Publ.
56. Shoenfeld Y, Tincani A, Gershwin ME (Guests Editors). Gender sex hormones pregnancy and autoimmunity. This is a compilation of Separate Special Issues of Journal of Autoimmunity (Vol. 38/2.3) and Autoimmunity Reviews (Vol.11/6.7), 2012, pp. 1-544. Published for the 8<sup>th</sup> International Congress on Autoimmunity, Granada, Spain, 2012. Elsevier Publ.
57. Shoenfeld Y. Meroni P.L. (Editors). The General Practice Guide to Autoimmune Diseases. PABST Science Publishers, Lengerich. 2012; pp. 1-331.
58. Yehuda Shoenfeld, Pier Luigi Meroni, and Ricard Cervera (Editors). E-book: Immunotherapeutic Agents for SLE. 93 pages. February, 2012 Copyright © 2012 Future Medicine Ltd doi: 10.2217/9781780840529 eISBN.
59. Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y (Editors). "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361
60. Juan Manuel Anaya, Yehuda Shoenfeld, Adrian Rojas-Villarraga, Roger A. Levy, Ricard Cervera (Editors). Autoimmunity from bench to bedside. El Rosario University Press, Bogota, Colombia. PP. 1-839, 2014.

#### **CHAPTERS IN BOOKS**

1. Sohar E, Shoenfeld Y. Medicine and medical forces. In: Israel Army and Defence (Hebrew). Editors: Schiff Z, Haber E and Bitan Z. Modan 1976.



2. Shapiro Y, Sohar E, Magazanik A, Shoenfeld Y. Sweat studies in patients with plantar hyperhidrosis. (Chapt 71). In: Selected Topics in Environmental Biology. Editors: Bhatia B, China GS, Singh B, 1975. pp. 453-454.
3. Shoenfeld Y, Shapiro Y. I. Adjustment to the climatic conditions in the cold dessert. pp. 128-133. II. Cold injuries in the dessert. In: The Dessert-Past, Present and Future. Editor: Sohar E, Reshafim, Tel-Aviv (Hebrew), 1977.
4. Sohar E, Shoenfeld Y, Shapiro Y. The climate, condition and way of life in the Jordan Valley Judea and Samaria (Hebrew). Editors: Shmueli A, Grossman D and Zeevi R. Onaan, Jerusalem.
5. Shoenfeld Y, Sohar E, Ohry A, Shapiro Y. Cardiovascular and pathophysiological effects of the sauna. In: Internal Medicine: Topics. Editors: Louhija A and Valtonen V. Karger S. New-York, 1977. pp. 322-330.
6. Shvartz E, Meroz A, Magazanik A, Shoenfeld Y. An assessment of exercise and heat orthostatism. In: Physical Fitness Assessment: Principles, Practices and Application. Editors: Shepard RJ and Lavallee A. Charles C Thomas, Springfield, Ill. 1978. pp. 102-110.
7. Shoenfeld Y, Schwartz RS. Hamatologic manifestations of SLE. In: The Clinical Management of Systemic Lupus Erythematosus. Editor: Peter H. Schur, Grune & Stratton, N.Y. 1983. pp. 123-137.
8. Shoenfeld Y, Schwartz RS. The production of monoclonal atnibodies by human-human hybridomas: Their application to studies of autoimmune diseases. In: Human Hybridomas and Monoclonal Antibodies. Editors: E.G. Engelman et al. Plenum Press N.Y. 1985. pp. 247-260.
9. Shoenfeld Y, Schwartz JA, Schwartz RS, Stollar BD. Anti-DNA Antibodies in: Systemic Lupus Erythematosus. Editor: M. Lahita. Academic Press, N.Y. 1986.
10. Keydar I, Tsarfaty I, Smoradinsky N, Sahar E, Shoenfeld Y. Human monoclonal antibodies directed against MuMTV antigens from human breast cancer cells. In: New Experimental Modalities in the Control of Neoplasia. Editor: P. Chandara. Plenum Press, 1987.
11. Shoenfeld Y, Tomer Y, Ben-Yehuda O. Treatment of autoimmune diseases: New modalities. In: Prospective on Autoimmunity. Editor: IR Cohen. CRC Press, USA, 1987.
12. Shoenfeld Y. Analyses of anti-DNA idiotypes. In: Perspective on Autoimmunity. Editor: IR Cohen. Academic Press, 1987.
13. Shoenfeld Y, Cohen IR. Infection and autoimmunity. In: The Antigens, Editor: M. Sela. Academic Press, 1987. pp. 307-325.
14. Isenberg DA, Shoenfeld Y, Schwartz RS. The importance of the study of monoclonal antibodies in SLE. In: SLE. Editor: Smolen JS & Zielinski CC. Springer-Verlag, Berlin, 1987.
15. Shoenfeld Y, Tsarfaty I, Smoradinsky N, Keydar I. In vitro immunization of PBL with HuMTV, and the production of human MAbs reacting with MMTV and HuMTV. In: In vitro Immunization in Hybridomas. Science Pub. Amsterdam, 1988.
16. Smoradinsky N, Tsaarfaty I, Ghendler Y, Argov S, Bakimer R, Krup M, Shoenfeld Y. Human monoclonal antibodies directed against viral antigens. In: Breast Cancer: Scientific and Clinical Progress. Editors: Rice MA, Hagen JL, Lopez DN. Kluwes Academic Pub. N.Y. USA. 1988, pp. 174-184.
17. Amital-Teplizki H, Shoenfeld Y. The human anti-DNA idiootype (16/6 idiootype). In: Monoclonal Antibodies, Cytokines and Arthritis. Editor: Kresina TF. Marcel Dekker, New-Yrok, 1991. pp. 435-464.
18. Shoenfeld Y. Ageing and autoimmunity: lesosns learnt from the presence of autoantibodies in patient with malignant conditions. In: Immunotherapy with Intravenous Immunoglobulins. Editor: P. Imbach. Academic Press. 1991. pp. 307-318.

19. Abu-Shakra M, Shoenfeld Y. Chapter 15. Chronic infection and autoimmunity. In: Molecular Immunobiology of Self - Reactivity. Editors: Bona CA, Kaushik AK. Marcel-Dekker. Inc. New-York 1992, pp. 284-313.
20. Alkan M, Shoenfeld Y. BCG. In: Encyclopedia of Immunology. Editor: Roitt I. Academic Press. N.Y. USA 1992. pp. 221-222.
21. Assali A, Shoenfeld Y. Benign familial neutropenia. In: Genetic Diversity Among Jews: Diseases and Markers at the DNA Level. Editors: Bone-Tamir B, Adan A. Oxford University Press N.Y. 1992. pp. 267-274.
22. Shoenfeld Y. Autoimmunity and autoimmune diseases like SLE. In: Systemic Lupus Erythematosus (2nd Ed) Editor: R.G. Lahita. Churchill Livingstone. N.Y. USA, 1992. pp. 1-14.
23. Buskila D, Shoenfeld Y. Anti-DNA antibodies. In Idem. pp. 205-206.
24. Tomer Y, Shoenfeld Y. Idiotypes, antinuclear antibodies anti-idiotypes and autoimmunity. In: Enfermedades Autoinmunes del Tejido Conectivo. Editors: Kamashta MA, Font J, Hughes GRV. Ediciones Doyma, Madrid, Spain. 1992. pp. 29-41.
25. Cohen J, Bakimer R, David N, Shoenfeld Y. Early pregnancy loss and the anti-phospholipid syndrome. In: Implantation and Early Pregnancy in Humans. Editors: Barnea F, Check JH, Grudzinskas JG, Maruo T. The Parthenon Pub. Group. New-York, USA. 1993, pp. 333-355.
26. Buskila D, Shoenfeld Y. Experimental models of SLE. In: The Kidney in Collagen Vascular Diseases. Editors: Grishman E, Churg J, Needle MA, Venkatasehan VS. Raven Press 1993. pp. 5-22.
27. Ehrenfeld M, Shoenfeld Y. Hematology and Oncology in Rheumatology. Chapter 1.3.8. In: Oxford Textbook of Rheumatology. Editors: Maddison PJ, Isenberg DA, Woo P, Glass DN. Oxford University Press, Oxford U.K. 1993. pp. 154-163.
28. Buskila D, Shoenfeld Y. Anti-DNA idiotypes: Their pathogenic role in autoimmunity. In: Concept in Immunopathology Clinical and Molecular Aspects of Autoimmune Diseases 8:85-114, 1993.
29. Buskila D, Shoenfeld Y. Manipulation of anti-DNA idiotypes: A possible treatment approach to autoimmune disease. In: Concept Immunopathol Clin and Molec Aspects of Autoimmune Dis. 8:114-128, 1993.
30. Shoenfeld Y. Idiotypic induction of autoimmune diseases: In: The Impact of Biotechnology on Autoimmunity. Eds: Dalgleish AG, Albertini A, Paoletti R. Kluwer Academic Pub. 1994. pp. 73-80.
31. Mozes E, Shoenfeld Y. Experimental systemic lupus erythematosus: Role of the idiotypic network. In: Autoimmune Disease Models: A Guidebook. Editors: Cohen IR, Miller A. Academic Press Inc. USA. pp. 245-253, 1994.
32. George J, Shoenfeld Y: Actin autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 10-12, 1996.
33. Youinou P, Maran R, Dueymes M, Shoenfeld Y: Autoantibody subclasses. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 103 - 108, 1996.
34. Lorber M, George J, Shoenfeld Y: Hidden Autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 357 - 363, 1996.
35. Abu-Shakra M, Buskila D, Shoenfeld Y: Idiotypes and anti-idiotypic antibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 408 - 416, 1996.
36. George J, Shoenfeld Y: Natural autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 534 - 539, 1996.
37. Cervera R, Shoenfeld Y: Pathogenic mechanisms. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 607- 617, 1996.

38. Fishman P, Merimsky O, Baharav E, Shoenfeld Y: Tyrosinase autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 842 - 845, 1996.
39. Guest Editor: Shoenfeld Y: "The dead sea: A source of life" therapeutic and economic potential. Special issue of the Isr J Med Sci: 1996 Vol 32(Suppl).
40. Shoenfeld Y, Ehrenfeld M: Hematologic Manifestations. In: The Clinical Management of Systemic Lupus Erythematosus (SLE). (2<sup>nd</sup> Ed.). Editor: Peter H. Schur. Lippincott-Raven, N.Y., U.S.A., pp. 95-108, 1996.
41. Abu-Shakra M, Buskila D, Shoenfeld Y: Idiotypes and anti-idiotypes. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 53-65, 1997.
42. Buskila D, Abu-Shakra M, Shoenfeld Y: Idiotypes and anti-DNA antibodies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 75-89, 1997.
43. Dayan YB, Amital H, Shoenfeld Y: Idiotypes of anti-Ro and anti-La. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 95-99, 1997.
44. Bakimer R, Shoenfeld Y: Idiotypes of anti-phospholipid antibodies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 119-129, 1997.
45. Abu-Shakra M, Buskila D, Shoenfeld Y: Idiotypes of platelet associated antibodies (autoimmune thrombocytopenia). In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 165-169, 1997.
46. Buskila D, Abu-Shakra, Shoenfeld Y: Manipulation of autoantibody idiotypes in autoimmune diseases. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 203-215, 1997.
47. Merimsky O, Fishman P, Shoenfeld Y: Cancer therapy with anti-idiotypic antibodies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Editors: Yehuda Shoenfeld, Ron Kennedy, Soldano Ferrone. Pub. Elsevier, pp. 407-417, 1997.
48. Levy Y, George J, Langewitch P, Lorber M, Bar-Dayan Y, Gilburd B, Zandman-Goddard G, Fabbrizzi F, Shoenfeld Y: Novel aspects of IVIG treatment in autoimmune diseases. In: Proceedings of the XIX ILAR Congress of Rheumatology. 456-458, Singapore, 8-13 June, 1997.
49. Shoenfeld Y: Autoantibodies - antigen driven or idiotypically induced. In Proceeding of the XIX ILAR Congress of Rheumatology. 230-233, Singapore, 8-13 June, 1997.
50. Shoenfeld Y, Buskila D: Animal models for systemic lupus erythemathosus. In: Proceedings of the XIX ILAR Congress of Rheumatology. 186-187, Singapore, 8-13 June, 1997.
51. Shoenfeld Y, Blank M, Ziporen L: Animal models for antiphospholipid syndrome (APS). In: Proceeing of the XIX Ilar Congress of Rheumatology , 420-423, Singapore, 8-13 June, 1997.
52. Ehrengeld M, Pras M, Shoenfeld Y. Is familial mediterranean fever an autoimmune disease or an immune mediated condition? In: Familial Mediterranean Fever. Sohar E, Gafni J, Pras M (Eds.) Freund Publishing House Ltd., London, 267-278, 1997.
53. Abu-Shakra M, Buskila D, Shoenfeld Y. Introduction – Idiotypes and Anti-idiotypes. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Keneddy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.53-63.

54. Buskila D, Abu-Shakra M, Shoenfeld Y. Idiotypes of Anti-DNA Antibodies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.75-88.
55. Bar Dayan Y, Amital H, Shoenfeld Y. Idiotypes of Anti-Ro and Anti-La. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.95-97.
56. Bakimer R, Shoenfeld Y. Idiotypes of Anti-Phospholipid Antibodies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.119-128.
57. Abu-Shakra M, Buskila D, Shoenfeld Y. Idiotypes of Platelet Associated Antibodies (Autoimmune Thrombocytopenia). In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. pp.189-192.
58. Abu-Shakra M, Buskila D, Shoenfeld Y. Idiotypes of Natural Autoantibodies and Monoclonal Gammopathies. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.193-203.
59. Buskila D, Abu-Shakra M Shoenfeld Y. Manipulation of Autoantibody Idiotypes In Autoimmune Diseases. In: Idiotypes in Medicine Autoimmunity, Infection and Cancer. Eds: Shoenfeld Y, Kennedy RC, Feronne S. Elsevier, Amsterdam, The Netherlands, 1997. Pp.227-238.
60. Ehrenfeld M, Shoenfeld Y: Chapter 1.3.8 Oncology and Haematology. in: Oxford Textbook of Rheumatology (Maddison et al – Eds). Oxford University Press, 1998, Oxford U.K. pp. 288-298.
61. Tinkani A, Shoenfeld Y. Animal models of Anti-Phospholipid Syndrome. in: Reumatologia V Teorii a Praxi V. Eds: Josef Rovenski. 1998: pp. 217-227. Vydavatelstvo Osveta. Banska Bystrica. Slovakia.
62. George J, Alkan M, Shoenfeld Y. BCG In: Encyclopedia of Immunology. Editor I Roitt, P. Delves. Academic Press. USA. p. 335-336, 1998.
63. Shoenfeld Y, Shere Y, The idiotypic network in autoimmune diseases – Induction and Treatment. pp. 124-134 in: Pathogenic and Diagnostic Relevance of Autoantibodies. Eds: Conrad K, Humbel RL, Member M, Shoenfeld Y, Tan & N.
64. Amital H, Shoenfeld Y, Autoimmunity and autoimmune Diseases such as SLE. In: Systemic Lupus Erythematosus, Ed: R.G.Lahita, Academic Press San-Diego, USA pp. 1-16, 1998.
65. Sherer Y, Bar-Dayan Y, Shoenfeld Y. The Dual Relationship Between Thymectomy and Autoimmunity: The Kaleidoscope of Autoimmune Disease. Sudhir paul, University of Texas/Houston Medical Scholl, Houston, TX. pp. 1-448, 1998.
66. Blank M, Ziporen L, Krause L, Shoenfeld Y. Immunomodulation of Experimental Antiphospholipid Syndrome: Lessons from Murine Models. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 81-84, 1999.
67. Shoenfeld Y, Cervera R. Innovations in Autoimmunity in the Last Decade. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 7-18, 1999.
68. Merimsky O, Shoenfeld Y, Fishman P. A Focus on Anti-Tyrosinase Antibodies in Melanoma and Vitiligo. In: The Decade of Autoimmunity: (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 261-268, 1999.
69. Zurgil N, Gerbat S, Langevitz P, Tishler M, Ehrenfeld M, Kaufmann M, Deutsch M, Shoenfeld Y. Detection of Cellular Activity in Autoimmune Disorders by the Cellscan System. In: The Decade of Autoimmunity: (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 295-304, 1999.
70. Barak V, Shoenfeld Y. Cytokines in Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 313-322, 1999.

71. Buskila D, Abu-Shakra M, Shoenfeld Y. Prolactin and Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 339-346, 1999.
72. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus and Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 355-364, 1999.
73. George J, Shoenfeld Y. Introduction: The immune system, the autoimmune state and autoimmune disease. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 1-18, 2000.
74. Abu-Shakra M, Buskila D, Shoenfeld Y. Rheumatoid arthritis and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 19-30, 2000.
75. Abu-Shakra M, Buskila D, Shoenfeld Y. SLE and Cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 31-40, 2000.
76. Aron-Maor A, Shoenfeld Y. PSS (Scleroderma) and Cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 45-48, 2000.
77. Tishler M, Shoenfeld Y. Paraneoplastic Syndromes. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 121-132, 2000.
78. Tomer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 141-150, 2000.
79. Sherer Y, Shoenfeld Y. Thymoma and autoimmune diseases. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 249-252, 2000.
80. Prindiville T.P., Cantrell M.C., Shoenfeld Y, Gershwin E.M. Apoptosis: The relation between anti-fas antibodies, and immunosurveillance against cancer and autoimmunity. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 1-19, 2000.
81. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus, autoimmunity and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 285-298, 2000.
82. George J, Shoenfeld Y. The smoking - cancer - autoimmunity connection. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 309-316, 2000.
83. Buskila D, Abu-Shakra M, Shoenfeld Y. Anti-idiotypic in autoimmunity. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 365-378, 2000.
84. Blank M, Krause I, Shoenfeld Y. The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome. In: "Hughes Syndrome Antiphospholipid syndrome (Ed: M.A. Khamashta) Springer Publ : 379-385, 2000.
85. Blank M, Krause I, Shoenfeld Y. Molecular mimicry: lessons from experimental models of systemic lupus erythematosus and antiphospholipid syndrome. (Chap. 16) in: Molecular Mimicry, Microbes, and Autoimmunity. (Editors: M.W. Cunningham, R.S. Fujinami), 2000, ASM Press, Washington, D.C. pp. 223-233.
86. Fishman P, Shoenfeld Y. Intravenous immunoglobulin (IVIg) as an inhibitor of tumor growth: from autoimmunity to cancer. (Chap. 13 ) in: Old Herborn University Seminar Monograph. (Editors: Peter J. Heidt, Volker D. Rusch, Dirk Van Der Waaij), 2001, Herborn Litterae, pp:93-107.
87. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin (IVIg) in autoimmune diseases - expanding indications and increasing specificity. (Chap. 13 ) in: Old Herborn University Seminar Monograph. Editors: Peter J. Heidt, Volker D. Rusch; Dirk Van Der Waaij, 2001, Herborn Litterae, pp:85-91.

88. Shoenfeld Y, Haratz D, Wick G. Introduction: autoimmunity an additional 'risk factor' for atherosclerosis. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 1-2, 2001.
89. Goldkorn T, George J, Lavrentiadou S.N., Ravid T, Tsaba A, Shoenfeld Y, Haratz D. Ceramide pathway and apoptosis in autoimmunity and atherosclerosis. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 55-72, 2001.
90. Watkins S.M., German G.J., Shoenfeld Y, Gershwin E. Lipid and immunity. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 87-111, 2001.
91. Shoenfeld Y, George J, Sherer Y, Haratz D. Atherosclerosis: evidence for the role of autoimmunity. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 139-142, 2001.
92. Matsuura E, Kobayashi K, Kasahara J, Shoenfeld Y, Koike T. Oxidized autoantigens in atherosclerosis. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 143-150, 2001.
93. Sherer Y, Blank M, Vaarala O, Shaish A, Shoenfeld Y. Anti-prothrombin antibodies in thrombosis and atherosclerosis. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 185-190, 2001.
94. Zurgil N, Levy Y, Gilburd B, Trubiankov E, Deutch M, Shagran Y, Shoenfeld Y. Detection of cellular activity in atherosclerosis by the novel cellscan system. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D. and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 191-200, 2001.
95. Meroni PL, Raschi E, Testoni C, Riboni M, Praprotnik S, Shoenfeld Y. Functional heterogeneity of pathogenic anti-endothelial cell antibodies. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D. and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 211-220, 2001
96. Rauova L, Chapman J, Shoenfeld Y. Brain vasculitis and antiphospholipid syndrome. In: Brain disease therapeutic strategies and repair. Publication: Martin Dunitz; pp: 193-200, 2001.
97. Shoenfeld Y, Blank M. Infectious origin of antiphospholipid syndrome. In: From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies (Report of the 6th Dresden Symposium on Autoantibodies Sept. 4-7, 2002). K Conrad, M. Fritzler, M. Meurer, U. Sack, Y Shoenfeld (Editors). PABST Science Pub. , Germany, 2002, pp: 149-160.
98. Blank M, Sherer Y, Shoenfeld Y. Autoantibodies associated with reproductive failure. In: From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies (Report of the 6th Dresden Symposium on Autoantibodies Sept. 4-7, 2002). K Conrad, M. Fritzler, M. Meurer, U. Sack, Y Shoenfeld (Editors). PABST Science Pub. , Germany, 2002, pp: 300-313.
99. Blank M, Sherer Y, Shoenfeld Y. Novel perspectives in the treatment of the antiphospholipid syndrome - from anticoagulation to immunomodulation. In: The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: p. 421, 2002
100. Shere Y, Shoenfeld Y. Antiphospholipid antibodies in human and murine atherosclerosis. In: The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 137-141, 2002.
101. Zandman-Goddard G, Blank M, Shoenfeld Y. Antiphospholipid antibodies and infections-drugs. In: The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 343-358, 2002

102. Asherson RA, Cervera R, Piette JC, Shoenfeld Y. Milestones in the antiphospholipid syndrome. In: *The Antiphospholipid Syndrome II: Autoimmune Thrombosis*. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 3-9, 2002.
103. Shoenfeld Y, Sherer Y, Blank M. Systemic involvement in the antiphospholipid syndrome: lessons from animal models. In: *The Antiphospholipid Syndrome II: Autoimmune Thrombosis*. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 101-106, 2002.
104. Ehrenfeld M, Amital H, Shoenfeld Y. Cytokines, Th1/Th2 and adhesion molecules in the antiphospholipid syndrome. In: *The Antiphospholipid Syndrome II: Autoimmune Thrombosis*. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 107-112, 2002.
105. Abu-Shakra M, Shoenfeld Y. Lessons from monoclonal antiphospholipid antibodies. In: *The Antiphospholipid Syndrome II: Autoimmune Thrombosis*. Asherson RA, Cervera R, Pietter JC, Shoenfeld Y. (Editors). Elsevier Publ. Amsterdam, The Netherlands: pp. 113-118, 2002.
106. Chapman J, Shoenfeld Y. Neurological and Neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. In: *Neuroendocrine immune basis of the rheumatic diseases II*. Cutolo M, Bijlsma J W.J, Lahita R G, Masi A T, Straub R H, Bradlow L (Editors) *Annals of the New York Academy of Sciences*, Volume 966, 2002.
107. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin as therapy for RA. In: *Targeted Therapies in Rheumatology*. Josef S Smolen, Peter E Lipsky (Editors). Martin Dunitz; Taylor & Francis Group, London and New York, 2003.
108. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin as an immunomodulatory agent in systemic lupus erythematosus and lupus nephritis. In: *Intravenous Immunoglobulins in the Third Millennium*. Marinos C Dalakas, Peter J Spath (Editors). The Parthenon Publishing Group. pp. 357, 2003.
109. Krause I, Shoenfeld Y. Intravenous immunoglobulin for fibrosis, atherosclerosis and malignant conditions. In: *Intravenous Immunoglobulins in the Third Millennium*. Marinos C Dalakas, Peter J Spath (Editors). The Parthenon Publishing Group. pp. 361, 2003.
110. Sherer Y, Pauletto P, Shoenfeld Y. Atherosclerosis and autoimmunity. In: *The Heart in Systemic Autoimmune Diseases*, volume 1. Andrea Doria, Paolo Pauletto (Editors). Roland A. Asherson (Series Editor). Elsevier Publ. Amsterdam, The Netherlands: pp. 89-95, 2003.
111. Rattazzi M, Shoenfeld Y, Pauletto P. Innate Immunity, inflammation, and atherogenesis. In: *The Heart in Systemic Autoimmune Diseases*, volume 1. Andrea Doria, Paolo Pauletto (Editors). Roland A. Asherson (Series Editor). Elsevier Publ. Amsterdam, The Netherlands: pp. 77-88, 2003.
112. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: *Systemic LUPUS Erythematosus 4<sup>th</sup> edition*. Robert G. Lahita (Editor), Elsevier Publication, Amsterdam, The Netherlands) pp. 3-27, 2004.
113. Amital H, Shoenfeld Y. The etiopathogenesis of autoimmunity. In: "Stem cell therapy for autoimmune disease". Eds: Richard K. Brut & Alberto M. Marmont. Laandes Bioscience Georgetown, Texas, USA, pp: 106-112, 2004
114. Blank M, Shoenfeld Y. Autoimmune pregnancy loss – experimental models. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 71-84, 2004.
115. Blank M, Nur I, Meidler R, Bar L, Slutzki L, Gilburd B, Shoenfeld Y. Peptide mimetics of anti-dsDNA idiotypes as a tool for Lupus-specific IVIG preparation: specificity and efficacy in the treatment of experimental SLE. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds:

K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, p: 106, 2004.

116. Meroni PL, Shoenfeld Y. Receptors of the innate immunity as targets for circulating autoantibodies: antiphospholipid syndrome as a paradigm. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 118-125, 2004.
117. Inagaki J, Kondo A, Lopez LR, Shoenfeld Y, Matsuura E. Anti-laminin-1 autoantibodies in reproductive failure: animal and human studies. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 243-252, 2004.
118. Zandman-Goddard G, Blank M, Langevitz P, Pras M, Levy Y, Witte T, Doria A, Rovinsky J, Shoenfeld Y. Elevated anti-serum amyloid component P (SAP) antibodies in SLE patients correlate with disease activity. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 259-260, 2004.
119. Matsuura E, Kobayashi K, Shoenfeld Y, Lopez LR. Atherogenic role of protein-modified oxidized low-density lipoproteins and their autoantibodies. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 388-405, 2004.
120. Marai I, Shoenfeld Y. Autoantibodies and recurrent miscarriages. In: "From animal models to human genetics: research on the induction and pathogenicity of autoantibodies" report on the 7<sup>th</sup> Dresden symposium on autoantibodies September 1-4, 2004, Eds: K.Conrad, M.P. Bachmann, E.K.L. Chan, M.J.Fritzler, R.L.Humbel, U.Sack, Y.Shoenfeld. Pabst Science Publishers, Germany, pp: 406-421, 2004.
121. Shoenfeld Y, Rose NR. Introduction: Infection and Autoimmunity. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam The Netherlands, pp:1-4,2004.
121. Aron Maor-A, Shoenfeld Y. Vaccination and autoimmunity. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 105-116, 2004.
122. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 171-179, 2004.
123. Severin M.C., Shoenfeld Y. Parvovirus B19 infection and its association to autoimmune disease. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 181-188, 2004.
124. Abu Shakra M, Shoenfeld Y. Parasitic infection and autoimmunity. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 439-448, 2004.
125. Blank M, Eosemsteom M, Asherson RA, Cervera R, Shoenfeld Y. The infectious origin of the antiphospholipid syndrome. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 473-490, 2004.
126. Zandman-Goddard G, Shoenfeld Y. SLE and infections. In: Infection and Autoimmunity. Yehuda Shoenfeld & Noel R. Rose (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 491-503, 2004.
127. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. In: AIDS vaccines and related topics, 2004. Aldar S. Bourinbaiar (Editor). Immunitor Corporation Co., Ltd , Thailand, 2004.



128. Tsabari R, Chapman J, Shoenfeld Y, Schwammenthal Y. asculitides – miscellaneous vasculitides. In: Neurologic involvement in systemic autoimmune diseases, volume 3. Doruk Erkan, Steven R. Levine (Editors). Elsevier Publ. Amsterdam- The Netherlands, pp: 217-227, 2004.
129. Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atheros and malignant conditions. In: Adoptive Immunotherapy Methods and Protocols. Burkhard Ludewig & Matthias W. Hoffmann (Editors). Humana Press, Totowa, New Jersey, pp: 403-408, 2004.
130. Tishler M, Shoenfeld Y. BCG vaccination, autoimmunity and bladder cancer. In: Progress in Bladder Cancer Research. A.M. Mallory (Editor). Horizons in Cancer Research Vol. 6 ISBN 1-59454-129-9 NOVA science Publishers, Inc., pp.: 147-153, 2005.
131. Tishler M, Shoenfeld Y. Vaccines and autoimmunity. In: The Autoimmune diseases 4<sup>th</sup> Ed. Noel R. Rose & Ian R. Mackay (Editors). Elsevier Publ. Amstersan – The Netherlands, pp: 309 – 316, 2005.
132. Meroni PL, Mondini M, Airo P, Riboldi P, Shoenfeld Y, Gariglio M, Landolfo S. The human interferon-inducible protein IFI16: a mediator of inflammation and a target for autoimmunity. In: From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on autoantibodies held in Dresden on September 12-15,2007. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y Shoenfeld, A.S. Wiik (Editors). Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publishers, Germany, pp. 210-215.
133. Sherer Y, Shoenfeld Y. Anti-phospholipid antibodies as predictors of autoimmune disease manifestations. In: From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on autoantibodies held in Dresden on September 12-15,2007. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y Shoenfeld, A.S. Wiik (Editors). Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publishers, Germany, pp. 370-377.
134. Shoenfeld Y. Prediction of autoimmunity – more than just autoantibodies. In: From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on autoantibodies held in Dresden on September 12-15,2007. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y Shoenfeld, A.S. Wiik (Editors). Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publishers, Germany., pp. 2-5.
135. Shoenfeld Y. Toubi E. Protective autoantibodies: Role in homeostasis, clinical importance and therapeutic potential. In: From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on autoantibodies held in Dresden on September 12-15,2007. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y Shoenfeld, A.S. Wiik (Editors). Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publishers, Germany, pp. 62-76.
136. Szyper Kravitz M, Shoenfeld Y. Clinical and pathological significance of autoantibodies against protective molecules. In: From Etiopathogenesis to the prediction of autoimmune diseases: Relevance of autoantibodies, report on the 8<sup>th</sup> Dresden symposium on autoantibodies held in Dresden on September 12-15,2007. K. Conrad, E.K.L Chan, M.J. Frizler, U. Sack, Y Shoenfeld, A.S. Wiik (Editors). Autoantigens, Autoantibodies, Autoimmunity Volume 5- 2007. Pabst Science Publisher, Germany, pp. 131-140.
137. Blank M, Praprotnik S, Shoenfeld Y. Systemic vasculitis autoantibodies targeting endothelial cells. In: Endothelial Biomedicine. William C Aird (Editor). Cambridge University Press. 2007. pp: 1411.
- 137a Twig G, Sherer Y, Blank M, Shoenfeld Y. Antiphospholipid syndrome – pathophysiology. In: Recurrent Pregnancy Loss causes, controversies and treatment. Howard JA Carp (Editor). Informa Healthcare, 2007. pp: 285.
138. Papageorgiou N.P, Shoenfeld Y. Autoantibodies in gastrointestinal autoimmune diseases. In: Handbook of Systemic Autoimmune Diseases. Josep Font, Manuel Ramos-Casals and Juan Rodes (Editors). Elsevier B.V. 2008. Volume 8 Chapter 17.

139. Peeva E, Zandman-Goddard G, Shoenfeld Y. Gender bias in murine lupus. In: Handbook of Systemic Autoimmune Diseases. Series Editor: Ronald A. Asherson..Endocrine Manifestations of systemic autoimmune diseases. Edited by: Sara E, Walker & Luis J. Jara. 2008. Volume 9; Chapter 3. pp: 21-27.
140. Carp HJA, Ornoy A, Shoenfeld Y. Autoantibodies and infertility in autoimmune diseases. In: Handbook of Systemic Autoimmune Diseases. Series Editor: Ronald A. Asherson..Endocrine Manifestations of systemic autoimmune diseases. Edited by: Sara E, Walker & Luis J. Jara. 2008. Volume 9; Chapter 14. pp: 157-172.
141. Arnson Y, Amital H, Shoenfeld Y. The immunoendocrine role of Vitamin D in autoimmunity. In: Handbook of Systemic Autoimmune Diseases. Series Editor: Ronald A. Asherson..Endocrine Manifestations of systemic autoimmune diseases. Edited by: Sara E, Walker & Luis J. Jara. 2008. Volume 9; Chapter 26. pp: 293 – 299.
142. Rohan Willis, Yehuda Shoenfeld, Silvia S. Pierangeli, Miri Blank. What is the Origin of Antiphospholipid Antibodies? D. Erkan, S.S. Pierangeli (Editors). In: Antiphospholipid Syndrome Insights and Highlights from the 13<sup>th</sup> International Congress on Antiphospholipid Antibodies. Springer Publication, 2012. Part II pages: 23- 40.
- 142a. Maurizio Cutolo, M. Plebani, Yehuda Shoenfeld, Luciano Adorini, Angela Tincani. Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases. Chapter 14 in Book: Vitamins and Hormons Vol. 86, Elsevier Publ. 2011; ISSN 0083-6729, DOI: 10.1016/B978-0-12-386960-9.00014-9.
143. Michal Solomon, Yehuda Shoenfeld, Gisele Zandman-Goddard. Task force report on non-criteria manifestations: Skin. D. Erkan, S.S. Pierangeli (Editors). In: Antiphospholipid Syndrome Insights and Highlights from the 13<sup>th</sup> International Congress on Antiphospholipid Antibodies. Springer Publication, 2012. Part III pages: 235 – 246.
144. Zolta ´n Szekanecz, Gy¶orgy Kerekes, and Yehuda Shoenfeld. Chapter 26: Anti-Inflammatory Therapeutic Approaches. PP. 513-528. In book: G. Wick and C. Grundtman (eds.), Inflammation and Atherosclerosis, DOI 10.1007/978-3-7091-0338-8\_26, # Springer-Verlag/Wien 2012.
145. Miri Blank, Tomer Bashi, Yehuda Shoenfeld. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Chapter 18 pp. 353-361, in book: Human monoclonal antibodies. Editor: Michal Steinitz. PP. 1-364, Humana Press, 2013.
146. Moran Landau Rabbi, Ilan Ben-Zvi, Nancy Agmon-Levin, Yehuda Shoenfeld. Environment, immune dysfunction, and systemic lupus erythematosus. Chapter 8 pp. 193-213, in book: Immunotoxicity, immune dysfunction, and chronic disease. Editors: Rodney R. Dietert and Robert W. Luebke. PP. 1- 451. Humana Press 2012.
147. Perricone C, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Chapter No. 1/1 in book: "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". Editors: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y. 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361.
148. Borella E, Shoenfeld Y. Vitamin D in infection and autoimmunity. Chapter No. 1/4 in book: "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". Editors: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y. 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361.
149. Rosario C, Shoenfeld Y. The hyperferritinemic syndrome in infection and autoimmunity. Chapter No. 1/6 in book: "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". Editors: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y. 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361.
150. Blank M, Jordan L, Bashi T, Shoenfeld Y. Harnessing parasitic infection to treat autoimmunity. Chapter No. 2/23 in book: "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". Editors: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y. 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361.

151. Gilburd B, Agmon-Levin N, Martins T, Petzold A, Matthias T, Shoenfeld Y. HELIOS, a bright future for ANA – automated indirect immunofluorescence (IIF) assay. Chapter No. 6.2/90 in book: "Infection, Tumors and Autoimmunity. Report on the 11th Dresden Symposium on Autoantibodies held in Dresden on September 1-4, 2013". Editors: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Steiner G, Shoenfeld Y. 2013 Pabst Science Publishers, 49525 Lengerich. PP.1-361.
152. Anaya JM, Rojas-Villarraga A, Shoenfeld Y. From the mosaic of lautoimmunity to the autoimmune tautology. Chapter No. 14 in book: "Autoimmunity from bench to bedside", Editors: Juan Manuel Anaya, Yehuda Shoenfeld, Adrian Rojas-Villarraga, Roger A. Levy, Ricard Cervera.El Rosario University Press, Bogota, Colombia. PP. 1-839, 2014.
153. Arango MT, Shoenfeld Y, Cervera R, Anaya JM. Infection and autoimmune diseases. Chapter No. 19 in book: "Autoimmunity from bench to bedside", Editors: Juan Manuel Anaya, Yehuda Shoenfeld, Adrian Rojas-Villarraga, Roger A. Levy, Ricard Cervera.El Rosario University Press, Bogota, Colombia. PP. 1-839, 2014.
154. Blank M, Israeli E. Gertel S. Amital H, Shoenfeld Y. Molecular mimicry in autoimmunity and vaccination Chapter No. 21 in book: "Autoimmunity from bench to bedside", Editors: Juan Manuel Anaya, Yehuda Shoenfeld, Adrian Rojas-Villarraga, Roger A. Levy, Ricard Cervera.El Rosario University Press, Bogota, Colombia. PP. 1-839, 2014.
155. Zandman Goddard G, Shoenfeld Y. Intravenous Immunoglobulin customized therapy. Chapter No. 41 in book: "Autoimmunity from bench to bedside", Editors: Juan Manuel Anaya, Yehuda Shoenfeld, Adrian Rojas-Villarraga, Roger A. Levy, Ricard Cervera.El Rosario University Press, Bogota, Colombia. PP. 1-839, 2014.
156. Soriano A, Blank M, Shoenfeld Y. Genetics and origin of antiphospholipid syndrome. Chapter No. \_\_\_\_ in book: "Antiphospholipid antibody syndrome. From bench to bedside". Editor: Pierre Luigi Meroni. Springer publication. PP. 1-263, 2014.

#### **ARTICLES (Over 33,000 citations until 2013)**

1. Shoenfeld Y, Ehrenfeld NA, Fried A. Osteogenesis imperfecta. Harefuah 83:319-322, 1972.
2. Shoenfeld Y, Schreibman S, Pick AI. AFP in embryonal cell carcinoma of the testis. Harefuah 85:163-165, 1973.
3. Shoenfeld Y, Sclerovsky S. T wave changes in urticaria. Harefuah 85:359-362, 1973.
4. Shoenfeld Y, Pick AI, Frohlichman R, Schriebman S. Non-secretory multiple myeloma. Harefuah 86:540-543, 1974.
5. Shoenfeld Y, Shapiro Y, Harel O. Adjustment to climatic conditions of the Sinai desert. Harefuah 87:452-454, 1974.
6. Shoenfeld Y, Sclerovsky S. Patterns of T wave changes in ECG in urticaria. Brit J Derm 90:283-288, 1974.
7. Pick AI, Shoenfeld Y, Schriebman S, Frohlichman R, Pinkhas J. Multiple myeloma: A study of 40 patients. Isr J Med Sci 10:1371-1378, 1974.
8. Pick AI, Shoenfeld Y. IgA-heavy chain (alpha chain) disease. Harefuah 87:77-79, 1974.
9. Pick AI, Shoenfeld Y. Treatment of multiple myeloma. Harefuah 86:558-560, 1974.
10. Shoenfeld Y, Schreibman S, Pick AI. AFP in testicular carcinoma. Urol Int 30:162-171, 1975.

11. Shoenfeld Y, Shapiro Y. Hyperhidrosis palmaris and plantaris. Harefuah 88:184-185, 1975.
12. Shoenfeld Y, Shapiro Y. Neurocirculatory asthenia. Harefuah 89:414-416, 1975.
13. Shoenfeld Y, Pick AI. Lymphocyte, plasma cell and the immune response. Harefuah 88:466-474, 1975.
14. Shoenfeld Y, Shapiro Y, Fischer BK, Dvoretzky I. Sweating in the "adhidrotic type" of congenital ectodermal dysplasia. Dermatology 180:277-282, 1975.
15. Shoenfeld Y, Fried A, Ehrenfeld EN. Osteogenesis imperfecta: Review of the literature and presentation of 29 cases. Amer J Dis Child 129:679-694, 1975.
16. Pick AI, Shoenfeld Y, Schreiberman S, Weiss C, Ben-bassat M. AFP assay, significance and clinical application. Ny St J Med 27:1403, 1975.
17. Liberman P, Shoenfeld Y. Malignant hyperthermia. Harefuah 89:120-131, 1975.
18. Shapiro Y, Shoenfeld Y. Methods in investigating physical fitness. Harefuah 88:578-579, 1975.
19. Pick AI, Shoenfeld Y, Schreiberman S, Frohlichman R, Pinkhas J. The effectiveness of melphalan in multiple myeloma. Modern Medicine 5:117, 1975.
20. Shoenfeld Y, Koren G, Shapiro Y. Physiology and pathophysiology of exposure to cold. Harefuah 90:124-128, 1976.
21. Shoenfeld Y, Shapiro Y, Koren G. Superficial cold lesions. Harefuah 90:229-231, 1976.
22. Shoenfeld Y, Zohar E, Ohry A, Shapiro Y. Heat stress: Comparison of short exposure to wet and dry saunas. Arch Phys Med Rehab 57:126-131, 1976.
23. Shoenfeld Y, Kurchin A, Shapiro Y, Machtiger A, Adar R. Phenomena associated with sympathectomy following hyperhidrosis. Harefuah 90:309-311, 1976.
24. Shoenfeld Y. B lymphocyte activation. Harefuah 90:578-581, 1976.
25. Shoenfeld Y, Pick AI, Schreiberman S, Kessler H, Dintzman M. Alpha-feto-protein in a 3 year old child with hepatoma. Tumori 62:43-50, 1976.
26. Shoenfeld Y, Shapiro Y, Machtiger A, magazanik A. Sweat studies in hyperhidrosis palmaris and plantaris. Dermatologica 152:257-263, 1976.
27. Buchner A, Malinek A, Shoenfeld Y. Physiologic pigmentation of the gingiva. Harefuah 90:12-13, 1976.
28. Shapiro Y, Koren G, Shoenfeld Y, Sohar E. Accidental hypothermia in healthy adults. Harefuah 90:164-167, 1976.
29. Koren G, Shoenfeld Y, Shapiro Y. II. Accidental hypothermia. Harefuah 90:175-180, 1976.
30. Pick AI, Shoenfeld Y. Disturbances in immunological mechanisms and development of malignancy. Harefuah 90:373-379, 1976.
31. Shilo S, Shoenfeld Y, Cabili S, Sohar E. Hypothermia secondary to endocrine dysfunction. Harefuah 90:419-421, 1976.
32. Drory Y, Shoenfeld Y, Shapiro Y, Hanne N. Athlete's heart syndrome. Harefuah 91:90-95, 1976.
33. Dvoretzky I, Shoenfeld Y, Fischer BK, Shapiro Y. Congenital ectodermal dysplasia: presentation of 7 cases. Harefuah 91:227-229, 1976.

34. Biernfeld C, Shapiro Y, Shoenfeld Y. Comparison of the climatic data in the west and east inclinations of the Judean mountains. Meteorology 1:34-37, 1976.
35. Sohar E, Shoenfeld Y, Shapiro Y, Ohry A, Cabili S. Effects of exposure to Finnish sauna. Isr J Med Sci 12:1275-1282, 1976.
36. Drory Y, Shoenfeld Y, Hanne N, Kellerman JJ. ECG changes in top athletes. Cardiology 61:267-278, 1976.
37. Shoenfeld Y, Shapiro Y. Physical activity, physical fitness and health. Harefuah 91:125-128, 1977.
38. Shoenfeld Y, Shapiro Y, Drory Y, Hanne N, Kellerman J. Aerobic work capacity in 1200, 18-60 year old men and 400 athletes. Isr J Med Sci 13:240-244, 1977.
39. Shoenfeld Y, Shapiro Y, Maechtiger A, Portugeeze D, Sohar E. Aerobic work capacity in male and female high school students. Isr J Med Sci 13:245-252, 1977.
40. Shoenfeld Y, Shapiro Y. Orthostatism in healthy people and spinal cord injury. Harefuah 92:219-222, 1977.
41. Shoenfeld Y, Djaldetti M, Weinberger A, Asherow J, Pinkhas J. A family with hereditary ovalocytosis. Harefuah 92:351-352, 1977.
42. Shoenfeld Y, Berliner S, Weinberger A, Pinkhas J. Hereditary ovalocytosis. (Editorial) Harefuah 92:358-359, 1977.
43. Shoenfeld Y, Shapiro Y, Sohar E. The F and its influence on the human body. Harefuah 92:512-514, 1977.
44. Shoenfeld Y, Coffee drinking and myocardial infarction. Harefuah 93:44-45, 1977.
45. Shoenfeld Y, Weinberger A, Ben-bassat M, Pinkhas J. Generalized pruritus in metastatic adenocarcinoma of the stomach. Dermatologia 155:122-124, 1977.
46. Shoenfeld Y, Pick AI, Danziger Y, Kalazci I, Frohlichman R, Pinkhas J. Immunoglobulin changes in SLE. Ann Allergy 39:99-102, 1972.
47. Shoenfeld Y, Pick AI, Schreiberman S, Zelikovsky A, Wollach Y, Mintz U, Udassin R, Pinkhas J. Our experience with the carcinoembryonic antigens (CEA and AFP). Harefuah 93:177-181, 1977.
48. Shoenfeld Y, Weinberger A, Pinkhas J. Hereditary benign leukopenia. harefuah 93:203-204, 1977.
49. Shoenfeld Y, Shapiro Y, Protugeeze D, Modan M, Sohar E. Maximal backpack load for long distance hiking. J Sport Med 17:147-153, 1977.
50. Shoenfeld Y, Shapiro Y, glazevsky Y, drory Y, Kellermann JJ, Sohar E. Rehabilitation of patients with NCA (neurocirculatory asthenia) through a short term training program. Amer J Phys Med 56:1-5, 1977.
51. Pick AI, Varsano D, Ben-Bassat M, Shoenfeld Y. Agammaglobulinemia, plasma cell dyscrasia and amyloidosis in a 12 year old child. Amer J Dis Child 131:682-686, 1977.
52. Nord E, Shoenfeld Y, Pinkhas J, DeVries A. Cytomegalovirus mononucleosis. Harefuah 92:466-467, 1977.
53. Pick AI, Shoenfeld Y, Schreiberman S, Frohlichman R. Asymptomatic (benign) monoclonal gammopathy - a study of 100 patients. Ann Clin Lab Sci 7:335-343, 1977.
54. Pick AI, Shoenfeld Y, Zelikovsky A, Wollach Y, Mintz U. Diagnostic significance of CEA concentration - A study of 61 patients with malignancies. Amer J Protocol 28:37-43, 1977.
55. Shapiro Y, Shoenfeld Y. Physiological changes of the cardiovascular system on exertion. Harefuah 93:155-156, 1977.

56. Udassin R, Shoenfeld Y, Shapiro Y, Bierenfeld C, Sohar E. Serum glucose and lactic concentrations during prolonged strenuous exercise in man. Amer J Phy Med 56:249-256, 1977.
57. Shvartz E, Meroz A, Magazanik A. Shoenfeld Y, Shapiro Y. Exercise and heat orthostatism and the effect on heat acclimatization and physical fitness. Avi Space Environ Med 48:836, 1977.
58. Shoenfeld Y, Udassin R, Ohry A, Shapiro Y, Sohar E. Age and sex differences in short exposure to extreme heat. J Appl Physiol 44:1-4, 1978.
59. Shoenfeld Y, Miraz D, Pick AI. Tumors of the urinary bladder and the immunological system. Harefuah 94:193-195, 1978.
60. Shoenfeld Y, Berliner S. Crohn's disease and the immunological system. Harefua 94:240-241, 1978.
61. Shoenfeld Y, Shapiro Y, Ohry A, Levy Y, Udassin R, Drory Y, Rozin Y, Sohar E. Orthostatic hypotension in amputees and subjects with spinal cord injuries. Arch Phys Med Rehab 59:138-141, 1978.
62. Shoenfeld Y, Pick AI, Weinberger A, Ben-Bassat M, Pinkhas J. Pleural effusion as a presenting sign in multiple myeloma. Respiration 36:160-164, 1978.
63. Shoenfeld Y, Avidor E, Eldar M, Vidne B, Levy M, Pinkhas J. Squamos cell carcinoma associated with sarcoidosis in the lung. Oncology 35:112-113, 1978.
64. Shoenfeld Y, Udassin R, shapiro Y, Bierenfeld C, Magazanik A. Optimal backpack load for short distances. Arch Phys Med rehab 59:281-285, 1978.
65. Shoenfeld Y. CPC - Sezary syndrome and bacterial endocarditis. Harefuah 95:95-100, 1978.
66. Shoenfeld Y, Pick AI, Gura V, Frohlichman R, Pinkhas J. Systemic lupus erythematosus associated with mixed cryoglobulinemia and circulating anticoagulant. South Afr J Med 54:1056-1058, 1978.
67. Shoenfeld Y, Weinberger A, Avishar R, Zamir R, Gazit E, Joshua H, Pinkhas J. Familial leukopenia among Yemenite Jews. Isr J Med Sci 14:1271-1274, 1978.
68. Shoenfeld Y, Udassin R, Bierenfeld C, Sohar E. The work capacity in high school students in the "kibbutz" in Israel. J Sport Med 18:385-390, 1978.
69. Delpre G, Shoenfeld Y, Weinberger A, Avidor I, Rousso I, Kadish U, Pinkhas J. Infiltration lymphocytaire lecemique et ulcere chronique simulant und cancer de l'estomac. Gastroenterol Clin Biol 2:71-76, 1978.
70. Berliner S, Shoenfeld Y, Weinberger A, Pinkhas J. Polyarteritis nodosa - Survey of 26 patients. Rheumatologica 36:137-143, 1978.
71. Pick AI, Shoenfeld Y, Herskovitz M, Ben-bassat M, Ducziminer M, Schreibman S, frohlichman R, Sheinberg A. Macroglobulinemia - a survey of 33 patients. Harefuah 94:253-263, 1978.
72. Glanz I, Eldar M, Shoenfeld Y, Pitlik S, Tchernilas I, Pinkhas J. Chronic eosinophilic pneumonia. Harefuah 96:66-69, 1978.
73. Neeman A, Shoenfeld Y, Eldar M, Pinkhas J. Eosinophilic gastroenteritis. Harefuah 95:108, 1978.
74. Sohar E, Bierenfeld C, Shoenfeld Y, Shapiro Y. Description and forecast of summer climate in physiologically significant terms. Int J Biometerol 22:75-81, 1978.
75. Eldar M, Shoenfel Y, Pinkhas J. Diagnostic parameters in SBE. Harefuah 95:271-272, 1978.
76. Shapiro A, Shoenfeld Y, Shapiro Y. The effect of standardized submaximal work load on intraocular pressure. Brit J Ophtahlmol 62:679-681, 1978.

77. Sohar E, Udassin R, Shoenfeld Y, Magazanik A, Revach Z. Cold induced profuse sweating on back and chest. Lancet 2:1073-1075, 1978.
78. Avisar R, Savir H, Shoenfeld Y. Prevalence of pterygium in Israel. Harefuah 95:161-162, 1978.
79. Livne P, Eldar M, Shoenfeld Y, Dintsman m, Pinkhas J. Recurrent gastrointestinal bleeding associated with aortic stenosis. Harefuah 95:395-396, 1978.
80. Berliner S, Shoenfeld Y, Shaklai M, Sidi Y, Pick AI, Pinkhas J. Transient mixed cryoglobulinemia associated with chronic myelocytic leukemia. Biomedicine 29:259, 1978.
81. Shoenfeld Y, Pick AI. Hyperviscosity syndrome in plasma cell dyscrasia. Harefuah 96:161-163, 1979.
82. Shoenfeld Y. Inbar O. The anaerobic capacity. Harefuah 96:557-558, 1979.
83. Shoenfeld Y. Clinico-pathological conferences: CPC, progressive dyspnea, dry cough, syncope, hemoptysis, loss of weight, death. Harefuah 97:313-317, 1979.
84. Pick AI, Shoenfeld Y, Frohlichman R, Weiss H, Vana D, Schreibman S. Plasma cell dyscrasia: Analysis of 423 patients. JAMA 241:2275-2278, 1979.
85. Weinberger A, Shoenfeld Y, Zamir R, Gazit E, Joshua H, Pinkhas J. HLA antigens in genetic neutropenia of Yemenite Jews. Vox Sang 36:105-108, 1979.
86. Shapiro A, Shoenfeld Y, Shapiro Y. The effect of exposure to heat on intraocular pressure. Grafe Archiv Ophthalmologie 210:183-185, 1979.
87. Berliner S, Shoenfeld Y, Zegenreich A, Meiraz D, Pinkhas J. Testicular lymphoma: Presentation of 6 patients. Harefuah 96:573-574, 1979.
88. Shapiro Y, Magazanik A, Udassin R, Shvartz E, Shoenfeld Y. Heat intolerance in former heatstroke patients. Ann Int Med 90:913-916, 1979.
89. Weitzman A, Eldar M, Shoenfeld Y, Hischorn M, Wijssenbeek H, Pinkhas J. Hypercalcemia-induced psychopathology in malignant disease. Brit J Psychiat 135:363-366, 1979.
90. Aderka D, Shoenfeld Y. The interferon: Mode of action and therapeutic action. Harefuah 96:299-300, 1979.
91. Eldar M, Shoenfeld Y, Zaizov R, Fogel R, Asherov G, Liban E, Pinkhas J. Pulmonary alveolar proteinosis associated with Fanconi's anemia. Respiration 38:177-180, 1979.
92. Pick AI, Eldar M, Douer D, Levo Y, Weiss C, Shoenfeld Y, Pinkhas J. Depressed PHA transformation and acute leukemia in macrolobulinemia. Cancer 44:1741-1744, 1979.
93. Aderka D, Eldar M, Shoenfeld Y, Ravid M, Feuerman E, Pimkhas J. Epidermal ridge disarrangement and Hamman-Rich syndrome. Dermatology 160:21-24, 1980.
94. Berliner S, Shoenfeld Y, Livni E, Pinkhas J. Allergic purpura following intravenous administration of interferon. Acta Hematol 62:178, 1979.
95. Ravid M, Shoenfeld Y. The use of the reference list. Harefuah 97:141-142, 1979.
96. Epstein Y, Udassin R, Shapiro Y, Shoenfeld Y. Anthropological and physiological characteristics of the different Jewish ethnic groups in Israel. S Afric J Phys Sports Phys Educ Rec 2:5-8, 1979.
97. Shoenfeld Y, Mor R, Avidor E, Weinberger A, Pinkhas J. Diagonal ear lobe crease and coronary risk factors. J Amer Ger Soc 28:184-188, 190.

98. Shoenfeld Y, Keren G, Shimoni T, Sohar E. Walking - a quick method for improving physical fitness. JAMA 243:2062-2063, 1980.
99. Shoenfeld Y, Eldar M, Bedazovsky B, Levy M, Pinkhas J. Aortic stenosis associated with gastrointestinal bleeding: A survey of 612 patients. Amer Heart J 137:179-182, 1980.
100. Shoenfeld Y, Shaulian E, Shaklai M, Krugliak Y, Feuerman E, Pinkhas J. Circulating anticoagulant and serological tests for syphilis. Acta Dermatovener 60:365-367, 1980.
101. Shoenfeld Y, berliner S, Pinkhas J, Beutler E. Gaucher's disease and dysproteinemia. Acta Haematol 64:241-243, 1980.
102. Shoenfeld Y, Livni E, Shaklai m, Pimkhas J. Sensitization to ibuprofen in SLE. JAMA 244:547-548, 1980.
103. Shoenfeld Y, Shaulian E, Berliner S, Shaklai M, Krugliak y, Pinkhas J. Thromboembolic phenomeon in patients with "lupus type circulating anticoagulant". Rheumatologica 51:417-424, 1980.
106. Beldegrin A, Shoenfeld Y, Pick AI, Vana D. Age related distribution of serum immunoglobulin concentrations in 1003 healthy children and adults. Biomedicine 33:8-12, 1980.
107. Eldar M, Neeman A, Shoenfeld Y, Pinkhas J. Transient mixed cryoglobulinemia associated with typhoid hepatitis. New Instanbul Contro Cli Res 13:55-57, 1980.
108. Berliner S, Neeman A, Shoenfeld Y, Eldar M, rousso I, Kadish U, Pinkhas J. Salazopyrin induced eosinophilic pneumonia. Respiration 39:119-120, 1980.
109. Neeman A, Berliner S, Shoenfeld Y, Kadish U, Pinkhas J. Salazopyrine induced tachycardia. Biomedicine 33:1-2, 1980.
110. Udassin R, Keren G, Shoenfeld Y. Acclimatization to heat. Harefuah 98:3-33, 1980.
111. Eldar M, Shoenfeld Y, Douer D, Pinkhas J. Hypercalcemia in Hodgkin's disease. Hematologia 65:459-463, 1980.
112. Berliner S, Shoenfeld Y, Pinkhas J. Mixed connective tissue disease. Harefuah 98:475-477, 1980.
113. Eldar M, Carel R, Shoenfeld Y. Hypertension and obesity. Harefuah 93:427-428, 1980.
114. Berliner S, Shoenfeld Y, Pinkhas J. Splenectomy in myeloproliferative diseases. Harefuah 98:274-275, 1980.
115. Shoenfeld Y, Berliner S, Neeman A, Kadish M, Pinkhas J. Cryoglobulinemia in chronic liver diseases. Amer J Gastroenterol 74:439-440, 1980.
116. Berliner S, Shoenfeld Y, Eldar M, Pinkhas J. Inappropriate ADH secretion secondary to fibrothorax. Respiration 29:283-285, 1980.
117. Aderka D, Shoenfeld Y, Santo M, Berliner S, Pinkhas J. Life threatening hypophosphatemia in a patient with acute myeloid leukemia. Acta Haematol 64:117-119, 1980.
118. Garfunkel D, Shoenfeld Y, Gadoth N, Pinkhas J. Oculomotor nerve paresis-presenting sign of acute myeloid leukemia. Hamatologia 65:769-771, 1980.
119. Shoenfeld Y, Avidor I, Liban E, Levy M, Pinkhas J. Leiomyosarcoma of the pulmonary artery. Respiration 41:208-213, 1981.
120. Shoenfeld Y, Gurewich Y, Gallant LA, Pinkhas J. Prednisone-induced leukocytosis: The influence of dosage, method and duration of administration on the degree of leukocytosis. Amer J Med 71:773-778, 1981.



121. Shoenfeld Y, Hage S. The effect of hypophosphatemia on peripheral blood cells. *Harefuah* 101:126-127, 1981.
122. Berliner S, Shoenfeld Y, Pinkhas J. The leukomogenic action of cytotoxic drugs. *Harefuah* 100:44-45, 1981.
123. Shoenfeld Y, Aloni D, Keren G, Shaklai M, Djaldetti M, Pinkhas J. Effect of physical effort on the white blood cells in benign familial leukopenia. *Acta Haematol* 65:108-113, 1981.
124. Aderka D, Shoenfeld Y, Berliner S, Shaklai M, Pinkhas J. Spontaneous remission of erythroleukemia following interstitial pneumonia. *NY St J Med* 41:772-773, 1981.
125. Udassin R, Harari L, Shoenfeld Y, Keren G. Cholinergic urticaria: A seasonal disease. *Arch Int Med* 141:1029-1030, 1981.
126. Shoenfeld Y, Pinkhas J. Chronic benign neutropenia. *Harefuah* 100:198-199, 1981.
127. Avisar R, Shoenfeld Y, Pick AI, Creter D, Cohen A, Djaldetti M, Savir H. Plasma cell dyscrasia. part I: Fluorescein angiography findings in plasma cell dyscrasia. *Metab Pediat Ophthal* 5:171-175, 1981.
128. Berliner S, Shoenfeld Y, Shaklai M, Pinkhas J. Conservative treatment of Budd-Chiari syndrome in polycythemia vera. *Hematologia* 66:220-222, 1981.
129. Shapiro A, Shoenfeld Y, Konikoff F, Shapiro Y. The relationship between body temperature and intraocular pressure. *Ann Ophthalmol* 28:159-161, 1981.
130. Berliner S, Weinberger A, Shoenfeld Y, Pinkhas J. Autoimmune disease in mice. *Harefuah* 100:529-530, 1981.
131. Bogard CH, Shoenfeld Y, Pinkhas J. Passive smoking. *Harefuah* 100:345-347, 1981.
132. Shaulian E, Shoenfeld Y, Berliner S, Shaklai M, Pinkhas J. Surgery in patients with circulating anticoagulant. *Int Surg* 66:157-159, 1981.
133. Giller S, Berliner S, Shoenfeld Y, Pinkhas J. Surgery in patients with hepatitis. *Medicine Int* 19: 211-215, 1981.
134. Berliner S, Shoenfeld Y, Dean H, Pinkhas J. Pulmonary hypertension in a patient with Marfan's syndrome. *Respiration* 41:214-215, 1981.
135. Shoenfeld Y, Keren G, Birenfeld C, Sohar E. Age, weight, and heart rate at rest as predictors of aerobic fitness. *J Sport Med* 21:377-382, 1981.
136. Shoenfeld Y, Hager S, Berliner S, Gallant LA, Pinkhas J. Hypophosphatemia as a diagnostic aid in sepsis. *NY St J Med* 82:163-165, 1982.
137. Shoenfeld Y, Modan M, Berliner S, Yair V, Shaklai M, Shisky A, Pinkhas J. The mechanism of benign hereditary neutropenia. *Arch Int Med* 142:797-799, 1982.
138. Lavie G, Shoenfeld Y, Shaklai M, Aderka D, Pick AI, Pinkhas J. Homogeneous populations of macrophages from histiocytic lymphoma patients as a source for macrophage subpopulations which differ in immunoregulatory properties. *Cancer* 50:69-77, 1982.
139. Aderka D, Djaldetti M, Shoenfeld Y, Shaklai M, Berliner S, Weinberger A, Pinkhas J. Morphological platelet anomalies in thrombotic thrombocytopenic purpura. *Acta Haematol* 67:119-123, 1982.
140. Berliner S, Shoenfeld Y, Dean H, Avisar R, David M, Pinkhas J. Primary pulmonary hypertension: A fact of a diffuse angiopathic process. *Respiration* 43:76-79, 1982.

141. Shoenfeld Y, Schwartz RS. Hybridomas: A potent new biotechnology: The production and the use of monoclonal antibodies. *Harefuah* 102:479-481, 1982.
142. Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, Pinkhas J. Gaucher's disease: A disease with chronic stimulation of the immune system. *Arch Pathol Lab Med* 106:388-391, 1982.
143. Shoenfeld Y, Baruch n, Livni E, Santo M, Pinkhas J. Carbamazepine (Tegretol)-induced thrombocytopenia. *Acta Haematol* 68:74, 1982.
144. Silverberg DS, Carel RS, Shoenfeld Y, Snir C. Errors in blood pressure recording. *Harefuah* 102:76-78, 1982.
145. Shoenfeld Y, Hsu-Lin SC, Gabriel JE, Silberstein LE, Furie BC, Furie B, Stollar BD, Schwartz RS. Production of monoclonal autoantibodies by human-human hybridomas. *J Clin Invest* 70:205-208, 1982.
146. Aderka D, Shoenfeld Y, Pinkhas J. Central nervous system involvement in patients with lymphoma. *Harefuah* 102:124-125, 1982.
147. Shoenfeld Y, Rotenberg M, Berliner S, Gallant LA, Garfinkel D, Shaklai M, Pinkhas J. Absence of predictive parameters for CNS involvement in adult non-lymphocytic leukemia at time of diagnosis. *Scand J Haematol* 28:335-340, 1982.
148. Shoenfeld Y, Rauch J, Massicotte H, Datta SK, Schwartz JA, Stollar BD, Schwartz RS. Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. *New Eng J med* 308:414-420, 1983.
149. Shoenfeld Y, Aderka D, Sandbank M, Gadoth N, Santo M, Pinkhas J. Fatal peripheral neurolymphomatosis following remission of histiocytic lymphoma. *Neurology* 33:243-245, 1983.
150. Isenberg DA, Shoenfeld Y. The rheumatologic complication of hematologic disorders. *Semin Arthritis Rheum* 12:348-358, 1983.
151. Shoenfeld Y, Isenberg DA, Rauch J, Madaio MP, Stollar BD, Schwartz RS. Idiotypic cross reactions of monoclonal human lupus autoantibodies. *J Exp Med* 158:718-730, 1983.
152. Shoenfeld Y, Shindel D, Neri A. Leukocytosis in pregnancy and labour. *Harefuah* 104:69-70, 1983.
153. Isenberg DA, Shoenfeld Y, and Schwartz RS. Multiple serological reactions and their relationship to clinical activity in systemic lupus erythematosus. A study of 56 patients. *Arthritis Rheum* 27:132-138, 1984.
154. Shoenfeld Y, Pinkhas J. Drug induced lupus. *Harefuah* 105:75-77, 1983.
155. Berliner S, Shoenfeld Y, Sidi Y, Weinberger A, Hazaz B, Pecht M, Zaizov R, Pinkhas J. SLE and lymphoma: A family study. *Scand J Rheumatol* 12:310-314, 1983.
156. Schwartz JA, Datta SJ, Shoenfeld Y, Isenberg DA, Stollar BD, Schwartz RA. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus antibodies. *Clin Immunol Immunopathol* 31:261-271, 1984.
157. Fox H, McCarthy P, Schwartz JA, Shoenfeld Y, Miller KB. Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and B cell proliferation? *Cancer* 54:312-314, 1984.
158. Shoenfeld Y, Berliner S, Ayalone A, SHaklai M, Djaldetti M, Pinkhas J. Monoclonal gammopathy in patients with chronic and acute myeloid leukemia. *Cancer* 54:280-283, 1984.
159. Isenberg DA, Shoenfeld Y, Madio M, Reichlin M, Stollar BD, Schwartz RS. Measurement of anti-DNA antibody idiotypes to monitor the course of SLE. *Lancet* 2:418-422, 1984.
160. Isenberg DA, Shoenfeld Y, Schwartz RS. The use of hybridomas to analyze autoimmunity. *Brit Med Bull* 40:262-266, 1984.

161. Carel RS, Shoenfeld Y, Eldar M, Silverberg DS, Eldar Z, Pinkhas J, Mor G. Casual blood pressure: Its relationship to several cardiovascular risk factors in middle-aged men. *Pub Health (London)*, 98:209-215, 1984.
162. Shoenfeld Y, Schwartz RS. Genetic and immunologic factors in autoimmune diseases. *New Eng J Med* 311:1019-1029, 1984.
163. Massicotte H, Rauch J, Shoenfeld Y, Tannenbaum H. Influence of fusion cell ratio and cell plating density on the production of human-human hybridomas secreting anti-DNA autoantibodies from patients with SLE. *Hybridoma* 3::215-222, 1984.
164. Berliner S, Weinberger A, Shoenfeld Y, Sandbank M, Hazaz B, Joshua H, Rosen M, Pinkhas J. Ibuprofen causes meningitis in (NZB/W)F1 mice. *Arthritis Rheum* 28:104-107, 1985.
165. Shoenfeld Y. The production of human-hybridomas and their contribution to the research of autoimmune diseases. *Harefuah* 107:134-135, 1982.
166. Shoenfeld Y, Pinkhas J. Antibody activity of monoclonal immunoglobulin components in plasma cell dyscrasia. *Harefuah* 97:420-422, 1984.
167. Garfinkel D, Bogard H, Salomon F, Aderka D, Shoenfeld Y, Weinberger A, Pinkhas J. Polymyalgia rheumatica and temporal arteritis in a married couple. *Am J Med Sci* 287:48-49, 1984.
168. Shoenfeld Y, Birenmaum O, Livni E, Boimovitch B, Scheinberg A, Pinkhas J. Sensitization to ampicilin in infectious mononucleosis. *Harefuah* 97:174-176, 1984.
169. Shoenfeld Y, Ben-Tal O, Berliner S, Pinkhas J. The outcome of bacterial infection in subjects with benign familial leukopenia. *Biomedicine* 38:23-26, 1984.
170. Aderka D, Shoenfeld Y, Pinkhas J. The thymic hormones: their function and therapeutic potential. *Harefuah* 97:244-247, 1984.
171. Shoenfeld Y, Schwartz JA, Schwartz RS. Antibodies to cytoskeleton proteins in autoimmune diseases. *Harefuah* 107:291-193, 1984.
172. Ben-Yehuda O, Shoenfeld Y. The T-cell receptor. *Harefuah* 108:46-48, 1985.
173. Aderka D, Shoenfeld Y. Oncogenes in medicine. *Harefuah* 109:31-35, 1985.
174. Silberstein LE, Shoenfeld Y, Schwartz RS, Berkman EM. A combination of IgG and IgM autoantibodies in chronic cold agglutinin disease. Immunologic studies and response to splenectomy. *Vox Sang* 48:105-109, 1985.
175. El-Roeiy A, Shoenfeld Y. Autoimmunity and pregnancy. *Amer J Rep Immunol Microbiol* 9:25-32. 1985.
176. Shoenfeld Y, Smorodinsky NI, Lavie G, Hazaz B, Joshua HJ, Pinkhas J. Human human monoclonal autoantibodies bind to Raji cells. *Immunol Lett* 11:121-126, 1985.
177. Shoenfeld Y, Zamir R, Joshua H, Lavie G, Pinkhas J. Human monoclonal anti-DNA antibodies react as lymphocytotoxic antibodies. *Eur J Immunol* 15:1024-1028, 1985.
178. Isenberg DA, Shoenfeld Y, Walport M, Brill S, Weinberger A, Pinkhas J. Detection of cross-reactive anti-DNA antibody idiotype in the serum of lupus patients and their relatives. *Arthritis Rheum* 28:999-1007, 1985.
179. Shoenfeld Y, Hareuveni M. The MuMTV and its relation to human and breast carcinoma. *Harefuah* 109:338-342, 1985.
180. El-Roeiy A, Shoenfeld Y. Zinc, the immune system, and autoimmunity. *Harefuah* 109:406-408, 1985.

181. Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non-hematological malignancies - A possible tumor-associated marker. J Cancer Res Clinical Oncol 111:54-58, 1986.
182. Shoenfeld Y. The analysis of common idiotypes of human monoclonal anti-DNA autoantibodies in SLE and related conditions. Clin Immunol Newsletter 7:70-72, 1986.
183. Molad Y, Shoenfeld Y. Q fever endocarditis. Harefuah 110:47, 1986.
184. El-Roiey A, Gross WL, Ludeman J, Isenberg DA, Shoenfeld Y. Preferential secretion of common anti-DNA idiomotype (16/6 Id) and anti-polynucleotide antibodies by mononuclear cells, following stimulation with Klebsiella pneumonia. Immunol Lett 12:313-319, 1986.
185. Dudeney C, Shoenfeld Y, Jones M, Mackworth-Young C, Shall S, Isenberg DA. A study of anti-poly (ADP-ribose) antibodies and an anti-DNA antibody idiomotype and other immunological abnormalities in lupus family members. Ann Rheum Disease 45:502-507, 1986.
186. Shoenfeld Y, Ben-Yehuda O, Naparstek Y, Wilner Y, Frohlichman F, Schattner A, Lavie G, Joshua H, Pinkhas J, Kennedy RC, Schwartz RS, Pick AI. The detection of a common idiomotype of anti-DNA antibodies in the sera of patients with monoclonal gammopathies. J Clin Immunol 6:194-204, 1986.
187. Progozin CH, Shoenfeld Y. Eaton-Lambert's syndrome - a new autoimmune condition. Harefuah 110:536-538, 1986.
188. Shoenfeld Y, Witz IP. Hybridomas from unimmunized individuals. Immunol Today 7:350-351, 1986.
189. Sukenik S, El-Roiey A, Shoenfeld Y. Lupus anticoagulant and anticardiolipin antibodies in SLE. Acta Hematol 76:86-89, 1986.
190. Shoenfeld Y, Hizi A, Tal R, Lavie G, Mor C, Shteren S, Mammon Z, Pinkhas J, Keydar I. Human monoclonal antibodies derived from lymph nodes of a female patient with breast carcinoma react with MuMTV polypeptides. Cancer 59:43-50, 1986.
- 190a. Shoenfeld Y. How to determine the academic rank of physicians. Harefuah, 11: 579, 1986. א"י חוב י"א 1.6.86 .
191. Kleiner-Baumgarten A, Keynan A, Shoenfeld Y. Scabies associated angioimmunoblastic lymphadenopathy. Acta Hematol 76:166-168, 1986.
192. Shoenfeld Y, Vilner Y, Coates ARM, Rauch J, Lavie G, Shaul D, Pinkhas J. Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp. Immunol 1986; 66: 255 – 261.
193. Piura B, Shoenfeld Y. Autoimmune disease in pregnancy. Harefuah 111:85-92, 1986.
194. Shoenfeld Y. The crisis in internal medicine. Can research solve the problem? Harefuah 111:100-101, 1986.
195. Konikoff F, Shoenfeld Y, Magazanik A, Shapiro Y. Effects of salt loading during exercise in a hot dry climate. Biomedicine 40:296-300, 1986.
196. Shoenfeld Y. Promotion in medical school: a suggestion. Harefuah 110:579-580, 1986.
- 196a. Shoenfeld Y. Publishing articles in Harefuah. Harefuah 112: 36-37, 1987.
197. Shoenfeld Y, Brill S, Weinberger A, Pinkhas J, Isenberg DA. High levels of a common anti-DNA idiomotype (16/6 Id), a genetic marker for SLE. Acta Hematol 76:107-109, 1986.
198. Sela O, El-Roiey A, Isenberg DA, Kennedy RC, Colaco CB, Pinkhas J, Shoenfeld Y. A common anti-DNA antibody idiomotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum 30:50-55, 1987.

199. Piura B, [Shoenfeld Y](#). Sex hormones and autoimmune diseases. *Harefuah* 112:192-195, 1987.
200. Varticovsky L, Schattner A, Pick AI, [Shoenfeld Y](#). Anti-platelet and anti-DNA IgM in Waldenstrom's macroglobulinemia and ITP. *Amer J Hematol* 24:351-355, 1987.
201. Arad-Dann H, Isenberg DA, [Shoenfeld Y](#), Offer D, Sperling J, Sperling R. Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic diseases associated with myositis. *J Immunol* 138:2463-2468, 1987.
202. [Shoenfeld Y](#), El-Roeiy A, Ben-Yehuda O, Pick AI. Detection of anti-histone activity in sera of patients with monoclonal gammopathies. *Clin Immunol Immunopathol* 42:250-258, 1987.
203. [Shoenfeld Y](#), Isenberg DA. DNA antibody idiotypes: a review of their genetic, clinical and immunopathologic features. *Semin Arthritis Rheum* 16:245-252, 1987.
204. El-Roeiy A, Sela O, Isenberg DA, Kennedy RL, [Shoenfeld Y](#). The sera of patients with Klebsiella infections contain a common anti-DNA idiotype (16/6 Id) and anti-polynucleotide activity. *Clin Exp Immunol* 67:507-515, 1987.
205. Neeman A, [Shoenfeld Y](#), Kadish M. Does duodenal ulcer lead to an early diagnosis of gastric cancer? *J Clinical Gastroenterol* 9:37-39, 1987.
206. [Shoenfeld Y](#), Segol G, Segol O, Stollar BD, Isenberg DA. Anti-histones antibodies in the serum of lupus patients and their relatives. *Arthritis Rheum* 30:169-175, 1987.
207. Isenberg DA, Maddison P, Swana G, Jones M, Dudeney C, El-Roeiy A, [Shoenfeld Y](#). Profile of autoantibodies in the sera of patients with tuberculosis, Klebsiella and other gram-negative infections. *Clin Exp Immunol* 67: 516-523, 1987.
208. Sela O, [Shoenfeld Y](#). Infecting agents and autoimmune diseases. *Harefuah* 112:285-288, 1987.
209. Avinoach I, [Shoenfeld Y](#). The lupus band test: its diagnostic value. *Harefuah* 112:554-556, 1987.
210. Konikoff F, Isenberg D, Kennedy RC, Kuperman O, [Shoenfeld Y](#). Common anti-DNA idiotypes in chronic liver diseases. *Clin Immunol Immunopathol* 43:265-270, 1987.
211. Teplizki H, Buskila D, Isenberg DA, Coates ARM, Sukenik S, Horowitz J, [Shoenfeld Y](#). Low serum anti-TB glycolipid antibodies titer in the sera of patients with SLE as an indicator of CNS involvement. *J Rheumatol* 14:507, 1987.
212. Sela O, El-Roeiy A, Pick AI, [Shoenfeld Y](#). Immunoglobulin levels in Klebsiella and TB infection. *Immunol Lett* 15:117-220, 1987.
213. Buskila D, [Shoenfeld Y](#). HLA system and autoimmunity. *Harefuah* 112:398-402, 1987.
214. Isenberg DA, Feldman R, Dudeney C, Konikoff F, Jones D, Erbing A, [Shoenfeld Y](#). A study of anti-polynucleotide antibodies, anti-Klebsiella (K30) antibodies and anti-DNA antibody idiotypes in ankylosing spondylitis. *Brit J Rheumatol* 26:168-171, 1987.
215. Sela O, baumgarten A, [Shoenfeld Y](#). Ibuprofen induced asthmatic attacks. *Harefuah* 112:345-346, 1987.
216. El-Roeiy A, Gleicher N, Isenberg D, Kennedy RC, [Shoenfeld Y](#). A common anti-DNA idiotype and other autoantibodies in sera of offspring of mothers with SLE. *Clin Exp Immunol* 68:528-534, 1987.
217. [Shoenfeld Y](#), Shohat R. Myocardial infarction in Yemenite Jews and benign familial leukopenia neutropenia. *Harefuah* 112:484-450, 1987.

218. Slor H, Sobe T, [Shoenfeld Y](#). Quantitation of antinuclear autoantibodies by ELISA: Specificity correlation with other methods and clinical significance. *Quart Med Rev* 1:6-10, 1987.
219. Konikoff F, [Shoenfeld Y](#), Isenberg DA, Theodore E, Moroz CH. Placental type isoferitins in chronic liver diseases. *J Hepato-Gastroenterol* 34:65-67, 1987.
220. Tomer Y, Ben-yehuda O, [Shoenfeld Y](#). Treatment of autoimmune diseases. *Harefuah* 112:608-612, 1987.
221. [Shoenfeld Y](#), Vilner Y, Reshef T, Klajman A. Common anti-DNA idiotypes (32/15 and 16/6) in sera of patients with drug-induced lupus. *J Clin Immunol* 7:410-417, 1987.
222. Teplizki H, Alkan M, Coates ARM, [Shoenfeld Y](#). ELISA measurement of antibodies titer to PPD and mycobacteria derived phosphoglycolipids as an aiding tool to the diagnosis of active pulmonary tuberculosis. *Isr J Med Sci* 23:1121-1124, 1987.
223. Bakimer R, Kennedy R, [Shoenfeld Y](#). Vaccination with anti-idiotypic antibodies. *Harefuah* 114:19-22, 1988.
224. Isenberg DA, [Shoenfeld Y](#). The origin and significance of anti-DNA antibodies. *Immunol Today* 8:279-281, 1987.
225. Teplizki H, [Shoenfeld Y](#). Vaccines against AIDS - difficulties and solutions. *Harefuah* 113:354-358, 1987.
226. Smorodinski NI, Argov S, Ghendler Y, bakimer R, Krup M, Lupu R, Keydar I, [Shoenfeld Y](#). Human monoclonal antibodies derived from pleural effusion lymphocytes of a patient with breast carcinoma react with human breast cancer associated antigens (HMTV) and MMTV polypeptides. *Exp Cell Biol* 55:237-249, 1987.
227. Konikoff F, [Shoenfeld Y](#), Isenberg DA, Barrison I, Sobe T, Theodor E, Slor H. Anti-RNP antibodies in chronic liver diseases. *Clin Exp Rheumatol* 5:359-361, 1987.
228. Ben-Yehuda O, Tomer Y, [Shoenfeld Y](#). Advances in therapy of autoimmune diseases. *Semin Arthritis Rheum* 17:206-220, 1988.
229. Dror Y, Slor H, [Shoenfeld Y](#). The clinical significance of anti-Sm and anti-RNP autoantibodies. *Harefuah* 114:140-144, 1988.
230. Isenberg DA, [Shoenfeld Y](#). An analysis of autoimmunity through studies of DNA antibody idiotypes. *Autoimmunity* 1:67-75, 1988.
231. Teplizki H, Slor H, [Shoenfeld Y](#). Anti-Ro and anti-La autoantibodies in autoimmune condition. *Harefuah* 114:88-92, 1988.
232. Hundert I, [Shoenfeld Y](#). Autoimmune conditions in the eye. *Harefuah* 114:352-355, 1988.
233. Mendelovic S, Brocke S, [Shoenfeld Y](#), Ben-Bassat M, Meshorer A, Bakimer R, Mozes E. Induction of a SLE-like disease in mice by a common anti-DNA idiomorph. *Proc Nat Acad Sci (USA)* 85:2260-2264, 1988.
234. Smorodinsky NI, Cahalon L, Argov S, Witz IP, [Shoenfeld Y](#). Naturally occurring tumor-reactive autoantibodies: a monoclonal antibody from normal mice reacts with tumor cells and with DNA. *Immunol Lett* 18:43-50, 1988.
235. [Shoenfeld Y](#), Ben-Yehuda O, Messinger Y, Bentwitch Z, Rauch J, Isenberg DA, Gadoth N. Autoimmune diseases other than lupus share common anti-DNA idiotypes. *Immunol Lett* 17:285-290, 1988.
236. Dang H, Takei M, Isenberg DA, [Shoenfeld Y](#), Bakimer R, Rauch J, Talal N. Expression of an interspecies idiomorph in sera of SLE patients and their first degree relatives. *Clin Exp Immunol* 71:445-450, 1988.
237. El-Roeiy A, Valesini G, Friberg J, [Shoenfeld Y](#), Kennedy R, Gleicher N. Autoantibodies and common idiotypes in men and women with sperm antibodies. *Amer J Obstet Gynecol* 158:596-603, 1988.

238. Shoenfeld Y, Levene A, Blank M, Argov S, Krup M, Fleishmakher E, Sukenik S, Teplizki H. A human monoclonal anti-DNA antibody derived from a patient with polymyositis having the common lupus 16/6 idiotype. Immunol Lett 19:77-84, 1988.
239. Shoenfeld Y, Teplizki H, Buskila D, Leideman J, Gross W. Immunoglobulin secretion of mononuclear cells induced by various mitogens. Int J Immunopharmacol 10:352-367, 1988.
240. Mendlovic S, Shoenfeld Y, Bakimer R, Segal R, Dayan M, Mozes E. In vitro T cell function specific to anti-DNA idiotype and serological markers in patients with SLE. J Clin Immunol 8:178-198, 1988.
241. Shoenfeld Y, Isenberg DA. Mycobacteria and autoimmunity. Immunology Today 9:178-181, 1988.
242. Avinoach I, Teplizki H, Shoenfeld Y. Serological markers in diagnosis of CNS involvement in SLE. Harefuah 114:387-390, 1988.
243. Tomer Y, Shoenfeld Y. Ageing and autoantibodies. Autoimmunity 1:141-149, 1988.
244. Asali A, Shoenfeld Y. More about benign familial neutropenia. Harefuah 114:192-194, 1988.
245. Chaim N, Sela O, Shoenfeld Y. Autoimmune syndrome in malignant diseases. Harefuah 114:239-242, 1988.
246. Shoenfeld Y. Autoimmune diseases: multiple factors involved in the etiology. Isr J Med Sci 24:351-352, 1988.
247. Mozes E, Mendlovic S, Bentwitch Z, Brautbar C, Shoenfeld Y. T cell-helper factors in autoimmunity. Isr J Med Sci 24:355-358, 1988.
248. Sela O, Shoenfeld Y. IgA deficiency and autoimmunity. Harefuah 114:560-564, 1988.
249. Chaim N, Shoenfeld Y. Autoantibodies in malignant states. Harefuah 114:615-619, 1988.
250. Shoenfeld Y, Alkan ML, Sali A, Carmeli Y, Katz M. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Hematol 41:273-277, 1988.
251. Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest 17:389-424, 1988.
252. Sela O, Shoenfeld Y. Complement deficiencies and autoimmune diseases. Harefuah 115:129-135, 1988.
253. Firer MA, Shoenfeld Y, Isenberg DA, Slor H. The use of ELISA for the measurement of autoantibodies to nuclear antigens: comparison with other methodologies. Isr J Med Sci 24:747-750, 1988.
254. Zurgil N, Shafir S, Slor H, Shoenfeld Y. Identification of anti-Sm and anti-RNP autoantibodies by immunoblotting and immunoassay. Isr J Med Sci 24:751-754, 1988.
255. Mozes E, Shoenfeld Y, Brocke S, Mendlovic S. Induction of experimental SLE in mice. Isr J Med Sci 24:741-744, 1988.
256. Piura B, Tauber E, Dror Y, Sarov B, Naggan L, Slor H, Shoenfeld Y. Antinuclear antibodies in pregnancy. Harefuah 115:360-363, 1988.
257. Teplizki H, Shoenfeld Y. Achievements and progress in medicine - 1987. Harefuah 115:394-397, 1988.
258. Shoenfeld Y, Rotem Y. 1988 Nobel Prize for Medicine and Physiology. Harefuah 115:404, 1988.
259. Shoenfeld Y, Zamir R. The significance of HLA studies in human-human hybridomas. Tissue Antigens 32:209-213, 1988.

260. Moroz CH, Landsberg L, Cohen Y, Goldstein J, Quastel MR, Shoenfeld Y. Radioimmuno-detection of tumors with monoclonal antiplacental ferritin antibody: Preliminary results. Oncology 46:35-39, 1988.
261. Sela O, Shoenfeld Y. Cancer in autoimmune disease. Sem Arthritis Rheum 18:77-85, 1988.
262. Smordinsky NI, Ghendler Y, Bakimer R, Chaitchuk S, Keydar I, Shoenfeld Y. Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer-associated antigens by anti-idiotypic antibodies. Eur J Immunol 18:1713-1718, 1988
- 262a. Isenberg DA, Williams W, Le Page S, Swana G, Feldman R, Addison I, Bakimer R, Shoenfeld Y. A comparison of autoantibodies and common DNA antibody idiotypes in SLE patients and their spouses. Brit J Rheumatol 27:431-435, 1988.
263. Sela O, Hertzanu I, Shoenfeld Y. Fulminant hepatic failure due to hepatitis A. Harefuah 116:95-96, 1989.
264. Swissa M, Shoenfeld Y. The clinical significance of anti-histone antibodies. Harefuah 117:117-119, 1989.
265. Piura B, tauber E, Sarov B, Naggan L, Shoenfeld Y. Antinuclear autoantibodies in sera of healthy pregnant women and their offspring. Amer J Rep Immunol 18:116-119, 1988.
266. Abu-Shakra M, Sukenik S, Shoenfeld Y. Recurrent ischemic necrosis of the bones in young male with SLE. Harefuah 116:197-199, 1989.
267. Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunology Today 10:123-126, 1989.
268. Eldar M, Shoenfeld Y. Harmful effects of smoking. Harefuah 116:283-287, 1989.
269. Blank M, Mendlovic S, Mozes E, Shoenfeld Y. Induction of SLE-like disease in naive mice with a monoclonal anti-DNA antibody derived from a patient with polymyositis carrying 16/6 Id. J Autoimmunity 1:683-691, 1988.
270. Goshen E, Livne A, Krupp M, Hammerstrom L, Dighiero G, Slor H, Shoenfeld Y. Antinuclear and related autoantibodies in sera of healthy subjects with IgA deficiency. J Autoimmunity 2:51-60, 1989.
271. Konikoff F, Swissa M, Shoenfeld Y. Autoantibodies to histones and their subfractions in chronic liver diseases. Clin Immunol Immunopathol 51:77-82, 1989.
272. Abu-Shakra M, Fritch E, Ben-Arosh D, Shoenfeld Y. Tuberculosis in a general hospital; is the incidence increasing? Harefuah 117:351-354, 1989.
273. Yadin O, Sarov B, Naggan L, Slor H, Shoenfeld Y. Natural autoantibodies in the serum of healthy woman-a five year follow-up. Clin Exp Immunol 75:402-406, 1989.
274. Abu-Shakra M, Krupp M, Argov S, Buskila D, Slor H, Shoenfeld Y. The detection of anti-Sm-RNP activity in sera of patients with monoclonal gammopathies. Clin Exp Immunol 76:349-353, 1989.
275. Shoenfeld Y, Isenberg D. Anti-DNA antibody idiotypes: their pathogenic role and prognostic significance in SLE. Diagnostic and Clinical Testing 27:52-55, 1989.
276. Teplizki H, Buskila D, Alkan M, Coates ARM, Baumgarten A, Shoenfeld Y. Elisa measurements of antibody titer to purified protein derivative and mycobacteria-derived phosphoglycolipids: tool for diagnosing active pulmonary tuberculosis. Isr J Med Sci 23:1121-1124, 1988.
277. Buskila D, Shoenfeld Y. Subgroups of patients with SLE. Harefuah 117: 470-475, 1989.



278. Argov S, Jaffe C, Krupp M, Slor H, Shoenfeld Y. Autoantibody production by patients with Leishmania. Clin Exp Immunol 76:190-197, 1989.
279. Mendlovich S, Fricke H, Shoenfeld Y, Mozes E. The role of anti-idiotypic antibodies in the induction of experimental SLE in mice. Eur J Immunol 19:729-734, 1989.
280. Buskila D, Abu-Shakra M, Amital-Teplizki H, Coates ARM, Krupp M, Sukenik S, Shoenfeld Y. Serum monoclonal antibodies derived from patients with multiple myeloma react with mycobacterial phosphoinositides and nuclear antigens. Clin Exp Immunol 76:378-383, 1989.
281. Rotem Y, Amital-Teplizki H, Shoenfeld Y. Another encounter with an old foe: autobreak of poliomyelitis in Israel-1988. Viral Immunol 2:57-60, 1989.
282. Shoenfeld Y, Amital-Teplizki H, Mendlovic S, Blank M, Mozes E, Isenberg DA. The role of the human anti-DNA idiotype 16/6 in autoimmunity. Clin Immunol Immunopathol 51:313-325, 1989.
283. Malatzky-Goshen E, Shoenfeld Y. AIDS and autoimmunity. Autoimmunity 3:201-212, 1989.
284. Shoenfeld Y, Segol O. Anti-histone antibodies in SLE and other autoimmune diseases. Clin Exp Rheumatol 7:265-271, 1989.
285. Hundert I, Bakimer R, Amital-Teplizki H, Slor H, Yassur Y, Palestine A, Nussenblatt RB, Shoenfeld Y. Antinuclear autoantibodies in uveitis. Clin Exp Rheumatol 7:237-241, 1989.
286. Amital-Teplizki H, Shoenfeld Y. Chorea: A rare expression of neuropsychiatric manifestation of SLE. Isr J Med Sci 25:549-551, 1989.
287. Vardy DA, Khoury M, Ben-Meir P, Ben-Yakar Y, Shoenfeld Y. Full skin thickens burns caused by contact with the pavement in a heat stroke victim. Burns 15:115-116, 1989.
288. Zurgil N, Konikoff F, Bakimer R, Slor H, Shoenfeld Y. Detection of anti-mitochondrial antibodies characterization by ELISA and immunoblotting. Autoimmunity 4:289-293, 1989.
289. Grunebaum E, Malatzky-Goshen E, Shoenfeld Y. Natural Killer cells and autoimmunity. Immunol Res 8:292-304, 1989.
290. Abu-Shakra M, Shoenfeld Y. Gm allotype system and autoimmune diseases. Immunol Res 8:282-291, 1989.
291. Shoenfeld Y. Experimental and induced animal models of SLE and Sjogren's syndrome. Current Opinion in Rheumatology 1: 360-368, 1989.
292. Slor H, Shafir S, Isenberg DA, Granados J, Alarcon-Segovia D, Shoenfeld Y. The genetic of autoimmunity: The familial tendency of SLE. Isr J Med Sci 25:678-682, 1989.
293. Shoenfeld Y. Why are autoimmune diseases so diversified? Pathogenic idiotypes-an additional etiological factor. Isr J Med Sci 25:667-669, 1989.
294. Shoenfeld Y. Is SLE an autoimmune disease? The role of pathogenic idiotypes. Harefuah 117:333-337, 1989.
295. Mozes E, Brocke S, Fricke H, Dayan M, Shoenfeld Y, Mendlovic S. New experimental autoimmune models. Isr J Med Sci 25:692-695, 1989.
296. Mozes E, Brocke S, Shoenfeld Y, Mendlovic S. The role of idiotype network in the induction of experimental SLE. J Cell Biochem 40:173-181, 1989.
297. Konikoff F, Isenberg DA, Barrison I, Theodor E, Shoenfeld Y. Antinuclear autoantibodies in chronic liver diseases. Hepatogastroenterol 36:341-345, 1989.

298. Yadin O, Sarov B, Naggan L, Shoenfeld Y. Familial studies on the occurrence of natural autoantibodies. Nat Immun Growth Regul 8:325-330, 1989.
299. Arad-Dann H, Isenberg J, Sperling R. Autoantibodies against a nuclear 56Kd protein: a marker for inflammatory muscle disease. J Autoimmunity 2:877-888, 1989.
300. Tomer Y, Shoenfeld Y. The significance of T-suppressor cells in the development of autoimmunity. J Autoimmunity 2:739-758, 1989.
301. Amital-Teplizki H, Avnoach I, Coates ARM, Kooperman O, Blank M, Shoenfeld Y. Binding of monoclonal anti-DNA and anti-TB glycolipid to brain tissue. Autoimmunity 4:277-287, 1989.
302. Blank M, Palestine A, Nussenblatt R, Shoenfeld Y. Down regulation of autoantibody levels by cyclosporine and bromocriptine in patients with uveitis. Clin Immunol Immunopathol 54:87-94, 1990.
303. Huminer D, Tomer Y, Pitlick S, Shoenfeld Y. Autoantibodies in cancer patients: are they tumor related or age related. Autoimmunity 5:232-233, 1990.
304. Page SH, Dudeney C, Hall S, Shoenfeld Y, Isenberg DA. Disease specificity of antibodies to poly (ADP-Ribose): Their relationship to anti-DNA antibodies and to disease activity in lupus. Autoimmunity 5:169-177, 1990.
305. Thomas MAB, Frampton G, Isenberg DA, Shoenfeld Y, Akinsola A, Ramzy M, Lilliywhite J, Williams DGA. Common anti-DNA idiotype and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. J Autoimmunity 2:803-812, 1989.
306. Blank M, Krup M, Mendlovic S, Fricke H, Mozes E, talal N, Coates ARM, Shoenfeld Y. The importance of the pathogenic 16/6 idiotype in the induction of SLE in naive mice. Scand J Immunol 31:45-52, 1990.
307. Piura B, Shoenfeld Y. Recurrent abortions and the primary anti-phospholipid syndrome. Harefuah 118:158-161, 1990.
308. Konnikoff F, Pecht M, Theodore E, Shoenfeld Y. Primary biliary cirrhosis: lymphocyte subsets and function in a time frame. Hepatology 10:526-527, 1989.
309. Assali A, Shoenfeld Y. Renal crisis with normal blood pressure in a patient with scleroderma. Harefuah 118:319-320, 1990.
310. Blank M, Sredni B, Albeck M, Mozes E, Shoenfeld Y. The effect of the immuno modulator agent AS-101 on interleukin-2 production in SLE induced in mice by a pathogenic anti-DNA antibody. Clin Exp Immunol 79:443-447, 1990.
311. Swissa M, Shoenfeld Y. Immunological abnormalities in autoimmune liver diseases. Harefuah 118:264-268, 1990.
312. Mendlovic S, Brocke S, Fricke H, Shoenfeld Y, Bakimer R, Mozes E. The genetic regulation of the induction of experimental SLE. Immunology 69:228-236, 1990.
313. Goshen E, Livne A, Nagy J, Sarov I, Shoenfeld Y. Antinuclear autoantibodies in sera of patients with IgA nephropathy. Nephron 55:33-36, 1990.
314. Shoenfeld Y, Mozes E. Pathogenic idiotypes of antibodies and autoimmunity: A lesson from a new syndrome of experimental SLE. FASEB J 4:2646-2651, 1990.
315. Blank M, Mendlovic S, Fricke H, Mozes E, Talal N, Shoenfeld Y. Sex hormone involvement in the induction of experimental SLE by a pathogenic anti-DNA idiotype in naive mice. J Rheumatol 17:311-317, 1990.
316. Shoenfeld Y. Idiotypes and autoimmunity. Curr Opinion in Immunol 2:593-597, 1990.

317. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia: unresolved enigma. Cancer 65:2554-2558, 1990.
318. Abu-Shakra M, Shoenfeld Y. Human anti-DNA idiotype (16/6 idiotype): pathogenic role in autoimmunity. Human Ab hybridomas 1:10-14, 1990.
319. Avinoah I, Amital-Teplizki H, Kuperman O, Isenberg DA, Shoenfeld Y. Characteristics of anti-neuronal antibodies in SLE patients with and without CNS involvement: The role of mycobacterial cross-reacting antigens. Isr J Med Sci 26:367-373, 1990.
320. Avishar R, Cretzer D, Shoenfeld Y, Cohen A, Savir H. Hyperviscosity syndrome and eye involvement. Harefuah 118:696-699, 1990.
321. Mackworth-Young CG, Shoenfeld Y. Future directions in anti-DNA antibody idiotype research. J Autoimmunity 3:389-393, 1990.
322. Isenberg DA, Bakimer R, Diamond B, ebling F, Hahn B, Rauch J, Schwartz RS, Shoenfeld Y, Staines NA, Zouali M, Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. J Autoimmunity 3:393-415, 1990.
323. Shoenfeld Y. New autoimmune conditions. Isr J Med Sci 26:663-666, 1990.
324. Zurgil N, Bakimer R, Slor H, Kaplan M, Moutsopoulos H, Shoenfeld Y. Pyruvate dehydrogenase as an antigen to detect anti-mitochondrial antibodies. Isr J Med Sci 26:682-686, 1990.
325. Mozes E, Mendlovic S, Kalush F, Waisman A, Shoenfeld Y, Fricke H. Immunoregulation of autoimmune diseases. Isr J Med Sci 26:688-691, 1990.
326. Asali S, Shoenfeld Y. Vitamin D and the immune system. Harefuah 119:390-392, 1990.
327. Abu-Shakra M, Krup M, Slor Y, Shoenfeld Y. Anti-Sm-RNP activity in sera of patients with rheumatic and autoimmune diseases. Clin Rheumatol 9:346-355, 1990.
328. Mendlovic S, Segal R, Shoenfeld Y, Mozes E. Anti-DNA idiotype and anti-idiotype specific T cell responses in patients with SLE and their first degree relatives. Clin Exp Immunol 82:504-508, 1990.
329. Stein N, Tomer Y, Shoenfeld Y. High levels of bilirubin in hepatitis A infection of a patient with G6PD deficiency. Harefuah 119:126-130, 1990.
330. Shachar A, Shoenfeld Y. Additional applications to captopril. Harefuah 119:280-284, 1990.
331. Tomer Y, Kessler A, Many A, Shoenfeld Y. Superior vena cava occlusion in a patient with antiphospholipid syndrome. J Rheumatol 18:95-97, 1991.
332. Fricke H, Offen D, Mendlovic S, Shoenfeld Y, Bakimer R, Sperling J, Mozes E. Induction of experimental SLE in mice by immunization with a monoclonal anti-La autoantibody. Int Immunol 2:225-230, 1989.
333. Blank M, Smorodinsky NI, Keydar I, Chaitchik S, Shoenfeld Y. The production of human monoclonal anti-MMTV antibodies by in vitro immunization with anti-idiotypic antibodies. Immunol Lett 28:65-72, 1991.
334. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome by passive transfer of anti-cardiolipin antibodies. Proc Nat Acad Sci 88:3069-3073, 1991.
335. Shoenfeld Y. Ageing, autoantigen specific Ts cells, involution of the thymus, autoimmunity and autoimmune diseases. Autoimmunity 8:251-252, 1991.
336. Livneh A, Zemer D, Pras M, Shoenfeld Y. Activity scores in systemic lupus erythematosus. Harefuah 120:134-138, 1991.

337. Tomer Y, Shoenfeld Y. The erythrocyte sedimentation rate in modern medicine. *Harefuah* 120:199-203, 1991.
338. Buskila D, Shoenfeld Y, Averbuch Heller Z, Abramsky O. Neurologic complications in primary Sjogren's syndrome. *Harefuah* 120:260-263, 1991.
339. Swissa M, Schul V, Korish S, Livneh A, Pras M, Shoenfeld Y. Determination of autoantibodies in patients with familial Mediterranean fever and their first degree relatives. *J Rheumatol* 18:606-608, 1991.
340. Weiss P, Shoenfeld Y. Shifts in autoimmune diseases: the kaleidoscope of autoimmunity. *Isr J Med Sci* 27:216-217, 1991.
341. Weiss P, Shoenfeld Y. Primary biliary cirrhosis is a multisystem disorder. *Ann Med Intern* 142:283-287, 1991.
342. Amital-teplizki H, Shoenfeld Y. Has schizophrenia an immunologic basis. *Harefuah* 120:392-394, 1991.
343. Tomer Y, Shoenfeld Y. The idiotypic network in autoimmunity. *Giorn It Allergol Immunol Clin* 1:3-15, 1991.
344. Asaly A, Shany S, Shoenfeld Y. Increased serum levels of vitamin D metabolites in black Bedouins with benign familial leukopenia. *Eur J Int Medicine* 2:55-61, 1991.
345. Shoenfeld Y, Khoury M, Ben-Yehuda O, Sela O, Abu-Shakra M, Goshen E. Hypophosphatemia in sepsis. *Eur J Int Med* 2:67-72, 1991.
346. Rahama D, Abu-Shakra M, Shoenfeld Y. Parasites and autoimmunity. *Harefuah* 121:104-108, 1991.
347. Rotem Y, Shoenfeld Y. Bibliography - the Achilles heel of medical articles. *Harefuah* 121:63-64, 1991.
348. Stein M, Reshef A, Shoenfeld Y. The significance of anti-neutrophil cytoplasmic antibody (ANCA). *Harefuah* 120:592-596, 1991.
349. Levy Y, Shoenfeld Y. Raynaud's phenomenon-can we predict a systemic disease? *Harefuah* 120:660-663, 1991.
350. Abu-Shakra M, Shoenfeld Y. Parasitic infection and autoimmunity. *Autoimmunity* 9:337-344, 1991.
351. Fricke H, Mendlovic S, Blank M, Shoenfeld Y, Ben-bassat M, Mozes E. Idiotypic specific T cell lines inducing experimental SLE in mice. *Immunology* 73:421-427, 1991.
352. Tomer Y, Cohen J, Shoenfeld Y. Clinical aspects of antiphospholipid antibody syndrome. *Harefuah* 120:514-520, 1991.
353. Grunebaum E, Chaitchuk S, Shoenfeld Y. Pancreatic carcinomas, sex hormones receptors and treatment with tamoxifen. *Harefuah* 120: 340-343, 1991.
354. Piura B, Tauber J, Slor H, Shoenfeld Y. Antinuclear autoantibodies in healthy nonpregnant and pregnant women and their offspring. *Amer J Reproductive Immunol* 26:28-31, 1991.
355. Buskila D, Shoenfeld Y. Anti-DNA idiotypes. Their pathogenic role in autoimmunity. *Clin Molecular Aspects of Autoimmune Diseases (Karger)* 8:85-113, 1992.
356. Buskila D, Shoenfeld Y. Manipulation of anti-DNA idiotypes. A possible treatment approach to autoimmune diseases. *Clin Molecular Aspects of Autoimmune Diseases (Karger)* 8:114-129, 1992.
357. Shoenfeld Y. Pathogenic anti-DNA idiomorph (16/6 Id) in SLE. *Rheumatology* 11:91-96, 1991.
358. Firer M, Spivak T, Shoenfeld Y, Silhor H. The effects of incubation temperature and coating procedure on the measurement of antibodies to cardiolipin. *J Immunol Methods* 143:31-39, 1991.

359. Zurgil N, Bakimer R, Kaplan N, Youinou P, Shoenfeld Y. Anti-pyruvate dehydrogenase in primary biliary cirrhosis. J Clin Immunol 11:239-245, 1991.
360. Argov S, Shattner Y, Burstein R, Handzel ZT, Shoenfeld Y. Autoantibodies in male homosexuals and HIV infection. Immunol Lett 30:31-36, 1991.
361. Blank M, Ben-Bassat M, Shoenfeld Y. Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA antibody idiotype. Cell Immunol 137:474-486, 1991.
362. Blank M, Mendlovic S, Mozes E, Coates ARM, Shoenfeld Y. Induction of SLE in naive mice with T cell lines specific for human anti-DNA antibody SA-1 (16/6 Id<sup>+</sup>) and for mouse tuberculous antibody (TB/68) antibody (16/6 Id<sup>+</sup>). Clin Immunol Immunopathol 60:471-483, 1991.
363. Tomer Y, Mendlovic S, Kukulansky T, Mozes E, Shoenfeld Y, Globerson A. Effects of aging on the induction of SLE in mice. Mechanisms of Ageing and Development 58:233-244, 1991.
364. Vilarreal GM, Alarcon-Segovia D, Villa AR, Cabral AR, Shoenfeld Y. Presence of a 16/6 related human anti-DNA common idiotype (SA1) in the anti-cardiolipin antibodies of patients with primary antiphospholipid syndrome. J Rheumatol 18:1537-1541, 1991.
365. Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Amer J Reprod 26:118-123, 1991.
366. Shoenfeld Y, Ferrone S, Bombardieri S. New aspects in the treatment of immunomediated diseases. Clin Exp Rheumatol 9:663-673, 1991.
367. Dannenberg Gh.D., Shoenfeld Y. Stress reaction and the immune system. Harefuah 120:455-459, 1991.
368. Shoenfeld Y. Primary biliary cirrhosis and autoimmune rheumatic diseases: Prediction and prevention. Isr J Med Sci 28:113-116, 1992.
369. Shoenfeld Y. Biochis H, Abramsky O. Will physicians-researchers vanish? Harefuah 122: 122-123, 1992.
370. Shoenfeld Y, Meroni PL. The beta-2 glycoprotein-I ( $\beta_2$ -GP-I) and anti-phospholipid antibodies. Clin Exp Rheumatol 10:205-208, 1992.
371. Tomer Y, Neufeld MY, Shoenfeld Y. Coma with triphasic wave pattern in EEG as a complication of temporal arteritis. Neurology 42:439-440, 1992.
372. Shoenfeld Y, Rotem Y. Homeopathy: permit or forbid. Harefuah 122:195-196, 1992.
373. Levy Y, Shoenfeld Y. Viral and autoimmune mechanisms in the etiology of dilated idiopathic cardiomyopathy. Harefuah 122:245-249, 1992.
374. Tomer Y, Shoenfeld Y. The relationship between the lupus anticoagulant, anti-cardiolipin antibodies and anti-phospholipid antibodies. Isr J Med Sci 28:38-41, 1992.
375. Zurgil N, Bakimer R, Moutsopolous HM, Youinou P, Kaplan MM, Shoenfeld Y. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 12:201-209, 1992.
376. Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leukemia and Lymphoma 7:117-122, 1992.
377. Zandman-Goddard G, Shoenfeld Y. Leukomoid reaction in a patient with pulmonary edema. Isr J Med Sci 28:307, 1992.
378. Teplizki-Amital H, Sela B, Shoenfeld Y. Autoantibodies to brain polynucleotides in patients with schizophrenia. Immunol Res 11:66-73, 1992.

379. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 89:1558-1663, 1992.
380. Krause I, Cohen J, Blank M, Bakimer R, Cartman A, Hohmann A, Valesini G, Asherson RA, Kamashta MA, Hughes GRV, Shoenfeld Y. Distribution of two common idiotypes of anti-cardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, SLE and monoclonal gammopathies. Lupus 1:91-96, 1992.
381. Shoenfeld Y, S;pr J. Shafir S, Krause I, granados J, Villarreal GM, Alarcon-Segovia D. Diversity and pattern of inheritance of autoantibodies in families with multiple cases of SLE. Ann Rheum Dis 51:611-818, 1992.
382. Weiss P, Shoenfeld Y. Anti-mitochondrial autoantibodies in primary biliary cirrhosis: breaking the code. Giorn It Allergol Immunol Clin 1:583-592, 1991.
383. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 10:391-393, 1992.
384. Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiootype. J Autoimmunity 5:495-509, 1992.
385. Fishman P, Shoenfeld Y, Hart J, Zigelman R, Shamir Y, Feldberg D, Inbar O, Sredni D, Djaldetti M. Interleukin-3 like activity levels in pregnant wome: possible modulation by progesterone. J Reprod Immunol 22:211-216, 1992.
386. Shoenfeld Y, Alarcon-Segovia D. The mosaic of SLE: Highlights of the third international conference on SLE. Lupus 1:269-283, 1992.
387. Amital-Teplizki H, Bearman JE, Miele JR, Sukenik S, Shoenfeld Y. A multidimensional autoantibody analysis specifying SLE patients with neuropsychiatric symptomatology. Isr J Med Sci 28:422-427, 1992.
388. Weiss P, Shoenfeld Y. Primary biliary cirrhosis: Increasing problem. Isr J Med Sci 28:726-728, 1992.
389. Schlesinger N, Ben-Bassat C, Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res 11:98-103, 1992.
390. Shoenfeld Y, Meroni PL. The beta-2 glycoprotein I and antiphospholipid antibodies. Clin Exp Rheumatol 10:205-209, 1992.
391. Fishman P, Shoenfeld Y. Vitiligo as an autoimmune disease. Harefuah 123:339-341, 1992.
392. Fishman P, Bakimer R, Blank M, sredni D, Djaldetti M, Shoenfeld Y. The putative role of cytokines in the induction of primary anti-phospholipid syndrome. Clin Exp Immunol 90:266-270, 1992.
393. Buskila D, Weige D, Shoenfeld Y. The detection of anti-Ro/SS-A and anti-La/SS-B activity of human serum monoclonal immunoglobulins (monoclonal gammopathies). Hum Antibod Hybridoma 3:75-80, 1992.
394. Amital H, Klemperer I, blank M, Yassar Y, Palestine A, Nussenblatt RB, Shoenfeld Y. Analysis of autoantibodies among patients with primary and secondary uveitis: high incidence in patients with sarcoidosis. Int Arch Allergy Immunol 99:34-36, 1992.
395. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 10:391-393, 1992.
396. Shoenfeld Y. Pathogenic natural autoantibodies. Isr J Med Sci 29:142-145, 1992.
397. Fishman P, Shoenfeld Y. Cytokines, interleukin-3 and autoimmunity. Isr J Med Sci 29:159-164, 1992.

398. Shoenfeld Y. Induction of experimental primary and secondary anti-phospholipid syndrome in anive mice. Amer J Reproduct Immunol 28:219-222, 1992.
399. Blank M, Ben-Bassat M, Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheumat 35:1350-1355, 1992.
400. Vitali C, Bombardieri S, Moutsopoulos M, Shoenfeld Y, et al. Preliminary criteria for the classification of Sjogren's syndrome. Arthritis Rheumat 36:340-347, 1993.
401. Finkelstein Y, Adler Y, Lorber M, Shoenfeld Y. Anti-phospholipid syndrome in young persons with acute myocardial infarction. Harefuah 124:146-149, 1993.
402. Shoenfeld Y. What is going to happen as for the prediction of autoimmune disorders is concerned. Ann Med Intern 143:525-526, 1992.
403. Levy Y, Shoenfeld Y. Treatment of Raynaud's phenomenon. Harefuah 124:288-291, 1993.
404. Zarhari D, Shoenfeld Y. Polymyositis and anti-Jo-1 antibodies. Harefuah 124:206-210, 1993.
405. Tomer Y, Buskila D, Shoenfeld Y. Pathogenic significance and diagnostic value of lupus autoantibodies. Int Arch Allergy Immunology 100:293-306, 1993.
406. Gruschwitz MS, Shoenfeld Y, Krupp M, Gershwin ME, Penner E, Brezinschcek HP, Wick G. Antinuclear antibody profile in UCD line 200 chickens: A model for progressive systemic sclerosis. Int Arch Allergy Immunol 100:307-313, 1993.
407. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, Shoenfeld Y. Prevention of fetal-loss in experimental anti-phospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 91:1834-1837, 1993.
408. Shoenfeld Y, Blank M, Aharoni R, Teitelbaum D, Arnon R. Manipulation of autoimmune diseases with T-suppressor cells: lesson from experimental SLE and EAE. Immunol Lett 36:109-116, 1993.
409. Shoenfeld Y. The pneumonia-urinary tract infection syndrome: Loss of diagnostic ability in medicine. Harefuah 124:590-592, 1993.
410. Krause I, Buskila D, Shoenfeld Y. Prolactin and bromocriptine in rheumatic and autoimmune diseases. Harefuah 124:775-779, 1993.
411. Shoenfeld Y. Pathogenic natural autoantibodies. Clin Immunol News Lett 13:13-36, 1993.
412. Dueymes M, barrier J, Shoenfeld Y, Youinou P. Relationship of interleukin-4 to isotypic distribution of anti-dsDNA antibodies in SLE. Int Arch Allergy Immunol 101:408-415, 1993.
413. Inbar Y, Zurgil N, gilburt C, Shoenfeld Y. Antimitochondrial antibodies and primary biliary cirrhosis. Harefuah 125:148-153, 1993.
414. Kra-Oz Z, Lorber M, Shoenfeld Y, Scharff Y. Inhibitions of natural anti-cardiolipin autoantibodies. Clin Exp Immunol 93:265-268, 1993.
415. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by low molecular weight heparin. Amer J Obstet Gynecol 169:423-426, 1993.
416. Krause I, Blank M, gilburt B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Repro Immunol 29:155-161, 1993.
417. Shoenfeld Y. The kaleidoscope of autoimmunity. Autoimmunity 15:245-251, 1993.

418. Shurtz-Swirsky R, Inbar O, Blank M, Cohen J, Bakimer R, Barnea ER, Shoenfeld Y. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Amer J Reproduc Immunol 29:206-210, 1993.
419. Grenbaum E, Lanfer M, Shoenfeld Y. Autoantibodies in systemic sclerosis. Harefuah 124:370-374, 1993.
420. Neshet G, Blank M, Shoenfeld Y. The perinuclear factor - a specific diagnostic marker for rheumatoid arthritis. Harefuah 124:415-419, 1993.
421. Maran R, Dueymes M, Pennec YL, Casburn-Budd R, Shoenfeld Y, Youinou P. Predominance of IgG subclass of anti-Ro/SS-A, but not anti-La/S-B antibodies in primary Sjogren's syndrome. J Autoimmunity 6:379-387, 1993.
422. Shoenfeld Y. Car accident - a personal angle. Harefuah 1993; 124: 445 – 448.
- 422a. Shoenfeld Y. Car accident - a personal angle. Isr J Med Sci 1993; 29:484 - 488.
423. Shoenfeld Y. Induction of experimental models in autoimmunity. Harefuah 123:528-534, 1992.
424. Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yechezkel G, Ferrone S, Zigelman R, Chaitchik S, Djaldetti M. Vitiligo autoantibodies are effective against melanoma. Cancer 72:2365-2367, 1993.
425. Zandman-Goddard G, Ehrenfeld M, Shoenfeld Y. Silicone implants for breast augmentation and autoimmune diseases. Harefuah 125:360-364, 1993.
426. Benbassat C, Schlesinger M, Luderschmidt C, Valentini G, Tirri G, Shoenfeld Y. The complement system and systemic sclerosis. Immunol Res 12:312-315, 1993.
427. Bakimer R, Gilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gammaglobulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 69:97-102, 1993.
428. Fishman P, Shoenfeld Y. Lessons from experimental anti-phospholipid syndrome. Semin Clin Immunol 6:39-46, 1993.
429. Zurgil N, Bakimer R, Tincani A, Faden D, Cohen J, Lorber M, Valesini G, Shoenfeld Y. Detection of anti-phospholipid and anti-DNA antibodies and their idiotypes in newborns of mothers with anti-phospholipid syndrome and SLE. Lupus 2:233-238, 1993.
430. Cohen J, Bakimer R, Blank M, Valesini G, Shoenfeld Y. Pathogenic serum IgG anti-cardiolipin antibodies and the idiotypic network. Ann Rheumat Dis 52:742-748, 1993.
431. Amital H, Shoenfeld Y. Autoimmunity and schizophrenia: an epiphenomenon or an etiology. Isr J Med Sci 29:593-597, 1993.
432. Buskila D, Shoenfeld Y. Anti-DNA Idiotypes: Their Pathogenic Role in Autoimmunity. In: Concept in Immunopathol Clin and Molec Aspects of Autoimmune Dis. 8:85-114, 1993.
433. Buskila D, Shoenfeld Y. Manipulation of Anti-DNA Idiotypes: A Possible Treatment Approach to Autoimmune Disease. In: Concept in Immunopathol Clin and Molec Aspects of Autoimmune Dis. 8:114-128, 1993.
434. Cohen AD, Cohen Y, Shoenfeld Y. Ca 15-3 a tumor marker in breast cancer. Harefuah 125:484-488, 1993.
435. Gilburd B, Stein M, Tomer Y, Tanne D, Abramski O, Chapman Y, Ahiron A, Blank M, Shoenfeld Y. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic. Autoimmunity 16:23-27, 1993.
436. Shoenfeld Y. Idiotypic induction of autoimmunity: A new classification of autoimmune diseases. Isr J Med Sci 2:11-14, 1994.



437. Fishman P, Kamashta M, Ehrenfeld M, Vianna J, Hughes GRV, sredni D, Zigelman R, Sabo G, Shoenfeld Y. Interleukin-3 immunoassay in systemic lupus erythematosus patients: preliminary data. Int Arch Allergy Immunol 100:215-218, 1993.
438. Cohen JR, Luxman D, Bakimer R, Blank M, David MP, Shoenfeld Y. The antiphospholipid syndrome (APLS): obstetric and reproductive impacts. Isr J Obstet Gynecol 4:19-21, 1993.
439. Yativ N, Buskila D, Blank M, burek CL, rose NR, Shoenfeld Y. The detection of antithyroglobulin activity in human serum monoclonal immunoglobulins (monoclonal gammopathies). Immunol Res 12:330-337, 1993.
440. Shoenfeld Y. The significance of experimental models of systemic lupus erythematosus and anti-phospholipid syndrome induced by idiotypic manipulation. Isr J Med Sci 30:10-18, 1993.
441. Ben-Bassat K, Schlesinger M, Shoenfeld Y. The complement system in primary biliary cirrhosis. J Clin Lab Immunol 38:51-61, 1993.
442. Buskila D, Shoenfeld Y. Animal models of SLE in : G.S. Panayi (Ed): Immunology of the Connective tissue Diseases. Kluwer Academic Pub. Boston, USA 22:157-192, 1993.
443. Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 21:100-104, 1994.
444. Amital-Teplizki H, Shoenfeld Y. Early detection of autoimmune diabetes mellitus. Harefuah 126:211-214, 1994.
- 444a. Cohen A. D, Shoenfeld Y, Gopas J, Cohen Y. Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels. Breast Cancer Research and Treatment 30: 197-200, 1994.
445. Shoenfeld Y. Idiotypic induction of autoimmune disease: in: The Impact of Biotechnology on Autoimmunity. Eds: Dalglish AG, Albertini A, Paoletti R. Kluwer Academic Publishers. 1994 pp. 73-80.
446. Gilburd B, Stein M, Tomer Y, Tanne D, Abramsky O, Chapman Y, Ahiron A, Blank M, Shoenfeld Y. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic? Autoimmunity 16:23-27, 1993.
447. Avidan B, Maran R, Shoenfeld Y. Early detection of micrometastases. Harefuah 126:268-271, 1994.
448. Cohen AD, Piura B, Cohen Y, Shoenfeld Y. CA-125 in the diagnosis and prognosis of epithelial ovarian cancer. Harefuah 126:283-285, 1994.
449. Yodfat O, Shoenfeld Y. Penicillamine - A friend or an enemy. Harefuah 126:328-334, 1994.
450. Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, Guedes LH, Shoenfeld Y. Anti-mitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol 14:14019, 1994.
451. Asherson RA, Shoenfeld Y. The significance of antibodies to DNA in the primary antiphospholipid syndrome. Clin Exp Rheumatol 12:1-3, 1994.
452. Amital-Teplizki H, Shoenfeld Y. Early detection of autoimmune diabetes mellitus. Harefuah 126:211-214, 1994.
453. Ahmed AE, Peter JB, Shoenfeld Y. Autoimmune thrombocytopenia purpura. Clin Immunotherapeutics 1:348-357, 1994.
454. Shoenfeld Y. Idiotypic induction of autoimmune diseases: a new aspect of infection and autoimmunity. In: The Impact of Biotechnology on Autoimmunity. Edited Dalglish AG, Albertini A, Paoletti R. Kluwer Acad Pub 1994 Boston, USA.
455. Adler Y, Goddard G, Tomer Y, Ravid M, Eherfeld M, Shoenfeld Y, Zemer D. Usefulness of colchicine in preventing recurrences of pericarditis. Amer J Cardiol 73:916-917, 1994.

456. Valesini G, Shoenfeld Y. A new player in the antiphospholipid syndrome: The  $\beta_2$  glycoprotein I cofactor. Autoimmunity 14:105-110, 1992.
457. Reyes H, Dearing L, Shoenfeld Y, Peter JB. Anti-phospholipid antibodies: A critique of their heterogeneity and hegemony. Sem Thrombosis & Hemostasis 20:89-100, 1994.
458. Rahima D, Tarrab-Hazdai R, Blank M, Arnon R, Shoenfeld Y. Anti-nuclear antibodies associated with schistosomiasis and anti-schistosomal antibodies associated with SLE. Autoimmunity 17:127-141, 1994.
459. Zandman-Goddard G, Weiss P, Avidan B, Bar-Meir S, Shoenfeld Y. Acute varicella infection heralding Wilsonian crisis. J Clin gastroenterol 18:265-266, 1994.
460. Adler Y, Salozhin K, tonqueze ML, Shoenfeld Y, Youinou P. Anti-endothelial cell antibodies: a need for standardization. Lupus 3:77-84, 1994.
461. Merimsky O, Shoenfeld Y, Yechezkel G, Chaitchik S, Aziz E, Fishman P. Vitiligo-and melanoma - associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunopathol 38:411-416, 1994.
462. Baharav M, Fishman P, Shoenfeld Y. Superantigens and autoimmunity. Harefuah 126:715-719, 1994.
463. Cohen J, Bakimer R, Blank M, valesini G, Shoenfeld Y. Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy. Clin Exp Immunol 97:181-186, 1994.
464. Tomer Y, Blank M, Shoenfeld Y. Suppression of experimental antiphospholipid syndrome and SLE in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum 8:1236-1244, 1994.
465. Kronenberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor like activity in monocytes by anti-cardiolipin antibodies. J Immunology 153:1328-1332, 1994.
466. Tishler M, Aharon A, ehrenfeld M, Avni I, Bendet E, Bombardieri S, Yaron M, Shoenfeld Y. Sjogren's syndrome in Israel: Primary versus secondary disease. Clin Rheumatol 13:438-441, 1994.
467. Shoenfeld Y, Fishman P. Role of Il-3 in the antiphospholipid syndrome. Lupus 3:259-261, 1994.
468. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y. Immunization with anticardiolipin cofactor ( $\beta_2$ GP-I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmunity 7:441-455, 1994.
469. Buskila D, Shoenfeld Y. Anti-DNA antibodies: Their idiotypes and SLE. Clin Rev Allergy 12:237-253, 1994.
470. Tishler Y, Gilburd B, Shoenfeld Y, Yaron M. Anti-Ro (SSA) antibodies in patients with rheumatoid arthritis - a possible marker for gold induced side effects. J Rheumatol 21:1040-1042, 1994.
471. Bakimer R, Cohen JR, Shoenfeld Y. What really happens to fecundity in autoimmune diseases? Immunol Allergy Clinics North Amer 14:701-724, 1994.
472. Shoenfeld Y, Amital H, Ferrone S, Kennedy RC. Anti-idiotypes and their application under autoimmune, neoplastic and infections conditions. Int Arch Allergy Immunol 105:211-224, 1994.
473. Bendet E, Ehrnfeld M, Avni I, Tishler M, Nacadeziv S, Kronenberg J, Shoenfeld Y. Consensus: Diagnostic criteria for Sjogren's syndrome. Harefuah 127:342-344, 1994.
474. Mozes E, Shoenfeld Y. Experimental systemic lupus erythematosus: Role of the idiotypic network. In: Autoimmune Disease Models: A Guidebook. Ed: Cohen IR, Miller A. Academic Press Inc. USA. Pp. 245-253, 1994.
475. Merimsky O, Shoenfeld Y, Chaitchik S, Yechezkel G, Fishman P. Antigens and antibodies in malignant melanoma. Tumor Biol 15:188-202, 1994.

476. Levy Y, Dueymes M, Pennec YL, Shoenfeld Y, Youinou P. IgA in Sjogren's syndrome. Clin Exp Rheumatol 12:543-551, 1994.
477. Amital H, Shoenfeld Y. Thromboembolic events in heparin induced thrombocytopenia. Harefuah 127:448-450, 1994.
478. Maran R, Deuyes M, Adler Y, Shoenfeld Y. Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members. J Clin Immunol 14:723-326, 1994.
479. Lorber M, Gershwin ME, Shoenfeld Y. The coexistence of SLE with other autoimmune diseases: The kaleidoscope of autoimmunity. Sem Arthritis Rheum 24:105-113, 1994.
480. Blank M, Manosroi J, Tomer Y, Manosroi A, Kopolovic J, Charcon-Polak S, Shoenfeld Y. Suppression of experimental SLE with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol 98:434-441, 1994.
481. Shoenfeld Y, Blank M. Effect of long acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. Lupus 3:397-400, 1994.
482. Aharon A, Zandman-goddard g, Shoenfeld Y. Autoimmune multiorgan involvement in elderly men, is it SLE? Clin Rheumatol 13:631-635, 1994.
483. Amital H, Schiby G, Rosenmann Y, Shoenfeld Y. Clinico-pathological conferences: When assumptions are insufficient: Sarcoidosis. Harefuah 127:564-568, 1994.
484. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 8:1296-1301, 1994.
485. Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rozman B, Shoenfeld Y. Anticardiolipin antibodies in infections are heterogeneous in their dependency on  $\beta_2$ -glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus 3:515-521, 1994.
- 485a Baudet-Pommel M, Albuissou E, Kemeny JL, Falvard F, Ristori JM, Fraysse MP, Sauvezie B, and the European Community study group on diagnostic criteria for Sjogren's syndrome (EEC COMAC), Clermont-Ferrand, Lille, Paris, and Brest, France; Pisa, Brescia, Padua, and Rome, Italy; Ioannina, Greece; Manchester, London, Bath, and Bristol, United Kingdom; Copenhagen, Denmark; Barcelona, Spain; Tel-Hashomer and Tel Aviv, Israel (Ehrenfeld M, and Shoenfeld Y); Erlangen, Germany; Utrecht, The Netherlands; Helsinki, Finland; Malmo, Sweden; and Vienna, Austria.  
Early dental loss in Sjogren's syndrome. Histologic correlates. Oral Surg Oral Med Pathol. 78: 181-6, 1994.
486. Shoenfeld Y, Tomer Y, Blank M. A new experimental model for Wegener's granulomatosis. Isr J Med Sci 31:13-16, 1995.
487. Aron AL, Gharavi AE, Shoenfeld Y. Mechanisms of action of antiphospholipid antibodies in the antiphospholipid syndrome. Int Arch Allergy Immunol 106:8-12, 1995.
488. Lorber M, Kra-Oz Z, Gilburd B, Shoenfeld Y. Natural (anti-phospholipid-PDH-DNA) autoantibodies and their physiologic serum inhibitors. Isr J Med Sci 31:31-35, 1995.
489. Zandman-Goddard G, Langevitz P, Shoenfeld Y. Anti-thymocyte globulin therapy in autoimmune diseases. Harefuah 128:104, 1995.
490. Cohen AD, Shoenfeld Y. Goodpasture's syndrome as an autoimmune disease - identification of the autoantigen. Harefuah 128:100-103, 1995.
- 490a. Paz Y, Shoenfeld Y. The treatment of a widespread cancer of the colon and rectum: quality of life vs pronlongation of life? Harefuah 128: 231-233, 1995.

491. Blank M, Krauze I, Lanir N, Vardi P, Gilburd B, Tincani A, Tomer Y, Shoenfeld Y. Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation, the importance of the T cell. Arth Rheum 1: 115-122, 1995.
492. Reyes H, Dearing L, Bick RL, Shoenfeld Y, Peter JB. Laboratory diagnosis of antiphospholipid syndrome. Clin Lab Med 15:85-109, 1995.
493. Amital H, Tur-Caspa I, Hendler I, Shoenfeld Y. Catalytic antibody-structure and possible applications. Harefuah 128:295-299, 1995.
494. Shoenfeld Y, Blank M, Fishman P. Antiphospholipid syndrome: from the laboratory bench to the patients' bedside. Lupus 4 (suppl) 1:S33-S36, 1995.
495. Shoenfeld Y. Idiotypic induction of autoimmunity: do we need an autoantigen? Clin Exp Rheumatol 12 (suppl 11):S37-S40, 1994.
496. Buskila D, Shoenfeld Y. Disorders of the immune system leading to autoimmunity. In: Multi-Systemic Autoimmune Disease: An Integrated Approach. Eds: L. Kater Hb de la Faille. Elsevier, The Netherlands pp. 1-17, 1995.
497. Meroni PL, Khamashta MA, Youinou P, Shoenfeld Y. Mosaic of anti-endothelial antibodies: Review of the first international workshop on AECA. Clinical and pathological significance. Lupus 4:95-99, 1995.
498. Tishler M, Alosachie I, Chapman Y, Korcyn A, Lorber M, Mevorach D, Tane D, Barka N, Lin HC, Segovia DA, Youinou P, Peter JB, Shoenfeld Y. Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus. Lupus 4:145-147, 1995.
499. Blank M, Krause I, Buskila D, Teitelbaum D, Kopolovic J, Afek A, Goldberg I, Shoenfeld Y. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells. Cellular Immunol 162:114-122, 1995.
500. Cohen J, Bakimer R, David M, Shoenfeld Y. Early pregnancy loss and the antiphospholipid syndrome. In: Implantation and Early Pregnancy in Humans. Edited: Barnea ER, Check JH, Grudzinskas JG, Marno T. The Parthenon Pub Group, New-York, USA, pp. 333-354, 1994.
501. Bar-Meir E, Teuber SS, Lin HC, Alosacie I, Goddard G, Terrybery J, Barka N, Shen B, Peter JB, Blank M, Gershwin ME, Shoenfeld Y. Multiple autoantibodies in patients with silicone breast implants. J Autoimmunity 8:267-277, 1995.
502. Gilburd B, Weiss P, Bakimer R, Shoenfeld Y. Identification and characterization of antimitochondrial autoantibodies in sera of patients with monoclonal gammopathies. Immunol Lett 45:163-166, 1995.
503. Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA antibody that induces experimental SLE in mice is encoded by a V<sub>H</sub>4 gene segment. Int Immunol 7:689-696, 1995.
504. Shoenfeld Y. Anti-DNA antibodies: is DNA a self antigen or shelf antigen or are autoimmune rheumatic diseases immunogen driven? Rheumatol Europe 24:17-20 (supp 2), 1995.
505. Cohen J, Bakimer R, Shoenfeld Y. Fecundity in autoimmune diseases. Early Pregnancy Biology and Medicine. 1:93-105, 1995.
506. Bakimer R, Blank M, Kosashvilli D, Ichikawa K, Khamashta MA, Hughes GRV, Koike T, Shoenfeld Y. Antiphospholipid syndrome and the idiotypic network. Lupus 4:204-208, 1995.
507. Adler Y, Lamour A, Jamin C, Menez JF, Le Corre R, Shoenfeld Y, Youinou P. Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors. Clin Exp Rheumatol 13:315-319, 1995.
508. Le Tonqueze M, Salozhin K, Dueymes M, Piette JC, Kovalev V, Shoenfeld Y, Youinou P. Role of  $\beta_2$ -glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 4:179-186, 1995.

509. Shoenfeld Y. Idiotypic network, pathogenic autoantibodies and autoimmunity. Clin Exp Immunol 101 (suppl):26-28, 1995.
510. Youinou P, Meroni PL, Khamashta MA, Shoenfeld Y. A need for standardization of the anti-endothelial-cell antibody test. Immunol Today 16:363-364, 1995.
511. Aron AL, Cuellar RL, Brey RL, Meceown S, Espinoza LR, Shoenfeld Y. Early onset of autoimmunity in MRL/++ mice following immunization with  $\Gamma_2$  glycoprotein I. Clin Exp Immunol 101:78-81, 1995.
512. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, Shoenfeld Y. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 22:1068-1074, 1995.
513. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Rudniki C, Shoenfeld Y. Aspirin modulates interleukin-3 production: Additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 22:1086-1090, 1995.
514. Buskila D, Berezin M, Gur H, Lin HC, Alosachie I, Terryberry JW, Barka N, Shen B, Peter JB, Shoenfeld Y. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmunity 8:415-424, 1995.
515. Amital H, Tur-Kaspa I, Tashma Z, Hendler I, Shoenfeld Y. Catalytic antibodies: Structure and possible applications. In: Antibody Engineering Protocols. Ed. S. Paul Humana Press Totowa, New-Jersey 1995 pp. 203-210.
516. Zandmann-Goddard G, Lorber M, Shoenfeld Y. Systemic lupus erythematosus and thymoma - A double-edged sword. Int Arch Allergy Immunol 108:99-102, 1995.
517. Shoenfeld Y. Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 26:3211-3213, 1994.
518. Blank M, Tomer Y, Slavin S, Shoenfeld Y. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation. Scand J Immunol 42:226-234, 1995.
519. Cohen AD, Shoenfeld Y. Use and mechanism of action of IVIG in autoimmune diseases. Harefuah 129:123-126, 1995.
520. Adler Y, Finkelstein Y, Zandman-Goddard G, Blank M, Lorber M, Faden D, Shoenfeld Y. The presence of antiphospholipid antibodies in acute myocardial infarction. Lupus 4:309-313, 1995.
521. Blank M, Tomer Y, Stein M, Kopolovic J, Wiik A, Meroni PL, Conforti G, Shoenfeld Y. Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 102:120-129, 1995.
522. Baharav E, Merimsky O, Altomonte M, Shoenfeld Y, Pavlovic M, Malo M, Ferrone S, Fishman P. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Res 5:337-343, 1995.
523. George J, Shoenfeld Y. Infections, idiotypes and SLE. Lupus 4:333-335, 1995.
524. Green L, Vinker S, Amital H, Amir T, Bar-Dayana Y, Levi Y, Shoenfeld Y. Pseudotumor cerebri in systemic lupus erythematosus. Sem Arthritis Rheum 25:103-108, 1995.
525. Yanai-Landau H, Amital H, Bar-Dayana Y, Levy Y, Gur H, Lin HC, Alosachie IJ, Peter JB, Shoenfeld Y. Autoimmune aspects of primary pulmonary hypertension. Pathobiology 63:71-75, 1995.
526. Gur H, Shen G, Surjita M, Terryberry J, Alosachie I, Barka N, Lin HC, Peter JB, Meroni PL, Kaplan M, Gershwin E, Shoenfeld Y. Autoantibody profile of primary sclerosing cholangitis. Pathobiology 63:76-82, 1995.

527. Brik R, Tenenbaum G, Blank M, [Shoenfeld Y](#), Barzilai D, Bloch K, Vardi P. D-penicillamine-induced autoantibodies in a mouse model. [Clin Exp Rheumatol](#) 13:483-488, 1995.
528. Tishler M, Alosachie I, Barak N, Lin HC, Gershwin ME, Peter JB, [Shoenfeld Y](#). Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. [Clin Exp Rheumatol](#) 13:497-500, 1995.
529. Finkelstein Y, Adler Y, Levy Y, Youinou P, [Shoenfeld Y](#). Viral myocarditis: are we dealing with an autoimmune phenomenon? [Ann Med Intern](#) 146:322-324, 1995.
530. Levy Y, George J, [Shoenfeld Y](#). The occurrence of thromboembolic events following airplane flights - "The economy class syndrome". [Isr J Med Sci](#) 31:621-623, 1995.
531. Terryberry J, Sutjita M, [Shoenfeld Y](#), Gilburd B, Tanne D, Lorber M, Alosachie L, Barka N, Lin HC, Youinou P, Peter JB. Myelin-and microbe-specific antibodies in Guillain-Barre syndrome. [J Clin Lab Analysis](#) 9:308-319, 1995.
532. George J, [Shoenfeld Y](#). Atherosclerosis as an autoimmune disease. [Harefuah](#) 129:257-259, 1995.
533. [Shoenfeld Y](#), Blank M, Fishman P. Antiphospholipid syndrome: from the laboratory bench to the patients' bedside. [Lupus](#) 4 (suppl 1):S33-S36, 1995.
534. Bar-Dayyan Y, Levy Y, [Shoenfeld Y](#). Cerebral infarction in Crohn's disease. [Harefuah](#) 129:173-175, 1995.
535. Tomer Y, Gilburd B, Blank M, Lider O, Hershkoviz R, Fishman P, Zigelman R, Meroni PL, Wiik A, [Shoenfeld Y](#). Characterization of biological active antineutrophil cytoplasmic antibodies induced in mice. [Arthritis Rheum](#) 38:1375-1381, 1995.
536. Cohen A, [Shoenfeld Y](#). The viral autoimmunity relationship. [Viral Immunology](#) 8:1-9, 1995.
537. George J, [Shoenfeld Y](#). The Hanta viruses - clinical syndromes. [Harefuah](#) 129:421-423, 1995.
538. George J, Adler Y, [Shoenfeld Y](#). Apoptosis (programmed cell death) in autoimmunity - autoimmunological aspects. [Harefuah](#) 129:339-341, 1995.
539. Horoshovski H, Amital H, Katz M, [Shoenfeld Y](#). Pseudotumour cerebri in SLE. [Clin Rheumatol](#) 14:708-710, 1995.
540. Cohen J, Bakimer R, [Shoenfeld Y](#). Fecundity in autoimmune diseases. [Early Pregnancy Biology and Medicine](#) 1:93-105, 1995.
541. Levy Y, [Shoenfeld Y](#). Images in allergy and immunology. [Int Arch Allergy & Immunology](#) 108:339, 1995.
542. Abu-Shakra M, Buskila D, Lorber M, Khamashta M, Alarcon-Segovia D, [Shoenfeld Y](#). The mosaic of SLE-II: highlights of the fourth international conference on systemic lupus erythematosus - 1995. [Lupus](#) 4:438-449, 1995.
543. Krause I, Hacham S, Gilburd B, Damianovitch M, Blank M, [Shoenfeld Y](#). Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. [Clin Immunol Immunopathol](#) 77:229-235, 1995.
544. George J, Adler Y, Zhang J, [Shoenfeld Y](#), Youinou P. Apoptosis and its association with autoimmunity. [Clin Rheumatol](#) 14:505-509, 1995.
545. [Shoenfeld Y](#), Beresovski A, Zharhary D, Tomer Y, Swissa M, Sela E, Zimran S, Zevin S, Gilburd B, Blank M. Natural autoantibodies in sera of patients with Gaucher's disease. [J Clin Immunol](#) 15:363-372, 1995.

- 545a. Bean P, Sutphin MS, Liu YS, Anton R, Reynolds TB, Shoenfeld Y, Peter JB. Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem 41: 858-861, 1995.
546. Fishman P, Shoenfeld Y. Aspirin, interleukin-3 and the antiphospholipid syndrome. Isr J Med Sci 32:13-17, 1996.
547. Buskila D, Shoenfeld Y. Prolactin, bromocriptine and autoimmune diseases. Isr J Med Sci 32:23-27, 1996.
548. Shoenfeld Y. Pathogenicity of anti-basement membrane (NC1) antibodies: an experimental Goodpasture's syndrome. Isr J Med Sci 32:29-31, 1996.
549. Lerner A, Blank M, Shoenfeld Y. Celiac disease and autoimmunity. Isr J Med Sci 32:33-36, 1996.
550. George J, Avidan B, Shoenfeld Y. Iatrogenic damage. Harefuah 130:53-55, 1996.
551. Guedes L.S, Barbosa B, Gilburd B, Shoenfeld Y, Scheinberg M.A. Autoantibodies in leprosy sera , Clin Rheumatol 15:26-28, 1996.
552. Levy Y, George J, Hojnic M, Ehrenfeld M, Lorber M, Bombardieri S, Shoenfeld Y. Comparison of clinical and laboratory parameters for systemic lupus erythematosus activity in Israelis versus Europeans. Isr J Med Sci 32:100-104, 1996.
553. Peer O, Bar-Dayan Y, Shoenfeld Y. Satisfaction among patients of homeopathic clinic. Harefuah, 130:86-89, 1996.
554. George J, Levy Y, Shoenfeld Y. Mixed connective tissue disease: thirty three years of uncertainty. Harefuah, 130: 99-103, 1996.
555. Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunology Lett 48: 129-132, 1995.
556. Fishman P, Falach-Vaknin E, Sredni B, Meroni P.L, Tincani A, Dicker D, Shoenfeld Y. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Amer J Reproduct Immunol 35: 80 - 84, 1996.
557. Tomer Y, Gilburd B, Sack J, Davies TF, Meshorer A, Burek CL, Rose NR, Shoenfeld Y. Induction of thyroid autoantibodies in naive mice by idiotypic manipulation. Clin Immunol Immunopathol 78: 180 - 187, 1996.
558. Yodfat O, Blank M, Krause I, Shoenfeld Y. The pathogenic role of anti-phosphatidylserine antibodies: Active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Clin Immunol Immunopathol 78: 14 - 20, 1996.
559. Shoenfeld Y, Gilburd B, Hojnik M, Damianovich M, Hacham S, Kopolovic Y, Polak-Charcon M, Goldberg I, Afek A, Hun-Chi L, Peter JB. Induction of Goodpasture antibodies to noncollagenous domain (NC1) of type IV collagen in mice by idiotypic manipulation. Hum Ab Hybridomas, 6: 122 - 128, 1995.
560. Shoenfeld Y, George J, Peter JB. Guillain-Barre as an autoimmune disease. Int Arch Allergy & Immunol 109: 318 - 326, 1996.
561. George J, Shoenfeld Y. Fungal infections and autoimmune diseases. Harefuah 130: 388 - 390, 1996.
562. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93: 1574 - 1587, 1996
563. Bar-Dayan Y, Amital H, Levy Y, Shoenfeld Y. Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Isr J Med Sci 32: 288 - 291, 1996
564. Barka N, Shen GQ, Shoenfeld Y, Alosachie IJ, Gershwin ME, Reyes H, Peter JB. Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A(IgA) deficiency. Clin Diag Lab Immunol 2: 469 - 472, 1995.

565. Carp HJA, Achiron R, Mashiach S, Shoenfeld Y, Gazit E, Toder V. Intravenous immunoglobulin in women with five or more abortions. Amer J Reproductive Immunol 35: 360 - 362, 1996.
566. George J, Levy Y, Shoenfeld Y. Immune network and autoimmunity. Internal Medicine 35: 3 - 9, 1996.
567. Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus (SLE). J Rheumatol 23 : 629 - 632, 1996.
568. Shoenfeld Y. Clinical practice today. Harefuah 130: 606 - 607, 1996.
569. Del Papa N, Guidali L, Sironi M, Shoenfeld Y, Mantovani A, Tincani A, Balestrieri G, Radice A, Sinico RA, Meroni PL. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis Rheum 39: 758 - 766, 1996.
570. George J, Shoenfeld Y. Pregnancy and antiphospholipid syndrome. A report and relevant abstracts from the 4th Int. Conference on SLE. Jerusalem March 1995. Early Pregnancy Biology and Medicine 2: 53 - 69, 1996.
571. George J, Shoenfeld Y. Actin autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 10-12, 1996.
572. Youinou P, Maran R, Dueymes M, Shoenfeld Y. Autoantibody subclasses. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 103 - 108, 1996.
573. Lorber M, George J, Shoenfeld Y. Hidden Autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 357 - 363, 1996.
574. Abu-Shakra M, Buskila D, Shoenfeld Y. Idiotypes and anti-idiotypic antibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 408 - 416, 1996.
575. George J, Shoenfeld Y. Natural autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 534 - 539, 1996.
576. Cervera R, Shoenfeld Y. Pathogenic mechanisms. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 607- 617, 1996.
577. Fishman P, Merimsky O, Baharav E, Shoenfeld Y. Tyrosinase autoantibodies. In: Autoantibodies. Editors: James B. Peter, Yehuda Shoenfeld. Elsevier, Amsterdam, The Netherlands, pp. 842 - 845, 1996.
578. Shoenfeld Y. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J Autoimmunity 9: 235 - 239, 1996.
579. Damianovich M, Gilburd B, George J, Del Papa N, Afek A, Goldberg I, Kopolovic Y, Roth D, Barkai G, Meroni PL, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in vasculitis. J Immunol 156: 4946 - 4951, 1996.
580. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilburd B, Yechezkel G, Youinou P, Fishman P. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105: 84 - 88, 1996.
581. Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, Blank M, Sandbank Y, Vilardell-Tarres M, de Torres I, Weinberger A, Asherson RA, Kopolovic Y, Shoenfeld Y. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5: 196 - 205, 1996.
582. Tomer Y, Shoenfeld Y. Finding a valid model for human Wegener's granulomatosis: comment on the article by Tomer et al. Arthritis Rheum 39: 1262 - 1263, 1996.
583. Levy Y, George J, Shoenfeld Y. Severe blastocystis hominis in an elderly man. J Infection 33: 57 - 59, 1996.



584. Shoenfeld Y, Grunebaum E, Laufer M, Zurgil N, Bakimer R, Lunderschmidt A, Valentini G, Tirri G, Blank M. Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Isr J Med Sci 32: 537-541, 1996.
585. Keusch J, Levy Y, Shoenfeld Y, Youinou P. Analysis of different glycosylation states in IgG subclasses. Clinica Chimica Acta 252: 147 - 158, 1996.
586. George J, Levy Y, Shoenfeld Y. Infections and autoimmunity - emerging clinical trials. Turk J Immunol 1: 11-13, 1996.
587. Swissa M, Lerner A, Sasaki T, Sela E. Blank M, Shoenfeld Y. The diverse pathogenic potential of anti-DNA antibodies from various sources to induce experimental systemic lupus erythematosus. Pathobiology 64: 32-39, 1996.
588. Tomer Y, Viegas OAC, Swissa M, Koh SCL, Shoenfeld Y. Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol 14: 275-280, 1996.
589. Sukenik S, Shoenfeld Y. The dead sea is alive. Isr J Med Sci 32 (Suppl 3): 1-3, 1996.
590. Tishler M, Shoenfeld Y. The medical and scientific aspects of spa therapy. Isr J Med Sci 32: (suppl 3) 8-10, 1996.
591. Zandman-Goddard G, George J, Levy Y, Blank M, Slavin S, Shoenfeld Y. Modulation of experimental systemic lupus erythematosus with linomide. Lupus 5: 328-333, 1996.
592. Ehrenfeld M, Buskila D, Tishler M, Lorber M, Shoenfeld Y. Rheumatology in Israel. Brit J Rheumatol 35: 778-780, 1996.
593. Baharav E, Gur H, Fishman P, Ziporen L, Blank M, Aelion J, Kotb M, Shoenfeld Y. Superantigens and experimental SLE induced by idiotypic dysregulation. Clin Exp Rheumatol 14: 359 - 366, 1996.
594. Amital H, Swissa M, Bar-Dayana Y, Buskila D, Shoenfeld Y. New therapeutic avenues in autoimmunity. Res Immunol (Inst. Pasteur) 147: 361-376, 1996.
595. Amital H, Blank M, Shoenfeld Y. Th1/Th2 cells and autoimmunity. Harefuah 131: 189-193, 1996.
596. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental APS: lessons from murine models. Lupus 5: 458-462, 1996.
597. Bar-Dayana Y, Shahar A, Rick J, Shoenfeld Y. Clinico-Pathological Conferences: Severe fatal shock after syncope in an old man. Harefuah 131: 360-363, 1996.
598. George J, Shoenfeld Y. Cellular immune responses in rheumatic fever. Harefuah 131: 321-323, 1996.
599. Galperin C, Shoenfeld Y, Gilburd B, Esterre P, Meroni PL, Del Papa N, Halpern GM, Andriantsimahavandy A, Gershwin ME. Anti-neutrophil cytoplasmic antibodies in patients with chromomycosis. Clin Exp Rheumatol 14: 479-483, 1996.
600. Amital H, Shoenfeld Y. Nucleosomes, DNA and SLE : Where is the starting point ? Clin Exp Rheumatol 14: 475-478, 1996.
601. Shoenfeld Y, Ehrenfeld M. Hematologic manifestations. In: The Clinical Management of Systemic Lupus Erythematosus (SLE). (2<sup>nd</sup> Ed.). Editor: Peter H. Schur. Lippincott-Raven, N.Y., U.S.A., pp. 95-108, 1996.
602. Leibovitch L, Levy Y, Shoenfeld Y. Pancreatitis induced by clarithromycin. Ann Int Med 125: 701. 1996.
603. Krause I, Blank M, Shoenfeld Y. Treatment of systemic lupus erythematosus and antiphospholipid syndrome: From experimental models to patients' bedside. Int Arch Allergy Immunol 111: 355-361, 1996.
604. Aharon-Maor A, Shoenfeld Y. Interleukin 12 - polyfunctional cytokine. Harefuah 131: 501-505, 1996.

605. Bar-Dayana Y, Gurstein A, Zilinski I, Shoenfeld Y. Playing with fire. *Harefuah* 131: 474-476, 1996.
606. Levy Y, Sologov M, George J, Shoenfeld Y. "BCG itis" - sepsis following BCG treatment. *Harefuah* 131: 541-543, 1996.
607. Aharon-Maor A, Shoenfeld Y. Everything you wanted to know about magnesium and didn't dare to ask. *Harefuah* 131: 556-558, 1996.
608. Shoenfeld Y. No Russian immigrants, no women, no Hebrew. *Harefuah* 131: 604-605, 1996.
609. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. *Immunol Res* 15: 315 - 322, 1996.
610. Levy Y, George J, Eli Y, Shoenfeld Y. Partial lipodystrophy and complement dysfunction. *Turk J Immunol* 2: 43-45, 1996
611. Shoenfeld Y, Krause I. Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. *Transplantation Proceed* 28: 3096-3098, 1996.
612. Tishler M, Shoenfeld Y. Anti-heat-shock protein antibodies in rheumatic and autoimmune diseases. *Semin Arthritis Rheum* 26: 558-563, 1996.
613. George J, Levy Y, Afek A, Yaniv R, Shoenfeld Y. Leucocytoclastic vasculitis after coronary bypass artery grafting. *Brit J Dermatol* 135: 1015 - 1016, 1996.
614. Zandman-Goddard G, George J, Blank M, Levy Y, Yanai P, Halperin T, Shoenfeld Y, Barak V. The effects of early and late administration of M-20 derived interleukin-1 inhibitor on experimental systemic lupus erythematosus. *Immunol Lett* 53: 77-82, 1996.
- 614a. Amital H, Tur-Kospa I, Tashma Z, Hendler I, Shoenfeld Y. Catalytic antibodies: generation, nature and possible role as chemical warfare scavengers. *Military Medicine* 161: 1/1996, p. 7.
615. Youinou P, Isenberg DA, Kalsi JK, Dugoujon JM, Ravirajan CT, Muller S, Blanco F, Piette JC, Guillevin L, Jouquan J, Semana G, Salmon D, Shoenfeld Y, Bach JF. Interplay of four idiotypes and interaction with autoantibodies in lupus patients, their relatives and their spouses. *J Autoimmunity* 9: 767-775, 1996
- 615a. Dopamine and kidneys - the protective effect on the kidneys - legend or reality. Yussim E, Yogev Y, Segal E, Shoenfeld Y. *Harefuah*, 130: 480-483, 1996.
616. Tishler M, Shoenfeld Y. Tuberculose et auto-immunite: ou en sommes - nous ? *Annales de L' Institut Pasteur* 7: 133-136, 1996.
- 616.a. Krause I, Blank M, Shoenfeld Y. Immunointerventions in experimental model for antiphospholipid syndrome. *Ann Med Interne* 147: 50-53 (suppl), 1997.
617. Levy Y, Ziporen L, Gilburd B, George J, Polak-Charcon S, Amital H, Cledes J, Youinou P, Shoenfeld Y. Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice. *Hum Antibody Hybridomas* 7: 91-96, 1996.
- 617.a. Dueymes M, Levy Y, Ziporen L, Piette JC, Shoenfeld Y, Youinou P. Do some antiphospholipid antibodies target endothelial cells? *Ann Med Interne* 147: 22-23 (suppl): 1997.
618. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. *Ann Rheum Dis* 56: 5-11, 1997.
619. Shoenfeld Y, Rotem Y. Physicians and the battle against road accidents. *Harefuah* 132: 183-184, 1997.
620. Ziporen L, Blank M, Shoenfeld Y. Animal models for antiphospholipid syndrome in pregnancy. *Rheum Dis Clin of North America* 23: 99-117, 1997.

621. George J, Levy Y, Shoenfeld Y. Smoking and immunity. An additional player in the mosaic of autoimmunity. Scand J Immunol 45: 1-6, 1997.
622. Shoenfeld Y. T cell help and antiphospholipid antibody immunogenesis (letter). Arthritis Rheumat 40: 196-197, 1997.
623. Shoenfeld Y. Why did the entity of effort syndrome disappear ? Harefuah 132: 266, 1997.
624. Bar-Dayan Y, Levy Y, Bar-Zohar D, Shoenfeld Y. Immunological aspects of endocarditis. Harefuah 132: 288-290, 1997.
625. Cohen AD, Shoenfeld Y. Vaccine-induced Autoimmunity. J Autoimmunity 9: 699-703, 1996.
626. George J, Gilburd B, Shoenfeld Y. The emerging concept of pathogenic natural antibodies. Human Antibodies Hybridoma 8: 70-75, 1997.
627. Bar-Zohar D, Bar-Dayan Y, Shoenfeld Y. Advances in immunotherapy and treatment of Bechet's disease. Harefuah 132: 350-353, 1997.
628. Maran R, Dueymes M, Le Corre R, Renaudineau Y, Shoenfeld Y, Youinou P. IgG subclasses of human autoantibodies. Ann Med Interne 148: 29-38, 1997.
629. Sherer Y, Bar-Dayan Y, Shoenfeld Y. Selective inhibitors of cyclooxygenase-2: an upgrade in nonsteroidal anti-inflammatory drugs. Harefuah 132: 411-416, 1997.
630. Bar-Dayan Y, Blank M, Amital H, Afek A, Polak-Charcon S, Shoenfeld Y. Short term effect of high dose insulin on thymic morphology of ICR female mice. Diabetes Research 32: 27-35, 1997.
631. Zimlichman R, Shoenfeld Y. Calcium blockers and cancer - is there any link between them? Harefuah 132: 876-878, 1997.
632. Shoenfeld Y, George J. Induction of autoimmunity: A role for the idiotypic network in B lymphocytes and autoimmunity. (Ed:Chiorazzi N, Labrita RG, Ravelka K, Ferrarimi M) Ann N Y Acad Sci 815: 342-349, 1997.
633. Gruenbaum E, Shoenfeld Y. Pathogenesis of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Harefuah 32: 665-669; 1997.
634. Shovman O, George J, Shoenfeld Y. Ischemic hepatitis in congestive heart failure after an episode of hypotension. Harefuah 132: 459-460, 1997.
635. Gruenbaum E, Shoenfeld Y. Nucleosomes as an autoantigen in SLE. Harefuah 132:475-478, 1997 .
636. Shoenfeld Y, Lorber M, Yucel T, Yazici H. Primary antiphospholipid syndrome emerging following thymectomy for myasthenia gravis: additional evidence for the kaleidoscope of autoimmunity. Lupus 6: 474-476, 1997.
637. Sherer Y, Bar-Dayan Y, Shoenfeld Y. Thymoma, thymic hyperplasia, thymectomy in autoimmune diseases. Int J Oncol 10:939-943, 1997
638. Fishman P, Merimsky O, Shoenfeld Y. Autoimmunity and cancer-beneficial relationship: a new concept for the production of human monoclonal antibodies. Int J Oncol 10:901-904, 1997.
639. Merimsky O, Shoenfeld Y, Baharav E, Zigelman R, Fishman P. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibody Hybridoma 7:151-156, 1996.
640. Sherer Y, Bar Dayan, Shoenfeld Y. Vasculitis: classification, mechanisms, animal models and treatment. Harefuah 132: 567-572, 1997.

641. Fishman P, Merimsky O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase-the bridge between melanoma and vitiligo. Cancer 79: 1461-1464, 1997.
642. Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, Ferrone S, Fishman P. Melanoma-associated hypopigmentation: Where are the antibodies? Am J Clin Oncol (CCT):19; 613-618,1996.
643. Shoenfeld Y. Anti-DNA Antibodies: Is DNA the self antigen or a shelf antigen, or are all autoimmune diseases immunogen driven? Immunoregulation in Health and Disease, Academic Press, New York, Lukic ML, Colic M, Stoikovic MM, Cuperlovic K (Eds.) pp.139-148, 1997.
644. Shoenfeld Y, Wysenbeek AJ. Systemic lupus erythematoses in Israel. Harefuah 132:636-638,1997.
645. George J, Blank M, Hojnik M, Bar-Meir E, Koike E, Matsuura M, Lorber M, Aviram M, Shoenfeld Y. Oxidized low-density lipoprotein (Ox LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS). Clin Exp Immunol: 108;227-233,1997
646. Blank M, Cines DB, Arepally G, Eldor A, Afek A, Shoenfeld Y. Pathogenicity of human anti-platelet factor 4(PF4)heparin in vivo: generation of mouse anti-PF4/ heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol 108:333-339,1997.
647. Afek A, Ziporen L, Shoenfeld Y. Libman-Sacks endocarditis-a jubilee year. Harefuah 132:718-719,1997.
648. Shoenfeld Y. Finding a valid model for antineutrophil cytoplasmic antibody-related vasculitis. Letter (comment) Arthritis Rheum 5: 986-987,1997.
649. Aharon A, Levy Y, Bar Dayan Y, Afek A, Zandman-Goddard, Skurnik Y, Fabrizzi F, Shoenfeld Y. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 6: 408-411,1997.
650. George J, Levy Y, Shoenfeld Y. The idiotypic network. Animal models and clinical implications. Japanese J Rheumatol 7 (invited article) : 75-82, 1997.
651. Tomer Y, Lider O, Gilburd B, Hershkovitz R, Meroni PL, Wiik A, Shoenfeld Y. Anti-neutrophil cytoplasmic antibody-enriched IgG induces adhesion of human T lymphocytes to extracellular matrix proteins. Clinical Immunol Immunopathol 83: 3; 245-253, 1997.
652. George J, Levy Y, Kallenberg CGM, Shoenfeld Y. Infections and Wegener's granulomatosis - a cause and effect relationship? Q J Med 90: 367-373,1997.
653. Shoenfeld Y. Autoantibodies - antigen derived or idiotypically induced. In: Proceedings of the XIX ILAR Congress of Rheumatology. pp 230-233, Singapore 8-13 June, 1997.
654. Shoenfeld Y, Buskila D. Animal models for Systemic Lupus Erythematosus. In: Proceedings of the XIX ILAR Congress of Rheumatology, pp 186-187, Singapore 8-13 June, 1997.
655. Shoenfeld Y, Blank M, Ziporen L. Animal models for antiphospholipid syndrome (APS). In: Proceedings of the XIX ILAR Congress of Rheumatology. pp 420-423, Singapore, 8-13 June, 1997.
656. Levy Y, George J, Langewitch P, Lorber M, Bar-Dayan Y, Gilburd B, Zandman-Goddard G, Fabrizzi F, Shoenfeld Y. Novel aspects of IVIG treatment in autoimmune diseases. In: Proceedings of the XIX ILAR Congress of Rheumatology, pp 456-458 Singapore, 8-13 June, 1997.
657. Ziporen L. Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid syndrome: a mouse model. J Clin Invest 100:613-619, 1997.
658. George J, Blank M, Gilburd B, Hojnik M, Shenkman B, Tamarin I, Varon D, Matsura E, Koike T, Shoenfeld Y. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human  $\beta$  2-glycoprotein I. Int Immunol 9: 6; 913-921, 1997.
659. Villarreal GM, Drenkard C, Villa AR, Slor H, Shafir S, Bakimer R, Shoenfeld Y, Alarcón Segovia D. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. Lupus 6: 425-435, 1997.

660. Ehrenfeld M, Pras M, Shoenfeld Y. Is familial mediterranean fever an autoimmune disease or an immune mediated condition? In: Familial Mediterranean Fever. Sohar E. Gafni J, Pras M. (Eds.) Freund Publishing House Ltd. London, 267-278,1997.
661. Adler Y, Shoenfeld Y. Colchicine as therapy for recurrent pericarditis. Harefuah, 133: 100-102, 1997.
662. Sherer Y, Bar-Dayan Y, Shoenfeld Y. Hemorrhagic diathesis. Harefuah, 133: 98-99,1997
663. George J, Shoenfeld Y. Editorial. The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis. Lupus 6: 559-560, 1997
664. Shoenfeld Y. Heparin-induced thrombocytopenia as an autoimmune disease - idiotypic evidence for the role of anti-heparin/PF4 autoantibodies. Israel Journal of Medical Sciences 33: 4; 243-245, April 1997.
665. Zurgil N, Gerbat S, Langevitz P, Tishler M, Ehrenfeld M, Shoenfeld Y. Intracellular fluorescence polarization measurements by the cellscan system:detection of cellular activity in autoimmune disorders. Isr J Med Sci 33: 4; 273-279, April 1997.
666. Sherer Y, Bar Dayan Y, Shoenfeld Y. Thymectomy and autoimmune diseases - The dual connection. Sem Clin Immunol 1: 5-11, 1997.
667. Konrad K , Humbel E T, Shoenfeld Y. Autoantibodies - diagnostic, pathogenic and prognostic relevance. Clin Exp Rheumatol 15: 457-465, 1997.
668. Shovman O, George J, Shoenfeld Y. Q fever endocarditis and bicuspid aortic valve. Harefuah 133: 281-283, 1997.
669. Moses S, Motro M, Shoenfeld Y. Blunt trauma causing emboli from friable atherosclerosis plaques. Harefuah 133: 355-357, 1997.
670. George J, Gilburd B, Levy Y, Afec A, Damianovich Y, Ghirardello A, Doria A, Todesco S, Shoenfeld Y. Autoantibody dominance pattern following idiotypic manipulation of naive mice by immunization with anti-U1RNP antibodies. Pathobiology 65: 204-209, 1997.
671. Bar-Dayan Y, Shoenfeld Y. Magnesium fortification of water a possible step forward in preventive medicine? Ann Med Interne 6:440-444, 1997.
672. Bar-Dayan Y, Levy Y, Amital H, Shoenfeld Y. Aspirin for prevention of myocardial infarction, a double edge- sword. Ann Med Interne 6: 148: 430-433, 1997.
673. Levy Y, George J, Abraham A, Afek A, Livneh A, Shoenfeld Y. Subcutaneous T-cell lymphoma in a patient with rheumatoid arthritis not treated with cytotoxic agents. Clin Rheumatol 16:606-608,1997.
674. Grunebaum E, Renandineau E, Shoenfeld Y. Anti-endothelial cell antibodies-clinical significance. Harefuah 133: 458-462, 1997.
675. Sherer Y, Shoenfeld Y. Tumor metastases: mechanisms and dissemination pathways. Harefuah 133:564-570,1997.
676. George J, Afek A, Gilburd B, Levy Y, Blank M, Kopolovic J, Harats D, Shoenfeld Y. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 6:723-729, 1997.
677. Tishler M, Maran R, Langevitz P, Livneh A, Gazit E, Gilburd P, Youinou P, Shoenfeld Y. Antiperinuclear factor – clinical , serological and genetic correlates in Israeli patients with rheumatoid arthritis. Rheumatol Int 17: 141-143.
678. Rotman P, Levy Y, Shoenfeld Y. Primary biliary cirrhosis – association or overlap with other autoimmune diseases. Isr J Med Sci 33: 823-825, 1997.
679. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus, autoimmunity and rheumatic disease. Lupus 6: 685-690, 1997.
680. Shovman O, George J, Shoenfeld Y. Primary subclavian vein thrombosis after physical exertion. Harefuah 133: 610-613, 1997.
681. Mendelovic S, Doron A, Shoenfeld Y. Schizophrenia – an autoimmune disease? Harefuah 133: 629-632, 1997.

- 681B. Finkekstein Y, Adler Y, Nussinovitch M, Shoenfeld Y. Continuous infusion versus intermittent administration of furosemide in pediatric and adult patients with severe congestive heart failure. Pediatr. Grenzgeb. 36: 181-184, 1997.
682. Sherer Y, Shoenfeld Y. Tumor metastases – new experimental anti-metastatic therapies. Harefuah 133: 636-642, 1997
- 682B Aharon-Maor A, Shoenfeld Y. Cimetidine - an unexpected ally. Isr J Med Sci 33: 363-365, 1997.
683. Sherer Y, Shoenfeld Y. Infectious agents and atherosclerosis. Harefuah 134: 204-207, 1998.
684. Barak V, Schwartz A, Kalichman I, Nisman B, Gurman G, Shoenfeld Y. Prevalence of hypophosphatemia in sepsis and infection: The role of cytokines. Amer J Med 104: 40-47, 1998.
685. Blank M, George J, Fishman P, Levy Y, Toder V, Savion S, Barak V, Koike T, Shoenfeld Y. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis & Rheumatism 41: 224-232, 1998.
686. Amital H, Levi Y, Shoenfeld Y. Antiphospholipid syndrome and vasculitis – just a coincidence? Harefuah 134: 273-276, 1998.
687. Ehrenfeld M, Shoenfeld Y: Chapter 1.3.8 Haematology and Oncology in Rheumatology: Oxford Textbook of Rheumatology (Maddison et al – Eds). Oxford University Press, 1998, Oxford U.K. pp. 288-298.
688. Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: *In Vivo* study in naive mice. J. Clin Immunol. 18, 52-60, 1998.
689. Aharon-Maor A, Levy Y, Shoenfeld Y. Fibrosarcoma after silicone breast augmentation: associated? Harefuah, 134: 339-441, 1998.
690. Ehrenfeld M, Shoenfeld Y. Breast silicone implant and autoimmunity: coincidence or cause and effect relationship? Harefuah, 134: 361-364, 1998.
691. George J, Blank M, Levy Y, Meroni PL, Damianovich M, Tiniani A, Shoenfeld Y. Differential effects of anti- $\beta$ -glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97: 900-906, 1998.
692. Levy Y, George J, Ziporen L, Cledes J, Amital H, Bar-Dayana Y, Afek A, Youinou P, Shoenfeld Y. Massive proteinuria as a main manifestation of primary antiphospholipid syndrome. Phatobiology 1998; 66: 49-52.
693. Sherer Y, Shoenfeld Y. Stem cells transplantation – a cure for autoimmune diseases. Lupus 7, 137-140, 1998.
694. Gafter A., Bar-Dayana Y., Shoenfeld Y. Cow milk feeding in infancy: is it a predisposing factor to insulin-dependent diabetes mellitus? Harefuah 134; 489-492, 1998.
695. Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer. Oncol Rep. 5:753-761, 1998.
696. Reifen R, Blank M, Afek A, Kopilowiz Y, Sklan D, Gershwin ME, German B, Yoshida S, Shoenfeld Y. Dietary polyunsaturated fatty acids decrease anti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mouse model of systemic lupus erythematosus. Lupus 7, 192-197, 1998.
697. Karsten C, Levy Y, Blank M, Jurgen M, Karl-Heinz F, Beate R, Shoenfeld Y. The pathogenic 16/6 idiotype in patients with silica associated systemic lupus erythematosus (SLE) and in uranium miners with increased risk for development of SLE. J Rheumatol 25:4, 660-666, 1998.
698. Tincani A, Shoenfeld Y. Animal Models of Anti-Phospholipid Syndrome. in: Reumatologia V Teorii a Praxi V. Eds: Josef Rovenski. 1998: pp. 217-227. Vydavatelstvo Osveta. Banska Bystricia. Slovakia.
699. Levy Y, George J, Barak V, Shoenfeld Y. Early detection of recurrent mono-metastases of breast cancer to endocrine tissues by following CEA levels. Oncol Reports, 4: 623-624: 1997.
700. Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 15; 101 : 2029-2035: 1998.
701. Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, Sander DM, Shoenfeld Y, Ahmed A, Van de Water J, Gershwin ME, Garry RF. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet , 351: 1620-1624: 1998.
702. Sherer Y, Shoenfeld Y. Bone marrow transplantation for severe autoimmune diseases: treatment of choice or a treatment of no choice? Harefuah, 134: 785-787: 1998.

703. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138; 147-152: 1998.
704. Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes-Genis A, Sagie A, Bayes de Luna A, Spodick DH. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation, 97: 2183-2185: 1998.
705. Afek A, Kopolovic J, Shoenfeld Y. Cytomegalovirus and atherosclerosis. Harefuah 134: 869-871, 1998.
706. Levy Y, Gilburd B, George J, Del Papa N, Mallone R, Damianovich M, Blank M, Radice A, Renaudineau Y, Youinou P, Wiik A, Malavasi F, Meroni P.L., Shoenfeld Y. Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA. Int Immunol 10: 861-868, 1998.
707. Assouline-Dayana Y, Levi Y, Shoenfeld Y. Viagra, the first oral treatment for impotence. Harefuah 135; 1-2, 1998.
708. Shemer J, Shoenfeld Y. Viagra – utility and risk. Harefuah 135; 20-23, 1998.
709. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation: An autoimmune phenomenon. Immunol Res 18: 55-60, 1998.
710. George J, Alkan M, Shoenfeld Y. BCG In: Encyclopedia of Immunology. Editor: I Roitt, P. Delves. Academic Press. USA. p. 335-336, 1998.
711. Shoenfeld Y, Sherer Y, Fishman P. Interleukin-3 and pregnancy loss in antiphospholipid syndrome. Scand J Rheumatol. 27 (suppl) 107: 19-22, 1998.
712. Shoenfeld Y, Sherer Y, Blank M. Antiphospholipid syndrome in pregnancy – animal models and clinical implications. Scand J Rheumatol. 27 (suppl) 107: 33-36, 1998.
713. Sherer Y, Shoenfeld Y. Anti-phospholipid autoantibodies – do they have a pathogenic role in infertility? Scand J Rheumatol. 27 (suppl) 107: 40-43, 1998.
714. Sherer Y, Blank M, Shoenfeld Y. Immunomodulation of experimental antiphospholipid syndrome. Scand J Rheumatol. 27 (suppl) 107: 48-52, 1998.
715. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with  $\beta$  2-glycoprotein I. Circulation. 98: 1108-1115, 1998.
716. Krause I, Blumenfeld Z, Malchinsky M, Cohen S, Blank M, Eldor A, Weksler B, Schweitzer K, Shoenfeld Y. Anti-endothelial cell antibodies in the sera of hyperprolactinemic women. Lupus 7: 377-382. 1998.
717. Shoenfeld Y. Introduction: Autoantibodies as a clinical diagnostic tool. Clin Rev Allergy & Immunol 16: 205-206, 1998.
718. Ahmed AEE, Peter J B, Shoenfeld Y. Autoantibodies in angioneurotic edema. Clin Rev Allergy & Immunol. 16: 207-210, 1998.
719. Merimsky O, Shoenfeld Y, Fishman P. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Clin Rev Allergy & Immunol 16: 227-236, 1998.
720. Terryberry JW., Shoenfeld Y, Peter J. B. Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants. Clin Rev Allergy & Immunol. 16: 265-273, 1998.
721. Alosachie IJ, Terryberry JW, Mevorach D, Chapman Y, Lorber M, Torre D, Youinou P, Peter JB, Shoenfeld Y. Central nervous System (CNS) involvement in SLE: The diagnostic role of antibodies to neuronal antigens. Clin Rev Allergy & Immunol. 16: 275-284, 1998.
722. Kollmeier A, Kreditor M, George J, Levy Y, Shoenfeld Y. Functional properties of antiendothelial cell antibodies. Clin Rev Allergy & Immunol. 16: 297-311, 1998.
723. Shen GQ, Shoenfeld Y, Peter JB. Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Clin Rev Allergy & Immunol. 16: 321-334, 1998.
724. George J, Patnaik M, Bakshi E, Levy Y, Ben-Daviv A, Ahmed A, B. Peter J, Shoenfeld Y. Hantavirus seropositivity in Israeli patients with renal failure. Viral Immunol. 11: 103-8, 1998.

725. Shoenfeld Y, Haratz D, George J. Atherosclerosis and the antiphospholipid syndrome: A link unravelled? Lupus 7: 140-143, 1998.
726. Shoenfeld Y, Ziporen L. Lessons from experimental APS models. Lupus 7: 158-161, 1998.
727. George J, Gilburd B, Hohnik M, Levy Y, Langevitz P, Matsuura, Koike Takao, Shoenfeld Y. Target recognition of  $\beta$  2-Glycoprotein ( $\beta$  2GPI)-dependent anticardiolipin antibodies: Evidence for involvement of the fourth domain of  $\beta$  2GPI in antibody binding. J Immunol, 160: 3917-3923, 1998.
728. Krause I, Blank M, Shoenfeld Y. Idiotypic induction of autoimmunity. J Biolo Reg d Homeost Agents, 12, 49-52, 1998.
729. Bordron A, Dueymes M, Levy Y, Jamin C, Ziporen L, Piette JC, Shoenfeld Y, Youinou P. Anti-endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies. Arthritis Rheum, 41:1738-47, 1998.
730. Levy y, Afek A, Sherer Y, Bar-Dayana y, Shibi R, Kopolovic J, Shoenfeld Y. Malignant thymoma associated with autoimmune diseases: A retrospective study and review of the literature. Sem Arthritis Rheumat, 28: 73-80,1998.
731. Amital H, Shoenfeld Y, Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. System Lupus Erythematosus, AP-Academic press, 3<sup>rd</sup> Ed. 1-16,1998. (Editor R. Sahita).
732. A. Aharon-Maor, Shoenfeld Y, The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus. Harefuah, 135:295-298, 1998.
733. Shoenfeld Y, Kleidoscopic Autoimmunity. Harefuah, 135, 262-263, 1998.
734. Abu-Shakra M, Buskila D, Shoenfeld Y. Idiotypes of autoantibodies. APLAR J Reumatol 2: 54-64; 1998.
735. Sherer Y, Shoenfeld Y, Environmental factors and scleroderma. Harefuah, Vol.135 No.9: 370-373, 11/1998.
736. Amital H, Levy Y, Blank M, Barak V, Langevitz P, Afek A, Nicoletti F, Kopolovic J, Gilburd B, Meroni PL, Shoenfeld Y. Immunomodulation of murine experimental SLE-like disease by interferon- $\gamma$ . Lupus 7: 445-454, 1998.
737. Nezlin C, Alarcon-Segovia D, Shoenfeld Y. Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. J Autoimmun 1998, 11:489-493.
738. Skurnik Y, Shoenfeld Y. Health effects of cigarette smoking. Clin Dermatol 1998,16:545-56.
739. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998, 92:3250-9.
740. Shoenfeld Y. Autoantibodies-antigen driven or idiotypically induced. Bratisl Lek Listy, 99:410-2, 1998.
741. Ahmed AE Peter JB, Shoenfeld Y. ANCA testing. New developments and clinical implications. Clin Rev. Allergy Immunol 16:303-11,1998.
742. Sherer Y, Bar-Dayana Y, Shoenfeld Y. The Dual Relationship Between Thymectomy and Autoimmunity. The Kaleidoscope of Autoimmune Disease. Autoimmune Reactions, Ch.23, pp.371-382 ,Edited by: Sudhir Paul, Human Press Inc., Totowa, New Jersey, U.S.A., 1998.
743. Sherer Y, Bakshi E, Rotman P, Levy Y, Shoenfeld Y. Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia., Int J Mol Med 2:343-348, 1998 .
744. Winder A, Shoenfeld Y, Hochman R, Keren G, Levy Y, Eldor A. High-Dose Intravenous  $\gamma$  g-globulins for herparin induced thrombocytopenia: A prompt response. J Clin Immunol, 18: 330-334; 1998.
745. Blank M., George J, Barak V, Tincany A, Koike T, Shoenfeld Y. Oral tolerance to low dose  $\beta$ 2-glycoprotein-I: immunomodulation of experimental antiphospholipid syndrome. J Immunol, 161: 5303-12, 1998.
746. Sherer Y, Shoenfeld Y, Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant, 22: 873-81, 1998.
747. Portugese S, Amital H, Tenenbaum A, Bar-Dayana Y, Levy Y, Afek A, Shemesh J, Shoenfeld Y. Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis. Clin Cardiol; 21: 813-816, 1998.



748. Bar-Dayyan Y, Gershwin M.E., Levy Y, Amital H, Shoenfeld Y. Primary biliary cirrhosis: Is (and how much of) the pathology preventable? Immunologic Research 18: 117-121, 1998.
749. Ziporen L, Shoenfeld Y. Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside. Hematol Cell Ther 40: 175-82, 1998.
750. Galeazzi M, Bellisai F, Sebastiani GD, Marcolongo R, Houssiau F, Cervera R, Levy Y, George J, Sherer T, Shoenfeld Y. Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 16: 717-20, 1998.
751. Tincani A, Spatola L, Cinquini M, Meroni P, Balestrieri G, Shoenfeld Y. Modèles animaux de syndrome antiphospholipidique. Rev Rhumatisme. [Ed.Fr]: 65: 676-681, 1998. [Engl. Ed.]: 65:614-618, 1998.
752. Shoenfeld Y, Gharavi A, Koike T.  $\beta$ 2GP-I in the anti phospholipid (Hughes') syndrome - from a cofactor to an autoantigen - from induction to prevention of antiphospholipid syndrome. Lupus 7: 503-506, 1998.
753. Goldstein S.E, Levy Y, Shoenfeld Y. Pulmonary hypertension and multivalvular damage caused by anorectic drugs. Harefuah 135: 491, 1998.
754. Sherer Y, Shoenfeld Y. Report on the catalytic and super antibodies satellite meeting held in conjunction with the 10<sup>th</sup> International Congress of Immunology. [WWW.rheuma21st.com](http://WWW.rheuma21st.com), 15.11.98.
755. Afek A, George J, Shoenfeld Y, Gilburd B, Levy Y, Shaish A, Keren P, Jankovic Z, Goldberg I, Kopolovic J, Haratz D. Enhancement of atherosclerosis in beta-2 glycoprotein I - immunized apolipoprotein E - deficient mice. Pathobiology 67: 19-25, 1999
756. Bar-Dayyan Y, Blau A, Skurnik Y, Shoenfeld Y. Renal biopsy in the elderly - to do or not to do? Harefuah 135: 645, 1998.
757. Amital H, Shoenfeld Y. Cytokines, antibodies to cytokines and autoimmunity. Drug of Today 34: 825-835, 1998.
- 757A. Amital H, Shoenfeld Y. Autoimmunity and Autoimmune Diseases such as SLE . Chapter in book: Systemic Lupus Erythematosus. Ed: R.G.Lahita, Academic Press San-Diego, USA pp. 1-16, 1998.
758. Nahum A, Levy Y, Shoenfeld Y. Ocular manifestations in the antiphospholipid syndrome. Harefuah 136: 50, 1999.
759. Ben-Ari T, Bar-Dayyan Y, Shoenfeld Y. Low cholesterol, depression and unexplained deaths - the link and the mystery. Harefuah 136: 82, 1999.
760. Sherer Y, Bar-Zohar D, Levy Y, Shoenfeld Y. Thromboembolic phenomena in patients with hereditary factor XI deficiency. Ann Med Interne 149: 492-494, 1998.
761. Zandman-Goddard G, Blank M, Ehrenfeld M, Gilburd B, Peter J, Shoenfeld Y. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J Rheumatol 26: 73-7, 1999.
762. Ehrenfeld M, Gur H, Shoenfeld Y. Rheumatologic features of hematologic disorders. Curr Opin Rheumatol. 11: 62-7, 1999.
763. Blank M, Eldor A, Tavor S, Ziporen L, Cines DB, Arepally G, Afek A, Shoenfeld Y. A mouse model for heparin - induced thrombocytopenia. Semin Hematol 36: 12-16, 1999.
764. Bar-Meir E, George J, Shoenfeld Y. Hyperhomocysteinemia - a risk factor for vascular disease? Harefuah 136: 129, 1999.
765. Blank M, Ziporen L, Krause L, Shoenfeld Y. Immunomodulation of Experimental Antiphospholipid Syndrome: Lessons from Murine Models. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 81-84, 1999.
766. Shoenfeld Y, Cervera R. Innovations in Autoimmunity in the Last Decade. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 7-18, 1999.
767. Merimsky O, Shoenfeld Y, Fishman P. A Focus on Anti-Tyrosinase Antibodies in Melanoma and Vitiligo. In: The Decade of Autoimmunity: (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 261-268, 1999.

768. Zurgil N, Gerbat S, Langevitz P, Tishler M, Ehrenfeld M, Kaufmann M, Deutsch M, Shoenfeld Y. Detection of Cellular Activity in Autoimmune Disorders by the Cellscan System. In: The Decade of Autoimmunity: (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 295-304, 1999.
769. Barak V, Shoenfeld Y. Cytokines in Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 313-322, 1999.
770. Buskila D, Abu-Shakra M, Shoenfeld Y. Prolactin and Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 339-346, 1999.
771. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus and Autoimmunity. In: The Decade of Autoimmunity. (Ed: Y. Shoenfeld). Elsevier Publ Amsterdam, The Netherlands: 355-364, 1999.
772. Harats D, George J, Levy Y, Khamashta M.A., Hughes G.R.V, Shoenfeld Y. Atheroma: links with antiphospholipid, antibodies Hughes syndrome and lupus. Q J Med 92: 57-59, 1999.
773. Goldstein G, Levy Y, Shoenfeld Y. The X-ANCA-immunological aspects and clinical significance. Harefuah, 136: 280-282, 1999.
774. Mendelovic S, Doron A, Shoenfeld Y. Depression and the immune system. Harefuah, 136: 288-190, 1999.
775. George J, Gilburd B, Shoenfeld Y. Autoantibody spread may explain multiple antibodies. The Immunologist 7/6 ; 189-193., 1999.
776. Ben-Ari T, Bar-Dayan Y, Shoenfeld Y. Low cholesterol, depression and unexplained deaths - the link and the mystery. Harefuah, 136: 82-85, 1999
777. Sherer Y, Shoenfeld Y. The Antiphospholipid (Hughes') Syndrome: An Entity to Be Expanded. AJRI Am J of Reproductive Immunol, 41:113-116, 1999.
778. George J, Shoenfeld Y, Afek A, Gilburd B, Keren P, Shaish A, Kopolovic J, Wick G, Harats D. Enhanced Fatty Streak Formation in C57BL/6J Mice by Immunization With Heat Shock Protein-65. Arterioscler Thromb Vasc Biol, 19: 505-510, 1999.
779. Renaudineau Y, Revelen R, Levy Y, Gilburd B, Shoenfeld Y, Youinou P. Anti-endothelial cell antibodies in systemic sclerosis. Clin Dian Lab Immunol, 6: 150-60, 1999.
780. Amital H, Langevitz P, Leby Y, Afek A, Goldberg I, Pras M, Livneh A, Shoenfeld Y. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease [In Process Citation]. Clin Exp Rheumatol, 17: 99-102, 1999.
781. George J, Gilburd B, Langevitz P, Levy Y, Nezlín R, Harats D, Shoenfeld Y. Beta(2) glycoprotein I containing immune-complexes in Lupus patients: association with thrombocytopenia and lipoprotein (a) levels. Lupus 8: 116-120, 1999.
782. Chapman J, Cohen-Armon M, Shoenfeld Y. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneuroosomes. Lupus 8: 127-133, 1999.
783. Levy Y, Portugese S, Amital H, Shoenfeld Y. Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis. Clin Cardiol 21: 813-816, 1998 - reply. Clin Cardiol 22: 158-158, 1999.
784. Sherer Y, Levy Y, Shahar A, Leibovich L, Konen E, Shoenfeld Y. Survival without surgical repair of acute rupture of the right ventricular free wall. Clin Cardiol 22: 319-320 , 1999.
785. Sherer Y, Shoenfeld Y. A malignancy work-up in patients with cancer-associated (paraneoplastic) autoimmune diseases: pemphigus and myasthenic syndromes as cases in point (Review). Oncol Rep, 6: 665-668, 1999.
786. Shoenfeld Y, Sherer Y. Blood and marrow transplantation in autoimmune diseases reported at 25<sup>th</sup> annual meeting of European Group for Blood and Marrow Transplantation. [http://www.rheuma 21<sup>st</sup>.com/archives](http://www.rheuma21st.com/archives), 21/4/99.
787. Levy Y, George J, Fabbriizzi F, Rotman P, Paz Y, Shoenfeld Y. Marked improvement of Churg-Strauss Vasculitis with intravenous gammaglobulins. South Med J 92: 412-4, 1999.
788. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Nat Acad Sci (USA) 96: 5164-5168, 1999.

789. Quaranta S, Shulman H, Ahmed A, Shoenfeld Y, Peter J, McDonald GB, de Water JV, Coppel R, Ostlund C, Worman HJ, Rizzetto M, Tsuneyama K, Nakanuma Y, Ansari A, Locatelli F, Pagenin S, Rosina F, Manns M, Gershwin ME. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 91: 106-16, 1999.
790. Amital H, Shoenfeld Y. Microchimeras - the secret path that leads to immunity? *Harefuah*, 136: 618-619.
791. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis - related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis. Lupus 8: 220-226, 1999.
792. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 18: 170-173, 1999.
793. Saraux A, Jouquan J, Le Goff P, Youinou P, Levy Y, Piette J-C, Guillevin L, Semana G, Salmon D, Viard J-P, Bach J-F, Shoenfeld Y. Environment factors may modulate antiphospholipid antibody production in familial members of patients with systemic lupus erythematosus. Arthritis & Rheumatism 42: 1062-1063, 1999.
794. Abu Shakra M, Buskila D, Shoenfeld Y. Molecular mimicry between host and pathogen: examples from parasites and implication. Immunology Letters 67: 147-152, 1999.
795. George J, Harats D, Gilbourd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of beta2-Glycoprotein I (Apolipoprotein H) to human atherosclerosis plaques: potential implications for lesion progression. Circulation 99: 2227-2230, 1999.
796. Shoenfeld Y. European forum on antiphospholipid antibodies. [http:// www.rheuma21st.com/archives/euro\\_antiphos.html](http://www.rheuma21st.com/archives/euro_antiphos.html): 1-8, 1999.
797. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18: 238-240, 1999.
798. Shoenfeld Y, Sherer Y. Cancer and antibodies to p53. *Harefuah*, 136: 868-869, 1999.
799. Edelson G, Levy Y, Shoenfeld Y. Relapse of sarcoidosis after alternative medical treatment. *Harefuah*, 136: 849-850, 1999.
800. Krause I, Blank M, Levy Y, Koike T, Barak V, Shoenfeld Y. Anti-idiotypic immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol, 117: 190-197, 1999.
801. Blank M, Krause I, Goldkorn TZ, Praprotnik S, Livneh A, Langevitz P, Kaganovsky E, Morgenstern S, Cohen SH, Barak V, Eldor A, Weksler B, Shoenfeld Y. Monoclonal anti-endothelial cell antibodies from Takayasu arthritis activate endothelial cells from large vessels. Arthritis & Rheum, 42: 1421-32, 1999.
802. George J, Aron A, Levy Y, Gilburd B, Ben-David A, Renaudineau Y, Zonana-Nachach A, Youinou P, Harats D, Shoenfeld Y. Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: Relationship with vascular access thrombosis and thromboembolic events. Hum Antibodies 9: 125-31, 1999.
803. Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus 8: 324-327, 1999.
804. Zurgil N, Levy Y, Deutsch M, Gilburd B, George J, Harats D, Kaufman M, Shoenfeld Y. Reactivity of peripheral blood lymphocytes to oxidized low-density lipoprotein: a novel system to estimate atherosclerosis employing the cellscan. Clin Cardiol 22: 526-532, 1999.
805. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayyan Y, Fabrizzi F, Terryberry J, Peter J, Shoenfeld Y. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy and Immunol 119: 231-238, 1999.
806. George J, Harats D, Bakshe E, Adler T, Levy Y, Gilburd B, Shoenfeld Y. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68: 263-266, 1999.
807. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmunity 13: 129-135, 1999.
808. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol 11: 1247-1251, 1999.

809. Shoenfeld Y, Mathieu A. Clinical and laboratory features of SLE: involvement of the central nervous system. Archived Reports <http://www.rheuma21st.com/archives/featuresle.html> (31.07.99) 1-9, 1999.
810. Krause I, Tomer Y, Elias D, Blank M, Gilbourd B, Cohen I.R, Shoenfeld Y. Inhibition of diabetes in NOD mice by idiotypic induction of SLE J Autoimmunity 13: 49-55, 1999.
811. George J, Shoenfeld Y, Haratz D. The involvement of Beta 2-Glycoprotein I ( $\beta$ 2GPI) in human and murine atherosclerosis. J Autoimmunity 13: 57-60, 1999.
812. Shapira S, Bar-Dayana Y, Gershwin M.E, Shoenfeld Y. Prediction and prevention of primary biliary cirrhosis. Harefuah, 137: 39-41, 1999.
813. Bayer P.M, Bauerfeind S, Bienvenu J, Fabien N, Frei P.C, Gilburd B, Heide K-G, Hoier-Madsen M, Meroni P.L, Monier J.C, Monneret G, Panzeri P, Shoenfeld Y, Spertini F, Wiik A. Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmunity 13: 89-93, 1999.
814. Ehrenfeld M, Langevitz P, Shoenfeld Y. Anti-cytokine therapy in inflammatory joint diseases. Harefuah, 137 : 120-123, 1999.
815. Bengtsson A, Nezhlin R, Shoenfeld Y, Sturfelt G. DNA levels in circulating immune complexes decrease at severe SLE flares - correlation with complement component C1q. J Autoimmunity 13: 111-119, 1999.
816. Sherer Y, Levy Y, Fabrizzi F, Shoenfeld Y. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs of Today, 35: 513-518, 1999.
817. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin (IVIG) therapy in autoimmune diseases - SLE, antiphospholipid syndrome, vasculitis. What is new? [http://www.rheuma21st.com/archives/cutting\\_edge\\_immunoglobulin.html](http://www.rheuma21st.com/archives/cutting_edge_immunoglobulin.html) (16.09.99) 1-5, 1999.
818. Afek A, Shoenfeld Y, Manor R, Goldberg I, Ziporen L, George J, Polak-charcon S, Amigo MC, Garcia-Torres R, Segal R, Kopolovic J. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8: 502-507, 1999.
819. Avdalovic M, Duhel L, Shoenfeld Y, Gershwin M.E. Physiological functions of leukocyte adhesion molecules and their implication in pathology. Semin Clin Immunol 2: 7-15, 1999.
820. George J, Harats D, Shoenfeld Y. Inflammatory and immune aspects of atherosclerosis. IMAJ 1: 112-116, 1999.
821. Krause I, Blank M, Shoenfeld Y. New treatment avenues: oral tolerance - mechanisms and applicability to human diseases. IMAJ 1: 45-49, 1999.
822. Shoenfeld Y, Alarcon-Segovia D, Buskila D, Abu-Shakra M, Lorber M, Sherer Y, Berden J, Meroni PL, Valesini G, Koike T, Alarcon-Riquelme M.E.; Frontiers of SLE: review of the 5<sup>th</sup> International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998. Sem Ar & Rheum Vol 29, No. 2: 112 - 130, Oct19 99.
823. George J, Shoenfeld Y. Accelerated atherosclerosis in the antiphospholipid syndrome secondary to SLE: is there a role for anti-beta2GPI antibodies? [Rheumat 21<sup>st</sup> com/archives/cutting\\_edge\\_atherosclerosis.html](http://www.rheumat21st.com/archives/cutting_edge_atherosclerosis.html) , 4.10.1999.
824. Tomer Y, Barak V, Gilbourd B, Shoenfeld Y. Cytokines in experimental autoimmune vasculitis: evidence for a Th2 type response. Clin Exp Rheumatol; 17: 521-6, 1999.
825. Levy Y, Sherer Y, George J, Fabrizzi F, Shoenfeld Y. Use of intravenous immunoglobulin in idiopathic membranous nephropathy. Int Med 38; 11: 917, 1999.
826. Levy Y, George J, Langevitz P, Harats D, Doolman R, Sela B-A, Shoenfeld Y. Elevated homocysteine levels in patients with Raynaud's syndrome. J Rheumatology; 26: 2383-2385, 1999.
827. Bar-Dayana T, Barshack I, Blank M, Goldberg I, Levy Y, Kopolovic J, Fishman P, Shoenfeld Y. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int J Oncol 15: 1091-1096, 1999.
828. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 8: 705-712, 1999.

829. Blank M, Waisman A, Mozes E, Koike T, Shoenfeld Y. Characteristics and pathogenic role of anti- $\beta$  2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome. Int Immunol 12: 1917-1926, 1999.
- 829a. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18: 238-240, 1999.
830. Shoenfeld Y, Avisar R, Tomsic M, Bombardieri S. Archived reports: VII international symposium of Sjogren's Syndrome. Venice, Italy, December 1-4, 1999. <http://www.rheuma21st.com/archives/Sjogren99.html>. 25.12.1999 : 1-13.
- 830a. Adler Y, George J, Shoenfeld Y, Fink N, Herz I, Mager A, Assali A, Harats D, Sagie A. Association between mitral annulus calcification and anti  $\beta$  2-glycoprotein I antibody levels. J Noninvasive Cardiol III: 111-115, 1999.
831. Ram R, Levy Y, Shoenfeld Y. Prostacyclin-a new hope: its function and indications for therapeutic use. Harefuah, 138: 54-58, 2000.
832. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity - 'Vaccinosis': a dangerous liaison? J Autoimmunity, 14: 1-10, 2000.
833. Landau Y.E., Shoenfeld Y. A pure simuove - an autoimmune disease: auto-antibodies to tissue transglutaminase in celiac disease. Harefuah. 138: 122-126, 2000.
834. Krause I, Blank M, Shoenfeld Y. Peptide immunotherapy: lessons from experimental models of systemic lupus erythematosus and antiphospholipid syndrome. [http://www.rheuma21st.com/archives...ng\\_edge\\_Peptideimmunotherapy.html](http://www.rheuma21st.com/archives...ng_edge_Peptideimmunotherapy.html) , 1.2.2000 1-5.
835. Asherson Ronald A, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J Rheumatol, 27: 1: 12-14, 2000.
836. Sherer Y, Shaish A, Levkovitz H, Keren P, Janackovic Z, Shoenfeld Y, Harats D. Magnesium fortification of drinking water suppresses atherogenesis in male LDL-receptor - deficient mice. Pathobiology, 67: 207-213, 1999.
837. Nicoletti F, Di Marco R, Zaccone P, Xiang M, Magro G, Grasso S, Morrone S, Santoni A, Shoenfeld Y, Garotta G, Meroni P. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus - like syndrome in MRL-lpr / lpr mice. Eur J Immunol, 30: 438-447, 2000.
838. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother 34: 120-2, 2000.
839. Adler Y, Finkelstein Y, Guindo J, Rodriguez De La Serna A, Bayes -Genis A, Bayes De Luna A, Shoenfeld Y, Sagie A, Spodick DH. Recurrent peicarditis as a manifestation of familial mediteranean fever. Circulation 101: E71-72, 2000.
840. Afek A, George J, Gilburd B, Rauova L, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun, 14: 115-121, 2000.
841. George J, Shoenfeld Y. Autoimmunerkrankungen: Mosaiksteine der pathogenese, autoimmune faktoren bei der entstehung der atherosklerose. Aspekte, 8-15,12/99.
842. Shoenfeld Y. The internal medicine subspeciality in the third millenium - where do we go? I accuse! Harefuah, 138: 407-409, 2000.
843. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, Lindor KD. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 32: 182-7, 2000.
844. Sherer Y, Livneh A, Levy Y, Shoenfeld Y, Langevitz P. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome - a novel overlap syndrome. Lupus 9: 42-46, 2000.
845. Aharon-Maor A, Shoenfeld Y. The good, the bad and the ugly of vaccination. IMAJ 2: 225-227, 2000.
846. George J, Shoenfeld Y. Introduction: The immune system, the autoimmune state and autoimmune disease. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 1-18, 2000.

847. Abu-Shakra M, Buskila D, Shoenfeld Y. Rheumatoid arthritis and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 19-30, 2000.
848. Abu-Shakra M, Buskila D, Shoenfeld Y. SLE and Cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 31-40, 2000.
849. Aron-Maor A, Shoenfeld Y. PSS (Scleroderma) and Cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 45-48, 2000.
850. Tishler M, Shoenfeld Y. Paraneoplastic Syndromes. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 121-132, 2000.
851. Tomer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 141-150, 2000.
852. Sherer Y, Shoenfeld Y. Thymoma and autoimmune diseases. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 249-252, 2000.
- 853.
854. Buskila D, Sikuler E, Shoenfeld Y. Hepatitis C virus, autoimmunity and cancer. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 285-298, 2000.
855. George J, Shoenfeld Y. The smoking - cancer - autoimmunity connection. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 309-316, 2000.
856. Buskila D, Abu-Shakra M, Shoenfeld Y. Anti-idiotypic in autoimmunity. In: Cancer and Autoimmunity. (Eds: Shoenfeld Y, Gershwin Eric M.) Elsevier Publ. Amsterdam, The Netherlands: 365-378, 2000.
857. Shoenfeld Y. Is the physician like the pilot? Lessons learned from two professions demanding great responsibility. Eur J Int Med 11: 127-129, 2000.
858. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 9: 223-227, 2000.
859. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit Rev Immunol; 20: 1-16, 2000.
860. Bar-Dayan Y, Kaveri SV, Kazatchkine MD, Shoenfeld Y. Is cancer an autoimmune process dependent on anti-apoptotic autoantibodies? Med Hypotheses, 55: 103-108, 2000.
861. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy in antiphospholipid syndrome. Rheumatology (Oxford), 39: 421-426, 2000.
862. Sherer Y, Levy Y, Fabrizio Fabbrizzi, Shoenfeld Y. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIG) - report of seven cases and review of the literature. Eur J Int Med 11: 85-88, 2000.
863. Levy Y, Sherer Y, George J, Rovinsky J, Ludac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y. Intravenous Immunoglobulin Treatment of Lupus Nephritis. Sem Arthritis Rheumatism 29: 321-327, 2000.
864. Cohen SH.B., Goldenberg M, Rabinovici J, Lidor A.L., Dulitzky M, Gilburd B, Shoenfeld Y, Schiff E. Anti-cardiolipin antibodies in fetal blood and amniotic fluid derived from patients with the anti-phospholipid syndrome. Eur. Soc Hum Reprod Embryol. 15:1170-1172,2000.
865. Shoenfeld Y, Kallenberg C. GM, 9<sup>th</sup> International vasculitis/ANCA workshop. Archived Reports [http://www.rheuma21st.com/archives/VASCULITIS\\_ANCA\\_WORKSHOP.html](http://www.rheuma21st.com/archives/VASCULITIS_ANCA_WORKSHOP.html) (27.4.2000) 1-5.

866. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol 18: 181-184, 2000.
867. Krause I, Blank M, Shoenfeld Y. The induction of experimental vascular diseases by immunization with pathogenic autoantibodies. Clin Exp Rheumatol : 18: 257-261, 2000.
868. Rauova L, Rovensky J, Shoenfeld Y. High dose intravenous immuoglobulins: a new step in the treatment of systemic lupus erythematosus. IMAJ 2: 388-392, 2000.
869. Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, Shoenfeld Y. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin Rheumatol 19: 207-211, 2000.
870. Sherer Y, Shoenfeld Y. Idiotypic network dysregulation: a common etiopathogenesis of diverse autoimmune diseases. Appl Biochem Biotechnol 83: 155-62; discussion 297-313, 2000.
871. Blank M, Krause I, Shoenfeld Y. The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome. In book: "Hughes Syndrome Antiphospholipid syndrome" (Ed: M.A. Khamashta) Springer Publ : 379-385, 2000
872. Bar-Meir E, Amital H, Levy Y, Kneller A, Bar-Daya Y, Shoenfeld Y. Mycoplasma-pneumoniae- induced thrombotic thrombocytopenic purpura. Acta Haematologica. 103: 112-115, 2000.
873. George J, Ahmed A, Patnaik M, Aadler Y, Levy Y, Harats D, Gilburd B, Terrybery J, Shen G-Q, Sagie A, Herz I, Snow P, Brandt J. Peter J, Shoenfeld Y. The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol 23: 453-456, 2000.
874. Meroni P.L., Del Papa N, Gilburd B, Raschi E, Panzeri P, Borghi M.O, Lindsey N, Shoenfeld Y. The story of the murine antiendothelial monoclonal antibody BGM: from patients' bedside to laboratory bench and from animal models to patients. Clin Rev Allergy & Immunol. 18: 3-10, 2000.
875. Lorber M, Shoenfeld Y. Hidden autoantibodies. Clin Rev Allergy & Immunol. 18: 3-10, 2000.
876. George J, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: The role of autoantigens. Clin Rev Allergy & Immunol. 18: 73-86, 2000. 79
877. Krause I, Blank M, Shoenfeld Y. Peptide immunotherapy in autoimmune diseases. Drug News & Perspectives 13: 78-84 , 2000
878. Shoenfeld Y. VI International Congress of Immunorehabilitation, Eilat, Israel, May 3-6, 2000. [http://www.rheuma21st.com/archives/immunorehab\\_shoenfeld.html](http://www.rheuma21st.com/archives/immunorehab_shoenfeld.html) , 26.6.2000 1-7.
879. Shovman O, Shoenfeld Y. Smoking, sex hormones and rheumatoid arthritis. Harefuah, 138; 949-951, 2000.
880. Shovman O, Gilbourd B, Langevitz P, Shoenfeld Y. Immunological and clinical aspects of anti-RA33 antibodies in various autoimmune diseases. Harefuah 138: 1043-1045, 2000.
881. George J, Shoenfeld Y, Gilbourd B, Afek A, Shaish A, Harats D. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or mycobacterium tuberculosis. Circ Res 86: 1203-1210, 2000.
882. Shoenfeld Y, Sherer Y, Jacob J, Harats D. Autoantibodies associated with atherosclerosis. Ann Med 32: 37-40, 2000.
883. Gur H., Bar-Dayan Y., Shoenfeld Y. Anti-P53 autoantibodies as diagnostic or prognostic markers of cancer. Sem Clin Immunol 1, 339-44, 2000.
884. Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for systemic lupus erythematosus. Eur J Int Med 11 130-134, 2000.

885. Sherer Y, Shoenfeld Y, Shaish A, Levkovitz H, Bitzur R, Harats D. Suppression of atherogenesis in female-low-density lipoprotein receptor knockout mice following magnesium fortification of drinking water: the importance of diet. Pathobiology 68: 93-98, 2000.
886. Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol, 18: 404-406, 2000.
887. Shoenfeld Y. Atherosclerosis and the immune system: is atherosclerosis an autoimmune disease? Sem Clin Immunol 1 : 5-6, 2000.
888. Kornberg A, Renaudineau Y, Blank M, Youinou P, Shoenfeld Y. Anti-beta2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. IMAJ - Isr Med Ass J 2: 27-31, 2000.
889. Terryberry J.F., Shoenfeld Y, Sherer Y, Levy Y, Fabrizio F, Ahmed A, Peter J.B. Detection of antibodies to gangliosides and glycolipids in various Intravenous Immunoglobulin (IVIg) preparations. Immunol Invest 29: 337-347, 2000.
890. Levy Y, Sherer Y, Mathieu A, Cauli A, Passiu G, Sann G, Janackovic Z, Blank M, Shoenfeld Y. Anti-cardiolipin antibody from a patient with antiphospholipid syndrome recognizes only an epitope expressed by cardiolipin/  $\beta$ 2-glycoprotein-I ( $\beta$ 2GPI) complex and induces APS. Clin Exp Rheum 18:479-84, 2000.
891. Shoenfeld Y, Blank M, Krause I. The relationship of anti-phospholipid antibodies to infections - do they bind to infecting agents or may they even be induced by them? Clin Exp Rheum 18: 431-2, 2000.
892. Blank M, Krause I, Shoenfeld Y. Molecular Mimicry: lessons from experimental models of systemic lupus erythematosus and antiphospholipid syndrome. (Chap. 16) in: Molecular Mimicry, Microbes, and Autoimmunity. Editors: M.W.Cunningham, R.S. Fujinami, 2000, ASM Press, Washington, D.C. pp. 223-233, 2000.
893. George J, Meroni P.L., Gilbord B, Raschi E, Harats D, Shoenfeld Y. Anti-endothelial cell antibodies in patients with coronary atherosclerosis. Immunol Letters 73: 23-27, 2000.
894. Shoenfeld Y. The revolution in medicine toward the third millennium: from a lecture to medical students on their first exposure to clinical medicine. Harefuah, 139: 109-110, 2000.
895. Shoenfeld Y, Haratz D, Jacob G. Heat shock protein 60/50, beta2-glycoprotein I and Oxidized LDL as players in murine atherosclerosis. J Autoimmunity 15: 199-202, 2000.
896. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome: insights from animal models. Curr Opin Hematol. 7: 321-4, 2000.
897. Meissner M, Sherer Y, Levy Y, Chwalinska H, Langevitz P, Shoenfeld Y. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 19:199-201, 2000.
898. Levy Y, Sherer Y, Ahmed A, Fabbrizzi F, Terryberry J, Qiu Shen G, Peter J.B., Shoenfeld Y. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat Immun (1998) 16: 207-214, 2000.
899. Praprotnik S, Rozman B, Blank M, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in systemic vasculitis. Wien Klin Wochenschr. 112/ 15-16: 660-664, 2000.
900. Sherer Y, Shoenfeld Y. The idiotypic network in antinuclear-antibody-associated diseases. Int Arch Allergy Immunol, 123: 10-15, 2000.
901. Shoenfeld Y. Eppur si muove (Galileo Galilei 1564- 1642): the idiotypic dysregulation of autoantibodies as part of the etiology of SLE. Lupus 9: 481 - 483, 2000.
902. George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y. Adoptive transfer of  $\beta$  2-glycoprotein I - reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102: 1822 - 1827, 2000.
903. Reifen R, Amital H, Blank M, Sklan D, Berkovich Z, Gershwin E, Shoenfeld Y. Linseed Oil suppresses the anti-beta-2-glycoprotein-I in experimental antiphospholipid syndrome. J Autoimmun 15: 381-385, 2000.
904. Shoenfeld Y, Krause I, Matalon SH, Sheer Y. 9<sup>th</sup> International Symposium on Antiphospholipid Antibodies, September 12-16, 2000, Tours, Loire Valley, France. [http://www.rheuma21st.com/archives/apls\\_shoenfeld.html](http://www.rheuma21st.com/archives/apls_shoenfeld.html) , 11.10.2000 pp: 1-10.
905. Sanna G, Piga M, Terribery JW, Pelz MT, Giagheddu S, Satta L, Ahmed A, Cauli A, Montaldo C, Passiu G, Peter JB, Shoenfeld Y, Mathieu A. Central nervous system involvement in systemic lupus erythematosus:



- cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus; 9: 573-83, 2000.
906. Aron-Maor A, Shoenfeld Y. Vaccination and arthritis revisited. [http://www.rheuma21st.com/archives/apls\\_shoenfeld\\_vaccination\\_revisited\\_html](http://www.rheuma21st.com/archives/apls_shoenfeld_vaccination_revisited_html) , 11.9.2000 pp: 1-6.
907. Rozen Y, Levy Y, Shoenfeld Y. Pulmonary adenocarcinoma in myasthenia gravis - autoimmunity and late development of malignancy. Harefuah; 139, 354-355, 2000.
908. Shoenfeld Y. Editorial: Changing of the Guard - tribute to Ya'acov Rotem. Harefuah; 138: 359, 2000.
909. Shoenfeld Y, Conrad K. Autoantigens and autoantibodies: diagnostic tools and clues to understanding autoimmunity. [http://www.rheuma21st.com/archives/shoenfeld\\_dresden.html](http://www.rheuma21st.com/archives/shoenfeld_dresden.html) , 9.11.2000 pp: 1-11.
910. Leibovitch L, Amital H, Levy Y, Langevitz P, Shoenfeld Y. Isotretinoin-induced adult onset Still's disease. Clin Exp Rheumatol; 18: 616-8, 2000.
911. Savion S, Blank M, Shepshelovich J, Fishman P, Shoenfeld Y. Ciprofloxacin affects pregnancy loss in CBA/JxDBA/2J mice possibly via elevation of interleukin-3 and granulocyte macrophage-colony stimulating factor production. AJRI 44: 293-298, 2000.
912. Shoenfeld Y. Are the research physicians an endangered species? Harefuah 139: 441-442, 2000.
913. Sherer Y, Shemesh J, Tenenbaum A, Praprotnik S, Harats D, Fisman E Z, Blank M, Motro M, Shoenfeld Y. Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain. Am J Cardiol 86: 1206-1311, 2000.
914. Shoenfeld Y, Pavelka K. 32<sup>nd</sup> Rheumatologic Scientific Conference of the Institute of Rheumatology and the Medical Faculty of Charles University, Prague, Czech Republic, 3<sup>rd</sup> November 2000. [File:///Shoenfeld/public/reprints...Shoenfeld - Prague - Rheumat21.htm](File:///Shoenfeld/public/reprints...Shoenfeld-Prague-Rheumat21.htm) , 2000, 1-4.
915. Levy Y, Sherer Y, Shoenfeld Y. Iloprost treatment of finger gangrene in a patient with Raynaud's Syndrome. IMAJ 2: 960-962, 2000.
916. Shro S, Chapman J, Shoenfeld Y. Central nervous system involvement in antiphospholipid syndrome. Harefuah, 140: 40-43, 2000.
917. Praprotnik S, Blank M, Levy Y, Tavor S, Boffa M-C, Weksler B, Eldor A, Shoenfeld Y. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 13: 203-210, 2000.
918. Matalon SH, Blank M, Ornoy A, Shoenfeld Y. The association between anti-thyroid antibodies and pregnancy loss. Am J Reprod Immunol Microbiol 45: 72-77, 2001.
919. Shoenfeld Y, Sherer Y, George Y, Harats D. Mexico-Israel Symposium: beta2-glycoprotein I in human and murine atherosclerosis. IMAJ 3: 85-87, 2001.
920. Leibe A, Shoenfeld Y. Association between periodontitis, gingivitis and atherosclerosis. Harefuah. 140: 126-128, 2001.
921. Sherer Y, Tenenbaum A, Blank M, Shemesh J, Harats D, Fisman E Z, Praprotnik S, Motro M, Shoenfeld Y. Autoantibodies to oxidized low-density lipoprotein in coronary artery disease. Am J Hypertension 14: 149-154, 2001.
922. Ehrenfeld M, Shoenfeld Y. Malignancies and autoimmune rheumatic diseases. J Clin Rheumatol. 7: 47-49, 2001.
923. Shoenfeld Y. Eppur si muove (Galileo Galilei 1564-1642): the idiotypic dysregulation of autoantibodies as part of the etiology of SLE. Harefuah, 140: 227-229, 2001.
924. Shoenfeld Y. Mass casualty events during night shifts in the internal medicine departments. Harefuah, 140: 230-231, 2001.
925. Cabral Antonio R, Shoenfeld Y. Highlights of the XXIX meeting of the Mexican Society of Rheumatology, February 9-13, 2001. <http://www.rheuma21st.com/archives/highlights29mexmeet.html> ,
926. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep. 3: 328-33, 2001.

927. Fishman P, Shoenfeld Y. Intravenous immunoglobulin (IVIg) as an inhibitor of tumor growth: from autoimmunity to cancer. (Chap. 13 ) in: Old Herborn University Seminar Monograph. Editors: Peter J. Heidt Volker D. Rusch; Dirk Van Der Waaij, 2001, Herborn Litterae, pp:93-107.
928. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin (IVIg) in autoimmune diseases - expanding indications and increasing specificity. (Chap. 13 ) in: Old Herborn University Seminar Monograph. Editors: Peter J. Heidt Volker D. Rusch; Dirk Van Der Waaij, 2001, Herborn Litterae, pp:85-91.
929. Abu Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10: 152-153, 2001.
930. Rauva L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y. High-dose intravenous immunoglobulins for lupus nephritis - a salvage immunomodulation. Lupus 10: 209-213, 2001
931. Arom-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 10: 237-240, 2001
932. Leiba A, Amital H, Gershwin ME, Shoenfeld Y. Diet and lupus. Lupus 10: 246-248, 2001
933. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 62: 133-137, 2001.
934. Asherson RA, Shoenfeld Y. The catastrophic antiphospholipid syndrome - a review of 115 patients and possible clues to pathogenesis and treatment. [http://www.rheuma21st.com/archives/cutting\\_asherson\\_caps.html](http://www.rheuma21st.com/archives/cutting_asherson_caps.html) , 2001, 1-16.
935. Sherer Y, Shoenfeld Y. Report on the European Atherosclerosis Society workshop on the immune system in atherosclerosis. [http://www.rheuma21st.com/archives/shoenfeld\\_immune\\_sys\\_atherosclerosis%10.html](http://www.rheuma21st.com/archives/shoenfeld_immune_sys_atherosclerosis%10.html) , 2001, 1-4.
936. Leibe A, Levy Y, Shoenfeld Y. Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy. Harefuah; 140: 392-394, 2001.
937. Gordon PA, George J, Khamashta M, Harats D, Hughes G, Shoenfeld Y. Atherosclerosis and autoimmunity. Lupus 10: 249-252, 2001
938. Shoenfeld Y, Krause Irit, Krause Ilan, Evelyn V. Hess. 6<sup>th</sup> International Lupus Conference Barcelona 26-28, March 2001. [http://www.rheuma21st.com/archives/shoenfeld\\_...html](http://www.rheuma21st.com/archives/shoenfeld_...html) , 2001, 1-11
939. Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M. BCG and autoimmunity: another two-edged sword. JAI 16: 235-240, 2001.
940. Abu Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60: 433-440, 2001.
941. Shemer Y, Shoenfeld Y. HAREFUAH peer review. Harefuah; 140: 403-405, 2001.
942. Rahamim-Cohen D, Shoenfeld Y. The mosaic of autoimmunity. A classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases. IMAJ 3: 381-382, 2001.
943. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. TRENDS in Immunol 22: 293-295, 2001.
944. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fishman E.Z, Harats D, George J, Levy Y, Peter J.B, Motro M, Shoenfeld Y. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, Beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 95: 20-24, 2001.
945. Leder AN, Flansbaum B, Zandman-Goddard G, Asherson R, Shoenfeld Y. Antiphospholipid syndrome induced by HIV. Lupus 10: 370-374, 2001.
946. Marai I, Levy Y, Goddard G, Shoenfeld Y. Following up of 90 patients with anti-phospholipid syndrome: manifestations of the disease, follow-up of antibodies titers and correlations with clinical manifestations in the Israeli population - patients in the Sheba medical center, Tel-Hashomer. Harefuah, 140: 495-500, 2001.
947. Von-Landenberg P, Shoenfeld Y. New approaches in the diagnosis of sepsis. IMAJ 3: 439-442, 2001.
948. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. [http://www.rheuma21st.com/archives...report\\_shoenfeld\\_duallymphoma.html](http://www.rheuma21st.com/archives...report_shoenfeld_duallymphoma.html) , 2001, 1-7. Blood Cells Mol Dis. 2001; 27: 750-6.

949. Ryhal B, DeMera RS, Shoenfeld Y, Peter JB, Gershwin ME. Are autoantibodies present in patients with subacute and chronic urticaria. J Investing Allergol Clin Immunol, 11: 16-20, 2001.
950. Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis & Rheum 44: 1484-1494, 2001.
951. Zandman-Goddard G, Shoenfeld Y. HIV and Autoimmunity. [http://www.rheuma21st.com/archives/file:///Shoenfeld/public/REPRINT...report\\_zandmann\\_shoenfeld\\_hiv.html](http://www.rheuma21st.com/archives/file:///Shoenfeld/public/REPRINT...report_zandmann_shoenfeld_hiv.html), 2001, 1-11.
952. Renaudineau Y, Grunebaum E, Krause I, Praprotnik S, Revelen R, Youinou P, Blank M, Gilburd B, Sherer Y, Luderschmidt C, Eldor A, Weksler B, Gershwin EM, Shoenfeld Y. Anti-endothelial cell antibodies (AECA) in systemic sclerosis - increased sensitivity using different endothelial cell substrates and association with other autoantibodies. Autoimmunity 33: 171-179, 2001.
953. Shoenfeld Y, Blank M, Sherer Y. Induction and treatment of the antiphospholipid syndrome - lessons from models. Eur J Clin Invest 31: 736-40, 2001.
954. Aron-Maor A, Shoenfeld Y. Editorial: Alternative therapies in rheumatic diseases – pros and cons. Lupus 10: 453-456, 2001.
955. Katzav A, Pick CG, Korezyn AD, Oest E, Blank M, Shoenfeld Y, Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 10: 496-499, 2001.
956. Shoenfeld Y. Atherosclerosis as an autoimmune condition. Harefuah 140: 720-722, 2001.
957. Shoenfeld Y, Krause I, Krause I, Khamashta M, Hughes G. The Sixth International Lupus Conference, Barcelona 24-28 March 2001. Lupus 10: 580-587, 2001.
958. Sherer Y, Wu R, Krause I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIG) preparations. Lupus 10: 568-570, 2001.
959. George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-deficient mice. J Am Coll Cardiol 38: 900-905, 2001.
960. Ehrenfeld M, Abu Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Molec Dis 27: 750-756, 2001.
961. Shoenfeld Y, Levy Y, Fishman P. Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. IMAJ 3: 698-699, 2001.
962. George J, Haratz D, Shoenfeld Y. Accelerated atheroma antiphospholipid antibodies, and the antiphospholipid syndrome. Rheum Dis Clin North Am. 27: 603-610, 2001.
963. Shoenfeld Y, Sidi Y, Ezra D. The department of internal medicine – returned to its formal glory. Harefuah; 140: 835-6, 2001.
964. Ehrenfeld M, Blank M, Shoenfeld Y, Hidvegi M. AVEMAR (a new benzoquinone-containing natural product) administration interferes with the response in experimental SLE and promotes amelioration of the disease. Lupus 10: 622-627, 2001.
965. Amital H, Levy Y, Davidson C, Lundberg I, Harju A, Kosach Y, Asherson RA, Shoenfeld Y. Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Sem Arth Rheum 31: 127-132, 2001.
966. Segal E, Shoenfeld Y. IVIG therapy in sepsis. Harefuah, 140: 955-958, 2001.
967. Carp HJ, Toder V, Gazit E, Airon R, Torchinski A, Mashiach S, Shoenfeld Y. Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. Am J Reprod Immunol 46: 268-73, 2001.
968. Shoenfeld Y, Takasaki Y, Yamamoto K, Koike T. Report: 7<sup>th</sup> International Workshop on Autoantibodies and Autoimmunity. [http://www.rheuma21st.com/archives//report\\_shoenfeld...html](http://www.rheuma21st.com/archives//report_shoenfeld...html)
969. Sherer Y, Wu R, Krause I, Gershwin A, Levy Y, Peter JB, Shoenfeld Y. Cytokine levels in various intravenous immunoglobulin (IVIG) preparations. Hum Antibodies 10: 51-53, 2001.
970. Sherer Y, Bizur R, Cohen H, Shaish A, Varon D, Shoenfeld Y, Harats D. Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 14: 173-179, 2001.

971. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AAL, Nabrosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M. Catastrophic antiphospholipid syndrome: Clue to the pathogenesis from series of 80 patients. Medicine (Baltimore) 80: 355-377, 2001.
972. Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest 61: 3-15, 2001.
973. Rauova L, Chapman J, Shoenfeld Y. Brain vasculitis and antiphospholipid syndrome. A chapter in book: Brain disease therapeutic strategies and repair. Publication: Martin Dunitz; pp: 193-200, 2001.
974. Gorshtein A, Shoenfeld Y. The mosaic of pemphigus. Harefuah 140: 1049-111053, 2001.
975. Shovman O, Levy Y, Gilburd B, Shoenfeld Y. Anti-inflammatory and immunomodulatory properties of statins. [http://www/rheuma21st.com/archives///report\\_shoenfeld\\_antiinfl\\_statins.html](http://www/rheuma21st.com/archives///report_shoenfeld_antiinfl_statins.html)
976. Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, Wang N, Rabinowitz R, Blank M, Shoenfeld Y, Chapman J. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol, 126: 570-577, 2001.
977. Carp H, Asherson R.A., Shoenfeld Y. Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role? J Clin Rheumatol 7:291-294, 2001.
978. Marai Y, Levi Y, Shoenfeld Y. Morbidity and mortality in systemic lupus erythematosus. Harefuah, 140: 1177-1180, 2001.
979. Shemer Y, Shoenfeld Y. A new reality - epidemiology of terror. Harefuah, 140: 994-996, 2001.
980. Sherer Y, Shoenfeld Y. Atherosclerosis: Is Atherosclerosis a cellular or humoral mediated autoimmune disease? Ann Rheum Dis. ; 61: 97-99, 2002.
981. Zan-Bar T, Aron A, Shoenfeld Y. Acupuncture therapy for rheumatoid arthritis. [http://www/rheuma21st.com/archives/cutting\\_shoenfeld\\_acupuncture.html](http://www/rheuma21st.com/archives/cutting_shoenfeld_acupuncture.html) , 2002.
982. Zurgil N, Levy Y, Gilburd B, Trubiankov E, Deutch M, Shagran Y, Shoenfeld Y. Detection of cellular activity in atherosclerosis by the novel cellscan system. In: Atherosclerosis and Autoimmunity; (Eds: Shoenfeld Y, Harats D. and Wick G.) Elsevier Publ. Amsterdam, The Netherlands: pp. 191-200, 2001.
983. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14: 121-122, 2002.
984. Lev S, Shoenfeld Y. The family of metalloproteinases and their immunomodulatory significance. Harefuah, 141, 118-110, 2002.
985. Rauova L, Rovensky J, Shoenfeld Y. Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. Springer Semin Immunopathol 23: 447-57, 2001
986. Fajka-Boja R, Hidvegi M, Shoenfeld Y, Ion G, Demydenko D, Tomoskozi-Farkas R, Vizler C, Telekes A, Resetar A, Monostori E. Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol 20: 563-570, 2002.
987. Marai I, Shoenfeld Y. Lupus-like syndrome due to minocycline. Harefuah 141: 151-152, 2002.
988. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmunity Rev 1: 21-27, 2002.
989. Merimsky O, Meller I, Inber M, Bar-Yehuda S, Shoenfeld Y, Fishman P. A possible role for IVIG in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int J Oncol 20: 839-43, 2002.
990. Lev S, Gilburd B, Lahat N, Shoenfeld Y. Prevention of tumor spread by matrix metalloproteinase-9 inhibitor: old drugs, new concept. Eur J Intern Med 13: 101-103, 2002.
991. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fishman EZ, Motro M, Shoenfeld Y. Autoantibodies to cardiolipin and Beta-2-Glycoprotein-I in coronary artery disease patients with and without hypertension. Cardiology 97: 2-5, 2002.
992. Bar-Dayan Y, Kaveri SV, Bar-Dayan Y, Pashov A, Shoenfeld Y, Kazatchkine MD. Anti-inflammatory effects of intravenous immunoglobulin (IVIG) in symposium in Immunology. VII Eibl, M. and Huber H. ed. Springer - Verlag. Herlag. Heidelberg. pp. 171-184.

993. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y. Bacterial I induction of autoantibodies to  $\beta$ 2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109: 797-804, 2002.
994. Sherer Y, Dulitzki M, Levy Y, Livneh A, Shoenfeld Y, Langevitz P. Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol 81: 161-163, 2002.2002.
995. Sherer Y, Molina V, Shoenfeld Y. Novel aspects in autoimmunity and autoimmune diseases: Summary of 3rd International Congress on Autoimmunity Geneva Switzerland, Feb. 20-24, 2002. [http://www/rheuma21st.com/archives/shoenfeld\\_3int\\_cong\\_autoimmun.html](http://www/rheuma21st.com/archives/shoenfeld_3int_cong_autoimmun.html) , 2002
996. Cervera R, Piette J-C, Font J, Khamashta M, Shoenfeld Y, Champs M.T., Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derkson R.H.W.M, dr Groot P.G., Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Groc J-C, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa M-C, Hughes G.R.V, Ongelmo M. Antiphospholipid syndrome. Clinical and immunologica manifestations and patterns of disease expression in a cohort of 1,000 patients. Arth Rheum 46: 1019-1027, 2002.
997. Grunebaum E, Levy Y, Shoenfeld Y. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment. IMAJ 4: 288-289, 2002.
998. Abu Shakra M, Ehrenfeld M, Shoenfeld Y. Systemic lupus erythematosus and cancer: associated or not? Lupus 11: 137-44, 2000.
999. Lerner A, Shoenfeld Y. Serological markers in inflammatory bowel disease: the pros and cons. Eur J Gastroenterol Hepatol 14: 103-105, 2002.
1000. Rauova L, Gilburd B, zZurgil N, Blank M, Guegas LL, Brickman CM, Cebecauer L, Deutsch M, Wiik A, Shoenfeld Y. Induction of biologically active antineutrophil cytoplasmic antibodies by immunization with human apoptotic polymorphonuclear leukocytes. Clin immunol 103: 69-78, 2002.
1001. Krause I, Wu R, Sherer Y, Patanik M, Peter J, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12: 133-139, 2002.
1002. Shoenfeld Y. Infection and atherosclerosis - impact on autoimmune rheumatic disease, Washington D.C., USA 29-30 April 2002 - Report. [http://www/rheuma21st.com/archives/report\\_infection\\_atherosclerosis.html](http://www/rheuma21st.com/archives/report_infection_atherosclerosis.html) , 2002
1003. Shovman O, Levy Y, Gilburd B, Shoenfeld Y. Antiinflammatory and immunomodulatory properties of statins. Immunologic Research 25: 271-286, 2002.
1004. Shoenfeld Y. The 10th International Vasculitis and ANCA Workshop, 25-28 April 2002, Cleveland, Ohio, USA. - Report. [http://www/rheuma21st.com/archives/report\\_10th\\_intern\\_vasculitis\\_part2.html](http://www/rheuma21st.com/archives/report_10th_intern_vasculitis_part2.html) , 2002.
1005. Shoenfeld Y, Sherer Y, Kalden JR. The expanding world of autoimmunity. Trends Immunol. 23: 278-279, 2002.
1006. Tincani A, Gilburd B, Abu-Shakra M, Blank M, Allegri F, Ottaviani R, Riboni M, Meroni P.L., Balestrieri G, Shoenfeld Y. Immunization of Naive BALB/c mice with human  $\beta$ 2Glycoprotein-I breaks tolerance to the murine molecule. Arth Rheum 46: 1399-1404, 2002.
1007. Assolin-Dayan Y, Leong A, Shoenfeld Y, Gershwin ME. Studies of sick building syndrome. IV Mycotoxicosis. J Asthma 39: 191-201, 2002.
1008. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. Concise communication: The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arth Rheumat 46: 1689-1690, 2002.
1009. Shoenfeld Y. Fading into extinction. Harefuah, 141: 442-443, 2002.
1010. Marai I, Bornstein Y, Shoenfeld Y. Medicine and intercessory prayer. Harefuah, 141: 527-529, 2002.
1011. Sherer Y, Hassin Y, Shoenfeld Y, Levy Y, Livneh A, Ohry A, Langevitz P. Transverse myelitis in patients with antiphospholipid antibodies - the importance of early diagnosis and treatment. Clin Rheumatol 21: 207-210, 2002.
1012. Grunebaum E, Blank M, Youinou P, Shoenfeld Y. The pathogenic role of anti-endothelial cell antibodies. [http://www/rheuma21st.com/archives/cutting\\_edge\\_grunebaum\\_antiendo.html](http://www/rheuma21st.com/archives/cutting_edge_grunebaum_antiendo.html) , 2002.

1013. Shoenfeld Y, Meroni P.L. International Meeting on Autoimmunity and Pregnancy Loss. 8 June, 2002, Park hotel Villa Fiorita, Italy. [http://www/rheuma21st.com/archives/report\\_shoenfeld\\_pregnancy.html](http://www/rheuma21st.com/archives/report_shoenfeld_pregnancy.html) , 2002.
1014. Chapman J, Shoenfeld Y. Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. ANNALS of the New York Academy of Sciences. 966: 415-424, 2002.
1015. Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Clev Clin J Med ,69 SII: 65-68, 2002.
1016. Matsuura E, Kazuko K, Junko K, Tatsuji Y, Hirofumi M, Koike T, Shoenfeld Y. Anti- $\beta_2$ -Glycoprotein I autoantibodies and atherosclerosis. Intern Rev Immunol 21: 51-66, 2002.
1017. Sherer Y, Levy Y, Shoenfeld Y. IVIG in autoimmunity and cancer-efficacy versus safety. Expert Opin Drug Saf. I(2): 153-158, 2002.
1018. Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y, Zandman-Goddard G, Hoefler E, Smolen JS, Shoenfeld Y. Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1-A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in mice. Clin Exp Rheumatol. 20: 517-24, 2002.
1019. Krause I, He XS, Gershwin ME, Shoenfeld Y. Brief report: immune factors in autism: a critical review. J Autism Dev Disord. 32: 337-45, 2002.
1020. Fishman P, Bar-Yehuda S, Shoenfeld Y. IVIG to prevent tumor metastases (review). Int J Oncol 21: 875-80, 2002.
1021. Shoenfeld Y, Blank M, Conrad K. 6th Dresden Symposium on Autoantibodies 4-7 September 2002. [http://www/rheuma21st.com/archives/report\\_6th\\_dresden\\_symposium\\_shoenfeld.html](http://www/rheuma21st.com/archives/report_6th_dresden_symposium_shoenfeld.html) , 2002.
1022. Grunebaum E, Blank M, Cohen S, Afek A, Kopolovic J, Meroni PL, Youinou P, Shoenfeld Y. The role of anti-endothelial cell antibodies in Kawasaki disease - *in vitro* and *in vivo* studies. Clin Exp Immunol 130: 233-240, 2002.
1023. Schwarz A, Furman G, Cohen G, Gilutz H, Brill S, Schily M, Gurevitch B, Shoenfeld Y. Association between hypophosphatemia and cardiac arrhythmias in the early stages of sepsis. Eur J Int Med 13: 434-438, 2002.
1024. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates *mycobacterium tuberculosis* - induced and high-fat-diet-driven atherosclerotic lesions. J Am Col Cardiol 7: 1333-8, 2002.
1025. Matalon S, Shoenfeld Y, Blank M, Yacobi S, Blumenfeld Z, Ornoy A. The effects of IgG purified from women with SLE and associated pregnancy loss on rat embryos in culture. Am J Reproduct Immunol 48: 296-304, 2002.
1026. Lev Sh, Shoenfeld Y. Cardiac valvulopathy in the antiphospholipid syndrome. Clin Rev Allergy Immunol, 23: 341-348, 2002.
1027. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, Rovensky J, Blank M. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14: 1303-1311, 2002.
1028. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95: 2032 - 2037, 2002.
1029. Shoenfeld Y, Orbach H, Blank M, Zandman-Goddard G, Gilburd B, Krause I, Chapman J, Sherer Y. Summary of the 10th International Congress on Antiphospholipid Antibodies. [http://www/rheuma21st.com/archives/report\\_26.11.2002](http://www/rheuma21st.com/archives/report_26.11.2002).
1030. Orbach H, Gilburd B, Brickman CM, Gerli R, Shoenfeld Y. Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis and predictor of an erosive disease. IMAJ 4, 892-893, 2002.
1031. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmunity Rev 1/6: 329-337, 2002.
1032. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmunity Rev 1/6: 348- 353, 2002.
1033. Assolin-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin E. Pathogenesis and natural history of osteonecrosis. Sem Arth Rheum 32: 94-124, 2002.

1034. Krause I, Blank M, Sherer Y, Gilburd B, Kvapil F, Shoenfeld Y. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 32: 3414-3424, 2002.
1035. Molina V, Blank M, Shoenfeld Y. Fibrotic diseases. Harefuah, 141: 973-978, 2002.
1036. Krause I, Shoenfeld Y. Autoimmune aspects of cytokines and anti-cytokine therapies. <http://www.rheuma21st.com/archives/report> , 25.11.2002.
1037. Short S, Katzav A, Korczyn AD, Litvinjuk Y, Hersherson R, CG Pick, Blank M, Zaech J, Shoenfeld Y, Sirota P, Chapman J. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 11: 736-743, 2002.
1038. Gorshtein A, Levy Y, Shoenfeld Y. Air flights and venous thromboembolism - a preventable condition. IMAJ 4 1080 - 1081, 2002,
- 1038a. Rottem M, Gershwin ME, Shoenfeld Y. Allergic disease and autoimmune effectors pathways. Developmental Immunology 9: 161-167, 2002.
1039. Shoenfeld Y. Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unrevealed. Trends in Immunology 24: 2-4, 2003.
1040. Siekmann JH, Allen LA, Watnik MR, Nestel P, Neumann CG, Shoenfeld Y, Peter JB, Patnik M, Ansari AA, Coppel RL, Gershwin ME. Titers of antibody to common pathogens: relation to food-based interventions in rural Kenyan schoolchildren. Am J Clin Nutr. 77: 242-9, 2003.
1041. Amital H, Rewald E, Levy Y, Bar-Dayyan Y, Manthorpe R, Engervall P, Sherer Y, Langevitz P, Shoenfeld Y. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62: 175-177, 2003.
1042. Borchers AT, Keen CL, Shoenfeld Y, Silva J Jr, Gershwin ME. Vaccines, viruses and voodoo. J Invest Allergol Clin Immunol 12:155-68, 2002.
1043. Guejes L, Zurgil N, Deutsch M, Gilburd B, Shoenfeld Y. The influence of different cultivating conditions on polymorphonuclear leukocyte apoptotic processes in vitro, I: the morphological characteristics of PMN spontaneous apoptosis. Ultrastruct Pathol 27: 23-32, 2003.
1044. Asherson RA, Shoenfeld Y. Human immunodeficiency virus infection, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheum 30: 214-219, 2003.
1045. Shovman O, Levy Y, Tal S, Shoenfeld Y. Omental Cake in a Male. IMAJ 5 73-74, 2003.
1046. Zandman-Goddard G, Levy Y, Weiss P, Shoenfeld Y, Langevitz P. Transverse myelitis associated with chronic hepatitis C. Clin Exp Rheum 21: 111-113, 2003.
1047. Aron-Maor A, Shoenfeld Y. BCG immunization and the 'Trojan Horse' phenomenon. Clin Rheum 22: 6-7, 2003.
1048. Von-Landenberg P, Matthias T, Zaech J, Schultz M, Lorber M, Blank M, Shoenfeld Y. Antiprothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome. Am J Reprod Immunol (AJRI) 49:51-56, 2003.
1049. Ingaki J, Sugiura-Ogasawara M, Nomizu M, Nakatsuka M, Ikuta K, Suzuki N, Kaihara K, Kobayashi K, Yasuda T, Shoenfeld Y, Aoki K, Matsuura E. An association of IgG anti-laminin-1 autoantibodies with endometriosis in infertile patients. Human Reprod 18: 544-549, 2003.
1050. Wu R, Shoenfeld Y, Sherer Y, Patnaik M, Matsuura E, Gilburd B, Koike T, Peter JB. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations – possible immunomodulation of atherosclerosis. Autoimmunity 36: 91-97, 2003.
1051. Rottem M, Shoenfeld Y. Allergy and autoimmunity. <http://www.Rheum21st.com>.
1052. Katzav A, Kloog Y, Lprzum A.D., Molina V, Blank M, Shoenfeld Y, Chapman J. Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiol 207: 47-50, 2003.
1053. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughes G.R.V. Atherogenic autoantigen: oxidized LDL complexes with  $\beta$ 2-glycoprotein I. Immunobiol 207: 17-22, 2003.
1054. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiol 207: 13-16, 2003.
1055. Zandman-Goddard G, Blank M, Sherer Y, Ehrenfeld M, Chapman J, Orbach H, Gilburd B, Krause I, Shoenfeld Y. 10<sup>th</sup> International Congress on antiphospholipid antibodies – summary. Autoimmunity Rev 2: 79-85, 2003.

1056. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmunity Rev 2: 86-93, 2003.
1057. Cohen H, Sherer Y, Shaish A, Shoenfeld Y, Levkovitz H, Bitzur R, Harats D. Atherogenesis inhibition induced by magnesium-chloride fortification of drinking water. Biological Trace Element Research 90: 251-260, 2002.
1058. Orbach H, Shoenfeld Y. Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis. Harefuah, 142: 182-165, 2003.
1059. Shoenfeld Y, Cutolo M. The glucocorticoid induced osteoporosis (GIO) international congress, March 2003, Turin, Italy. [http://www/rheuma21st.com/archives/report\\_gio\\_int\\_cong\\_shoenfeld\\_cutolo.html](http://www/rheuma21st.com/archives/report_gio_int_cong_shoenfeld_cutolo.html). April 3, 2003.
1060. Sherer Y, Shoenfeld Y. Summary of an expert conference on the use of IVIG. 14-15 February 2003, Berne. [http://www/rheuma21st.com/archives/report\\_expert\\_ivig\\_shoenfeld\\_sherer.html](http://www/rheuma21st.com/archives/report_expert_ivig_shoenfeld_sherer.html). 27 March, 2003.
1061. Sherer Y, Tartakover-Matalon S, Blank M, Matsuura E, Shoenfeld Y. Multiple autoantibodies associated with autoimmune reproductive failure. J Assisted Rep & Genetics 20: 53-57, 2003.
1062. Shoenfeld Y. 23<sup>rd</sup> European Workshop for Rheumatology Research Marseille France 27/2-2/3, 23-3-2003. <http://www/rheuma21st.com/archives/report> 11.4.3004 pp: 1-6.
1063. Tartakover-matalon S, Blank M, Levy Y, Carp H.J.A., Arad A, Burek L, Grunebaum E, Sherer Y, Ornoy A, Refetoff S, Weiss R.E, Rose N.R, Shoenfeld Y. The pathogenic role of anti-thyroglobulin antibody on pregnancy: evidence from an active immunization model in mice. Human Reproduction 18: 1094-1099, 2003.
1064. Haj-Yahja S, Sherer Y, Blank M, Kaetsu H, Smolinski A, Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 12: 364-369, 2003.
1065. Shamir R, Shoenfeld Y, Blank M, Eliakim R, Lahat N, Sobel E, Shinar E, Lerner A. The prevalence of celiac disease antibodies in patients with the antiphospholipid syndrome. Lupus 12: 394-399, 2003
1066. Conrad K, Sack U, Shoenfeld Y. From proteomics to molecular epidemiology: relevance of autoantibodies. Autoimmunity Rev. 2: 165-169, 2003.
1067. Rotman - Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or "injectiositis" – staphylococcus aureus multiple abscesses following intramuscular injections. IMAJ 5: 295-296, 2003.
1068. Shoenfeld Y, Shemer J. Why viral (SARS, Ebola and AIDS) epidemics now? Harefuah, 142: 324-325, 2003.
1069. Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. LUPUS 12, 436-442, 2003.
1070. Tartakover - Matalon S, Blank M, Matsuura E, Inagaki J, Nomizu M, Levy Y, Koike T, Sherer Y, Ornoy A, Shoenfeld Y. Immunization of naïve mice with mouse laminin-1 affected pregnancy outcome in a mouse model. Am J Reprod Immunol (AJRI) 50: 159-165, 2003.
1071. Abu Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy & Immunol 25: 13-24, 2003.
1072. Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy & Immunol 25: 29-40, 2003.
1073. Severin M.C., Levy Y, Shoenfeld Y. Systemic lupus erythematosus and parvovirus B-19. Casual coincidence or causative culprit? Clin Rev Allergy & Immunol 25: 41-48, 2003.
1074. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy & Immunol 25: 79-88, 2003.
1075. Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy & Immunol 25: 105-111, 2003.
1076. Shoenfeld Y. Systemic antiphospholipid syndrome. LUPUS 12, 497-498, 2003.
1077. Alarcon-Segovia D, Boffa MC, Branch W, Tincani A, Arnout JMMC, koike T, Piette J-C, Khamashta MA, Shoenfeld Y. Prophylaxis of the antiphospholipid syndrome: a consensus report. LUPUS 12, 499-503, 2003.
1078. Meroni PL, Moia M, Derksen RHW, Tincani A, McIntyre JA, Koike T, Piette J-c, Khamashta MA, Shoenfeld Y. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. LUPUS 12, 504-507, 2003.
1079. Brey RL, Chapman J, Levine SR, Ruiz-Irastorza G, Derksen RHW, Khamashta M, Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. LUPUS 12, 508-513, 2003.



1080. Chapman J, RAQND JH, Brey RL, Levine SR, Khamashta MA, Shoenfeld Y. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. LUPUS 12, 514-517, 2003.
1081. Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, Tincani A, Erkan D, Khamashta MA, Shoenfeld Y. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. LUPUS 12, 518-5523, 2003.
1082. Tincani A, Branch W, Levt RA, Piette JC, Carp H, Khamashta MA, Shoenfeld Y. Treatment of pregnant patients with antiphospholipid syndrome. LUPUS 12, 524-529, 2003.
1083. Asherson RA, Cervera R, De Groot PG, Erkan D, Boffa M-C, Piette J-C, Khamashta MA, Shoenfeld Y. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. LUPUS 12, 530-534, 2003.
1084. Blank M, Krause I, Wildbaum G, Karin N, Shoenfeld Y. TNF $\alpha$  DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. LUPUS 12, 546-549, 2003.
1085. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughew GRV. Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome. LUPUS 12, 550-554, 2003.
1086. Ornoy A, Yacobi S, Tartakover-Matalon S, Blank M, Blumenfeld Z, Miller RK, Shoenfeld Y. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. LUPUS 12, 573-578, 2003.
1087. Ferro D, Saliola M, Meroni PL, Valesini G, Caroselli C, Pratico D, Fitzgerald GA, Shoenfeld Y, Violi F. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J Thromb Haemost 1: 523-531, 2003.
1088. Jakab F, Shoenfeld Y, Balogh A, Michelatti M, Hoffmann A, Kahan Z, Lapis K, Mayer A, Sapy P, Szentpetery F, Telekes A, Thurzo L, Vagvolgyi A, Hidvegi M. A medical nutriment has supportive value in the treatment of colorectal cancer. British J of Cancer 89: 465-469, 2003.
1089. Bar-Meir E, Eherenfeld M, Shoenfeld Y. Silicone gel breast implants and connective tissue disease – a comprehensive review. Autoimmunity 36: 193-197, 2003.
1090. Nicoletti F, Di Marco R, Papaccio G, Conget I, Gomis R, Bernardini R, Sims JE, Shoenfeld Y, -Bendtsen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low-doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18 – binding protein: Fc construct. Eur J Immunol 33: 2278 – 2286, 2003.
1091. Rosman Y, Shoenfeld Y. The importance of the Cochrane Collaboration. Harefuah, 142: 674-676, 2003.
1092. Krause I, Valisini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J of Med 115: 390 – 397, 2003.
1093. Shoenfeld Y, Toubi E, Hiepe F. Eighth International Workshop on Autoantibodies and Autoimmunity Berlin, Germany, 10- 13, September 2003. Autoimmunity Rev 3; 77-84, 2004.
1094. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, Von Landenberg P, KFont J, Zaech J, Cervera R, Piette JC, Boffa MC, Khamashta MA, Bertolaccini ML, Hughes GRV, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jonsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Vriezman VB, Blank M. Prevalence and clinical correlations of antibodies against six b2-Glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 23: 377-383, 2003.
1095. Levy Roger A, Galarza C, Shoenfeld Y. I Latin American Congress of Immunology, Galapagos - September 15 – 18, 2003. Autoimmunity Rev 3: 76-87, 2004
1096. Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y. The Catastrophic Antiphospholipid Syndrome – Asherson's Syndrome. Ann Med Interne, 154: 195-196, 2003.
1097. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, Gilburd B, Corbanese S, Patnaik M, Zampieri S, Favaretto E, Laccarino L, Sherer Y, Todesco S, Pauletto P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62: 1071-1077, 2003.

1098. Mari A, Zandman-Goddard G, Shoenfeld Y. Apoptosis in systemic lupus erythematosus. *Harefuah*; 142: 844-847, 2003.
1099. Amital H, Gilburd B, Shoenfeld Y. Intelligent nutrition: health-promoting mechanisms of probiotics. *IMAJ* 5: 812-813, 2003.
1100. Levy Y, Uziel Y, Zandman-Goddard G, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. *Ann Rheum Dis* 62: 1221-1223, 2003.
1101. Rottem M. Shoenfeld Y. Asthma as a paradigm for autoimmune disease. *Int Arch Allergy Immunol* 32: 210-214, 2003.
1102. Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. *Hum Antibodies* 12:57-62, 2003.
1103. Bujanover Sh, Levy Y, Katz M, Leitner Y, Vinograd I, Shoenfeld Y. Lack of association between anti-phospholipid antibodies (APLA) and attention deficit/hyperactivity disorder (ADHD) in children. *Clin & Developmental Immunol*; 10: 105-109, 2003.
1104. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. *Ann Rheum Dis* 63: 31-35, 2004.
1105. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. *Nature Med* 10: 17-18, 2004.
1106. Zandman-Goddard G, Shoenfeld Y. Therapy with biologic agents in SLE. *APLAR J Rheum* 7:79-82, 2004.
1107. Asherson RA, Shoenfeld Y, Jacobs P, Bosman C. An unusually complicated case of primary sjogren's syndrome: development of transient "Lupus-type" autoantibodies following silicone implant rejection. *J Rheumatol* 31: 196-7, 2004.
1108. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. *Lupus* 12, 903-907, 2003.
1109. Tartakover-Matalon S, Shoenfeld Y, Blank M, Yacobi S, von-Landenberg P, Ornoy A. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. *Am J Reproduct Immunol (AJRI)* 51: 144-151, 2004.
1110. Toubi E, Shoenfeld Y. BLYS/BAFF: a potential target in the treatment of active systemic lupus erythematosus. *IMAJ* 6: 99-102, 2004.
1111. Marai I, Carp H, Shai S, Shabo R, Fishman G, Shoenfeld Y. Autoantibody panel screening in recurrent miscarriages. *Am J of Reproduct Immunol (AJRI)* 51: 235-240, 2004.
1112. Blank M, Asherson R.A., Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. *J Clin Immunol* 24: 12-23, 2004.
1113. Blank M, Shoenfeld Y. B-Cell targeted therapy in autoimmunity. [http://www.rheuma21st.com/archives/cutting\\_edge\\_b\\_cell\\_targeted\\_therapy\\_shoenfeld.html](http://www.rheuma21st.com/archives/cutting_edge_b_cell_targeted_therapy_shoenfeld.html). 08/03/2004.
1114. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, Generini S, Cerinic MM, Shoenfeld Y. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. *Arthritis & Rheum* 50: 1005-1007, 2004.
1115. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. *J Clin Immunol* 24: 107-114, 2004.
1116. Pierangeli S.S., Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, Roye-Green K, Harris EN, Shoenfeld Y. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. *J Autoimmun* 22: 217-225, 2004.
1117. Doria A, Shoenfeld Y, Pautetto P. Premature coronary disease in systemic lupus. *New Engl J Med* 350:1571-5, 2004.
1118. Doria A, Puttini PCS, Shoenfeld Y. A meeting review: Heart, rheumatism and autoimmunity. Milan, Italy February 5-7, 2004. *Autoimmunity Rev* 3:337-354, 2004.

1119. Gilburd B, Abu Shakra M, Shoenfeld Y, Giordano A, Bartoloni Bocci E, delle Monache F, Gerli R. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation – a homogeneous multiplexed system. Clin & Develop Immunol, 11: 53-56, 2004.
1120. Ziporen L, Polak-Charcon S, Korczyn AD, Goldberg I, Afek A, Kopolovic U, Chapman J, Shoenfeld Y. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin & Develop Immunol 11: 67-75., 2004.
1121. Zurgil N, Solodeev I, Gilburd B, Shafran Y, Afrimzon E, Avtalion R, Shoenfeld Y, Deutsch M. Monitoring the apoptotic process induced by oxidized low-density lipoprotein in Jurkat T-lymphoblast and U937 monocytic human cell lines. Cell Biochemistry & Biophysics 40: 97-113, 2004.
1122. Shoenfeld Y. 5<sup>th</sup> International symposium on IVIG: IVIG in the third millennium, 25-27 September 2003, Interlaken, Switzerland. Autoimmunity Rev 3: 234-241, 2004.
1123. Marai I, Shoenfeld Y, Bizzaro N, Villalta D, Doria A, Tonutti E, Tozzoli R. IgA and IgG tissue transglutaminase antibodies in systemic lupus erythematosus. LUPUS 13: 241-244, 2004.
1124. Shlyakhov E, Shoenfeld Y, Gilburd B, Rubinstein E. Evaluation of Bacillus anthracis extractable antigen for testing anthrax immunity. Clin Microbiol Infect 10: 421-424, 2004.
1125. Zan-Bar T, Aron Maor A, Shoenfeld Y. Acupuncture therapy for rheumatoid arthritis. [http://www.rheuma21st.com/archives/cutting\\_main\\_html](http://www.rheuma21st.com/archives/cutting_main_html). 27/04/2004.
1126. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: Systemic LUPUS Erythematosus 4<sup>th</sup> edition. Robert G. Lahita (Editor), Elsevier Publication, Amsterdam, The Netherlands) pp. 3-27, 2004.
1127. Gilburd B, Shovman O, Zandman-Goddard G, Schiffenbauer Y, Trubniykov E, Severin M, Shoenfeld Y. Autoantigen cell activation for rapid diagnosis of different autoimmune disordersL comparison of proliferation assays with a static cytometer (CellsScan). Clin Application Immunol 3: 316-323, 2004.
1128. Amital H, Rubinow A, Langevitz P, Shoenfeld Y. Refractory leg infection as an inducer of the catastrophic antiphospholipid syndrome. Ann Rheum Dis . 63: 1004, 2004 .
1129. Rottem M, Shoenfeld Y. Vaccination and allergy. Current Opinion in Otolaryngology & Head and Neck Surgery, 12: 223-231, 2004.
1130. Gerli R, Schillaci G, Giordano A, Bartoloni Bocci E, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E. CD4+ CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109: 2744-2748, 2004.
1131. George J, Yacov N, Breitbart E, Bangio L, Shaish A, Gilburd B, Shoenfeld Y. Harats D. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with  $\beta$ 2-glycoprotein I. Cardiovascular Research 62: 603-609, 2004.
1132. Shoenfeld Y. Anti-phospholipid syndrome from a systemic disease toward the infectious etiology. La Revue de medicine interne 25: 10-11, 2004.
1133. Amital H, Shoenfeld Y. The etiopathogenesis of autoimmunity. Chapter in book "Stem cell therapy for autoimmune disease". Eds: Richard K. Brut & Alberto M. Marmont. Landes Bioscience Georgetown, Texas, USA, pp: 106-112, 2004.
1134. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, Von Landenberg P, Lev N, Zaech J, Cervera R, Piette JC, Bertolaccini ML, Hughes GR, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jonsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Chapman J, Van-Breda-Vriezman PJ, Damoiseaux J. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 31: 1344-8, 2004.
1135. Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clin Immunol 112: 190-199, 2004.
1136. Veres K, Lakos G, Kerenyi A, Szekanez Z, Szegedi G, Shoenfeld Y, Soltesz P. Antiphospholipid antibodies in acute coronary syndrome. Lupus 13: 423-427, 2004.
1137. Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. IMAJ 6: 430-432, 2004.
1138. Toubi E, Shoenfeld Y. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity, 37: 183-188, 2004.

1139. Shoenfeld Y, Blank M. The infectious etiology of the antiphospholipid syndrome (APS). Autoimmunity Rev 3 Suppl. 1: 532-34, 2004.
1140. Erkan D, Asherson R, Shoenfeld Y. Intravenous immunoglobulin and antiphospholipid syndrome. Arthritis & Rheum 50: 2711-2712, 2004.
1141. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmunity Rev. 3: 423-53, 2004.
1142. Shoenfeld Y, Blank M. Autoantibodies associated with reproductive failure. Lupus 13: 643-648, 2004.
1143. Levy Y, Shovman O, Granit Ch, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Shoenfeld Y, Glikson M. Pericarditis following permanent pacemaker insertion. IMAJ 6: 599-602.
1144. Blank M, Shoenfeld Y. Antiphosphatidylserine antibodies and reproductive failure. Lupus 13: 661-665, 2004.
1145. Kuhna A, Rondinoneb R, Doria A, Shoenfeld Y. 1st International Conference on Cutaneous Lupus Erythematosus: a meeting review. [http://www.Rheuma21st.com/archives/report\\_cutaneous\\_lupus\\_shoenfeld\\_2004.html](http://www.Rheuma21st.com/archives/report_cutaneous_lupus_shoenfeld_2004.html)
1146. Achiron A, Mandel M, Shoenfeld Y. Multiple sclerosis and anti-phospholipid syndrome - one or two diseases? Harefuah 143: 724-726, 2004.
1147. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-Oxidized Low-Density Lipoprotein antibodies pathogenic or protective? Circulation 110:2552-2558, 2004.
1148. Wu R, Shoenfeld Y, Cerinic R, Gerli R, Gilburd B, Perfetto F, Shen G, Lehrhoff L, Morris R. Leptin, anti-HSP60, anti-HSP65 and anti-oxLDL in autoimmune rheumatic diseases. 12<sup>th</sup> International Congress of Immunology and 4 Annual Conference of FOCIS, Immunology 315 - 324, 2004..
1149. Blank M, Shani A, Goldberg I, Kopolovic J, Amigo MC, Magrini L, Shoenfeld Y. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thrombosis Research 114: 589-592, 2004.
1150. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Sem Arth Rheum 34: 501-537, 2004.
1151. Inagaki J, Kondo A, Lopez LR, Shoenfeld Y, Matsuura E. Anti-laminin-1 autoantibodies, pregnancy loss and endometriosis. Clin Dev Immunol. 11:261-6,2004
1152. Shoenfeld Y, Blank M, Achiron A, Chapman J, Gilburd B, Molina V, Toubi E. 4<sup>th</sup> International Congress on Autoimmunity. [http://www.Rheuma21st.com/archives/report\\_all\\_29Nov2004.html](http://www.Rheuma21st.com/archives/report_all_29Nov2004.html).
1153. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 33: 365-372, 2004.
1154. Toloza S.M.A, Uribe A.G, McGwin G Jr., Alarcon G.S., Fessler B.J., Bastian H.M., Vila L.M., Wu R, Shoenfeld Y, Roseman J.M., Reveille J.D. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Baseline predictors of vascular events. Arthritis & Rheum 50: 3947-3957, 2004.
1155. Zan-Bar Tal, Aron A, Shoenfeld Y. Acupuncture therapy for rheumatoid arthritis. APLAR J of Rheumatol 7: 207-214, 2004.
1156. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 34: 593-601, 2004.
1157. Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis and malignant conditions. In: Adoptive Immunotherapy Methods and Protocols. Burkhard Ludewig & Matthias W. Hoffmann (Editors). Humana Press, Totowa, New Jersey, pp: 403-408, 2004.
1158. Pras E, Neumann R, Zandman-Goddard G, Levy Y, Assia E.I., Shoenfeld Y, Langevitz P. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum 34: 602-609, 2004.
1159. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity, 37: 457-464, 2004.
1160. Strous RD, Shoenfeld Y. Revisiting old ghosts: prenatal viral exposure and schizophrenia. IMAJ 7: 43-45, 2005.
1161. Sanmarco M, Bardin N, Blank M, Pascal V, Christine Alessi M, Dign George F, Shoenfeld Y, Harle JR. Heterogeneity of anti-beta2-glycoprotein I antibodies. A factor variability in test results. Thromb Haemost 93: 80-7, 2005.

1162. Khamaisi M, Shoenfeld Y, Orbach H. Guillain-Barre syndrome following hepatitis B vaccination. Clin & Exp Rheumatol 22: 767-770, 2004.
1163. Kuhn A, Rondinoune R, Doria A, Shoenfeld Y. 1<sup>st</sup> International conference on cutaneous lupus erythematosus Dusseldorf, Germany, September 1-5, 2004. Autoimmunity Rev 4: 66-78, 2005.
1164. Szyper-Kravitz M, Zandmann-Goddard G, Lahita RG, Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am. 2005 31: 161-75, 2005.
1165. Deutsch M, Guejes L, Zurgil N, Shovman O, Gilburd B, Afrimzon E, Shoenfeld Y. Antineutrophil cytoplasmic autoantibodies penetrate into human polymorphonuclear leukocytes and modify their apoptosis. Clin Exp Rheumatol 22 (Supl. 36): S35 – S40, 2004.
- 1166.a Kondo A, Inagaki J, Kobayashi K, Tsukamoto H, Yamamoto D, Nakatsuka M, Suzuki N, Nomizu M, Amano S, Matsubayashi H, Yasuda T, Lopez L.R, Shoenfeld Y, Makino T, Matsuura E. Characterization of a murine anti-laminin-1 monoclonal antibody (AK8) produced by immunization with mouse-derived laminin-1. Clin & Develop Immunol 12: 67-73, 2005.
- 1166.b Shoenfeld Y, Grossman E, Livne A, Ezra D, Sidi Y, Farfel Z. Patients' families abuse the medical and nursing staff. Harefuah 144: 74-75, 2005.
1167. Rottem M, Szyper-Kravitz M, Shoenfeld Y. Atopy and asthma in migrants. Arch Allergy Immunol 136: 198-204, 2005.
1168. Goldberg I, Gilburd B, Szyper-Kravitz M, Kivity S, Chaim BB, Klein T, Schiffenbauer Y, Trubniykovr E, Brenner S, Shoenfeld Y. A novel system to diagnose cutaneous adverse drug reactions employing cellscan – comparison with histamine releasing test and Inf-gamma Relea Test. Clin Dev Immunol 12: 85-90, 2005.
1169. Selmi C, Battezzati PM, Tishler M, Shoenfeld Y, Gershwin ME. Vaccines in the 21<sup>st</sup> century: the genetic response and the innocent bystander. Autoimmunity Rev 4: 79-81, 2005.
1170. Zandman-Goddard G, Shoenfeld Y. Mycophenolate mofetil in animal model of autoimmune disease. LUPUS 14: s12-s16, 2005.
1171. Bartoloni Bocci E, Marchesi S, Delle Monache F, Vaudo G, Giordano A, Ragni Alunni F, Angrisani C, Mannarino E, Shoenfeld Y, Gerli R. Atherosclerosis subclinica in giovani pazienti con artrite reumatoide e bassa attività di malattia - Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Reumatismo 57: 16-21, 2005.
1172. Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, Rover J, Chapman J, Shoenfeld Y. Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. An Rheum Dis 18, 2005.
1173. Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y. Multiplexed atheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity 38: 105-9, 2005.
1174. Marai I, Tincani A, Balestrieri G, Shoenfeld Y. Anticardiolipin and anti-beta-glycoprotein-I antibodies. Autoimmunity 38: 33-38, 2005.
1175. Shoenfeld Y, Tincani A. Introduction autoantibodies – the smoke and the fire. Autoimmunity 38: 1-2, 2005.
1176. Gurevich V.S, Shovman O, Slutzky L, Meroni P.L, Shoenfeld Y. Statins and autoimmune diseases. Autoimmunity Rev 4: 123-129, 2005.
1177. Conrad K, Bachmann MP, Matsuura E, Shoenfeld Y. From animal models to human genetics: research on the induction and pathogenicity of autoantibodies. Autoimmunity Rev 4: 178-187, 2005.
1178. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmunity Rev 4: 153-161, 2005.
1179. Berkun Y, Gershwin ME, Shoenfeld Y. Autoimmune hepatitis: a part of the antiphospholipid syndrom ? IMAJ 7: 264-5, 2005.
1180. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66: 395-402, 2005.
1181. Symon Z, Schneebaum N, Eyal A, Tal S, Rozen N, Shoenfeld Y. Successful intravenous immunoglobulin therapy for resistant inflammatory pseudotumor of the orbit. Thyroid 15: 398-9, 2005.

1182. Blank M, [Shoenfeld Y](#). Experimental Models of Systemic Lupus Erythematosus: anti- dsDNA in murine lupus. [Rheumatology](#) advance access,published May 24, 2005
1183. Achiron A, Miron S, [Shoenfeld Y](#). Does the flap of a butterfly's wings in Brazil set off a tornado in Texas? The JC Virus story in multiple sclerosis. [IMAJ](#) 7: 283-5, 2005.
1184. Doria A, Sherer Y, Meroni PL, [Shoenfeld Y](#). Inflammation and accelerated atherosclerosis: basic mechanisms. [Rheum Dis Clin North Am](#). 31: 355-62, 2005.
1185. [Shoenfeld Y](#). Medicine in the twentieth-one century: how it has changed in the last 30 years. [Harefuah](#) 144: 332-334, 2005.
1186. Sapir T, Carp H, [Shoenfeld Y](#). Intravenous immunoglobulin (IVIG) as treatment for recurrent pregnancy loss (RPL). [Harefuah](#) 144: 415 – 420, 2005.
1187. [Shoenfeld Y](#), Katz U. IVIG therapy in autoimmunity and related disorders: our experience with a large cohort of patients. [Autoimmunity](#) 38: 123-137, 2005.
1188. Berkun Y, Mimouni D, [Shoenfeld Y](#). Pemphigus following hepatitis B vaccination – coincidence or causality? [Autoimmunity](#) 38: 117-119, 2005.
1189. Szyper-Kravitz M, Marai I, [Shoenfeld Y](#). Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. [Autoimmunity](#) 38: 247-255, 2005.
1190. Molina V, [Shoenfeld Y](#). Infection, vaccines and other environmental triggers of autoimmunity. [Autoimmunity](#) 38: 235-245, 2005.
1191. Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G, Binder SR, [Shoenfeld Y](#). Evaluation of the BioPlex™ 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. [Ann N.Y. Acad Sci](#) 1050: 280-388, 2005.
1192. Zandman-Goddard G, Orbach H, [Shoenfeld Y](#). Novel approaches to therapy for systemic lupus erythematosus: update 2005. [Expert Rev Clin Immunol](#) 1: 223 - 238, 2005.
1193. Zandman-Goddard G, Gilburd B, Shovman O, Blank M, Berdichevski S, Langevitz P, [Shoenfeld Y](#). The homogeneous multiplexed system – a new method for autoantibody profile in systemic lupus erythematosus. [Clin & Dev Immunol](#) 12: 107-111, 2005.
1194. Cervera R, Font J, Gomez-Puerta J A, Espinosa G, Cucho M, Biccocare;o S, Ramos-Casals M, Ingelmo M, Piette J-C, [Shoenfeld Y](#), Asherson R A for the Catastrophic antiphospholipid syndrome registry project group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. [Ann Rheum Dis](#) 64: 1205-1209, 2005.
1195. Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y, Shovman O, Witte T, Dproa A, Rovensky J, [Shoenfeld Y](#). Anti-serum amyloid component P (SAP) antibodies in SLE patients correlate with disease activity. [Ann Rheum Dis](#) 64; 1698-1702, 2005.
1196. Borchers A.T., Aoki C.A., Naguwa S.M., Keen C.L., [Shoenfeld Y](#), Gershwin M.E. Neuropsychiatric features of systemic lupus erythematosus. [Autoimmunity Rev](#). 4: 329-344, 2005.
1197. Cabral A.,R., Cabiedes J, Alcocer-Varela J, [Shoenfeld Y](#). Donato Alarcon-Segovia: a life dedicated to the study of autoimmunity. [Autoimmunity Rev](#) 4: 323-328, 2005.
1198. Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, Blonk M, [Shoenfeld Y](#). Livedo Reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. [Clin & Exp Rheum](#) 23: 499-504, 2005.
1199. Levy Y, Uziel Y, Zandman-Goddard G, Rotmen P, Amital H, Sherer Y, Langevitz P, Goldman B, [Shoenfeld Y](#). Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. [Ann N.Y. Acad Sci](#). 1051: 779-786, 2005.
1200. Sherer Y, Gerli R, Vaudo G, Schillaci G, Gilburd B, Giordano A, Bartoloni Bocci E, Aliegrucci R, Marchesi S, Mannarino E, [Shoenfeld Y](#). Prevalence of antiphospholipid and oxidized low-density lipoprotein antibodies in rheumatoid arthritis. [Ann N.Y. Acad Sci](#). 1051: 299-303, 2005.
1201. Gerli R, Sherer Y, Vaudo G, Schillaci G, Gilburd B, Giordano A, Bartoloni Bocci E, Aliegrucci R, Marchesi S, Mannarino E, [Shoenfeld Y](#). Early atherosclerosis in rheumatoid arthritis. Effects of smoking of thickness of the carotid artery intima media. [Ann N.Y. Acad Sci](#). 1051: 281-290, 2005.

1202. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N.Y. Acad Sci. 1051: 743-778, 2005.
1203. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease. Mechanisms and clinical applications. Ann N.Y. Acad Sci. 1051: 166-173, 2005.
1204. Inagaki J, Kondo A, Lopez L.R., Shoenfeld Y, Matsuura E. Pregnancy loss and endometriosis. Pathogenic role of anti-laminin-1 autoantibodies. Ann N.Y. Acad Sci. 1051: 174-184, 2005.
1205. Boros L.G., Nichelatti M, Shoenfeld Y. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune diseases. Ann N.Y. Acad Sci. 1051: 529-542, 2005.
1206. Israeli E, Grotto I, Gilburd B, Balicer R.D., Wiik A, Shoenfeld Y. Anti-saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54: 1232-1236, 2005.
1207. Kobayashi K, Lopez L.R., Shoenfeld Y, Matsuura E. The role of innate and adaptive immunity to Oxidized Low-density lipoprotein in the development of atherosclerosis. Ann N.Y. Acad Sci. 1051: 442-454, 2005.
1208. Pitashni M, Shoenfeld Y. B cell depletion in autoimmune rheumatic diseases. Autoimmunity Rev 4: 436-441, 2005.
1209. Ebert T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 14: 571-575, 2005.
1210. Shoenfeld Y, Toubi E. Protective autoantibodies. Arthritis & Rheum 52: 2599-2606, 2005.
1211. Shepshelovich D, Sherer Y, Shoenfeld Y. Accelerated atherosclerosis in rheumatoid arthritis. Harefuah 144: 561-563, 2005.
1212. Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Orbach H, Gerli R, Shoenfeld Y. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol 12: 197-202, 2005.
1213. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: A putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol 12: 175-180, 2005.
1214. Harel M, Gilburd B, Schiffenbauer YS, Shoenfeld Y. Application of a static fluorescence-based cytometer (the Cellscan) in basic cytometric studies, clinical pharmacology, oncology and clinical immunology. Clin Dev Immunol 12: 187-195, 2005.
1215. Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y. New therapeutic strategies for systemic sclerosis – a critical analysis of the literature. Clin Dev Immunol 12: 165-173, 2005.
1216. Shoenfeld Y. Anti-DNA idiotypes: from induction of disease to novel therapeutical approaches. Immunol Letters 100: 73-77, 2005.
1217. Twig G, Sherer Y, Shoenfeld Y. Dermatological manifestations in the antiphospholipid syndrome. Harefuah 144: 639-641, 2005.
1218. Szyper Kravitz M, Mishaal RA, Shoenfeld Y. Renal failure and low molecular weight heparins. A dangerous liaison ? The case of retroperitoneal hematoma. IMAJ 7: 600-601, 2005.
1219. Zimlichman E, Lahad A, Aron-Maor A, Kanevsky A, Shoenfeld Y. Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. IMAJ 7: 631-634, 2005.
1220. Toubi E, Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy areality? Lupus 14: 665-669, 2005.
1221. Blank M, Aron-Maor A, Shoenfeld Y. From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link? Lupus 14: 697-701, 2005.
1222. Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, Zanni D, Penco S, Boimi E, Ghirardello A, Caforio ALP, Bergantin A, Tombini V, Moreo A, Ashtamkar L, Doria A, Shoenfeld Y, Livneh A. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in large cohort of Caucasian patients. Lupus 14: 670-674, 2005.
1223. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y. Oxidized LDL /  $\beta$ 2-Glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14: 736-741, 2005.

1224. Szyper-Kravitz M, Sheinberg P, Sidi Y, Schiffenbauer Y, Trubniykov E, Shoenfeld Y. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. Int Arch Allergy Immunol 138: 334-336, 2005.
1225. Szyper-Kravitz M, Shoenfeld Y. Thrombocytopenic conditions – autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol 80: 232-242. 2005.
1226. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14: 802-808, 2005.
1227. Anaya JM, Shoenfeld Y. Multiple autoimmune disease in a patient with hyperprolactinemia. IMAJ 7: 740-741, 2005.
1228. Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, David M, Shoenfeld Y. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 142: 426-432, 2005.
1229. Ganor Y, Goldberg-Stern H, Blank M, Shoenfeld Y, Dobrynina LA, Kalashnikova L, Levite M. Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome. Autoimmunity 38: 417-424, 2005.
1230. Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, Shoenfeld Y. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 210: 749-754, 2005.
1231. Harel M, Aron-Maor A, Sherer Y, Blank M, Shoenfeld Y. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology 210: 743-747, 2005.
1232. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: 3337-3347, 2005.
1233. Vaudo G, Bartoloni Bocci E, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, Vitali C, Delle Monache F, Marchesi S, Mannarino E, Gerli R. Precocious Intima-Media Thickening in Patients with Primary Sjögren's Syndrome. Arthritis & Rheum 52: 3890-3897, 2005.
1234. Levy Y, Shenkman B, Tamarin I, Pazner R, Shoenfeld Y, Langebitz P, Savion N, Varon D. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Arthritis & Rheum 52: 4011-4017, 2005.
1235. Zandman-Goddard G, Shoenfeld Y. Infection and SLE. Autoimmunity 38: 473-485, 2005.
1236. Etzioni A, Sherer Y, Carp H, Mimouni D, Achiron A, Goddard G, Catz U, Shoenfeld Y. Indications – intravenous immunoglobulins – IVIG. Harefuah 144: 799-804, 2005.
1237. Shovman O, Sherer Y, Gilbourd B, Gerli R, Bartoloni E, Delle Monache F, Luccioli F, Shoenfeld Y. Low levels of heat shock proteins-60 and -65 autoantibodies in Sjogren's syndrome. IMAJ 7: 778-780, 2005.
1238. Doria A, Sarzi-Puttini P, Shoenfeld Y. 2nd Conference on heart, rheumatism and autoimmunity, Pescara, Italy, May 19-20, 2005. Rev Autoimmunity Rev 5: 55-63, 2006.
1239. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65: 2-6, 2006.
1240. McKnight K, Jiang Y, Hart Y, Cavery A, Wroe S, Blank M, Shoenfeld Y, Vincent A, Palace J, Land B. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65: 1730-1736, 2005.
1241. Szyper Kravitz M, Pitashny M, Shoenfeld Y. Protective molecules – C-reactive protein (CRP), serum amyloid P (SAP), pentraxin (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: relevance and clinical significance in autoimmunity. J of clin Immunol 25: 582-591, 2005.
1242. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin (IVIG) adverse effects and safe administration. Clin Rev in Allergy and Immunol; 29: 173-184, 2005.



1243. [Shoenfeld Y](#), Gershwin M.E. Intravenous immunoglobulin new indications and mechanisms of action. [Clin Rev in Allergy and Immunol](#); 29: 165-166, 2005.
1244. Sapir T, [Shoenfeld Y](#). Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. [Clin Rev in Allergy and Immunol](#); 29: 185-199, 2005.
1245. Blank M, Nur I, Toub O, Aron-Maor A, [Shoenfeld Y](#). Toward molecular targeting with specific intravenous immunoglobulin preparation. [Clin Rev in Allergy and Immunol](#); 29: 213-217, 2005.
1246. Zandman-Goddard G, Levy Y, [Shoenfeld Y](#). Intravenous immunoglobulin therapy and systemic lupus erythematosus. [Clin Rev in Allergy and Immunol](#); 29: 219-228, 2005.
1247. Harel M, [Shoenfeld Y](#). Intravenous immunoglobulin and Guillain-Barré Syndrome. [Clin Rev in Allergy & Immunol](#) ; 281-287., 2005.
1248. Sapir T, [Shoenfeld Y](#). Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. [Clin Rev in Allergy and Immunol](#); 29: 307-310, 2005.
1249. Matsuura E, Kobayashi K, Inoue K, [Shoenfeld Y](#). Intravenous immunoglobulin and atherosclerosis. [Clin Rev in Allergy and Immunol](#); 29: 311-319, 2005.
1250. Molina V, Blank M, [Shoenfeld Y](#). Intravenous immunoglobulin and fibrosis. [Clin Rev in Allergy and Immunol](#); 29: 321-326, 2005.
1251. Carp H.J, Sapir T, [Shoenfeld Y](#). Intravenous immunoglobulin and recurrent pregnancy loss. [Clin Rev in Allergy and Immunol](#); 29: 327-332, 2005.
1252. Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, [Shoenfeld Y](#), Hiepe F, Shun-le C, von Muhlen C.A, Locht H, Ho'pfl P, Wiik A, Reeves W, Fritzler M.J. International multicenter evaluation of autoantibodies to ribosomal P proteins [Clinical and Vaccine Immunol](#); 13: 77-83., 2006.
1253. Miyakis S, Lockshin M.D, Atsumi T, Branch W, Brey R, Cervera R, Derksen R. H. W. M., De groot P.G, Koike T, Meroni P.L, Reber G, [Shoenfeld Y](#), Tincani A, Vlachoyiannopoulos P.G, Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). [J Thromb and Haemostasis](#), 4: 295-306, 2006.
1254. Sherer Y, [Shoenfeld Y](#). Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. [Autoimmunity Reviews](#) 5; 153-155, 2006.
1255. Blank M, Gisondi P, Mimouni D, Peserico A, Piaserico S, [Shoenfeld Y](#), Reunala T, Zambruno G, Di Zenzo G, Girolomoni G. New insights into the autoantibody-mediated mechanisms of autoimmune bullous diseases and urticaria. [Clin Exp Rheumatol](#) 24 (Suppl.40): S20-S25, 2006.
1256. Sherer Y, [Shoenfeld Y](#). Mechanisms of disease: atherosclerosis in autoimmune diseases. [Nature clin Practice Rheumatol](#) 2: 99-106, 2006.
1257. Shovman O, Gilburd B, [Shoenfeld Y](#). Editorial: The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus – related atherosclerosis: a novel target for treatment? [The J of Rheumatol](#) 33: 3 : 445-447, 2006.
1258. Tishler M, [Shoenfeld Y](#). BCG immunotherapy – from pathophysiology to clinical practice. [Expert Opinion Drug Saf](#). 5: 225-229, 2006.
1259. Katzav A, Litvinjuk Y, Pick CG, Blank M, [Shoenfeld Y](#), Sirota P, Chapman J. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. [Behavioural Brain Research](#) 169: 289-293, 2006.
1260. Shovman O, Zandman-Goddard G, Sherer Y, Gilbourd B. Immune tolerance as a strategy for treatment of atherosclerosis. [Drug Discovery Today](#) . 2: 207-211, 2005.

1261. Zurgil N, Afrimzon E, Shartan Y, Shovman O, Gilburd B, Brikman H, Shoenfeld Y, Deutsch M. Lymphocyte resistance to lysophosphatidylcholine mediated apoptosis in atherosclerosis. Atherosclerosis 190: 73-83, 2007.
1262. Shepshelovitch D, Shoenfeld Y. Prediction and prevention of autoimmune diseases – additional aspects of the mosaic of autoimmunity. Lupus 15: 183-190, 2005.
1263. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 15: 191-197, 2005.
1264. Ricard Cervera, on behalf of the members of the "European Working Party on Systemic Lupus Erythematosus". Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". Autoimmune Reviews 5: 180-186, 2006.
1265. Toubi E, Kessel A, Rosnery I, Rozenbaumy M, Paranz D, Shoenfeld Y. The Reduction of Serum B-Lymphocyte Activating Factor levels following Quinacrine Add-On Therapy in Systemic Lupus Erythematosus. Scand J of Immunol 63: 299-303, 2006.
1266. Berlin T, Lubina A, Levy Y, Shoenfeld Y. Graves' Disease Presenting as Right Heart Failure. IMAJ 8: 217-218, 2006.
1267. Maoz D, Shoenfeld Y. Chronic fatigue syndrome. Harefuah 145: 272-275, 2006.
1268. Yehudai D, Shoenfeld Y, Toubi E. The Autoimmune characteristics of progressive or sudden sensorineural hearing loss. Autoimmunity 39: 153-158, 2006.
1269. Borchers AT, Swlmi C, Cheema G, Leem CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmunity Rev. 5: 279-298, 2006.
1270. Blank M, Krause I, Magrini L, Spina G, Kalil J, Jacobsen S, Thiesen HJ, Cunningham MW, Guilherme L, Shoenfeld Y. Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology; 45: 833-841, 2006.
1271. Ostensen M, Khamshita M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I, Derdsen R, Branch W, Motta M, Gordon C, Ruiz-Irastorza G, Spinillo A, Friedman D, Cimaz R, Czeizel A, Piette JC, Cervera R, Levy RA, Clementi M, De Carolis S, Petri M, Shoenfeld Y, Faden D, Valesini G, Tincani A. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 8: 209, 2006.
1272. Arazi-Kleinman T, Shepshelovich D, Shoenfeld Y. Severe anemia diagnosed on computed tomography. IMAJ. 8: 363, 2006.
1273. Asherson RA, Cervera R, Shepshelovich D, Shoenfeld Y. Nonthrombotic manifestations of the antiphospholipid syndrome: Away from thrombosis? J Rheumatol 33:6- 1038 – 1044, 2006.
1274. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol. 26: 299-307, 2006.
1275. Amital H, Gershwin ME, Shoenfeld Y. Editorial: Reshaping the mosaic of autoimmunity. Semin Arth & Rheum 35: 341-342, 2006.
1276. Shoenfeld Y, Poletaev A.B. Natural autoimmunity in physiology and pathology 1<sup>st</sup> Moscow International Conference, Moscow, Russia, September 15-17,2005. Autoimmun Rev 5: 357-363, 2006.
1277. Teplitzkyi V, Shoenfeld Y, TanayA. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 5, 319–325, 2006.
1278. Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, Doria A, Shinar Y, Livneh A, Adler Y, Shoenfeld Y, Mauric F, Palmieri G, Spodick DH. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. The Am J Cardiol 98: 267-271, 2006.

1279. Shovman O, Gilburd B, Zandman-Goddard G, Sherer Y, Shoenfeld Y. Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Cur Rheumatol Rep 2006; 8: 292 – 8.
1280. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann. N.Y. Acad. Sci. 1069: 322–345, 2006.
1281. Balint G, Apathy A, Gaal M, Telekes A, Resetar A, Blazso G, Falkay G, Szende B, Paksy A, Ehrenfeld M, Shoenfeld Y, Hidvegi M. Effect of Avemar® - a fermented wheat germ extract – on rheumatoid arthritis. Preliminary data. Clin & Exp Rheumatol 24: 325-328, 2006.
1282. Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Gueguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P. Association of  $\alpha$ -actinin-binding anti-double stranded DNA antibodies with lupus nephritis. Arth & Rheum 54: 2523-2532, 2006.
1283. Shoenfeld Y. Novel aspects of diagnostic test: multiple autoantigens, new algorithms and revolutionary techniques. LUPUS 15: 389-390, 2006.
1284. Wiik A, Cervera R, Haass M, Kallenberg C, Khamashta M, Meroni PL, Piette J-C, Schmitt R, Shoenfeld Y. European attempt to set guidelines for improving diagnostics of autoimmune rheumatic disorders. LUPUS 15: 391-396, 2006.
1285. Szyper-Kravitz M, Harel M, Gilburd B, Trubniykov E, Shoenfeld Y. Application of a static fluorescence-based cytometer: the CellScan in clinical immunology. LUPUS 15: 436-441, 2006.
1286. Ben-Ami D, Bar-Meir E, Shoenfeld Y. Stenosis in antiphospholipid syndrome: a new finding with clinical implications. LUPUS 15: 466-472, 2006.
1287. Rottem M, Krause I, Fraser A, Stojanovich L, Rovensky J, Shoenfeld Y. Autoimmune hemolytic; anaemia in the antiphospholipid syndrome. LUPUS 15: 473-477, 2006.
1288. Christopher A. Aoki, Chaim M. Roifman, Zhe-Xiong Lian, Christopher L. Bowlus, Gary L. Norman, Yehuda Shoenfeld, Ian R. Mackay, M. Eric Gershwin. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J of Autoimmunity 27: 50-53, 2006.
1289. Gershwin ME, Shoenfeld Y. Editorial: Entering a great period in autoimmunity. J of Autoimmunity 27: 1-2, 2006.
1290. Szyper Kravitz M, Shoenfeld Y. Autoimmunity to protective molecules: is it the *perpetuum mobile* (vicious cycle) of autoimmune rheumatic diseases?. Natur Clin Practice Rheum 2: 481- 490, 2006.
1291. Shalev T, Haviv Y, Segal E, Ehrenfeld M, Pauzner R, Levy Y, Langevitz P, Shoenfeld Y. Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheum 24: 230-236, 2006.
1292. Shoenfeld Y, Shemer J, Keren G. Peer review – is there a better system? Harefuah 145: 581-583, 2006.
1293. Eidelman LA, Shoenfeld Y. Resident's restricted hours of duty – who will benefit from it: patients, society or the physicians? Harefuah 145: 499-502, 2006.
1294. Reinstein E, Shoenfeld Y. Darier's Disease. IMAJ 8: 588 , 2006.
1295. Tishler M, Shoenfeld Y. Vaccines and autoimmunity. In: The Autoimmune diseases 4<sup>th</sup> Ed. Noel R. Rose & Ian R. Mackay (Editors). Elsevier Publ. Amstersan – The Netherlands, 2006. pp: 309 – 316.
1296. Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, antiphospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 45: iv-8-iv13, 2006.
1297. Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIG therapy in multiple sclerosis: 10 years experience. Autoimmunity 39: 513-517, 2006.

1298. Fischer C, Buschmann K, Blank M, Stachl A, Miesbach W, Shoenfeld Y, Lackner KJ, von Landenberg P. Identification of a peptide mimicking the binding pattern of an antiphospholipid antibody. Immunobiol 211: 695 – 699, 2006.
1299. Cervera R, Font J, Shoenfeld Y. European working party on systemic lupus erythematosus: a 15-year report. Autoimmun Rev 5: 549-553, 2006.
1300. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: A comprehensive model updated and revisited. J Autoimmunity 27: 71 – 80, 2006.
1301. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, Zuckerman E. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: Association with autoimmunity. J Autoimmunity 27: 134 – 139, 2006.
1302. Shoenfeld Y, Carp HJA, Molina V, Blank M, Cervera R, Balasch J, Tincani A, Faden D, Lojaco A, Doria A, Konova E, Meroni PL. Autoantibodies and prediction of reproductive failure. Amer J of Reproduct Immunol 56: 337-344, 2006.
1303. Levy Y, Almog O, Gorshtein A, Shoenfeld Y. The environment and antiphospholipid syndrome. Lupus 15: 784-790, 2006.
1304. Strous RD, Shoenfeld Y. To smell the immune system: Olfaction, autoimmunity and brain involvement. Autoimmune Rev. 6: 54-60, 2006.
1305. Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo P, D'Ambrosio R, Riboldi P, Meoni PL, Albano E, Shoenfeld Y, Gariglio M, Landolfo S. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis. The Interferon-inducible gene IFI16. Arthritis & Rheum 54: 3939-3944, 2006.
1306. Jovanova-Nesic K, Shoenfeld Y. MP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology. J of Neuroimmunology 181: 112-121, 2006.
1307. Ablin JN, Shoenfeld Y, Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. J Autoimmunity 27: 145-152, 2006.
1308. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S, Espinoza G, Font J, & The members of the CAPS Registry Group. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmune Rev 6: 94 – 97, 2006.
1309. Zimlichman E, Szyper-Kravitz M, Katz U, Shoenfeld Y. Intensive lipid-lowering therapy: obvious benefits, possible risks. IMAJ 8: 890-891, 2006.
1310. Molina V, Haj-Yahia S, Solodov I, Levy Y, Blank M, Shoenfeld Y. Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG). Autoimmunity 39: 711-717, 2006.
1311. Gordon B, Shoenfeld Y. Hypophosphatemia as a prognostic measure of evaluation. Harefuah 145; 11: 815-817, 2006.
1312. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 15: 3-10, 2006.
1313. Shovman O, Zandman-Goddard G, Gilburd B, Blank M, Ehrenfeld M, Bardechevski S, Stojanovich L, Langevitz P, Shoenfeld Y. Restricted specificity of anti-ribosomal P antibodies to SLE patients in Israel. Clin Exp Rheumatol 24: 694-7, 2006.
1314. Israeli E, Shoenfeld Y. Can we predict autoimmune diseases of the gastrointestinal tract and the liver by autoantibodies. Harefuah 146: 28-32, 2006.
1315. Szucs G, Timar O, Szekanecz Z, Der H, Kerekes G, Szamosi S, Shoenfeld Y, Szegedi G, Soltesz P. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology 46: 759-762, 2007.

1316. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies Involved in Neuropsychiatric SLE and Antiphospholipid Syndrome. Semin Arthritis Rheum 36:297-315, 2007.
1317. Toubi E, Shoenfeld Y. Clinical and Biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmunity Rev. 6; 119-125, 2007.
1318. Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa HP, Shoenfeld Y, Szegedi G. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmunity 27: 211-217, 2006.
1319. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. LUPUS 16: 39-45, 2007.
1320. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmune Rev. 6: 257-259, 2007.
1321. Schwartz N, Shoenfeld Y, Barzilai O, Cervera R, Font J, Blank M, Yacobi S, Patlas N, Cohen A, Mevorach D, Ornoy A. Reduced placental growth and hCG secretion *in vitro* induced by antiphospholipid antibodies but not by anti-Ro or anti-La: studies on sera from women with SLE/PAPS. LUPUS 16 : 110-120, 2007.
1322. Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, Blank M, Zhang W, Reichlin M, Shoenfeld Y. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arth & Rheum 56: 938-948, 2007.
1323. Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev in Allergy & Immunol 32: 37-46, 2007.
1324. Wu R, Shovman O, Zhang Y, Gilburd B, Zandman-Goddard G, Shoenfeld Y. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev in Allergy & Immunol 32: 47-55, 2007.
1325. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and autoimmunity. Clin Rev in Allergy & Immunol 32: 111-118, 2007.
1326. Le Pottier LE, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, Pers JO. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 27: 257-265, 2007.
1327. Krause I, Leibovici L, Blank M, Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus; 16, 176–180, 2007.
1328. Konova E, Atanasova M, Stoykov S, Velkova A, Shoenfeld Y. Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss. J Autoimmunity 28 46-54, 2007.
1329. Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: Myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6; 261–266, 2007.
1330. Shoenfeld Y, Dicker D, Mittelman M, Bitterman H. Internal medicine 2007 – where do we stand? To expand or to reduce? Harefuah 146 250-252, 2007.
1331. Paez MC, Gonzaalez MJ, Serrano NC, Shoenfeld Y, Anaya JM. Physiological and pathological implications of laminins: From the gene to the protein. Autoimmunity 40: 83-94, 2007.
1332. Sherer Y, Gerli R, Gilburd B, Bartoloni Bocci E, Vaudo G, Mannarino E, Shoenfeld Y. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16: 259-264, 2007.
1333. Schechter M, Marai I, Marai S, Sherer Y, Sela BA, Feinberg MS, Rubinstein A, Shoenfeld Y. The association of endothelial dysfunction and cardiovascular events in healthy subjects and patients with cardiovascular disease. IMAJ 9: 271-276, 2007.

1334. Nacci F, Righi A, Conforti ML, Miniati O, Fiori O, Martinovic D, Melchiorre D, Sapir T, Blank M, Shoenfeld Y, Pignone AM, Cerinic MM. Intravenous immunoglobulins (IVIg) improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 66: 977-979, 2007
1335. Toubi E, Shoenfeld Y. Protective autoimmunity in cancer (review). Oncology reports 17: 245-251, 2007.
1336. Shoenfeld Y. To smell autoimmunity: Anti-P-Ribosomal autoantibodies, depression, and the olfactory system. J Autoimmunity 28: 165-169, 2007.
1337. Nussinovitch U, Shoenfeld Y. Cachexia, malignancy and Tumor Necrosis Factor alpha (TNF $\alpha$ ). Harefuah 146: 349-351, 2007.
1338. Blank M, Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmunity 28: 62 – 68, 2007.
1339. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 6: 366 – 372, 2007.
1340. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6: 379 – 386, 2007.
1341. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arth & Rheum 56: 1736-1744, 2007.
1342. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutical considerations. Published online 8 Jun 2007; Ann Rheum Dis. 66: 1137–1142, 2007.
1343. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, Cervera R, Font J, Fridkin M, Thiesen H-J, Shoenfeld Y. The efficacy of specific IVIg anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol, 19: 857-865, 2007.
1344. Anaya J-M, Corena R, Castiblanco J, Rojas A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple; autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol 3: 623-635, 2007.
1345. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 16: 324-328, 2007.
1346. Jovanova-Nesic K, Shoenfeld Y. Autoimmunity in the brain. The pathogenesis insight from cell biology. Ann NY Acad Sci 1107: 142-134, 2007.
1347. Mieshbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Espinosa :G, Bucciarelli S. The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. Clin Rheumatol 26: 2109-2114, 2007.
1348. de Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 27: 246-256, 2007.
1349. Marai I, Shoenfeld Y. The beneficial effects of statins in autoimmune disease therapy. Drug News Perspect 20: 165-169, 2007.
1350. Altman A, Szyper-Kravitz M, Shoenfeld Y. Colchicine-induced rhabdomyolysis. Clin Rheumatol 2007, 26: 2197-2199.
1351. Zandman – Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmune Rev 6: 457 – 463, 2007.
1352. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein–Barr virus and cytomegalovirus in autoimmune diseases are they truly notorious? a preliminary report. Ann NY Acad Sci 1108: 567-577, 2007.
1353. Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I, Toubi E, Singh S, Asherson R, Fraser A, Gilburd B, Sapir T, Levy Y, Lukac J, Rozman B, Kveder T, Shoenfeld Y. Autoantibodies in nonautoimmune individuals during infections. Ann NY Acad Sci 1108: 584-593, 2007.

1354. Sherer Y, Matucci Cerinic M, Bartoli F, Blagojevic J, Conforti ML, Gilburd B, Ehrenfeld M, Shoenfeld Y. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann NY Acad Sci 1108: 259-267, 2007.
1355. Cervera R, Bucciarelli S, Espinosa G, Gomez-puerta JA, Ramos-Casals M, Shoenfeld Y, Piette JC, Asherson R. Catastrophic antiphospholipid syndrome. Lessons from the "CAPS Registry" – a tribute to the late Joseph Font. Ann NY Acad Sci 1108: 448-456, 2007.
1356. Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, Dayer JM, Roux-Lombard P, Fontao L, Kallenberg CGM, Bijl M, Matthias T, Fraser A, Zandman-Goddard G, Blank M, Gilburd B, Meroni PL. Autoantibodies against protective molecules – C1q, C-reactive protein, serum amyloid P, Mannose-binding lectin, and apolipoprotein A1. Ann NY Acad Sci 1108: 227-239, 2007.
1357. Sherer Y, Gerli R, Bartoloni Bocci E, Gilburd B, Vaudo G, Bistoni O, Shoenfeld Y. Heat-shock protein 65 autoantibodies are differently associated with early atherosclerosis in rheumatoid arthritis and in healthy subjects. Ann NY Acad Sci 1108: 408-413, 2007.
1358. Krause I, Blank M, Font J, Matthias T, Pfeiffer S, Weis I, Fraser A, Shoenfeld Y. Cross-reactive epitopes on  $\beta$ 2-glycoprotein-I and *Saccharomyces cerevisiae* in patients with the antiphospholipid syndrome. Ann NY Acad Sci 1108: 481-488, 2007.
1359. Shoenfeld Y. The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot. J Mol Med 85:907–909, 2007.
1360. Zandman- Goddard G, Krauthammer A, Shoenfeld Y. Intravenous immunoglobulin therapy in systemic lupus erythematosus. Hong-Kong Bulletin on Rheum Dis 7: 1-6, 2007.
1361. Szekanecz Z, Kerekes G, Der H, Sandor Z, Szabo Z, Vegvari A, Simkovics E, Soos L, Szentpetery A, Besenyei T, Szucs G, Szanto S, Tamasi L, Szegedi G, Shoenfeld Y, Soltesz P. Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci 1108: 349-358, 2007.
1362. Zandman- Goddard G, Solomon M, Barzilai A, Shoenfeld Y. Lupus erythematosus tumidus induced by sex reassignment surgery. J Rheumatol 34: 9-11, 2007.
1363. Shoenfeld Y, Cervera R, Haas M, Kallenberg C, Khamashta M, Meroni PL, Piette JC, Schmidt R, Wiik A. EASI- the European Autoimmunity Standardisation Initiative – A new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann NY Acad Sci 1109: 138-144, 2007.
1364. Carvalho ZF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Anti-Vitamin D, Vitamin D in SLE preliminary results. Ann NY Acad Sci 1109: 550-557, 2007.
1365. Weitzen R, Epstein N, Shoenfeld Y, Zimlichman E. Diagnosing diseases by measurement of electrical skin impedance. Ann NY Acad Sci 1109: 185- 192, 2007.
1366. Orbach H, Zandman- Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, Carvalho JF, Doria A, Shoenfeld Y. Novel biomarkers in autoimmune diseases. Prolactin, Ferritin, Vitamin D and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109: 385 – 400, 2007.
1367. Zandman- Goddard G, Krauthammer A, Shoenfeld Y. The steroid - sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol 3: 774 - 780, 2007.
1368. Appel S, Chapman J, Shoenfeld Y. Infection and vaccination in chronic fatigue syndrome: Myth or reality? Autoimmunity 40: 48 – 53, 2007.
1369. Telekes A, Resetar A, Balint G, Blazso G, Falkay G, Lapis K, Raso E, Szende B, Ehrenfeld M, Shoenfeld Y, Hidvegi M. Fermented Wheat Germ Extract (Avemar) Inhibits Adjuvant Arthritis. Ann NY Acad Sci 1110: 384 – 361, 2007.

1370. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, Toubi E. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179: 5571 – 5575, 2007.
1371. Damianovich M, Solomon AS, Blank M, Shoenfeld Y. Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin. Ann NY Acad Sci 1110: 567 – 577, 2007.
1372. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 6: 537 – 542, 2007.
1373. Shoenfeld Y. APS— More Systemic Disease than SLE. Clinic Rev Allerg Immunol ; 32:129 – 130, 2007.
1374. Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E. Clinical Thrombotic Manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allerg Immunol ; 32: 131–137, 2007.
1375. Toubi E, Shoenfeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allerg Immunol 32: 138 – 144, 2007
1376. Shovman O, Gilburd B, Barzilai o, Langevitz P, Shoenfeld Y. Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome. Clin Rev Allerg Immunol 32: 145 – 152, 2007.
1377. Carp HJA, Shoenfeld Y. Anti-phospholipid antibodies and infertility. Clin Rev Allerg Immunol 32: 159 – 161, 2007.
1378. Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allerg Immunol 32: 184 – 187, 2007.
1379. Yehudai D, Shoenfeld Y, Toubi E. Looking into the eyes of patients with antiphospholipid syndrome. Clin Rev Allerg Immunol 32: 192 – 197, 2007.
1380. Sherer Y, Shepshelovich D, Shalev T, Haviv Y, Segal E, Ehrenfeld E, Levy Y, Pauzner R, Shoenfeld Y, . Langevitz P. Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol 26: 1851 – 1855, 2007.
1381. Strous R, Shoenfeld Y. Behavioral changes in systemic lupus erythematosus are of an autoimmune nature. Nat Clin Prac Rheum 3; 11: 592-593, 2007.
1382. Carp HJA, Shoenfeld Y. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells— an additional mechanism in a multi factorial process. Rheumatology 46:1517–1519, 2007.
1383. Gerli R, Sherer Y, Bartoloni Bocci E, Vaudo G, Moscatelli S, Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis role of traditional and disease-related cardiovascular risk factors. Ann. N.Y. Acad. Sci. 1108: 372–381, 2007.
1384. Asherson RA, Cervera R, Shoenfeld Y. Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann. N.Y. Acad. Sci. 1108: 515–529, 2007.
1385. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Mauseuura E, Oguma K. Chronic infections and atherosclerosis. Ann. N.Y. Acad. Sci. 1108: 594–602, 2007.
1386. Ball-Rosen C, Primak-Rubinovicz H, Korczyn AD, Wand N, Farchi A, Shavit S, Shoenfeld Y, Chapman J. Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann. N.Y. Acad. Sci. 1109: 473–483, 2007.
1387. Schachter J, Katz U, Mahrer A, Barak D, Ziegel Ben David L, Nusbacher J, Shoenfeld Y. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann. N.Y. Acad. Sci. 1110: 305-314, 2007.
1388. Ram M, Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma – a myth or reality? . Ann. N.Y. Acad. Sci. 1110: 410-425, 2007.



1389. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines. Focus on tumor necrosis factor family members BAFF and APRIL. Ann. N.Y. Acad. Sci. 1110: 426-432, 2007.
1390. Amital H, Gilburd B, Shoenfeld Y. Probiotic supplementation with lactobacillus casei (Actimel) induces a Th1 response in an animal model of antiphospholipid syndrome. Ann. N.Y. Acad. Sci. 1110: 661-669 2007.
1391. Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Current Opinion in Rheumatol 19: 636-643, 2007.
1392. Blank M, Beinglass I, Shoenfeld Y. The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression. Expert Opin Biol Ther 7: 1283-1285, 2007.
1393. Abu Shakra M, Shoenfeld Y. Natural hidden autoantibodies. IMAJ 9: 748-749, 2007.
1394. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, Sarzi-Puttini P, Shoenfeld Y, Doria A. OxLDL/ $\beta$ 2GPI-anti-oxLDL/ $\beta$ 2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7: 52-58, 2007.
1395. Belizna CC, Richard V, Thuillez T, Lévesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 7: 46-51, 2007.
1396. Altman A, Szyper-Kravitz M, Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol Int 28: 6-9-612, 2007.
1397. Harel – Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic disease. Nat Clin Prac Rheumatol 3: 707- 715, 2007.
1398. Kobayashi K, Tada K, Itabe H, Ueno T, Liu P-H, Tsutsumi A, Kuwana M, Yasuda T, Shoenfeld Y, de Groot PG, Matsuura E. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16: 929-938, 2007.
1399. Shoenfeld Y. The need for a fifth faculty of medicine and where to locate it. Harefuah 146: 821-822, 2007.
1400. Sherer Y, Blank M, Shoenfeld Y. Antiphospholipid syndrome (APS): Where does it come from? Best Practice & Research Clin Rheum 21: 1071-1078, 2007.
1401. de Carvalho JF, Sherer Y, Shoenfeld Y. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 98: 1157 – 1159, 2007.
1402. Nussinovitch U, Shoenfeld Y. Ventricular conduction block. Harefuah 146: 940-944, 2007.
1403. Bassi N, Amital D, Amital H, Doria A, Shoenfeld Y. Chronic Fatigue Syndrome: Characteristics and Possible Causes for its Pathogenesis. IMAJ 10: 79-82, 2008.
1404. Shoenfeld Y, Meroni PL, Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 67: 438-442; 2008.
1405. Shoenfeld Y, Gershwin ME. Whither autoimmunity: the lessons of anti-CCP and B cell depletion. Clin Rev Allerg Immunot 34: 1-3, 2008.
1406. Ram M, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allerg Immunol 34: 1-3, 2008.
1407. Strous RD, Shoenfeld Y. The mosaic of schizophrenia: Has the time arrived to monitor the illness with biomarkers? Clinical Biochemistry 41: 353-354, 2008.
1408. Shoenfeld Y, Gilburd B, Abu-Shakra M., Amital H, Barzilai O, Berkun Y, Blank M, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Levy Y, Orbach H, Pordeus V, Ram M, Sherer Y, Toubi E, Tomer Y. The Mosaic of Autoimmunity: Genetic Factors Involved in Autoimmune Diseases-2008. IMAJ 2008;10: 3-7.

1409. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, Sherer Y. The mosaic of autoimmunity: Hormonal and environmental factors involved in autoimmune diseases – 2008. IMAJ 10: 8-12, 2008.
1410. Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, Gershwin ME. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases – 2008. IMAJ 10: 13-19, 2008.
1411. Blank M, Shoenfeld Y. The story of the 16/6 idiotype and systemic lupus erythematosus. IMAJ 10: 37-39, 2008.
1412. Szyper-Kravitz M, Altman A, de Carvalho JF, Bellisai F, Galeazzi M, Eshet Y, Shoenfeld Y. Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm. IMAJ 10: 48 – 51, 2008.
1413. Bar Sela S, Shoenfeld Y. Photocopy machines and occupational antiphospholipid syndrome. IMAJ 10:52-54 2008.
1414. Sherer Y, Kuechler S, Scali JJ, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. IMAJ 10: 55-57, 2008.
1415. Ram M, Shoenfeld Y. Hepatitis B: infection, vaccination and autoimmunity. Israel Med Assoc J (IMAJ) 10: 61- 64, 2008.
1416. Pordeus V, Barzilai O, Sherer Y, Luiz RR, Blank M, Bizzaro N, Villalta D, Anaya JM, Shoenfeld Y. A latitudinal gradient study of common anti-infectious agent antibody prevalence in Italy and Colombia. IMAJ 10: 65 - 68, 2008.
1417. Kanduc D, Serpico R, Lucchese A, Shoenfeld Y. Correlating low-similarity peptide sequences and HIV B-cell epitopes. Autoimmune Rev 7: 291-296, 2007.
1418. Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity. IMAJ 10: 83 – 84, 2008.
1419. Merrick –Kenig E, Shoenfeld Y. Harnessing vitiligo for melanoma treatment. Harefuah 147: 33-37, 2008.
1420. Shoenfeld Y. Doctors as naive (innocent) drug advertisers. Harefuah 147: 98-99, 2008.
1421. Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yin J, Bucciarelli S, Espinosa G, Levy R, Shoenfeld Y. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 38: 124 - 131, 2008.
1422. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, Csipo I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomjak E, Veres K, Szegedi G, Shoenfeld Y, Soltész P. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35: 3; 398-406, 2008.
1423. Singh A, Blank M, Shoenfeld Y. Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti- $\beta$ -2-glycoprotein-I autoantibodies. Rheumato Int 28: 661-665, 2008.
1424. Praprotnik S, Sodin-Semrl S, Tomsic M, Shoenfeld Y. The curiously suspicious: Infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun 30: 37-41, 2008.
1425. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 30: 74-83, 2008.
1426. Blank M, Gershwin EM. Editorial: (ABOUT YEHUDA SHOENFELD): Autoimmunity: From the mosaic to the kaleidoscope. J Autoimmun 30: 1- 4, 2008.

1427. Katz U, Gilburd B, Shoenfeld Y. Animal model of vasculitides. Clinic Rev Allerg Immunol 35: 11-18, 2008.
1428. Katz U, Shoenfeld Y. Pulmonary eosinophilia. Clinic Rev Allerg Immunol 34: 367-371, 2008.
1429. Sherer Y, Matthias T, Shoenfeld Y. Cutting edge issues in autoimmunity. Clinic Rev Allerg Immunol 34: 275 - 278, 2008.
1430. de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y. C-reactive protein and its implications in systemic lupus erythematosus. Acta Reum Port; 32:317-322, 2007.
1431. Carp H.J.A, Meroni P.L, Shoenfeld Y. Autoantibodies as predictors of pregnancy complications. Rheumatology 47: iii6-iii8, 2008.
1432. Tanne D, Katzav A, Beilin O, Grigoriadis N C, Blank M, Pick C G, von Landenberg Ph, Shoenfeld Y, Chapman J. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol of Dis 30: 56 - 64, 2008.
1433. Marai I, Shechter M, Langevitz P, Gilburd B, Rubenstein A, Matsura E, Sherer, Shoenfeld Y. Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease. Am J Cardiol 101: 1094 - 1097, 2008.
1434. Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 67: 724 – 725, 2008.
1435. Sherer Y, Pagnoux C, Chironi G, Simon A, Guillevin L, Mouthon L, Gilburd B, Shoenfeld Y. Carotid artery intima-media thickness, heat shock proteins and oxidized LDL autoantibodies in systemic necrotizing vasculitis. Rheumatol Int 28:1099–1103, 2008.
1436. Pordeus V, Szyper-Kravitz M, Levy RA, Vaz NM, Shoenfeld Y. Infections and autoimmunity : a panorama. Clinic Rev Allerg Immunol 34: 283 – 299, 2008
1437. Amital H, Govoni M, Ram M, Meroni PL, Barzilai O, Shoenfeld Y, Tincani A, Trotta F, Zarzi-Puttini P, Atzeni F. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol Suppl. 48: S27 – S32, 2008.
1438. Girschick HJ, Guilhermae L, Inman RD, Latsch K, Rihl M, Sherer Y, Shoenfeld Y, Zeidler H, Arienti S, Doria A. Bacterial triggers and autoimmune rheumatic diseases. Clin Exp Rheumatol Suppl. 48: S12 – S17, 2008.
1439. Perricone R, Perricone C, de Carolis C, Shoenfeld Y. NK cells in autoimmunity: a two-edged weapon of the immune system. Autoimmun Rev 7: 348 – 390, 2008.
1440. de Carvalho J F, Shoenfeld Y. Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination. European J of Int Med 19: 383 – 385, 2008.
1441. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: Tuberculosis and splenectomy as possible triggering factors? Another example of the "Mosaic" of autoimmunity. Letter to the Editor, The Journal of Rheumatology 35:6: 1224 - 1227, 2008
1442. Kessel A, Rosner I, Halasz K, Grushko G, Shoenfeld Y, Paran D, Toubi E. Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum 39: 66-70, 2008.
1443. Seite J-F, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIG? Autoimmun Rev 7: 435 – 439, 2008.
1444. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin – indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7: 445 - 452, 2008.
1445. Zsundman-Goddard G, Berkun Y, Barzilai O, Boaz M, Ram M, Anaya JM, Shoenfeld Y. Neuropsychiatric

- lupus and infectious triggers. Lupus 17: 380 – 384, 2008.
1446. Shoenfeld Y, Cervera R. Obituary: Asherson's syndrome of the catastrophic antiphospholipid antibodies. The Journal of Rheum 35: 10: 2066-2068, 2008.
1447. Blank M, Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems. Clinic Rev Allerg Immunol 34: 307 – 312, 2008.
1448. Youinou P, Shoenfeld Y. Autoantibody-triggered apoptosis of endothelial cells induces antiphospholipid antibody in infectious diseases. Current Trends in Immunol 8: 11-18, 2007.
1449. Ram M, Anaya J-M, Barzilai O, Izhaky D, Porat Katz B, Blank M, Shoenfeld Y. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev.7: 621–625, 2008.
1450. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derexen HWM R, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Piette JC, Espinosa G, Bucciarelli S, Pisoni CN, Bertolaccini ML, Boffa MC, Hughes G RV. (European Forum on Antiphospholipid Antibodies)\*.  
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1000 patients. Ann Rheum Dis. 68: 1428 – 1432, 2008.
1451. Zifman E, Amital H, Gilburd B, Shoenfeld Y. Antioxidants and smoking in autoimmune disease — Opposing sides 2 of the seesaw? Autoimmun Rev 8: 165-169, 2008.
1452. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: The example of anti-phospholipid antibodies. Autoimmun Rev.7: 585–587, 2008.
1453. Sagi L, Sherer Y, Trau H, Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev 8: 33-35, 2008.
1454. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: The conflicting relationship between human and their environment. Autoimmun Rev. 8: 1-4, 2008.
1455. Agmon-Levin N, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies – the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 8: 52 – 55, 2008.
1456. Shoenfeld Y. Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun. 31: 325-330, 2008.
1457. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic disease – mechanisms and clinical findings. Clin Rev Allerg Immunol 37: 20-28, 2009.
1458. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Clin Rev Allerg Immunol 37: 44-48, 2009.
1459. Shoenfeld Y. Computerized grading for academic promotions at the faculty of medicine. Harefuah 147 (8-9): 689, 2008.
1460. Bartůňková J, Kayserova J, Shoenfeld Y. Allergy and autoimmunity: parallels and dissimilarity. The Yin and Yang of immunopathology. Autoimmun Rev 8: 302-308, 2009.
1461. Ortega OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum, 39: 38 – 54, 2008.
1462. Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, Sherer Y, Shoenfeld Y. Infections and autoimmune thyroid diseases: Parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 8: 112-115, 2008.
1463. Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 31:393-398 , 2008.

1464. de Carvalho JF, Rodrigues Pereira RM, Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination. European J of Int Med 19: 575-578, 2008.
1465. Cervera R, Shoenfeld Y. Microangiopathic antiphospholipid antibody-associated syndromes: A tribute to Ronald Asherson. IMAJ 10: 894-895, 2008.
1466. Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. J Autoimmun 32: 1-6, 2009.
1467. Agmon-Levin N, Shoenfeld Y. Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 301: 57-64, 2008.
1468. Moscovitch S.D., Szyper-Kravitz M, Shoenfeld Y. Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: The olfactory and immune system interrelationship. Clinical Immunol 130: 235 – 243, 2008.
1469. Szamosi S, Csiki Z, Szomjak E, Szolnoki E, Szoke G, Szekanez Z, Szegedi G, Shoenfeld Y, Szucs G. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: Risk factors for accelerated macrovascular damage? Clinic Rev Allerg Immunol. 36: 145-149, 2008.
1470. Shoenfeld Y, Gershwin ME, Cervera R. Ronald A. Asherson – "In Memoriam". Clinic Rev Allerg Immunol. 36: 71-73, 2009.
1471. Rotar Z, Rozman B, de Groot PG, Sanmarco M, Shoenfeld Y, Meroni PL, CXervera R, Pengo V, Cimaz R, Avcin T, Carp HJA, Tincani A. Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? Lupus 18: 53-60, 2009.
1472. Konova E, Alexovska T, Atanasova M, Georgieva M, Todorova K, Lukanov T, Shoenfeld Y. Anti-elastin antibodies and elastin turnover in normal pregnancy and recurrent pregnancy loss. AJRI- Am J Reproduct Immunol 61: 167-174, 2009.
1473. Coelho V, Broert F, Binder RJ, Shoenfeld Y, Moudgil K. Heat-shock proteins: Inflammatory versus regulatory attributes. CSC - Cell Stress and Chaperones 13: 119-25, 2008.
1474. Ortega-Hernandez OD, Kivity Shaye, Shoenfeld Y. Olfaction, psychiatric disorders and autoimmunity: Is there a common genetic association? Autoimmunity 42: 80-88, 2009
1475. Gerli R, Vaudo G, Bocci EB, Schillaci G, Bistoni O, Shoenfeld Y. Different roles for anti-cyclic citrullinated peptide antibodies and; CD4+CD28 (null) cells in the acceleration of atherosclerosis in rheumatoid arthritis: Comment on the article by Farragher et al. Arthritis Rheum 60: 631-2, 2009.
1476. Agmon-Levin N, Kivity S, Shoenfeld Y. Editorial: Neuropsychiatric manifestations of systemic lupus erythematosus – a primary disease manifestation. J of Neuroimmun 207: 1-2, 2009.
1477. Shoenfeld Y, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nature Clin Pract Rheumatol 5: 99 – 105, 2009.
1478. Soltész P, Dér H, Kerekes G, Szodoray P, Szücs G, Dankó K, Shoenfeld Y, Szegedi G, Szekanez Z. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 28: 655 – 662, 2009.
1479. Agmon-Levin N, Porat-Katz B, Shoenfeld Y. Infection and Primary Biliary Cirrhosis. IMAJ 12: 112-115, 2009.
1480. Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiology of Aging 2011; 32:272-9.

1481. Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y. Infection and vasculitis. Rheumatology 48: 475–482, 2009.
1482. Cervera R, Bucciarelli S, Plasín MA, Gomez-Puerta GA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G, for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies) Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 32: 240-245, 2009.
1483. Kerekes G, Soltész P, Dér H, Veres V, Szabó Z, Végvári A, Szegeði G, Shoenfeld Y, Szekanez Z. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 28: 705-710, 2009.
1484. Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza Vaccine and Autoimmunity. IMAJ 11: 39-41, 2009.
1485. Shoenfeld Y. Olfactory defects point to nervous system involvement in lupus. The Rheumatologist 3/4: 15-17, 2009.
1486. Nussinovitch U, Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch Immunol Ther Exp, 57: 95-104, 2009.
1487. Agmon-Levin N, Ram M, Barzilai O, Porat-Katz B, Parikman R, Selmi C, Gershwin ME, Anaya JM, Youinou P, Bizzaro N, Tincani A, Tzioufas AG, Cervera R, Stojanovich L, Martin J, Gonzalez-Gay MA, Valentini G, Blank M, SanMarco M, Rozman B, Bombardieri S, De Vita S, Shoenfeld Y. Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 32: 261 – 266, 2009.
1488. Inbar R, Shoenfeld Y. Elevated cardiac troponins: the ultimate marker for myocardial necrosis, but not without a differential diagnosis. IMAJ 11: 50-53, 2009
1489. Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, Paran D, Porat Katz B, Kivity S, Langevitz P, Zandman-Goddard G, Shoenfeld Y. The sense of smell in systemic lupus erythematosus. Arth Rheum 60; 5: 1484-1487, 2009.
1490. Nussinovitch U, Shoenfeld Y. Autoimmune mechanisms in cardiovascular diseases. Harefuah 148: 173-6, 2009.
1491. Kivity S, Ortega-Hernandez O, Shoenfeld Y. Olfaction - A window to the mind. IMAJ 11: 238-243, 2009.
1492. Doring Y, Hurst J, Lorenz M, Prinz N, Clemens N, Drechsler MD, Bauer S, Chapman J, Shoenfeld Y, Blank M, Lackner KJ, von Landenberg P. Human antiphospholipid antibodies induce TNF $\alpha$  in monocytes via Toll-like receptor 8. Immunobiology 2010; 215: 230-41.
1493. de Carvalho JF, Pereira RM R, Shoenfeld Y. Vaccination for atherosclerosis. Clin Rev Allerg Immunol 38: 135 – 140, 2010.
1494. Matthias T, Shoenfeld Y. Challenges for the autoimmunologist. Clin Rev Allerg Immunol 38: 75 - 76, 2010.
1495. de Carvalho JF, Pereira RM R, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Frontiers in Bioscience E1, 501-509, 2009.
1496. Arad M, Zlochiver S, Davidson T, Shoenfeld Y, Adunsky A, Abboud S. The detection of pleural effusion using a parametric EIT technique. Physiol Meas 30: 421- 428, 2009.
1497. Paz Z, Shoenfeld Y. Antifibrosis: To reverse the irreversible. Clin Rev Allergy Immunol 38: 276 – 286, 2010.
1498. Arnsón Y, Shoenfeld Y, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arth Rheum 2010; 40: 97-108.
1499. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N. Shoenfeld Y. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol; 38: 201 – 269, 2010.

1500. Kasher-Meron M, Amital H, Shepshelovich D, Barzilai O, Ram M, Anaya JM, Gerli R, Bizzaro N, Shoenfeld Y. Infectious aspects and the etiopathogenesis of rheumatoid arthritis. Clin Rev Allergy Immunol ; 38: 287 – 291, 2010.
- 1500a. Erratum to: Clin Rev Allergy Immunol (2010) 38:287–29. Infectious Aspects and the Etiopathogenesis of Rheumatoid Arthritis. Michal Kasher Meron & Howard Amital & Daniel Shepshelovich & Ori Barzilai & Maya Ram & Juan-Manuel Anaya & Roberto Gerli & Nicola Bizzaro & Yehuda Shoenfeld.
1501. Blank M, Shoenfeld Y. Anti-phospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clin Rev Allergy Immunol 38: 141 – 147, 2010.
1502. Katzav A, Shoenfeld Y, Chapmen J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome Clin Rev Allergy Immunol 38: 196 – 200, 2010.
1503. Shoenfeld Y, Meroni PL, Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: Are they separate entities or just clinical presentations on the same scale? Curr Opin Rheumatol 21: 495 - 500, 2009.
1504. de Carvalho JF, Rodrigues Pereira RM, Trindade Viana VS, Bonfa E, Shoenfeld Y. Lack of antilipoprotein lipase antibodies in Takayasu's arteritis. Clin and Dev Immunol \_\_\_\_\_(in press), 2009.
1505. Ribeiro FM, Szyper-Kravitz M, Klumb EM, Lannes G, Ribeiro FRE, Albuquerque EMM, Shoenfeld Y. Can lupus flares be associated with tuberculosis infection? CRAI - Clin Rev Allerg Immunol 38: 163 – 168, 2010.
1506. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity, and Vitamin D. CRAI- Clin Rev Allerg Immunol 38: 169 – 177, 2010.
1507. Agmon-Levin N, Gilburd B, Kivity S, Porat-Katz B, Flitman-Katzevman I, Shoenfeld N, Paran D, Langevitz P, Shoenfeld Y. Anti-ribosomal-P antibodies in lupus patients and healthy controls: Evaluation of three ELISA assays. IMAJ 11: 403 – 406, 2009.
1508. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Autoimmunity and environment: Infections and autoimmunity – friends or foes? Trends in Immunology , 30;(8): 409 - 414, 2009.
1509. Damianovich M, Blank M, Raiter A, Hardy B, Shoenfeld Y. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIG). International Immunology 21:1057-1063 , 2009.
1510. Nolte JE, Altman A, Szyper-Kravitz M, Shoenfeld Y, Zimlichman E. Legionella-induced sudden hearing loss: a rare complication. Infection 37: 377-378, 2009.
1511. Zimlichman E, Szyper-Kravitz M, Unterman A, Goldman A, Levkovich A, Shoenfeld Y. How is my patient doing? Evaluating hospitalized patients using continuous vital signs monitoring . IMAJ 11: 382 – 384, 2009.
1512. Shoenfeld Y, Shemer J, Kerem G, Blachar Y, Eidelman LA, Borrow M. British medical journals play politics. IMAJ 11: 325 – 327, 2009.
1513. Neto RSN, de Carvalho JF, Shoenfeld Y. Screening tests for inflammatory activity: applications in rheumatology. Modern Rheumatology 19:469–477, 2009.
1514. Meroni PL, Tincani A, Alacron-Riquelme ME, Shoenfeld Y. European Forum on Antiphospholipid Antibodies: research in progress. LUPUS 18: 924-929, 2009.
1515. Zandman-Gpddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. LUPUS 18: 884-888, 2009.
1516. Papageorgiou NP, Altman A, Shoenfeld Y. Inflammatory bowel disease: Adverse effect of isotretinoin. IMAJ 11: 505-506, 2009.
1517. Shoenfeld Y, Gershwin ME. Preface – The autoimmunologist and the congresses of autoimmunity. Ann NY Acad Sci 1173: 1-3, 2009.

1518. Jovanova-Nesic K, Koruga D, Kojic D, Kostic V, Rakic L, Shoenfeld Y. Choroid plexus connexin 43 expression and gap junction flexibility are associated with clinical features of acute EAE. Ann NY Acad Sci 1173: 75-82, 2009.
1519. Orbach H, Amitai N, Barzilai O, Boaz M, Ram M, Zandman-Goddard G, Shoenfeld Y. Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin. Ann NY Acad Sci 1173: 174-179, 2009.
1520. Lazurova I, Benhatchi K, Rovensky J, Kozakova D, Wagnerova H, Tajtakova M, Shoenfeld Y, Macejova Z. Autoimmune thyroid diseases and autoimmune rheumatic disorders. Tow-sided analysis. Ann NY Acad Sci 1173: 211-216, 2009.
1521. Ben-Ami Shor D, Barzilai O, Ram N, Izhaky D, Porat-Katz B, Chapman J, Blank M, Anaya JM, Shoenfeld Y. Gluten sensitivity in multiple sclerosis. Experimental myth of clinical truth? Ann NY Acad Sci 1173: 343-349, 2009.
1522. Ortega-Hernandez OD, Cuccia MC, Bozzini S, Bassi N, Moscovitdh S, Diaz-Gallo LM, Blank M, Agmon-Levin N, Shoenfeld Y. Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen glass II alleles in chronic fatigue syndrome. Ann NY Acad Sci 1173: 589-599, 2009.
1523. Ortega-Hernandez OD, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann NY Acad Sci 1173: 600 - 609, 2009.
1524. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Ram M, Shoenfeld Y. The role of infections in the immunopathogenesis of systemic sclerosis – evidence from serological studies. Ann NY Acad Sci 1173: 627-632, 2009.
1525. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, Arango A, Garcia J, Shoenfeld Y. Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type-I diabetes mellitus and their close family members. Ann NY Acad Sci 1173: 633-639, 2009.
1526. Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y. Infectious serologies and autoantibodies in inflammatory bowel diseases. Insinuations at a true pathogenic role. Ann NY Acad Sci 1173: 640-648, 2009.
1527. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, Sherer Y, Anaya JM, Shoenfeld Y. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci 1173: 658-663, 2009.
1528. Plot L, Amital H, Barzilai O, Ram M, Bizzaro N, Shoenfeld Y. Infections may have a protective role in the etiopathogenesis of Celiac disease. Ann NY Acad Sci 1173: 670-674, 2009.
1529. Agmon-Levin N, Porat-Katz B, Barzilai O, Ram M, Lindeberg S, Frostegard J, Shoenfeld Y. Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann NY Acad Sci 1173: 675-682, 2009.
1530. Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A, Shoenfeld Y, Szekanecz Z. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann NY Acad Sci 1173: 814-821, 2009.
1531. Lidar M, Lipschitz N, Langevitz P, Barzilai O, Ram M, Porat-Katz B, Pagnoux C, Guilpain P, Sinico RA, Radies A, Bizzaro N, Damoiseaux J, Cohen Tervaert JW, Martin M, Guillevin L, Bombardieri S, Shoenfeld Y. Infectious serologies and autoantibodies in Wegener's granulomatosis and other vasculitides. INFECTIOUS WEGENER'S - Ann NY Acad Sci 1173: 649-657, 2009.
1532. Lidar M, Langevitz P, Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. IMAJ 11: 558-563, 2009.
1533. Samuel-Datum Moscovitch, Martine Szyper-Kravitz, Yehuda Shoenfeld. Olfacto: Smell: integrating neurodegeneration and autoimmunity – a personal view. Acta Reumatol Port 34: 190-196, 2009. (Portuguese).



1534. Zafrir Y, Agmon-Levin N, [Shoenfeld Y](#). Post-Influenza vaccination vasculitides a possible new entity. [J Clin Rheumatol](#) 15: 269-270, 2009.
1535. Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, [Shoenfeld Y](#). Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. [Clin & Exp Immunol](#) 158 (Suppl. 1): 43–50. 2009.
- 1536 Agmon-Levin N, Paz Z, Israeli E, [Shoenfeld Y](#). Vaccines and autoimmunity. [Nature Rev Rheumatol](#) 5: 648-652, 2009.
- 1537 [Shoenfeld Y](#). Infections, vaccines and autoimmunity. Editorial. [Lupus](#) 18: 1127 – 1128, 2009.
- 1538 Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, Blank M, Anaya J-M, [Shoenfeld Y](#). Infectious antibodies in systemic lupus erythematosus patients. [Lupus](#) 18: 1129 – 1135, 2009.
- 1539 Blank M, [Shoenfeld Y](#), Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. [Lupus](#) 18: 1136 – 1143, 2009.
- 1540 Zandman-Goddard G, [Shoenfeld Y](#). Parasitic infection and autoimmunity. [Lupus](#) 18: 1144 – 1148, 2009.
- 1541 Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N, Ram M, Blank M, Tincani A, Rozman B, Cervera R, [Shoenfeld Y](#). Common infectious agents prevalence in antiphospholipid syndrome. [Lupus](#) 18: 1149 – 1153, 2009.
- 1542 Ayada K, Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, Hatanaka K, Hirohata S, Yoshino T, [Shoenfeld Y](#), Matsuura E, Oguma K. Regulation of cellular immunity prevents *Helicobacter pylori*-induced atherosclerosis. [Lupus](#) 18: 1154 – 1168, 2009.
- 1543 Agmon-Levin N, Blank M, Paz Z, [Shoenfeld Y](#). Molecular mimicry in systemic lupus erythematosus. [Lupus](#) 18: 1181 – 1185, 2009.
- 1544 Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, [Shoenfeld Y](#). Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. [Lupus](#) 18: 1192 – 1197, 2009.
- 1545 Agmon-Levin N, Kivity S, Szyper-Kravitz M, [Shoenfeld Y](#). Transverse myelitis and vaccines: a multi-analysis. [Lupus](#) 18: 1198 – 1204, 2009.
- 1546 Israeli E, Agmon-Levin N, Blank M, [Shoenfeld Y](#). Adjuvants and autoimmunity. [Lupus](#) 18: 1217 – 1225, 2009.
- 1547 Levy Y, Rotman-Pikielny P, Ehrenfeld M, [Shoenfeld Y](#). Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. [Lupus](#) 18: 1226 – 1232, 2009.
- 1548 Domiciano Ds, Carvalho JF, [Shoenfeld Y](#). Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. [Lupus](#) 18: 1233 – 1238, 2009.
- 1549 Carvalho JF, Oereura RMR, [Shoenfeld Y](#). Vaccination, atherosclerosis and systemic lupus erythematosus. [Lupus](#) 18: 1209 – 1212, 2009.
- 1550 Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, [Shoenfeld Y](#). A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. [J Autoimmun](#) 34: 55-58, 2010.
- 1551 Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, ;Schneider M, Sherer Y, [Shoenfeld Y](#), Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. [Ann Rheum Dis](#) 69: 1269-1274, 2010.

- 1552 Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, Gershwin ME, Shoenfeld Y. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 33: 178 – 182, 2009.
- 1553 Lidar M, Lipschitz N, Langevitz P, Shoenfeld Y. The Infectious etiology of vasculitis. Autoimmunity 42: 432-8, 2009.
- 1554 Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J of Immunopathol & Pharmacol 22: 639-646, 2009.
1555. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun : 34: J168 – J177, 2010.
1556. Benkler M, Agmon-Levin N, Shoenfeld Y. Parkinson's disease, autoimmunity, and olfaction. Int J of Neuroscience 119: 2133-2143, 2009.
1557. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev . 9: A277–A287, 2010 .
1558. Saad T, Agmon-Levin N, Shoenfeld Y. Chronic stimulation of the immune system in sarcoidosis and monoclonal gammopathy of undetermined significance. Harefuah 148: 909-810, 2009.
1559. Shoenfeld Y, Shemer J, Keren G. Is it worthwhile to be a reviewer for a medical-scientific journal? Harefuah 148: 824, 2009.
1560. Kivity S, Borrow M, Shoenfeld Y. Hippocrates' oath is challenged. IMAJ 11: 581 – 584, 2009.
1561. Nussinovitch U, Ezra D, Nussinovitch N, Shoenfeld Y. Japanese-type apical hypertrophic cardiomyopathy. IMAJ 11: 705, 2009.
1562. Shoenfeld Y. The autoimmunologist: a profession being created. Harefuah 148: 706-7, 2009.
1563. Gerli R, Vaudo G, Bartoloni Bocci E, Schillaci G, Alunno A, Luccioli F, Hijazi DR, Mannarino E, Shoenfeld Y. Functional Impairment of Arterial Wall in Primary Sjögren's Syndrome: Combined Action of Immunological and Inflammatory Factors. Arth Care Res 62: 712-8, 2010.
1564. Rodrigues CEM, Carvalho JF, Shoenfeld Y. Antiphospholipid syndrome as a neurological disease. Current Rheumatol Rev 6: 12 – 17, 2010.
1565. Fattal I, Shental N, Mevorach D, Anaya JM, Livneh A, Langevitz P, Zandman- Goddard G, Pazner R, Lerner M, Blank M, Hincapie ME, Gafter U, Naparstek Y, Shoenfeld Y, Domany E, Cohen I. An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology 2010; 130: 337-43.
1566. de Carvalho JF, Pereira R MR, Shoenfeld Y. Current knowledge regarding Asherson's syndrome. Expert Rev Clin Immunol. 5: 587–591, 2009.
- 1566a. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst D E, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Garay Toth B, Tyndall A, Valentini GV, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, and the EUSTAR co-authors : \***EUSTAR co-authors**: Lund (F Wollheim, A Scheja); Moskwa (T Nevskaya, L Ananieva, E Nasonov); Paris (Y Allanore, A Kahan); Lille (E Hachulla, D Launay); Manchester (A Herrick); Newcastle (J van Laar); Geneva (C Chizzolini); Bucharest (C Ciurtin, D Opris, R Ionescu, M Capraru); Cluj-Napoca (S Rednic); Zurich (O Distler); Ankara (I Simsek, A Dinc); Istanbul (M Inanc); Graz (W Graninger); Tubingen (I Kotter); Oslo (JT Gran, O Midvedt); Katowice (E Kucharz); Lublin (D Krasowska, M Majdan); Bialystok (S Sierakowski); Coimbra (MJ Salvador, JA Pereira da Silva); Belgrade (N Damjanov); Madrid (P Carreira, P Garcia de la Pena Lefebvre); Debrecen (G Szucs, ZSzekanecz); Praha (R Becvar); Porto (P Pinto); Lisbon (P Coelho); Rijeka (S Novak); Basle (U Walker); Dresden (M Aringer); Gottingen (T Glaenz, CH Neumann, S Emmert); Berlin (M Worm, G Riemekasten); Koln (T Krieg, N Hunzelmann); Mainz (K Steinbrink); Muenster (C Sunderkotter); Stuttgart (S Heitmann); Hamburg (I Foldvari); Bari (F Iannone, G Lapadula); Brescia (P Air`); L'Aquila (R Giacomelli); Milan (R Scorza); Genova (M Rizzi, F Indiveri); Rome (V Riccieri); Padova (F Zulian); Ljubljana (B Rozman); Tokyo (K Takehara); Seoul (Jae-Bum Jun);

Philadelphia, (C Derk, N Sandorfi, S Jimenez); Johannesburg (M Tikly); Mosul (Saad Alhasani); Tel Hashomer (Y Shoenfeld); Haifa (A Balbir Gurmann).

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR Ann Rheum Dis 2009; 68: 620–628).

1567. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmunity 34: J258 - J265, 2010.
1568. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmunity 34: J163 – J167, 2010.
1569. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity; 42/6: 553-560, 2009.
1570. Sherer Y, Zinger H, Shoenfeld Y, Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43: 98-102 , 2010.
1571. Rodrigues CEM, Carvalhoa JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. European Journal of Clinical Investigation 4: 350-359, 2010.
1572. Amital H, Szekanez Z, Szücs G, Dankó K, Nagy E, Csépany T, Kiss E, Doria A, Corocher N, Agmon-Levin N, Orbach H, Barak V, Zandman-Goddard G, Shoenfeld Y. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 69: 1155-1157 , 2010.
1573. **Kivity S, Tsarfaty G, Agmon-Levin N, Blank M, Manor D, Konen E, Chapman J, Reichlin M, Wasson C, Shoenfeld Y, Kushnir T.** Abnormal olfactory function demonstrated by manganese-enhanced MRI in mice with experimental neuropsychiatric lupus. Ann NY Acad Sci; 1193: 70-77, 2010.
1574. Szekanez F, Shapitaanez E, Bako G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases – a mini-review. Gerontology 57: 3-10, 2011.
1575. Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nature Reviews Rheumatology 6: 468 – 476, 2010.
1576. Alard JE, Gaillard F, Daridon C, Shoenfeld Y, Jamin C, Youinou P. TLR2 is one of the endothelial receptors for  $\beta$ 2-Glycoprotein I. The Journal of Immunology 185: 1550 – 1557, 2010.
1577. Pavlovic M, Kats A, Cavallo M, Chen R, Hartmann JX, Shoenfeld Y. Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE . Autoimmunity Dis. Article ID 462841, 18 pages \_\_\_ 2010.
1578. Torres-Aguilar H, Sánchez-Torres C, Jara LJ, Blank M, Shoenfeld Y. IL-10/TGF-beta-Treated Dendritic Cells, Pulsed with Insulin, Specifically Reduce the Response to Insulin of CD4+ Effector/Memory T Cells from Type 1 Diabetic Individuals. J Clin Immunol. 2010; 30:659–668.
1579. Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, Shoenfeld Y, Doria A. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis. 69: 1704-1710, 2010 .
1580. Döring Y, Hurst J, Lorenz M, Prinz N, Clemens N, Drechsler MD, Bauer S, Chapman J, Shoenfeld Y, Blank M, Lackner KJ, von Landenberg P. Human antiphospholipid antibodies induce TNF $\alpha$  in monocytes via Toll-like receptor 8. Immunobiology. 215: 230-241, 2010.
1581. Praprotnik S, Agmon-Levin N, Porat-Katz B, Blank M, Meroni PL, Cervera R, Miesbach W, Stojanovich L, Szyper-Kravitz M, Rozman B, Tomsic M, Shoenfeld Y. Prolactin's role in the pathogenesis of the antiphospholipid syndrome. Lupus. 2010; 19:1515-19.
1582. Shoenfeld Y. What to wear – the physician's attire. Harefuah 149: 7: 433-434, 2010.
1583. Pablobic M, Kats A, Carvall M, Shoenfeld Y. Clinical and Molecular Evidence for Association of SLE with parvovirus B19. LUPUS 19: 783-92, 2010.

1584. Zandman-Goddard G, Peeva E, [Shoenfeld Y](#). Gender influences SLE-immune cells, genetics, experimental models and lupus patients. [Clin Exp Rheumatol](#) 28: 297-299, 2010.
1585. [Shoenfeld Y](#), Agmon-Levin N. 'ASIA' – autoimmune / inflammatory syndrome induced by adjuvants. [J of Autoimmun](#) 36: 4-8, 2011.
1586. Torres-Aguilar H, Blank M, Jara JL, [Shoenfeld Y](#). Tolerogenic dendritic cells in autoimmune diseases: Crucial players in induction and prevention of autoimmunity. [Autoimmun Rev](#). 10: 8-17, 2010.
1587. Balofsky A, Agmon-Levin N, [Shoenfeld Y](#). The new H1N1 and HPV vaccines and old fears. [Current Opinion in Rheumatology](#) 22:431–436, 2010.
1588. Gueta I, Altman A, [Shoenfeld Y](#). The effect of blocking TNF- $\alpha$  in patients with cancer-related cachexia and anorexia. [Harefuah](#) 149; 8: 512-514, 2010.
1589. Bartoloni E, [Shoenfeld Y](#), Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin. [Arthritis Care Res](#). 63: 178 – 183, 2011.
1590. Toubi E, [Shoenfeld Y](#). The role of vitamin D in regulating immune responses. [IMAJ – Isr Med Assoc J](#) 12: 174 – 5, 2010.
1591. Petricova J, Lazurova I, [Shoenfeld Y](#). Polycystic ovary syndrome and autoimmunity. [European J of Internal Med](#) 21: 369–371, 2010.
1592. Perricone C, Agmon-Levin N, Shoenfeld N, de Carolis C, Guarino MD, Gigliucci G, Milana I, Novelli L, Valesini G, Perricone R, [Shoenfeld Y](#). Evidence of impaired sense of smell in hereditary angioedema. [Allergy](#) 66: 149–154, 2011.
1593. Blank M, [Shoenfeld Y](#). Sialic acid–IVIg targeting CD22 . [Blood](#) 116: 1630 – 1632, 2010.
1594. Nussinovitch U, Eidelman L, [Shoenfeld Y](#). Placebo use in clinical studies. [Harefuah](#) 149/6: 365-369, 2010.
1595. Nussinovitch U, [Shoenfeld Y](#). Anti-tropopin autoantibodies and the cardiovascular system. [Heart](#) 96: 1518-1524, 2010.
1596. Gugliesi F, deAndrea M, Mondini M, Cappello P, Giovarelli M, [Shoenfeld Y](#), Merono PL, Gariglio M, Landolfo S. The proapoptotic activity of the interferon-inducible geneIFI16 provides new insights into its etiopathogenetic role in autoimmunity. [J Autoimmun](#) 35: 114 – 123, 2010.
1597. Souberbielle J-C, Body J-J, Lappe JM, Plebani M, [Shoenfeld Y](#), Wang TJ, Bischoff-Ferrari A, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guerin AP, Heckendorff L, Hollis BW, Ish-Shalom S, Gullaume Jean, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. [Autoimmun Rev](#) 9: 709–715, 2010.
1598. Unterman A, Nolte JES, Boaz M, Abady M, [Shoenfeld Y](#), Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta- analysis. [Semin Arthritis Rheum](#) 2011; 41: 1-11.
1599. Tomasoni L, Sitia S, Borghi C, Cicero A.F.G. Ceconi C, Cecaro F, Morganti A, De Gennaro Colonna V, Guazzi M, Morriconi L, Malavazos AE, marino P, Cavallino C, [Shoenfeld Y](#), Turiel M. Effects of treatment strategy on endothelial function. [Autoimmun Rev](#). 9: 840-844, 2010.
1600. Meroni PL, [Shoenfeld Y](#). Systemic lupus erythematosus and the SLE galaxy. [Autoimmun Rev](#). 10: 1-2, 2010.
1601. Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, David M, [Shoenfeld Y](#). Efficacy of intravenous immunoglobulin (IVIg) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. [Clin Exp Immunol](#); 162: 543–549, 2010.
1602. Nussinovitch U, [Shoenfeld Y](#). Atherosclerosis and macrovascular involvement in systemic sclerosis: Myth or reality. [Autoimmun Rev](#) 10 :259–266, 2011.

1603. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, Doria A, Cervera R, Miesbach W, Stojanovich L, Barak V, Porat-Katz BS, Amital H, [Shoenfeld Y](#). Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. *Ann Rheum Dis* 70: 145-150, 2011.
1604. Ergaz Z, Mevorach D, Goldzweig G, Cohen A, Patlas N, Yaffe P, Blank M, [Shoenfeld Y](#), Ornoy A. The embryotoxicity of sera from patients with autoimmune diseases on post-implantation rat embryos in culture persists during remission and is not related to oxidative stress. *Lupus* 19: 1623-1631, 2010.
1605. Oren Y, Shapira Y, Agmon\_levin N, Kivity S, Zafirir Y, Altman A, Lerner A, [Shoenfeld Y](#). Vitamin D insufficiency in a sunny environment: A demographic and seasonal analysis. *IMAJ* 12: 751 – 756 , 2010.
- 1606 Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Loannidis JP, Jayne DR, Kallenberg CG, Muller-Lander U, [Shoenfeld Y](#), Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 70:414-22, 2011.
1607. Van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Loannidis JP, Jayne DR, Kallenberg CG, Muller-Lander U, [Shoenfeld Y](#), Stojanovich L, Valesini G, Wulffraat NM, Bijl M. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Autoimmun Rev* 10: 341-352, 2011.
1608. Mahler M, Agmon-Levin N, van Liempt M, [Shoenfeld Y](#), Waka A, Hiepe F, Swart A, Guertler I, Fritzler MJ. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. *Rheumatol Int*. 2012; 32: 691-8.
1609. Bartoloni E, [Shoenfeld Y](#), Gerli R. Inflammatory and Autoimmune Mechanisms in the Induction of Atherosclerotic Damage in Systemic Rheumatic Diseases: Two Faces of the Same Coin. *Arth Care & Research* 63: 178 - 183, 2011.
1610. Nussinovitch U, [Shoenfeld Y](#). The clinical significance of Anti-Beta-1 adrenergic receptor autoantibodies in cardiac disease. *Clin Rev Allerg Immunol* 2013; 44: 75-83.
1611. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sanchez-Castanon M, Lopez-Hoyos M, Matucci-Cerinic M, Szuces G, Shapira Y, Szekanecz Z, [Shoenfeld Y](#). Serum 25-OH Vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective Cohort Study and review of the literature. *Autoimmun Rev* 10: 490-494, 2011.
1612. Rosenblum H, [Shoenfeld Y](#), Amital H. The common immunogenic etiology of chronic fatigue syndrome: From infections to vaccines via adjuvants to the ASIA syndrome. *Infect Dis Clin North Am* ; 25:851-63, 2011.
1613. Kivity S, Agmon-Levin N, Zisapfl M, Shapira Y, Nagy EV, Danko K, Szekanecz Z, Langevitz P, [Shoenfeld Y](#). Vitamin D and autoimmune thyroid diseases. *Cellular & Molecular Immunology* 2011; 8:243-7.
1614. Nussinovitch U, de Carvalho JF, Pereira RMR, [Shoenfeld Y](#). Glucocorticoids and the cardiovascular system: State of the art. *Current Pharmaceutical Design*, 16: 3574-3585, 2010.
1615. Cervera R, Teltpmodpi MG, Espinosa G, Cabral AR, Gonzalez EB, Erkan D, Vadya S, Adroque HE, Solomon M, Zandman-Goddard G, [Shoenfeld Y](#). Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. *LUPUS* 20: 165 – 173, 2011.
1616. Cervera R, Teltpmodpi MG, Espinosa G, Cabral AR, Gonzalez EB, Erkan D, Vadya S, Adroque HE, Solomon M, Zandman-Goddard G, [Shoenfeld Y](#). Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): Thrombocytopenia and skin manifestations. *LUPUS* 20: 174 – 181, 2011.

1617. Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H, Szekanecz Z, Szucs G, Rovensky J, Kiss E, Corocher N, Doria A, Stojanovich L, Ingegnoli F, Meroni PL, Rozman B, Gomez-Arbesu J, Blank M, [Shoenfeld Y](#). Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. [Clin Rev Allergy Immunol](#) 2013; 44: :23 – 30.
1618. Kessel A, Peri R, Haj T, Snir A, Slobodin G, Sabo E, Rosner I, [Shoenfeld Y](#), Toubi E. IVIG attenuates TLR-9 Activation in B cells from SLE patients. [J Clin Immunol](#) 31: 31-38, 2011.
1619. Israeli E, Agmon-Levin N, Blank M, [Shoenfeld Y](#). Macrophagic myofasciitis a vaccine (alum) autoimmune-related disease. [Clin Rev Allergy Immunol](#) 41:163–168, 2011.
1620. Hajdu SD, Agmon-Levin N, [Shoenfeld Y](#). Silicon and autoimmunity. [Eur J Clin Invest](#) 2011; 41: 203–211
- 1620a. Pavlovic M, Cavallo M, Kats A, Kotlarchyk A, Zhuang H, [Shoenfeld Y](#). From Pauling's abzyme concept to the new era of hydrolytic anti-DNA autoantibodies: a link to rational vaccine design? - A review. [J. Int Bioinform Res Appl](#). 2011; 7: 220-38.
- 1620b. Zimlichman E, Shinar Z, Rozenblum R, Levkovich S, Skiano S, Szyper-Kravitz M, Altman A, Amital H, [Shoenfeld Y](#). Using continuous motion monitoring technology to determine patient's risk for development of pressure ulcers. [J Patient Saf](#). 2011; 7: 181 - 4.
1621. Israeli E, Agmon-Levin N, Blank M, Chapman J, [Shoenfeld Y](#). Guillain-barre Syndrome – a classical autoimmune disease triggered by infection on vaccination. [Clin Rev Allergy Immunol](#) 42: 121-130, 2012.
1622. Idan R, Hajdu SD, Agmon-Levin N, [Shoenfeld Y](#). Hormonal therapy in a patient with ovarian agenesis and possible SLE: a choice to be made. [Clin Rheumatol](#). 2013; 32 Suppl 1: S43 – 5.
1623. Lerner A, Shapira Y, Agmon-evin N, Pacht A, Ben-Ami Shor D, Lopez HM, Sanchez-Castanon M, [Shoenfeld Y](#). The clinical significance of 25OH-Vitamin D status in Celiac disease. [Clin Rev Allergy Immunol](#) 2012; 42: 322 – 330.
1624. Shapira Y, Poratkatz BS, Gilburd B, Barzilai O, Ram M, Blank M, Lindeberg S, Frostegård J, Anaya JM, Bizzaro N, Jara LJ, Damoiseaux J, [Shoenfeld Y](#), Agmon Levin N. Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults. [Clin Rev Allergy Immunol](#) 2012; (42)2: 154-163
1625. Benkler M, Agmon-Levin N, Hassin-Baer S, Cohen OS, Ortega-Hernandez OD, Levy A, Moscovitch SD, Szyper-Kravitz M, Damianovich M, Blank M, Chapman J, [Shoenfeld Y](#). Immunology, Autoimmunity, and Autoantibodies in Parkinson's Disease. [Clin Rev Allergy Immunol](#) 2012; 42:164–171.
1626. Orbach H, Zandman-Goddard G, Boaz M, Agmon-Levin N, Amital H, Szekanecz Z, Szucs G, Rovensky J, Kiss E, Doria A, Ghirardello A, Gomez-Arbesu J, Stojanovich L, Ingegnoli F, Meroni PL, Rozman B, Blank M, [Shoenfeld Y](#). Prolactin and Autoimmunity : Hyperprolactinemia correlates with serositis and anemia in SLE patients. [Clin Rev Allergy Immunol](#) 2012; 42:189–198.
1627. Shelly S, Agmon-Levin N, Altman A, [Shoenfeld Y](#). Thymoma and autoimmunity. [Cell Mol Immunol](#). 2011; 8: 199-202.
1628. Agmon-Levin N, Lian Z, [Shoenfeld Y](#). Explosion of autoimmune diseases and the mosaic of old and novel factors. [Cell Mol Immunol](#) 8: 189–192, 2011.
1629. Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csépany T, Dankó K, Shapira Y, Zandman-Goddard G, Orbach H, Agmon-Levin N, [Shoenfeld Y](#). Ferritin and prolactin levels in multiple sclerosis. [IMAJ](#) 13: 91-5, 2011.
1630. Sagi L, Baum S, Agmon-Levin N, Sherer Y, Katz BS, Barzilai O, Ram M, Bizzaro N, Sanmarco M, Trau H, [Shoenfeld Y](#). Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature. [Autoimmun Rev](#) 10 : 527–535., 2011.
1631. Blank M, Baraam L, Eisenstein M, Fridkin M, Dardik R, Heldman Y, Katchalski-Katzir E, [Shoenfeld](#)

- Y. b2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3b expression and reduces experimental-antiphospholipid-syndrome. Journal of Autoimmunity 2011; 37: 8-17.
1632. Hajas A, Sandor J, Casathy L, Csipo I, Barath S, Paragh G, Seres I, Szegedi G, Shoenfeld Y, Bodolay E. Vitamin D insufficiency in a large MCTD population. Autoimmun. Rev 2011; 10: 317-24.
1633. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From Malaria to Autoimmunity. Clin Rev Allergy Immunol. 2012; 42: 145–153.
1634. Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayr J, Némethné ZG, Szegedi G, Shoenfeld Y, Sipka S, Soltész P, Szekanecz Z, Szántó S. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J. Rheumatol. 38: 723 – 729, 2011.
1635. Shoenfeld Y - Autoimmune (autoinflammatory) syndrome induced by adjuvants provides a diagnostic framework for enigmatic conditions. The Rheumatologist 6 No. 6: 26-32, 2011.
1636. Nussinovitch U, Shoenfeld Y. The diagnostic and clinical significance of Anti-Muscarinic receptor autoantibodies. Clin Rev Allergy Immunol 2012; 42:298–308.
1637. Nussinovitch U, Shoenfeld Y. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac diseases. Clin Rev Allergy Immunol 2013; 44: 98–108.
1638. Shoenfeld Y, Agmon-Levin N. Abstract of: 'ASIA' – autoimmune (auto-inflammatory) syndrome induced by adjuvant- a new syndrome to be defined. In: Abstracts of selected invited lectures. Lupus 20: 340-347, 2011.
1639. Laczik R, Szodoray P, Veres K, Szomjak E, Csipo I, Sipka S Jr., Shoenfeld Y, Szekanecz Z, Soltesz P. Assessment of IgG antibodies to oxidized LDL. in patients with acute coronary syndrome. Lupus 20: 730–735, 2011.
1640. Gershwin ME, Shoenfeld Y. Cutting-edge issues in organ-specific autoimmunity. Clin Rev Allerg Immunol. 41:123–125, 2011.
1641. Perricone R, Perricone C, Shoenfeld Y. Autoimmunity: When the immune system becomes the self-ish giant. Autoimmun Rev. 10: 575-576, 2011.
1642. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Schneider M, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, Ward MM, Werth VP, Carmona L. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmunity Reviews 10: 383–388, 2011.
1643. Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev 10: 244-247 , 2011.
1644. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases, Clin Rev Allergy Immunol 2012; 42: 247 – 255.
1645. Torres-Aguilar H, Blank M, Kivity S, Misgav M, Luboshitz J, Pierangeli S, Shoenfeld Y. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4+ T cell response to  $\beta$ 2GPI. Ann Rheum Dis 2012; 71: 120-128.
1646. Vasconcelos C, Kallenberg C, Shoenfeld Y. Refractory disease in autoimmune diseases. Autoimmun Rev 10: 653-654, 2011.
1647. Altman A, Nussinocitch U, Goitein O, Shoenfeld Y. Broken Heart Syndrome” (Takotsubo Cardiomyopathy). IMAJ 13: 643-644, 2011.

- 1647a. Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum 2011; 41:517-523.
1648. Ciechanover A, Shoenfeld Y, Shemer J, Eidelman L, Borrow M. Response to health in the occupied Palestinian territory. The Lancet The Lancet 2011; 378 (9802): author reply e1.
- 1648a. **Katz U, Shoenfeld Y, Zandman-Goddard G.** Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in **autoimmune** diseases. Curr Pharm Des. 2011; 17: 3166-75.
1649. Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev. 2012; 11: A377-A385.
1650. Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: The ego, the id and the superego. Joint Bone Spine. 2012;79:1-3.
- 1650a. Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. vaccination chez les patients atteints de maladies rhumatologiques chroniques ou auto-immunes: L'ego, le soi et le superego. Revue du Rhumatisme 2012; 79: 5-7. (Article in French – same as 1650).
1651. Kivity S, Gilburd B, Agmon-Levin N, Garcia-Carrasco M, Tzafrir Y, Sofer Y, Mandel M, Buttner T, Roggenbuck D, Maticci-Cerinic M, Danko K, Lopez Hoyos M, Shoenfeld Y. A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol 2012; 31:503–509.
1652. Shoenfeld Y. The future of autoimmunity. Clinic Rev Allerg Immunol 2012; 42: 113-120.
1653. Twig G, Shina A, Amital H, Shoenfeld Y. Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 2012; 38: J275-J281.
1654. Shoenfeld Y, Tincani A, Gershwin ME. Sex Gender and autoimmunity. J Autoimmune 2012; 38 : J71–J73.
1655. Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 21: 210-216, 2012.
1656. Appenzeller S, Tamires Lapa A, Freire de Carvalho J, Augusto Peres F, Shoenfeld Y. Cognitive dysfunction and antiphospholipid antibodies. Curr Rheumatol Rep 2012; 14:95–98.
1657. Gilat Y, Shoenfeld Y, Kotler M, Iancu I. Anti-ribosomal P antibody in schizophrenia. Isr J Psychiatry Relat Sci 48: No 4: 275-279, 2011.
1658. Shoenfeld Y. Silicone implants and breast cancer – is it so? Harefuah 151: 8, 2012.
1659. Shoenfeld Y, Agmon-Levin N. Autoimmune or auto-inflammatory syndromes induced by adjuvants. Harefuah 151: 9-11, 2012.
1660. Herscovici R, Szyper-Kravitz M, Altman A, Eshet Y, Nevo M, Agmon-Levin N, Shoenfeld Y. Superior vena cava syndrome – changing etiology in the third millennium. Lupus 21, 93–96, 2012.
1661. Appenzeller S, Tamires Lapa A, Guirau CR, de Carvalho JR, Shoenfeld Y. Cognitive impairment in antiphospholipid syndrome: evidence from animal model. Clin Rheumatol 2012; 31: 403-406.
1662. György Kerekes, Pál Soltész, Michael T. Nurmohamed, Miguel A. Gonzalez-Gay, Maurizio Turiel, Edit Végh, Yehuda Shoenfeld, Iain McInnes & Zoltán Szekanecz. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Rev Rheumatol 2012;8:224-234.
1663. Agmon-Levin N, Hughes GRV, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus 2012; 21: 118-120.



1664. Lidar M, Agmon-Levin N, Langevitz P, Shoenfeld Y. Silicone and scleroderma revisited. Lupus 2012; 21: 121-127.
1665. Zafirir Y, Gilburd B, Garcia Carrasco M, Kivity S, Sa'nchez-Castan~o'n M, Lo'pez-Hoyos M, Mandel M, Szymrka M, Shoenfeld Y, Agmon-Levin N. Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases. Immunol Research 2013; 56:451-456.
1666. Zafirir Y, Agmon-Levin N, Paz Z, Shilton T, Y Shoenfeld Y. Autoimmunity following Hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus 2012; 21: 146-152.
1667. de Carvalho JF, Appenzeller S, Shoenfeld Y. Editorial: Biologicals. Article ID 892873, 2 pages. Int J Rheumatol. Special issue on: Biological. Guest Editors: de Carvalho JF, Appenzeller S, Shoenfeld Y. Hindawi Publishing Corporation volume 2012;
1668. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjögren's syndrome, the old and the new. Best Practice & Research Clin Rheumatol 2012; 26: 105-117. Special issue on "New pearls on CTDs", Guest Editors: Y. Shoenfeld and N. Agmon-Levin.
1669. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment. Best Practice & Research Clin Rheumatol 2012; 26:61-72. Special issue on "New pearls on CTDs", Guest Editors: Y. Shoenfeld and N. Agmon-Levin.
1670. Katz U, Shoenfeld Y, Zakin V, Sherer Y, Sukenik S. Scientific evidence of the therapeutic effects of dead sea treatments: A systematic review. Semin Arthritis Rheum 2012 ; 42:186-200.+
1671. Shoenfeld Y. Letter to the Editor: HPV vaccines and autoimmune diseases. J Intern Med 2012; 272: 98;
1672. Artenjak A, Lakota K, Frank M, Cucnik S, Rozman B, Bozic B, Shoenfeld Y, Sodin-Semrl S. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmune Rev. 2012; 11: 873-882.
1673. Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012; 38: (2-3) J266-J274.
1674. Agmon-Levin N, Shoenfeld Y. The mirabilis period of autoimmunity. Best Pract Res Clin Rheumatol 2012; 26: 1-3 .
1675. Shapira Y, Agmon-Levin N, Selmi C, Petriková J, Barzilai O, Ram M, Bizzaro N, Valentini G, Matucci-Cerinic M, Anaya JM, Katz BS, Shoenfeld Y. Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun. 2012; 39:112-6.
1676. Anaya JM, , Shoenfeld Y, Cervera R. Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. Autoimmune Rev. 2012; 11: 249-251.
1677. Matsuura E, Lopez L.R., Shoenfeld Y, Ames P.R.J.  $\beta$ 2-glycomrotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity? Autoimmu Rev. 2012; 12: 241-249.
1678. Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus 2012; 21: 241-250.
1679. Ben-Ami Shor D, Orbach H, Boaz M, Altman A, Anaya JM, Bizzaro N, Tincani A, Cervera R, Espinosa G, Stojanovic L, Rozman B, Bombardieri S, De Vita S, Damoiseaux J, Villalta D, Tonuti E, Tozzoli R, Barzilai O, Ram M, Blank M Agmon-Levin N, Shoenfeld Y. Gastrointestinal-associated autoantibodies in different autoimmune diseases. Am J Clin Exp Immunol 2012;1:49-55.
1680. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012; 11: 593-595.
1681. Lidar M, Lipschitz N, Agmon-Levin N, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N, Damoiseaux J, Cohen Tervaert JW, deVita S, Bombardieri S, Shoenfeld Y. Infectious Serologies and

Autoantibodies in Hepatitis C and Autoimmune Disease-Associated Mixed Cryoglobulinemia. Clinic Rev Allerg Immunol 2012; 42:238–246.

1682. Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Current Opinion in Rheumatology 2012; 24:389-393.
1683. Anaya JM, Castiblanco J, Rojas-Villarraga A, Pineda-Tamayo R, Levy RA, Gómez-Puerta J, Dias C, Mantilla RD, Gallo JE, Cervera R, Shoenfeld Y, Arcos-Burgos M. The multiple autoimmune syndromes. A clue for the autoimmune tautology. Clin Rev Allerg Immunol 2012; 43: 256 - 64.
1684. Altman A, Szyper-Kravitz M, Agmon-Levin N, Gilburd B, Anaja JM, Barzilai O, Ram M, Bizzaro N, Stojanovich L, Damoiseaux J, Cohen Tervaert JW, Bombardieri S, Amital H, Shamis A, Shoenfeld Y. Prevalence of rubella serum antibody in autoimmune diseases. Rev Bras Reumatol (Revista Brasileira De Reumatologia) 2012; 52: 307-318.
1685. Shoenfeld Y, Keren G. Will I be a good doctor? Harefuah 2012; 151: 372. Hebrew.
1686. Mazor R, Kesler A, Shoenfeld Y. Erdheim-Chester disease: An orphan condition seeking treatment. IMAJ 2012; 14: 388 – 389.
1687. Doria A, Putterman C, Sarzi-Puttini P, Szekanecz Z, Shoenfeld Y. Controversies in rheumatism and autoimmunity. Autoimmun Rev 2012; 11: 555–557.
1688. Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with autoimmune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012; 11: 572-6.
1689. Shoenfeld Y, Shemer J, Keren G. The future of medicine in Israel. Harefuah 2011; 150: 624. Hebrew.
1690. Shoenfeld Y, Keren G, Shemer J. The search for medical information: the Israel Medical Association publishes update journals. Harefuah 2011; 150: 694-5. Hebrew.
1691. Shoenfeld Y. Withdrawing of IVIG compound from the market. Harefuah 2010; 149: 754-5. Hebrew.
1692. Agmon-Levin N, Kivity S, Tzioufas AG, López Hoyos M, Rozman B, Efes I, Shapira J, Shamis A, Amital H, Youinou P, Shoenfeld Y. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. Journal of Autoimmunity 2012; 39: 234 – 239.
1693. Blank M, Krause I, Dotan N, Anafi L, Eisenstein M, Cervera R, Meroni PL, Shoenfeld Y. Anti-GalNAc $\beta$ : A novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. Journal of Autoimmunity 2012; 39 : 420-427
1694. Zimlichman E, Szyper-Kravitz M, Shinar Z, Klap T, Levkovich S, Unterman A, Rozenblum R, , Rothschild JM, Amital H, Shoenfeld Y . Early recognition of acutely deteriorating patients in non-intensive care units: Assessment of an innovative monitoring technology. J Hospital Med. Vol 7, No 8, October 2012.
1695. Zimlichman E, Shinar Z, Rozenblum R, Levkovich S, Skiano S, Szyper-Kravitz M, Altman A, Amital H, Shoenfeld Y. Using continuous motion monitoring technology to determine patient's risk for development of pressure ulcers. J Patient Saf. 2011; 7: 181- 4.
1696. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/ inflammatory syndrome induced by adjuvants (ASIA). Lupus 2012; 21: 711-714.
1697. Amital H, Shoenfeld Y. Disease associations of vitamin D in autoimmune disorders – prevention and therapy. Standardy Medyczne/Pediatrics 2012; T.9, 620-622.
1698. Paez MC, Matsuura E, Diaz LA, Shoenfeld Y, Serrano NC, Anaya JM. Laminin-1 (LM-111) in preeclampsia and systemic lupus erythematosus. Autoimmunity. 2013; 46: 14-20.

1699. Elkayam O, Bendayan D, Segal R, Shapira Y, Gilburd B, Reuter S, Agmon-Levin N, [Shoenfeld Y](#). The effect of anti-tuberculosis treatment on levels, of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. [Rheumatol Int](#). 2013; 33 :949–953
1700. Borchers AT, Leibushor L, Naguwa SM, Cheema GS, [Shoenfeld Y](#), Gershwin ME. Lupus nephritis: A critical review. [Autoimmunity Reviews](#) 2012; 12: 174–194.
1701. Israeli E, [Shoenfeld Y](#). Wine and its positive effect on Human health. [Harefuah](#) 2012; 151: 716-7.
1702. Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, Ram M, Youinou P, [Shoenfeld Y](#). Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. [Exp Mol Pathol](#). 2012; 93: 386-90.
1703. [Shoenfeld Y](#), Rosenberg O, Kotler M, Dannon PN. Tricotillomania: pathopsychology theories and treatment possibilities. [IMAJ](#) 2012; 14 (2): 125–129.
1704. [Shoenfeld Y](#), Shemer J, Keren G, Blashar Y, Eidelman L, Borow M, The games go on: British medical journals play politics, again. [IMAJ](#) 2012; 14: 82–83.
1705. Keren G, Shemer J, [Shoenfeld Y](#). Peer review. [Harefuah](#) 2012; 151/ 10: 600 – 602. (Hebrew).
1706. Jovanova-Nesic K, [Shoenfeld Y](#), Spector NH. Vth Stromboli Conference, Jun 13-19, 2010: Aluminum excytotoxicity and neuro autoimmunity: The role of the brain expression of CD32a+ (FcγIIa), ICAM-1+ and CD 3ε in Aging. [Current Aging Science](#) 2012; Vol 5: No.3 0000-0000.
1707. Luciana P.C. Seguro, Cristina Rosario, Yehuda [Shoenfeld](#). Long-term complications of past glucocorticoid use. [Autoimmun Rev](#). 2013; 12: 629 – 632.
1708. Agmon-Levin N, Theodor E, Maoz Segal R, [Shoenfeld Y](#). Vitamin D in Systemic and Organ-Specific Autoimmune Diseases. [Clinic Rev Allerg Immunol](#) 2013; 45:256–266.
1709. Hughes GR, [Shoenfeld Y](#). Antiphospholipid antibody testing – slow progress? [Int J Clin Pract](#). 2012; 66: 533-5.
1710. Rinaldi M, Perricone R, Blank M, Perricone C, [Shoenfeld Y](#). Anti-Saccharomyces cerevisiae Autoantibodies in Autoimmune Diseases: from Bread Baking to Autoimmunity. [Clin Rev Allergy Immunol \(CRAY\)](#) 2013; 45:152–161.
1711. Ben-Ami Shor D, Harel M, Eliakim R, [Shoenfeld Y](#). The hygiene theory harnessing helminths and their ova to treat autoimmunity. [Clinic Rev Allerg Immunol \(CRAI\)](#) 2013; 45:211–216.
1712. Svetlicky N, Ortega-Hernandez AD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, Szyper Kravitz M, Blank M, [Shoenfeld Y](#). The advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade. [J Clin Immunol](#) 2013; 33 : Suppl 1: S27–S32.
1713. Shovman O, Langevitz P, Gilburd B, [Shoenfeld Y](#). Coincidence of granulomatosis and polyangiitis with atypical clinical manifestation and antiphospholipid syndrome. [Lupus](#) 2013; 22: 320–323.
1714. Ben-Ami Shor D, [Shoenfeld Y](#). Will worms cure rheumatoid arthritis? [Nature Rev. Rheumatol](#) 2013; 9: 138–140.
1715. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, [Shoenfeld Y](#). Infectome: A platform to trace infectious triggers of autoimmunity. [Autoimmune Rev](#). 2013; 12: 726 - 740.
1716. Appenzeller S, [Shoenfeld Y](#), de Carvalho JF. Editorial: Neurologic Manifestations of Autoimmune Diseases. [Autoimmune Diseases](#) Volume 2012, Article ID 683212, 2 pages.
1717. Lerner A, Agmon-Levin N, Shapira Y, Gilburd B, Reuter S, Lavi I, [Shoenfeld Y](#). The thrombophilic network of autoantibodies in celiac disease. [BMC Medicine](#) 2013; 11: 89.

1718. Katzav A, Grigoriadis NC, Evert T, Touloumi O, Blank M, Pick CG, [Shoenfeld Y](#), Chapman J. Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice. [BMC Medicine](#) 2013, 11:92.
1719. Rosman Z, [Shoenfeld Y](#), Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. [BMC Medicine](#) 2013, 11:88.
1720. Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya J.M, [Shoenfeld Y](#). Genetics and autoantibodies. [Immunol Research](#) 2013; 56:206–219.
1721. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, [Shoenfeld Y](#), Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality —a review of recent evidence. [Autoimmun Rev](#) 2013; 12: 976–989.
1722. Vera-Lastra O, Medina G, Del Pilar Cruz-Dominguez M, Jara LJ, [Shoenfeld Y](#). Autoimmune/ inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. [Expert Rev. Clin. Immunol.](#) 2013; 9: 361–373.
1723. [Shoenfeld Y](#). Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld. [BMC Medicine](#) 2013, 11:118.
1724. Shovman O, Langevitz P, Gilburd B, [Shoenfeld Y](#). Coincidence of granulomatosis and polyangiitis with atypical clinical manifestation and antiphospholipid syndrome. [Lupus](#) 2013; 22: 320-323.
1725. Tincani A, Andreoli L, Cavazzana I, Doria A, Favero M, Fenini M-G, Franceschini F, Lojaco A, Nascimbeni G, Santoro A, Semeraro F, Toniati P, [Shoenfeld Y](#). Novel aspects of Sjögren's syndrome in 2012. [BMC Medicine](#) 2013, 11:93.
1726. Perricone C, Agmon-Levin N, [Shoenfeld Y](#). Novel pebbles in the mosaic of autoimmunity. [BMC Medicine](#) 2013, 11:101.
1727. Kivity S, Katzav A, Arango M-T, Landau-Rabi M, Zafrir Y, Agmon-Levin N, Blank M, Anaya J-M, Mozes E, Chapman J, [Shoenfeld Y](#). 16/6-idiotypic antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus. [BMC Medicine](#) 2013, 11:90.
1728. Jovanova-Nesic K, [Shoenfeld Y](#), Spector N,H. Vth Stromboli Conference, Jun 13-19, 2010: Aluminum Excytotoxicity and NeuroAutotoImmunity: The Role of the Brain Expression of CD32a+  $\gamma$ Ia), ICAM-1+ and CD 3  $\epsilon$  in Aging. [Current Aging Science](#), 2012, 5, 0000-0000
1729. Rosario C, Seguro L, Vasconcelos C, [Shoenfeld Y](#). Is there a cure for systemic lupus erythematosus? [Lupus](#) 2013; 22, 417–421.
1730. Tomljenovic L, [Shoenfeld Y](#). Association between vaccination and Guillain-Barré syndrome (Comment). [The Lancet](#) 2013; 13: 730-1.
1731. Moudgil KD, Thompson SJ, Geraci F, De Paepe B, [Shoenfeld Y](#). *Editorial: Heat-Shock proteins in autoimmunity.* [Autoimmune Diseases](#), Hindawi Publishing Corporation, Volume 2013, Article ID 621417, 3 pages.
1732. Yehudai D, Toubi E, [Shoenfeld Y](#), Vadasz Z. Autoimmunity and novel therapies in immune-mediated thrombocytopenia. [Seminars in Hematology](#) 2013; 50: Suppl 1; pp. S100-S108.
1733. Ram M, Barzilai O, Shapira Y, Anaya JM, Tincani A, Stojanovich L, Bombardieri S, Bizzaro N, Kivity S, Agmon-Levin N, [Shoenfeld Y](#). *Helicobacter pylori* serology in autoimmune diseases – fact or fiction? [Clin Chem Lab Med](#) 2013; 51: 1075–1082.
1734. Zandman-Goddard G, [Shoenfeld Y](#). Editorial: Hemophagocytic Syndrome with hyperferritinemia: a Stormy Immunological Response. [IMAJ](#) 2013; 15: 187-188.

(This is an Editorial for article: Decruz D. et al. N2010 Adult-Onset Still's Disease Complicated by Hemophagocytic Syndrome and Catastrophic Antiphospholipid Syndrome Resulting in Four Limb Amputation. *IMAJ* 2013; 15: 192-194. ( Our reprint No.1734a).

1735. Colafrancesco S, Agmon-Levin N, Perricone C, [Shoenfeld Y](#). Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle. *Immunol Res* 2013; 56: 200–205.
1736. Chapman J, [Shoenfeld Y](#). Chronic inflammatory demyelinating polyradiculoneuropathy : revisiting the role of intravenous immunoglobulins. *IMAJ* 2013; 15: 293 – 294.
1737. Israeli E, [Shoenfeld Y](#). Open access medical journal. *Harefuah* 2013; 152/6: 314.
1738. Bogdanos DP, Smyk DS, Invernuzzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, [Shoenfeld Y](#). Tracing environmental markers of autoimmunity: introducing the infectome. *Immunol Research* 2013 ; 56: 220-40.
1739. Colafrancesco S, Perricone C, Tomljenovic L, [Shoenfeld Y](#). Human Papilloma Virus Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants. *Am J Reprod Immunol* 2013. 2013; 70:309-16.
1740. [Shoenfeld Y](#). Everything is Autoimmune Until Proven Otherwise. *Clin Rev Allerg Immunol* 2013; 45:149–151.
1741. Katzav A, Arango MT, Kivity S, Tanaka S, Givaty G, Agmon-Levin N, Honda M, Anaya JM, Chapman J, [Shoenfeld Y](#). Passive transfer of narcolepsy: Anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. *J Autoimmunity* 2013; 45: 24-30.
1742. Rosario C, Zandman-Goddard G, Meyron-Holtz EG, D'Crux DP, [Shoenfeld Y](#). The Hyperferritinemic Syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Medicine* 2013, 11:185.
1743. Mazor R, Manevich-Mazor M, [Shoenfeld Y](#). Erdheim-Chester Disease: a comprehensive review of the literature. *Orphanet Journal of Rare Diseases* 2013, 8:137
1744. Gatto Marriale, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, [Shoenfeld Y](#). Human papillomavirus vaccine and systemic lupus erythematosus. *Clin Rheumatol* 2013; 32:1301–1307
1745. McEllwee KJ, Gilhar A, Tobin DJ, Ramot Y, Sundberg JP, Nakamura M, Bertolini M, Inui S, Yokura Y, King LE, Duque-Estrada B, Tosti A, Keren A, Itami S, [Shoenfeld Y](#), Zlotogorski A, Paus Ralf. What causes alopecia areata? *Experimental Dermatology* 2013; 22: 609-626.
1746. Gershwin M.E, [Shoenfeld Y](#). Abul Abbas: An epitome of scholarship. *J Autoimmun* 2013; 45:1-6, In Press
1747. Gatto M, Iaccarino L, Ghirardello A, Bassi N, Pontisso P, Punzi L, [Shoenfeld Y](#), Doria A. Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. *Clinic Rev Allerg Immunol* (CRAY) 2013; 45: 267–280
1748. Agmon-Levin N, Rosario C, Porat-Katz B-S, Zandman-Goddard G, Meroni P, Cervera R, Stojanovich L, Blaank M, Pierangeli SS, Praprotnik S, de Meiso E, Parente Seguro L, Ruffatti A, Pengo V, Tincani A, Doria A, [Shoenfeld Y](#). Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). *Lupus* 2013; 22, 1327–1335.
1749. Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, [Shoenfeld Y](#). Autoimmune (Auto-Inflammatory) syndrome induced by adjuvants (ASIA) – animal models as a proof of concept. *Cuur Med Chem* 2013; 20: 4030 – 6.
1750. Nancy Agmon-Levin, Jan Damoiseaux, Cees Kallenberg, Ulrich Sack, Torsten Witte, Manfred Herold, Xavier Bossuyt, Lucille Musset, Ricard Cervera, Aresio Plaza-Lopez, Carlos Dias, Maria José Sousa, Antonella Radice, Catharina Eriksson, Olof Hultgren, Markku Viander, Munther Khamashta, Stephan Regenass, Luis Eduardo Coelho Andrade, Allan Wiik, Angela Tincani, Johan Rönnelid, Donald B Bloch, Marvin J Fritzler, Edward K L Chan, I Garcia-De La Torre, Konstantin N Konstantinov, Robert Lahita,

Merlin Wilson, Olli Vainio, Nicole Fabien, Renato Alberto Sinico, Pierluigi Meroni, Yehuda Shoenfeld. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. published online October 14, 2013 \_\_\_\_\_

1751. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Strategies and treatment alternatives in the management of Erdheim--Chester disease. Expert Opinion on Orphan Drugs 2013; [Early Online]\_\_\_\_\_ .
1752. Perricone c, Shoenfeld Y. EDITORIAL: Hepatitis B Vaccination and Undifferentiated Connective Tissue Disease. Another Brick in the Wall of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA). JCR: J. Clin Rheumatol, 2013; 19 (5): 231 – 233.
- 1752a (*This is the paper for the 1752 Editorial*): Bruzzese V, Zullo A, Hassan C. *Connective Tissue Disease Following Hepatitis B Vaccination*. JCR: J. Clin Rheumatol, 2013; 19 (5):280-281.
1753. Gershwin EM, Shoenfeld Y. Abul Abbas: An epitome of scholarship. J Autoimmun 2013; Sep. 45: 1-6. \_\_\_\_\_On line.
1754. Bogdanos DP, Smyk DS, Invernuzzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Infectome: A platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013; 12: 726-740.
1755. Horacio Berman, Ignasi Rodríguez-Pintó, Ricard Cervera, Nathalie Morel, Nathalie Costedoat-Chalumeau, Doruk Erkan, Yehuda Shoenfeld, Gerard Espinosa. For the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12 : 1085–1090.
1756. Blank M, Bashi T, Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIg) for therapy of autoimmune diseases. Chapter 18 in: Michael Steinitz (ed.), *Human Monoclonal Antibodies: Methods and Protocols*, Methods in Molecular Biology, 2014; vol 1060: 353-61.
1757. Elvira Favoino, Eleonora Isabella Favia, Liboria Digiglio, Vito Racanelli, Yehuda Shoenfeld, Federico Perosa. Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (NZB/NZW) F1 MICE. Clin Exp Immunol. 2014; 175: 32-40.
1758. Shoenfeld Y. Medicine in the digital era: the future is already here. Harefuah 2013; 152: 128.
1759. Lustrek M, Lorenz P, Kreutzer M, Qian Z, Steinbeck F, Wu D, Born N, Ziems B, Hecker M, Blank M, Shoenfeld Y, Cao Z, Glocker MO, Li Y, Fuellen G, rgen Thiesen HJ. Epitope Predictions Indicate the Presence of Two Distinct Types of Epitope-Antibody-Reactivities Determined by Epitope Profiling of Intravenous Immunoglobulins. Plos One 2013. Online. November 2013 | Volume 8 , Issue 11, e78605. \_\_\_\_\_ In press.
1760. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA). 2013: Unveiling the pathogenic, clinical and diagnostic aspects. Journal of Autoimmunity 2013; 47: 1-16.
1761. Israeli E, Shoenfeld Y. The Lancet against Israel. IMAJ 2013; 15: 203–204.
1762. Perricone C, Agmon-Levin N, Colafrancesco S, Shoenfeld Y. EDITORIAL: Vitamins and systemic lupus erythematosus: to D or not to D. Expert Rev. Clin. Immunol. 2013; 9: 397–399.
- 1762a (*This is the paper for the 1762 Editorial*): Chi Chiu Mok. *Vitamin D and systemic lupus erythematosus: an update*. Expert Rev. Clin. Immunol.2013; 9: 453–46.
1763. Shoenfeld Y. A hundred years of medical research in Israel. Harefuah 2013; 152: 4–6.
1764. Israeli E. Shoenfeld Y. Harnessing nature for treating infectious and autoimmune diseases: good and bad bacteria. Harefuah. 2013; 152: 188-9.

1765. Agmon-Levin N, Damoiseaux J, [Shoenfeld Y](#). Response to: "Detection of anti-nuclear antibodies, added-value of solid phase assay?" by Bossuyt and Fieuwys. *Ann Rheum Dis*. Published online Dec.6, 2013. \_\_\_\_ In press.
1766. Bogdanos DP, Smyk MBBs D, [Shoenfeld Y](#). Editorial: The microbiome of the lung. *IMAJ* 2013; 15: 766-767.
1767. Israeli E, [Shoenfeld Y](#). Medical research in Israel in 2013. *Harefuah* 2013; 152: 698 – 700.
1768. Rosario C, Garelick D, Greenberg G, Chapman J, [Shoenfeld Y](#), Langevitz P. Plaque morphea with neurological involvement - an extraordinary uncommon presentation. *Clin Rheumatol* 2013. \_\_\_\_ In press.
1769. Maślińska M, Perricone C, [Shoenfeld Y](#). Autoimmune/inflammatory syndrome induced by adjuvants – a new diagnostic problem or the solution of a diagnostic riddle. *Reumatologia* 2013; 51, 6: 437–444.
1770. Perricone C, Shoenfeld N, Agmon-Levin N, de Carolis C, Perricone R, Shoenfeld Y. Smell and Autoimmunity: A Comprehensive Review. *Clinic Rev Allerg Immunol*. 2013; 45:87–96.
1771. Cervera R, Serrano R, J Pons-Estel G, Ceberio-Hualde L, [Shoenfeld Y](#), de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RHW, de Groot PGD, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris J-C, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA. On behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicenter prospective study of 1000 patients. *Ann Rheum Dis* 2015; 74: 1011-1018.
1772. Agmon-Levin N, [Shoenfeld Y](#). The spectrum between antiphospholipid syndrome and systemic lupus erythematosus. Editorial. *Clin Rheumatol* 2014; 33:293–295.
1773. Reggia R, Andreoli L, Tincani A, Shoenfeld Y. Current treatment strategies for management of antiphospholipid syndrome. *Expert Opinion on Orphan Drugs* 2014; 2(3). 3: 205–215.
1774. Rodriguez-Pinto I, Agmon-Levin N, Amital H, Shoenfeld Y. Fibromyalgia and cytokines. *Immunology Letters* 2014; 161: 200–203.
1775. Tincani A, Andreoli L, [Shoenfeld Y](#). Antiphospholipid antibodies To anticoagulate or not to anticoagulate? Editorial. *Rheumatology* 2014; 53: 201-202.
1776. Kivity S, Arango MT, Ehrenfeld M, Tehori O, [Shoenfeld Y](#), Anaya JM, Agmon-Levin N. Infection and autoimmunity in Sjogren's syndrome: A clinical study and comprehensive review. *Jurnal of Autoimmunity* 2014; 51:17-22.
1777. Soriano A, Afeltra A, [Shoenfeld Y](#). Immunization with vaccines and Sjogren's syndrome. *Expert Rev.Clin. Immunol*. 2014; 10: 429–435.
1778. Selmi C, [Shoenfeld Y](#). Editorial: Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting. *BMC Medicine* 2014. \_\_\_\_  
<http://www.biomedcentral.com/1741-7015/12/50>

1779. Anaya JM, Shoenfeld Y, Cervera R. Editorial: Systemic Lupus Erythematosus. Autoimmune Diseases 2014; Volume 2014, Article ID 274323, 2 pages. In: Special issue on the topic of: "Systemic Lupus Erythematosus". Guest Editors: Anaya JM, Shoenfeld Y, Cervera R.
1780. Borella E, Neshet G, Israeli E, Shoenfeld Y. Vitamin D: a new anti-infective agent?. Ann. N.Y. Acad. Sci. 2014; 1317: 76-83.
1781. Soriano A, Butnaru D, Shoenfeld Y. Editorial: Long-term inflammatory conditions following silicone exposure: the expanding spectrum of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Clin Exp Rheumatol 2014; 32: 151-154.
1782. Leffler J, Stojanovich L, Shoenfeld Y, Bogdanovic G, Hesselstrand R, Blom A.M. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clinical and Experimental Rheumatology (Clin Exp Rheumatol) 2014; 32: 66-70.
1783. Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y. Postural Orthostatic Tachycardia with Chronic fatigue after HPV vaccination as part of the "Autoimmune / Autoinflammatory Syndrome Induced by Adjuvants": Case report and literature review. Journal of Investigative Medicine High Impact Case Reports 2014; 2: 1-8.
1784. Carvalho J.F, Criado P.R., Aoki V, Shoenfeld Y. Editorial: Autoimmunity diseases of the skin. Autoimmun Diseases, Hindawi Publishing Corporation 2013; Special issue on: Autoimmunity Diseases of the Skin. Volume 2013, article ID 584597, 2 pages.
1785. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, Agmon-Levin N, Shoenfeld Y, Ferrão C, Faria R, Vasconcelos C, Signorelli F, Espinosa G. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmunity Reviews 2014; 13: 699–707.
1786. Perricone C, Colafrancesco S, Shoenfeld Y. The hepatitis B vaccine and ASIA (autoimmune/inflammatory syndrome induced by adjuvants): Relationship with *Saccharomyces cerevisiae*. Case reports in Int Med. 2014; Vol.1 No.2. 6 pages. <http://crim.sciencedupress.com> .
1787. Aviva Katzav, Tal Ben-Ziv, Miri Blank, Chaim G. Pick, Yehuda Shoenfeld, Joab Chapman. Antibody-specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. Journal of Neuroimmunology 2014; 272: 10–15.
1788. von Gunten S, Shoenfeld Y, Blank M, Branch D.R., Vassilev T, Käsermann F, Bayry J, Kaveri S, Simon HU. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol 2014; 14: 349.
1789. M Rinaldi, C Perricone, O-D Ortega-Hernandez, R Perricone, Y Shoenfeld. Immune thrombocytopenic purpura: an autoimmune cross-link between infections and vaccines. Lupus 2014; 23: 554–567.
1790. Ishikawa LLW, Shoenfeld Y, Sartori A. Immunomodulation in human and experimental arthritis: including vitamin D, helminthes and heat-shock proteins. Lupus 2014; 23: 577-587.
1791. Goren E, Doron D, Portnoy O, Shoenfeld Y, Segal G. Case report: Silicone Breast Implants as Predisposing Factor for Non-Hodgkin's Lymphoma: An Additional Facet of Auto-Inflammatory Syndrome Induced by Adjuvant. J Med Cases. 2014; 5: 413-416.
1792. Reply to the Editor (related to CV 1739): Shoenfeld Y, Tomljenovic L. Authors' Reply: Human Papilloma Virus Vaccine and Primary Ovarian Failure. American Journal of Reproductive Immunology 2014; 71: 295 – 296
1793. Konikoff T, Konikoff F.M, Shoenfeld Y. Letter to the Editor: Israel–Gaza conflict. The Lancet 2014. [www.thelancet.com](http://dx.doi.org/10.1016/S0140-6736(14)61298-8) Published online August 1, 2014. [http://dx.doi.org/10.1016/S0140-6736\(14\)61298-8](http://dx.doi.org/10.1016/S0140-6736(14)61298-8).



1794. Colafrancesco S, Perricone C, Priori R, Valesini G, Shoenfeld Y. Sjögren's syndrome: Another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Journal of Autoimmunity 2014; 51: 10-16
1795. Fishbain D, Shoenfeld Y, Ashkenazi S. Basic research during residency in Israel: Is a change needed? Harefuahn 2013; 572-575.
1796. Schofield JR, Blitshteyn S, Shoenfeld Y, Hughes GRV. Postural tachycardia syndrome (POTS) and other autonomic disorders in antiphospholipid (Hughes) syndrome (APS). Lupus 2014; 23, 697–702.
1797. Fischer S, Agmon-Levin N, Shapira Y, Porat Katz BS, Graell E, Cervera R, Stojanovich L, Gomez Puertz JA, Sanmarti R, Shoenfeld Y. *Toxoplasma gondii*: bystander or cofactor in rheumatoid arthritis. Immunol Research 2013; 56: 287-292.
1798. Yaniv G, Twig G, Mozes O, Greenberg G, Hoffmann C, Shoenfeld Y. Central nervous system involvement in systemic lupus erythematosus: An imaging challenge. IMAJ 2013; 15: 382 - 386.
1799. Green I, Szyper-Kravitz M, Shoenfeld Y. Parotitis as the presenting symptom of Wegener's granulomatosis: Case report and meta-analysis. IMAJ 2013; 15: 188 – 192.
1800. Agmon-Levin N, Arango MT, Kivity S, Katzav A, Gilburd B, Blank M, Tomer N, Volkov A, Barshack I, Chapman J, Shoenfeld Y. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. Journal of Autoimmunity 2014; 54: 21e32.
1801. Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett. 2014; 161: 200-203.
1802. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Reviews 2014; 13: 981–1000.
1803. Perricone C, Toubi E, Valesini G, Shoenfeld Y. Editorial: Autoinflammation and Autoimmunity: Pathogenic, Clinical, Diagnostic and Therapeutic Aspects. IMAJ 2014; VOL 16 • October 2014.
1804. Soriano A, Afeltra A, Shoenfeld Y. Is atherosclerosis accelerated in systemic sclerosis? novel insights. Current Opinion in Rheumatology 2014; Volume 26 \_ Number 6 \_ November 2014.
1805. Borella E, Israeli E, Shoenfeld Y. Lipid Replacement Therapy: Is it a New Approach in Patients with Chronic Fatigue Syndrome? Journal of Autoimmune Diseases and Rheumatology. 2014; 2: 28-34.
1806. Yaniv G, Twig G, Ben-Ami Shor D, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y. A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients. Autoimmunity Reviews 2015; 14: 75-79.23
1807. Steinman L, Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela. Journal of Autoimmunity 2014; xxx 1e7. \_\_\_\_ In Press.
1808. Ben-Ami Shor D, Blank M, Reuter S, Matthias T, Beiglass I, Volkov A, Barshack I, Shoenfeld Y. Anti-ribosomal-P antibodies accelerate lupus glomerulonephritis and induce lupus nephritis in naïve mice. Journal of Autoimmunity 2014; 54 : 118e126.
1809. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, Agmon0-Levin N, Shoenfeld Y. The Hyperferritinemic Syndromes and CD163: a Marker of Macrophage Activation. IMAJ 2014; 16: 662-3.
1810. Soriano A, Neshet G, Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? Pharmacol Res. 2015; 92C:18-22
1811. Watad A, Agmon-Levin N, Gilburd B, Lidar M, Amital H, Shoenfeld Y. Predictive value o anti-citrullinated peptide antibodies: a real life experience. Immunol Res. 2014. \_\_\_\_ In Press.
1812. Watad A, Versini M, Jeandel PY, Amital H, Shoenfeld Y. Treating prolactinoma can prevent autoimmune diseases. Cellular Immunology 2015; 294: 84–86.

1813. Basyreva LY, Brodsky LB, Gusev AA, Zhapparova ON, Mikhailchik EV, Gusev SA, Matishov DG, Blank M, [Shoenfeld Y](#). Intravenous immunoglobulins (IVIG) enhance *in vitro* activation of neutrophils in C57BL/6 but not in CBA mice. [Immunome Research](#) 2013; pp.1-6.
1814. Basyreva LY, Brodsky LB, Gusev AA, Zhapparova ON, Mikhailchik EV, Gusev SA, Matishov DG, Blank M, [Shoenfeld Y](#). The effect of Intravenous Immunoglobulin (IVIG) on *In vitro* activation of circulating neutrophils from CBA and C57BL/6 mice with fibrosarcoma S37. [Immunome Research](#) 2013; pp.1-6.
1815. Agmon-Levin N, Zafrir Y, Kivity S, Balofsky A, Amital H, [Shoenfeld Y](#). Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' (ASIA). [Immunol Res](#). 2014; 60:376–383.
1816. Bazso A, Szodoray P, Suto G, [Shoenfeld Y](#), Poor G, Kiss E. Importance of intestinal microenvironment in development of arthritis. A systematic review. [Immunol Res](#) 2015; 61:172–176.
1817. Mazor RD, Manevich-Mazor M, Kesler A, Aizenstein O, Eshed I, Jaffe R, Pessach Y, Goldberg I, Sprecher E, Yaish I, Gural A, Ganzel C, [Shoenfeld Y](#). Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series. [BMC Medicine](#) 2014; 12: 221 (18.pp).
1818. Amital H, Agmon-Levin N, Shoenfeld N, Arnson Y, Amital D, Langevitz P, Balbir-Gurman A, [Shoenfeld Y](#). Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis. [Immunol Res](#). 2014; 60:201–207.
1819. Perricone C, Ceccarelli F, Neshet G, Borella E, Odeh Q, Conti F, [Shoenfeld Y](#), Valesini G. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. [Immunol Res](#). 2014. 60:226–235.
1820. Jozélio Freire de Carvalho, Roger Abramino Levy, [Shoenfeld Y](#). Antiphospholipid Syndrome and Antibodies. [Journal of Immunology Research](#) .Volume 2014, Article ID 942869, 2 pages.
1821. Bashi T, Bizzao G, Ben-Ami Shor D, Blank M, Shoenfeld Y. The mechanisms behind helminth's immunomodulation in autoimmunity. [Autoimmun Rev](#) 14 (2015): 98–104.
1822. Artenjak A, Locatelli I, Brelih H, Simonic DM, Ulcova-Gallova Z, Swadzba J, Musial J, Iwaniec T, Stojanovich L, Conti F, Valesini G, Avcin T, Cohen Tervaert JW, [Shoenfeld Y](#), Blank M, Ambrozic A, Sodin-Semrl S, B. Bozic B, Cucnik S. Immunoreactivity and avidity of IgG anti-b2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of b2-glycoprotein I. [Immunol Res](#). 2015; 61:35–44.
1823. Shovman O, Agmon-Levin N, Gilburd B, Martins T, Petzold A, Matthias T, [Shoenfeld Y](#). A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies. [Immunol Res](#). 2015; 61:135–140.
1824. Shovman O, [Shoenfeld Y](#), Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. [Immunol Res](#) 2015; 61:164–168.
1825. Bizzaro G, [Shoenfeld Y](#). Vitamin D and thyroid autoimmune diseases: the known and the obscure. [Immunol Res](#). 2015; 61:107–109.
1826. Agmon-Levin N, Kopilov R, Selmi C, Nussinovitch U, Sa´nchez-Castanon M, Lo´pez-Hoyos M, Amital H, Kivity S, Ershwin EM, [Shoenfeld Y](#). Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. [Immunol Res](#). 2015; 61:141–146.
1827. Ribeiro FM, Gomez VE, Albuquerque EMN, Klumb EM, [Shoenfeld Y](#). Lupus and leprosy: beyond the coincidence. [Immunol Res](#). 2015; 61:160–163.
1828. Selmi C, Ceribelli A, Naguwa SM, Cantarini L, [Shoenfeld Y](#). Safety issues and concerns of new immunomodulators in rheumatology. [Expert Opin. Drug Saf](#). 2015; 14: 389-99.
1829. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, Agmon-Levin N, [Shoenfeld Y](#),

- Valesini G. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res 2014; 60: 177–183.
1830. Ben-Ami Shor D, Bashi T, Lachnish J, Fridkin M, Bizzaro G, Barshak I, Blank M, Shoenfeld Y. Phosphorylcholine-tuftsins compound prevents development of dextran sulfate-sodium salt induced murine colitis: Implications for the treatment of human inflammatory bowel disease. Journal of Autoimmunity 2015; 56: 111-117.
1831. Dagan A, Kogan M, Shoenfeld Y, Segal G. When uncommon and common coalesce: adult onset Still's disease associated with breast augmentation as part of autoimmune syndrome induced by adjuvants (ASIA). Clin Rheumatol 2015; DOI 10.1007/s10067-015-2869-2. Published online 23 January 2015. In Press. \_\_\_\_.
1832. Caforio AL, Angelini A, Blank M, Shani A, Kivity S, Goddard G, Doria A, Schiavo A, Testolina M, Bottaro S, Marcolongo R, Thiene G, Iliceto S, Shoenfeld Y. Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol. 2015; 179: 166-77.
1833. Beatrix Kotlan B, Liskay G, Blank M, Csuka O, Balatoni T, Toth L, Eles K, Horvath S, Naszados G, Olasz J, Banky B, Toth J, Godeny M, Marincola FM, Kasler M, Shoenfeld Y. The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value. Immunol Res 2015; 61:11–23.
1834. Tsur A, Hughes GC, Shoenfeld Y, Carp H. Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications. Immunol Res 2015; 61:31–34.
1835. Bizzaro G, Shoenfeld Y. Vitamin D and autoimmune thyroid diseases: facts and unresolved questions. Immunol Res. 2015; 61:46–52.
1836. Butnaru D, Shoenfeld Y. Adjuvants and lymphoma risk as part of the ASIA spectrum. Immunol Res 2015; 61:79–89.
1837. Austin A, Tincani A, Kivity S, Arango MT, Shoenfeld Y. Transverse Myelitis Activation Post-H1N1 Immunization: A Case of Adjuvant Induction? IMAJ 2015; 17: 120-122.
1838. Watad A, Soriano A, Vaknine H, Shoenfeld Y, Amital H. Immune Mediated Myopathy following Long-Term Statin Therapy. IMAJ 2015; 17: 128-129.
1839. Watad A, Perelman M, Mansour R, Shoenfeld Y, Amital H. Etanercept-Induced Pneumonitis: Severe Complication of Tumor Necrosis Factor-Alpha Blocker Treatment. IMAJ 2015; 17: 130-132.
1840. Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a mosaic of clinical Presentations. BMC Medicine 2015; 13: 43-55.
1841. Artenjak A, Omersel J, Ahlin Grabnar P, Mlinaric-Rascan I, Shoenfeld Y, Sodin-Semrl S, Bozic B, Cucnik S. Oxidatively altered IgG with increased immunoreactivity to  $\beta$ 2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells. Lupus 2015; 24: 448–462.
1842. Soriano A, Shoenfeld Y. Editorial: Haemophagocytic lymphohistiocytosis: from diagnostic challenges to predictive possibilities. Lupus 2015; 24: 655–658.
1843. Bizzaro G, Shoenfeld Y. Vitamin D: a panacea for autoimmune diseases? Can. J. Physiol. Pharmacol. 93: 1–3 (2015) dx.doi.org/10.1139/cjpp-2014-0308. In Press \_\_\_\_.
1844. Sagi L, Baum S, Barzilai O, Ram M, Bizzaro N, SanMarco M, Shoenfeld Y, Sherer Y. Novel antiphospholipid antibodies in autoimmune bullous diseases. Human Antibodies 2014/2015; 23: 27–30.
1845. Shoenfeld Y, Caspi D. The digital doctor. Harefuah 2015; 154: 2-3.
1846. Versini M, Jeande PY, Bashi T, Bizzaro G, Blank M, Shoenfeld Y. Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications. BMC Medicine 2015; 13:81,1-16. \_\_\_\_ In press.

1847. Tomer Bashi, Miri Blank, Dana Ben-Ami Shor, Mati Fridkin, Mathilde Versini, Omer Gendelman, Alexander Volkov, Iris Barshak, Yehuda Shoenfeld. Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. J. Autoimmunity 2015; 1-7. In Press \_\_\_\_.
1848. Valesini G, Gerardi M.C., Iannuccelli C, Pacucci V.A. Pendolino M, Shoenfeld Y Shoenfeld. Citrullination and autoimmunity. Autoimmun Rev. 2015; 14: 490–497.
1849. Goren I, Segal G, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) evolution after silicone implants. Who is at risk? Clin Rheumatol 2015. Published online 16/4/2015. \_\_\_\_\_ In Press.
1850. Kivity Shaye, Yehuda Shoenfeld. Comment on the article by Lauvsnes et-al. Arthritis Rheumatology 2015. DOI 10.1002/art.39077.
1851. [Arango MT, Kivity S, Shoenfeld Y. Is narcolepsy a classical autoimmune disease? Pharmacol Res. 2015; 92: 6-12. doi: 10.1016/j.phrs.2014.10.005. Epub 2014 Oct 29.](#)
1852. Rodriguez-Pinto I, Soriano A, Espinosa G, Shoenfeld Y, Cervera R. Editorial: Catastrophic Antiphospholipid Syndrome: An Orchestra with Several Musicians. IMAJ 2014;16: 585-6.
1853. Arango MT, Kivity S, Chapman J, Shoenfeld Y. Narcolepsy – Genes, Infections and Vaccines: The Clues for a New Autoimmune Disease. IMAJ 2014; 16: 636-7.
1854. Selmi C, Cantarini L, Kivity S, Dagaan A, Shovman O, Zandman-Goddard G, Perricone C, Amital H, Toubi E, Shoenfeld Y. The 2014 ACR annual meeting: a bird's eye view of autoimmunity in 2015. Autoimmun Rev. 2015; 14: 622-632.
1855. Parra-Medina R, Molano-Gonzalez N, Rojas-Villaraga A, Agmon-Levin N, Arango MT, Shoenfeld Y, Anaya Jm. Prevalence of Celiac disease in Latin America: A systematic review and meta-regression. Plos One 2015; May 5. In Press \_\_\_\_.
1856. Gueta I, Shoenfeld Y, Orbach H. Intravenous immune globulins (IVIg) treatment for organizing pneumonia in a selective IgG immune deficiency state. Immunol Res 2014; 60:165-9.
1857. Mathilde Versini, Giorgia Bizzaro, Yehuda Shoenfeld. Helminths and Autoimmunity: the Good, the Bad and the Ugly. IMAJ 2015; 17: 249-250.
1858. Neshet G. , Soriano A, Shlomai A, Iadgarov Y, Shulimzon TR, Borella E, Dicker D, Shoenfeld Y. Severe ASIA syndrome associated with lymph node, thoracic, and pulmonary silicone infiltration following breast implant rupture: experience with four cases. Lupus 2015; 24, 463–468.
1859. [Bogdanos DP, Smyk DS, Rigopoulou EI, Sakkas LI, Shoenfeld Y.](#) Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity. Lupus. 2015; 24: 364-73.
1860. Secundo L, Snitz K, Weissler K, Pinchover L, Shoenfeld Y, Loewenthal R, Agmon-Levin N, Frumin I, Bar-Zvi D, Shushan S, Sobel N. Individual olfactory perception reveals meaningful nonolfactory genetic information. [www.pnas.org/cgi/doi/10.1073/pnas.1424826112](http://www.pnas.org/cgi/doi/10.1073/pnas.1424826112). In press \_\_\_\_.
1861. Valesini G, Gerardi C, Iannuccelli C, Pacucci VA, Pendolino M, Shoenfeld Y. Citrullination and autoimmunity. Autoimmun Rev. 2015; 14: 490-497.
1862. Bazso A, Szappanos A, Patocs A, Poor G, Shoenfeld Y, Kiss E. The importance of glucocorticoid receptors in systemic lupus erythematosus. A systematic review. Autoimmun Rev. 2015;14:349-51

1863. [Svetlicky N](#), [Kivity S](#), [Odeh Q](#), [Shovman O](#), [Gertel S](#), [Amital H](#), [Gendelman O](#), [Volkov A](#), [Barshack I](#), [Bar-Meir E](#), [Blank M](#), [Shoenfeld Y](#). ACPA specific IVIg attenuate collagen induced arthritis in mice. *Clin Exp Immunol*. 2015 Jun 30. doi: 10.1111/cei.12673. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/26132809> (In Press \_\_\_).
1864. Damoiseaux J, Andrade LE, Fritzler MJ, [Shoenfeld Y](#). Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. *Autoimmun Rev*. 2015; 14: 555-563.
1865. Gruber N, [Shoenfeld Y](#). A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. *Curr Opin Obstet Gynecol* 2015; 27:265–270.
1866. Rottem M, Geller-Bernstein C, [Shoenfeld Y](#). Atopy and Asthma in Migrants: The Function of Parasites. *Int Arch Allergy Immunol* 2015; 167: 41–46.
1867. Rosman Y, Lidar M, [Shoenfeld Y](#). Antibiotic therapy in autoimmune disorders. *Clin. Pract*. 2014; 11, 91–103.
1868. Baker B, Guimaraes LE, Tomljenovic L, Agmon-Levin N, [Shoenfeld Y](#). The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. *Expert Opin Drug Safety* 2015; 14: 1-8.
1869. Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. *Pharmacological Research*. Accepted 18-8-15.  
DOI: <http://dx.doi.org/doi:10.1016/j.phrs.2015.08.003>. \_\_\_ In press.